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Summary 
This thesis implies two chapters. The main topic of this thesis is presented in chapter one and 
discusses the synthesis of steroid-like analogues of cholesterol biosynthesis inhibitors. The 
potent DHCR24 inhibitor SH-42 and two related diols were the lead structures of the 
synthesised (seco-)steroidal analogues.  
A chiral pool synthesis, starting from vitamin D2, was performed to receive tri- and tetracyclic 
as well as seco-steroidal analogues with variation of ring A and B of the steroidal structure.  
In total, 30 SH-42 analogues were synthesised and their inhibitory activity towards the 
cholesterol biosynthesis was tested using a whole-cell assay developed in our group. Three 
analogues showed an inhibition of a cholesterol biosynthesis enzyme: Diol 55b showed a weak 
inhibition of the target enzyme DHCR24 and diols 97d and 169 inhibited the sterol C5 
desaturase (SC5D) by accumulation of lathosterol. In general, variation of ring A and B resulted 
in a loss of DHCR24 inhibition. These studies revealed that the steroidal structure is necessary 
for potent DHCR24 inhibitors.  
A part of these studies was published in the European Journal of Organic Chemistry[1]: 
D. Heerdegen, D. Kremer, M. M. Kornmayer, K. N. Kriegler, C. Müller, P. Mayer, F. Bracher, 
Eur. J. Org. Chem. 2020, accepted.  
The topic of the second chapter is a traceless isoprenylation of aldehydes via N-Boc-N-
allylhydrazones. In 2010, a publication by Thomson and co-workers presented a unique [3,3] 
sigmatropic rearrangement of N-Boc-N-allylhydrazones with the super acid triflimide as 
catalyst. In previous studies we designed and synthesised a novel N-Boc-N-allylhydrazine 
building block with two geminal methyl groups which form the isoprenyl group after 
rearrangement. In total, 17 N-Boc-N-allylhydrazones were synthesised and the scope and 
limitations of the rearrangement were studied. By variation of different acidic catalysts, 
protecting groups and solvents the optimum reaction conditions were explored and the reaction 
was carried out for six representative examples.  
These studies were published in the European Journal of Organic Chemistry[2]: 
D. Heerdegen, J. Junker, S. Dittrich, P. Mayer, F. Bracher, Eur. J. Org. Chem. 2020, 3680-
3687 (doi: 10.1002/ejoc.202000382).
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1. Introduction 
Too much of a good thing: hypercholesterolaemia, the presence of high levels of cholesterol 
in the blood, is one of the major risk factors for several diseases, e.g. atherosclerotic 
cardiovascular diseases (CVD).[3-4] Thus, the development and synthesis of potent and 
selective inhibitors of cholesterol biosynthesis is continuously of great interest in 
pharmaceutical research and especially of high necessity worldwide.  
1.1. Cholesterol biosynthesis and transport 
The biomolecule cholesterol (1) plays an important role in the mammalian organism, since it is 
an essential component of cell membranes regulating the membrane rigidity and fluidity. 
Moreover, it acts as a precursor for steroid hormones and bile acids, which are crucial for 
further regulation of metabolic processes.[5-6] The biosynthesis of cholesterol (1) comprises two 
main stages: the lanosterol biosynthesis, followed by the actual cholesterol biosynthesis, which 
consists of the BLOCH and the KANDUTSCH-RUSSELL pathway (Scheme 1).  
 
Scheme 1. Overview of the complete cholesterol biosynthesis, which is divided into the lanosterol biosynthesis 
(grey) and the actual cholesterol biosynthesis which proceeds via the BLOCH (lilac) and KANDUTSCH-RUSSELL (mint 
green) pathway. Enzymatic steps are marked in dark blue and the full names of the enzymes can be found in the 
abbreviation list (cf. [7-8]). 
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The mevalonate pathway is the first section of the lanosterol pathway (Scheme 1, marked in 
grey).[9] In the first steps acetyl-CoA is enzymatically converted to 3-hydroxy-3-methylglutaryl-
CoA (HMG-CoA) via acetyl-CoA-acetyltransferase (ACAT) and HMG-CoA synthase 
(HMGCS). Next, the irreversible reduction of HMG-CoA to mevalonic acid takes place, which 
is catalysed by HMG-CoA reductase (HMGCR). This step is described as the committed step 
in the cholesterol biosynthesis since this feedback regulatory effect is conveyed by changes in 
quantity and activity of HMGCR, depending on the available amount of cholesterol in cells. 
Then, mevalonic acid is converted to isopentenyl-5-pyrophosphate (IPP) in three steps. 
Reaching the squalene pathway, six units of IPP are needed to form one squalene. Geranyl-
PP and farnesyl-PP are significant intermediates, whereby the latter is a precursor for the 
biosynthesis of isoprenoids. Lastly, the conversion of squalene to squalene-2,3-epoxide and 
subsequent cascade cyclisation generates lanosterol.[5] The post-squalene pathway, thus the 
cholesterol biosynthesis, can proceed via the BLOCH (Scheme 1, marked in lilac) or the 
KANDUTSCH-RUSSELL (Scheme 1, marked in mint green) pathway.[10] Using isotope labeling, 
MITSCHE et al. showed, that the relative use of both pathways is tissue and cell specific.[8] The 
BLOCH pathway can be found, for example in adrenal glands and testes, while brain and skin 
utilise the KANDUTSCH-RUSSELL pathway.[8, 11] Starting from lanosterol, cholesterol (1) is formed 
in both pathways via seven steps. All in all, both pathways seem to be related with the main 
difference between them being the point at which the reduction of the Δ24-double bond in the 
side chain of the sterol intermediates takes place. The reduction is catalysed by the enzyme 
Δ24-dehydrocholesterol reductase (DHCR24), which will be discussed in chapter 1.4. in more 
detail. 
To understand the natural regulation and the impact of a disturbed cholesterol balance, it is 
important to understand the cholesterol transport. Figure 1 shows a shortened overview of the 
lipoprotein metabolism and cholesterol transport, respectively.[5, 12] Due to the poor water 
solubility of cholesterol, it is packed into carrier particles, the so-called lipoproteins, which 
consists of lipids (triglycerides, cholesterol esters and free cholesterol) and apolipoproteins, 
whereby the latter are inter alia ligands for receptors. The lipoproteins are divided based on 
their density into VLDL (very low density lipoproteins), IDL (intermediate density lipoproteins), 
LDL (low density lipoproteins) and the chylomicrons. Chylomicrons transport the dietary lipids 
(cholesterol and triglycerides) from the intestines to the liver via lymphatic tissues.[12-13] 
Triglycerides are lipolysed intro free fatty acids (FFA), which deposit in fatty and peripheral 
tissues and chylomicron remnants are taken up by the liver. The main location of cholesterol 
biosynthesis is the liver.[14] The cholesterol is enzymatically packed into VLDL (cholesterol 
esters and triglycerides), which is released to the blood system. After elimination of some 
triglycerides via hydrolysis, IDL is formed, whereby one part is absorbed by the liver and the 
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other part is formed to LDL via elimination of further triglycerides, which are lipolysed to FFA. 
LDL transports cholesterol to peripheral tissues and regulates the de novo cholesterol 
biosynthesis.[5, 15-16] Another important lipoprotein is HDL (high density lipoprotein). HDL 
transports surplus cholesterol from peripheral tissues back to the liver converting it into bile 
acids for excretion.[5, 12, 17]    
 
Figure 1. Shortened overview of the lipoprotein metabolism and reverse cholesterol transport (RCT) (cf. [5, 12]). 
As a result, HDL is responsible for the so-called reverse cholesterol transport (RCT),[18-19] and 
therefore for the cholesterol balance.  
1.2. Natural regulation and the impact of a disturbed cholesterol balance 
The cholesterol biosynthesis is naturally regulated at the committed step, the reduction of 
HMG-CoA to mevalonic acid, catalysed by HMGCR.[5, 9] HMGCR can be controlled in several 
ways, e.g. by the sterol regulatory element-binding protein 2 (SREBP2), a transcription factor 
which is anchored in the endoplasmic reticulum and is bound to the integrated membrane 
protein SREBP-cleavage activating protein (SCAP), the cholesterol sensor. When the 
cholesterol concentration decreases, the SCAP-SREBP2 complex moves in small vesicles to 
the GOLGI apparatus where it is released from the membrane in two proteolytic cleavages. 
Consequently, the released protein binds to the sterol regulatory element (SRE) DNA 
sequence in the nucleus and the transcription of HMGCR is increased. When the cholesterol 
level is too high, the proteolytic release of SREBP2 is blocked and the protein is degraded in 
the nucleus and the transcription is stopped.[5, 16, 20] The HMGCR activity can further be 
regulated by phosphorylation. In the liver, HMGCR can be deactivated by an AMP-dependent 
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proteinkinase (AMPK). In case of a cellular energy deficiency, the AMP level is high and as a 
result HMGCR is phosphorylated by AMPK. As a result, HMGCR is deactivated, which means 
the cholesterol biosynthesis is shutting down.[5, 16, 21] 
A genetically disturbed cholesterol balance can result in several diseases, e.g. NIEMANN-PICK 
type C disease, a neurodegenerative disease, whereby cholesterol accumulates with 
lysosomes. Besides neurodegeneration, an enlarged liver and spleen are typical symptoms.[16, 
22] The SCHNYDER corneal dystrophy describes the accumulation of cholesterol in the cornea, 
resulting in opacification. Due to HMGCR stabilisation, the cholesterol production is 
enhanced.[16, 23] In contrast, the SMITH-LEMLI-OPITZ syndrome represents a cholesterol 
deficiency, due to decreased activity of the enzyme ∆7-dehydrocholesterol reductase 
(DHCR7), leading to accumulation of 7-dehydrocholesterol. The consequence is mental and 
growth retardation.[16, 24] Another present health problem is hyperlipidaemia, which includes 
high levels of lipids like cholesterol, triglycerides and lipoproteins and is a risk factor for CVD.[4] 
A distinction is made here between primary (familial) and secondary (acquired) 
hyperlipidaemia. While the primary form has a genetic origin, the secondary form is caused by 
underlying reasons like diabetes mellitus or the use of certain drugs, such as diuretics or beta 
blockers.[25] Two subtypes of primary hyperlipidaemias are the common and the familial 
hypercholesterolaemia (FH), whereby both are induced by raised cholesterol levels due to 
LDL.[3] According to the World Health Organisation (WHO), raised cholesterol levels are a 
global health problem. Overall, a third of ischaemic heart disease cases result from 
hypercholesterolaemia and estimated to cause 2.6 million of global deaths.[26] The initial 
treatment of high cholesterol levels consists of a change of diet (reducing animal fats, 
increasing vegetables, dietary fibres, etc.) or lifestyle (limiting smoking and alcohol 
consumption, increasing physical activity).[27-28] If this does not lead to improvement, a medical 
treatment is required. 
1.3. Inhibitors of cholesterol biosynthesis  
Although inhibition of cholesterol biosynthesis is conceivable via interference in each 
enzymatic step, until now successful therapeutics only target the pre-squalene part. A clinically 
relevant class of inhibitors are statins,[29] which are used for the treatment of hyperlipidaemia 
and atherosclerosis. Statins reduce cholesterol synthesis by competitive inhibition of HMGCR. 
Consequently, the amount of cholesterol decreases, which results in an up regulation of 
hepatic LDL receptor expression. Therefore, more LDL can be taken up from the plasma into 
the cell, resulting in decreased LDL blood levels.[3] The first statin was Mevastatin (2), which 
was isolated from Penicillium citrinum, but due to side effects, 2 is not used therapeutically. 
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The first commercially introduced statin was Lovastatin (3), isolated from Aspergillus terreus.[30] 
Further synthetic statins are Fluvastatin (4) and Atorvastatin (5) (Figure 2).[31-32]  
 
Figure 2. Structures of isolated Mevastatin (2) and Lovastatin (3), and synthetic statins Fluvastatin (4) and 
Atorvastatin (5). 
Unfortunately, statins cause few side effects such as muscle pains, including cramps and 
weakness.[33] Another cholesterol-lowering agent with a different mechanism of action is 
Ezetimibe (6, Figure 3), which is generally accepted, but less effective than statins. It binds to 
the NIEMANN-PICK C1-like 1 receptor and thus inhibits the intestinal dietary and biliary 
cholesterol absorption.[3] Various guidelines recommend to use Ezetimibe (6) in combination 
therapy together with statins or in case of statin intolerance solely as monotherapy.[34]  
 
Figure 3. Structure of Ezetimibe (6). 
Nevertheless, there are inhibitors which target the post-squalene part, e.g. AY-9944 (7) and 
BM-15766 (8), which inhibit DHCR7, resulting in an accumulation of 7-dehydrocholesterol in 
tissues (Figure 4). However, both inhibitors show teratogenic effects and therefore the 
application of these inhibitors is limited to studies regarding the SMITH-LEMLI-OPTIZ 
syndrome.[35-36] 
 
Figure 4. Structures of DHCR7 inhibitors AY-9944 (7) and BM-15766 (8). 
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Another enzyme in the post-squalene part is DHCR24. It became a target of growing interest 
in the past years since it plays an integral role in research concerning cardiovascular diseases 
(CVD), ALZHEIMER’S disease (AD), hepatitis C virus (HCV) infections, certain types of cancer 
and desmosterolosis.[10, 37] GREEVE et al. showed that the Seladin-1 gene, that encodes for 
DHCR24, is down-regulated in neurons in vulnerable regions in AD.[38] HCV infection leads to 
increased DHCR24 expression in hepatocytes and plays a significant role in the viral 
replication, since treatment with DHCR24 inhibitor U18666A (19, structure shown in Figure 6) 
suppresses HCV replication. As a result, DHCR24 may act as a novel HCV drug target.[39] 
Desmosterolosis is a rare autosomal recessive disorder and describes the accumulation of 
desmosterol, due to defects on Seladin-1.[40] Psychomotor retardation, microcephaly, 
spasticity, development disorders, nystagmus or strabismus are consequences of this 
disease.[41] However, the relation between the phenotype of the disease and the accumulation 
of desmosterol is still unknown. Based on these diseases and the presumed strong 
involvement of cholesterol biosynthesis pathway, the importance of deeper understanding 
therof and in particular of the BLOCH and KANDUTSCH-RUSSELL pathway becomes clear.   
1.4. Insight in the BLOCH and KANDUTSCH-RUSSELL pathway  
To bring out why the BLOCH and KANDUTSCH-RUSSELL pathway are of special importance in 
cholesterol biosynthesis and related diseases Scheme 2 provides a closer look on the 
important steps of these pathways. The first thing to be noticed is that both pathways are not 
strictly separated from each other. While in the KANDUTSCH-RUSSELL pathway, the reduction 
of the double bond, the conversion of lanosterol (9) to 24,25-dihydrolanosterol (14), occurs in 
the initial step, in the BLOCH pathway the reduction of the double bond can occur in any sterol 
intermediate, crossing-over to the KANDUTSCH-RUSSELL pathway. Overall, lanosterol (9), 
zymosterol (10) or desmosterol (13) are the major substrates of DHCR24.[8, 42-44] The enzymatic 
reduction is a two-step process utilising NADPH as reducing agent. Thus, C-24 is protonated, 
forming a carbocation at C-25 with subsequent addition of a hydride of NADPH to C-25, leading 
to the saturated form.[43]  
Inhibition of DHCR24 (illustrated in Scheme 2 in red) results in an accumulation of desmosterol 
(13). Desmosterol (13) has been proven to be a ligand for the liver X receptor (LXR),[45] which 
regulates the immune and inflammatory responses and plays also an important role in 
metabolic processes like glucose metabolism[46-47] and inter alia in the cholesterol 
homeostasis.[10, 45, 48] The LXR belongs to the nuclear receptor superfamily of DNA-binding 
transcription factors and exists in two isoforms: LXRα is highly expressed in metabolically 
active tissues, like liver and intestine, adipose tissues, kidney and macrophages, whereas 
LXRβ is ubiquitously expressed.[45-46, 49] LXR is ligand-depending and can be regulated by 
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endogenous ligands, like desmosterol (13), as well as by synthetic LXR agonists, e.g. 
benzenesulfonamine compound T0901317.[50] To fulfil the requirements of a transcription 
factor, LXR heterodimerises with retinoid X receptor (RXR) and binds to LXR-response 
elements (DR4).[49]  
 
Scheme 2. Overview of the BLOCH and KANDUTSCH-RUSSEL pathway. Enzymes are written in dark blue. Possible 
inhibition of DHCR24 is marked in red (cf.[43]) 
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With the binding of ligands, a conformational change of the heterodimer occurs, and the 
nuclear receptor coactivator, the so-called steroid receptor coactivator-1 (SRC-1), will be 
recruited, resulting in an activation of the gene transcription.[45, 51] LXR induces RCT,[52-53] 
whereby the cholesterol is secreted into bile or catabolised into bile acids, which results in an 
increase of bile acid production.[54-55] Nevertheless, there are also disadvantages of an 
increased LXR activation. LXR expression is correlated with an increased lipogenesis resulting 
in the so-called fatty livers.[56-57] As a consequence, fatty livers can lead to the non-alcoholic 
fatty liver disease (NAFLD),[58] a metabolic disorder which is not caused by excessive alcoholic 
drinking and become the most common chronic liver disease in industrial countries.[48] The 
non-alcoholic steatohepatitis (NASH) is the inflammatory and progressive form of NAFLD and 
can develop further into liver fibrosis and cirrhosis.[48, 59] Since an inhibition of LXR may lead to 
down regulation of lipogenesis resulting in a decrease of fatty livers which could progress to 
NASH, the development of LXR inhibitors became an important research topic.[37, 60] 
Since desmosterol (13) is a good endogenous ligand for LXR, inhibition of DHCR24, leading 
to accumulated desmosterol can offer significant contribution to more detailed studies of the 
effect of desmosterol on LXR, e.g. studies towards inflammatory resolution.[37] 
1.5. Development of DHCR24 inhibitors 
Considering the broad involvement of DHCR24 and its substrates in biological processes, 
control and regulation of this enzyme are necessary for further advances in its research. 
Currently, there are several inhibitors, but most of them are known to be poorly selective or 
even toxic, which leads to an increasing demand in selective and potent inhibitors. The first 
drug, which was used clinically to lower cholesterol levels was the hypolipidemic Triparanol 
(18), also known as MER-29 (Figure 5). 
 
Figure 5. Structure of the non-steroidal DHCR24 inhibitor Triparanol (18). 
By inhibiting DHCR24, Triparanol (18) leads to decreased cholesterol and increased 
desmosterol levels.[61-62] However, Triparanol was withdrawn from commercial markets due to 
harmful side effects like hair loss, impotency or blindness from a form of cataracts.[63-64] 
Nevertheless, 18 is still used as reference substance in studies for novel DHCR24 inhibitors.  
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Figure 6 depicts steroidal DHCR24 inhibitors. U18666A (19) is not a selective DHCR24 
inhibitor, since it also inhibits the enzymes 2,3-oxidosqualene synthase and ∆7,8-isomerase in 
the cholesterol biosynthesis.[53, 65] DMHCA (20) is a synthetic LXR agonist and showed 
inhibitory effect on DHCR24, but the selectivity over other enzymes is not yet fully 
established.[52-53] The last steroidal DHCR24 inhibitor in this set is MGI-21 (21). This compound 
was designed and synthesised in our group in the course of the development of a group of 
lathosterol side chain amides, the so-called chemotype I.[66] 
 
Figure 6. Established steroidal DHCR24 inhibitors: U18666A (19), DMHCA (20), and MGI-21 (21). 
Compound MGI-21 (21), showed an inhibitory effect, but lacks in the necessary potency 
towards DHCR24 (IC50 = 823 nM for inhibition of overall cholesterol biosynthesis[43]). With the 
introduction of larger N-alkyl groups the selectivity was reduced and an additional undesired 
inhibitory effect on another enzyme in this pathway, lathosterol oxidase (sterol C5 desaturase), 
was observed.[43, 66] Based on these studies, our group recently developed new chemotypes 
of potent DHCR24 inhibitors. Besides chemotype I, inverse amides (chemotype II) and inverse 
esters (chemotype III) were synthesised.[43] Among these, synthesised inhibitors of chemotype 
III were identified as potent, selective and non-toxic inhibitors of DHCR24. In particular ester 
SH-42 (22) and the related free diols ∆7-23 and ∆5-24, whereby 23 is the unesterified version 
of SH-42 (22), showed promising results (Figure 7).  
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Figure 7. General structure of chemotype III (top), SH-42 (22) and related diols 23 and 24 and their IC50 values 
(bottom). The IC50 values refer to the inhibition of total cholesterol biosynthesis.[43] 
Regarding the inhibition of the total cholesterol biosynthesis these compounds have IC50 
values of 4.2 nM for SH-42 (22) and 0.1 nM and 2.5 nM for diols 23 and 24, respectively. The 
slightly higher IC50 value of SH-42 (22) can be explained by the rather labile ester function in 
the side chain, which can be transformed into the free hydroxy groups in vitro – a characteristic 
for a possible pro-drug. When comparing both diols, it could be shown, that the exact position 
of the double bond in ring B is not significant for the inhibition, since the IC50 values of the free 
diols 23 (∆7-double bond) and 24 (∆5-double bond) are similar. With their high potency, 
selectivity and non-toxicity, SH-42 (22) and its related free diols 23 and 24 represent a new 
class of DHCR24 inhibitors.[43] Therefore, the development of further selective inhibitors is 
oriented towards their structures.  
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2. Objective 
Recent research of our group showed, that inhibitors of chemotype III, especially diester SH-
42 (22) and its related free diols 23 and 24 are inhibitors of DHCR24 with high efficacy.[43] 
These inhibitors are derived from natural sterols (cholesterol and others) by semi-synthesis. A 
couple of structural variations had been performed in previous projects, and structure-activity 
relationships of steroidal DHCR24 inhibitors accessible on the route are meanwhile well 
understood.[43] In order to get access to novel chemotypes with close structural relationships 
to the lead structures, syntheses starting from non-steroidal compounds were envisaged. 
Therefore, the aim of this part of the thesis is the synthesis of steroid-like analogues of diols 
23 and 24. The focus was not set on the synthesis of esterified steroid analogues, since we 
first wanted to study the inhibitory effect of the free hydroxylic analogues before heading to 
prodrug-like analogues. Figure 8 shows both lead structures 23 and 24, whereby the petrol 
marked structure motifs should be maintained.  
 
Figure 8. Lead structures 23 and 24. The areas marked in petrol should be maintained in the target compounds. 
Rings C and D, as well as the side chain containing the alcohol function and the hydroxyl group 
at C-3 of the molecule, should be retained. Consequently, ring A and B should be modified, 
resulting in tri- and tetracyclic compounds and seco-steroidal analogues. In the following, the 
retrosyntheses of the desired target structures are shown.  
2.1. Tri- and tetracyclic compounds and seco-steroidal analogues with bridging at C-4 
based on central building block 26 (bearing rings C and D) 
The first retrosynthesis, which is shown in Scheme 3, shows inter alia, the formation of tri- and 
tetracyclic analogues. These should be obtained via DIELS-ALDER cycloaddition between 
various dienophiles and diene 25. Diene 25 should be formed based on central building block 
26 using cross-coupling reactions. Ketone 26 in turn should be obtained via ozonolysis of 
commercially available ergocalciferol (27), also known as vitamin D2, with subsequent TBDMS 
protection of the primary alcohol group and oxidation of the remaining secondary hydroxyl 
group. It is important to maintain and thus protect the free primary hydroxyl group in the side 
chain since it is a necessary element to act as a selective DHCR24 inhibitor.[43] Further 
analogues, which should also be obtained based on central building block 26 are seco-
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steroidal compounds with bridging at C-4 of the bicyclic building block 26. In this process, 
various aliphatic and aromatic residues should be introduced at C-4 position of ketone 26 via 
C-C bond formation using organometallic chemistry, C-C cross-coupling reactions, e.g. 
SUZUKI-MIYAURA cross-coupling, or olefination methods like WITTIG olefination.  
 
Scheme 3. Retrosynthesis of tri- and tetracyclic analogues based on diene 25 (top), and seco-steroidal analogues 
with bridging at C-4 based on the central building block 26 (bottom). Ketone 26 should be obtained from 
ergocalciferol (27). The moieties which should be introduced are marked in pink. 
2.2. Aromatic ring B and seco-steroidal analogues based on central building block 28c 
The first attempt of the second retrosynthesis, which is depicted in Scheme 4, shows the 
variation of ring A with concurrent formation of an aromatic ring B.  
 
Scheme 4. Retrosynthesis of the formation of an aromatic ring B based on central building block 28c (top), and 
seco-steroidal analogues with bridging at C-5 (bottom). Ketone 28c should be obtained from regioisomer 26, which 
in turn should be synthesised from ergocalciferol (27). The moieties which should be introduced are marked in pink.  
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The purpose of the formation of an aromatic ring B is, that both lead structures 23 and 24 
showed high efficacy towards the inhibition of DHCR24 (IC50 = 0.1 nM (23) and 2.5 nM (24)), 
whereby the position of the double bond is probably negligible. With an aromatic ring B, this 
moiety would be fully planar, and the effect of this geometrical change of the inhibitor can be 
studied. The aromatic ring B should be obtained via ROBINSON annulation of central building 
block 28c with methyl vinyl ketone and subsequent copper catalysed oxidative aromatisation. 
Ketone 28c should be formed based on the regioisomer 26, which was discussed in the first 
retrosynthesis (see chapter 2.1.) and should be synthesised from ergocalciferol (27). Another 
attempt based on central building block 28c is the synthesis of seco-steroidal analogues with 
bridging at C-5. Aliphatic and aromatic residues bearing hydroxyl groups should be attached 
via organometallic chemistry and C-C cross-coupling reactions like SONOGASHIRA cross-
coupling.    
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3. Results and Discussion 
First, the syntheses of the central building blocks are shown followed by the studies towards 
the synthesis of tri- and tetracyclic compounds and the formation of various seco-steroidal 
analogues with bridging at C-4 and C-5, respectively. Furthermore, during the practical work, 
a seco-steroidal analogue, with an aromatic ring B and a “broken” ring C could be successfully 
synthesised (see chapter 3.4.). 
3.1. Syntheses of the central building blocks 26 and 28c 
Based on ketone 26 and 28c all analogues, except the studies towards the variation of ring C 
(chapter 3.4.), were synthesised.  
3.1.1. Synthesis of ketone 26 
Central building block 26 was obtained in a three step synthesis (Scheme 5). Literature-known 
ozonolysis of ergocalciferol (27) with subsequent reduction using NaBH4 led to the INHOFFEN-
LYTHGOE diol 29 with 71% yield.[67-68] Since the primary hydroxyl group in the side chain is a 
necessary element in the structure of selective DHCR24 inhibitors,[43] it is crucial to selectively 
protect the alcohol function. Silyl groups are a common protecting group for alcohols, e.g. tert-
butyldimethylsilyl (TBDMS). TBDMS has a high stability against a variety of influences, for 
example strong bases like LDA (pKa = 35.7[69]) or reducing agents like LiAlH4,[70] which will be 
used in further syntheses. The desired mono-TBDMS-protected alcohol 30 was successfully 
obtained in quantitative yield.  
 
Scheme 5. Synthesis of ketone 26 starting from ergocalciferol (27) via ozonolysis, selective TBDMS protection and 
DESS-MARTIN oxidation.[68] 
The last step was the oxidation of the remaining secondary alcohol group. As oxidising agent, 
the hypervalent iodine compound DESS-MARTIN periodinane (DMP) was chosen.[71] In contrast 
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to chromium reagents like pyridinium dichromate (PDC), which are often used in literature,[72] 
DMP is a mild and less-toxic alternative and is easy to handle. The desired ketone 26 was 
isolated with 91% yield. 
3.1.2. Synthesis of ketone 28c 
Besides ketone 26, its regioisomer 28c is an important central building block for the following 
syntheses of various seco-steroids with bridging at C-5 and for the studies towards an aromatic 
ring B. This ketone was synthesised during the bachelor thesis of KATHARINA N. KRIEGLER 
under my supervision.[7] Scheme 6 depicts the retrosynthesis of ketone 28c. 
 
Scheme 6. Retrosynthesis of ketone 28c. 
Ketone 28c should be obtained via oxidation of alcohol 35 which in turn should be synthesised 
from alkene 32c using hydroboration. Alkene 32c should be generated based on central 
building block 26. 
Based on ketone 26, first, a SHAPIRO reaction,[73-74] which is a variation of the BAMFORD-
STEVENS reaction,[75] was attempted (Scheme 7).  
 
Scheme 7. Attempt for the synthesis of olefin 32c via SHAPIRO reaction. 
In this two-step process the appropriate tosylhydrazone 33 should be formed in a condensation 
reaction of ketone 26 with toluenesulfonylhydrazide (31, NH2NHTos). Deprotonation with n-
BuLi should result in an elimination of the aryl sulfinate, liberating N2 during aqueous work-up, 
leading to alkene 32c. Various reaction conditions for the formation of the tosylhydrazone 33 
were tested. Nevertheless, the desired tosylhydrazone could not be synthesised. Therefore, 
an alternative approach for the synthesis of alkene 32c was made.  
The idea was to convert ketone 26 into its enol triflate 34, which then could be easily 
transformed into alkene 32c in a palladium-catalysed hydride transfer (Scheme 8). The 
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synthesis of enol triflate 34 proceeded in quantitative yield using N-phenylbistrifluoromethane-
sulfonimide (phenyl triflimide) as triflating agent and NaHMDS as base.  
 
 
Scheme 8. Synthesis of alkene 32c via enol triflate 34. 
Because of the chosen reaction conditions (strong base and low temperature), the formation 
of the enol triflate proceeds under kinetic control and the easier accessible proton is eliminated. 
Thus, only the lower substituted enolate is formed and the stereochemical information at C-3a 
is maintained. For the following palladium-catalysed hydride transfer two literature-known 
reaction conditions were tested. A STILLE-type hydride transfer using Pd(PPh3)4 as catalyst and 
tributyltin hydride as hydride source[76] did not result in the desired product. An alternative way 
described by LIU et al. uses Pd(OAc)2 as catalyst and formic acid as hydride source.[77] A huge 
advantage of this reaction in contrast to the STILLE-type reaction is that there is no usage of 
toxic organotin reagents. The desired olefin was obtained with a high yield of 81%.  
To generate the target ketone 28c, a hydroxy group in C-5 position via hydroboration is 
introduced. Hereby the resulting stereochemistry of the secondary alcohol at C-5 is negligible 
since the desired compound has a ketone group at this position, resulting in the loss of 
stereoinformation. For hydroboration two boron reagents were tried. First, 9-borabicyclo-
[3.3.1]nonane (9-BBN), one of the most sterically hindered commercial borane reagents, was 
used. Due to strong steric hindrance, the reaction to the appropriate alkylborane proceeded 
very slowly and after 48 h TLC showed no conversion to the desired alcohol. Thus, the reaction 
was tried using the smaller borane reagent BH3·THF. After 24 h the formation of three products 
could be observed via TLC and isolated. NMR spectroscopy revealed that besides the epimer 
of alcohol 30 (see Scheme 5), compound 35b with 14% yield, the 5-hydroxy products 35a and 
35c were formed and isolated with yields of 44% and 8%, respectively (Scheme 9).  
 
Scheme 9. Hydroboration of 32c using BH3·THF. Alcohols 35a, 35b and 35c were isolated with yields of 44%, 14% 
and 8%. The generated stereocenters are marked in red. 
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The stereochemistry of the products was determined with NOESY spectroscopy. The NOESY 
spectrum of 35a showed no spatial coupling between the 5-H and 3a-H, while the NOESY 
spectrum of 35c showed a coupling between 5-H and 3a-H. Furthermore, the structure of 35a 
was confirmed by X-ray crystallography (Figure 9). 
 
Figure 9. Mercury depiction of the structure of 35a in the crystalline state. In this case, the hydroxyl group at C-5 is 
facing to the back, resulting in an R configuration. 
Since the desired ketone 28c has the carbonyl group at C-5, only isomers 35a and 35c were 
of interest.  
 
Scheme 10. Oxidation of 35a to central building block 28a using DMP. 
The alcohol function of 35a was oxidised, using DMP and the desired ketone 28c was isolated 
in 99% yield (Scheme 10). Futhermore, 35c was oxidised, resulting in 28c with 97% yield 
3.2. Variations of ring A and B – tri- and tetracyclic steroid-like analogues 
After successful synthesis of the central building blocks 26 and 28c, variations of ring A and B 
could be synthesised. In this chapter the synthesis of tri- and tetracyclic steroid analogues is 
discussed, including the studies towards the formation of an aromatic ring B.  
3.2.1. Variation of ring A – [4+2] cycloadditions 
The first chapter of tri- and tetracyclic steroid analogues focuses on the variation of ring A with 
maintenance of ring B. For this purpose, [4+2] DIELS-ALDER cycloadditions are a suitable option 
for the simultaneous construction of rings A and B. Scheme 11 shows the general 
retrosynthesis of the tri- and tetracyclic compounds. Tri- or tetracyclic compounds A should be 
formed after deprotection of DIELS-ALDER compounds B using diene 25. A huge benefit of this 
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reactions is, that the cycloaddition products contain a ∆7-double bond like lead structure 23. 
Diene 25 should be obtained from central building block 26 via an enol triflate, followed by 
vinylation in a cross-coupling reaction.  
 
Scheme 11. Retrosynthesis of tri- and tetracyclic compounds based on central building block ketone 26. The new 
generated ring A is marked in pink, whereby the dashed line indicates cycles as well as chains. 
3.2.1.1. Synthesis of diene 25 
For the synthesis of diene 25 a procedure from MAYER et al. was used, who synthesised 
tetracyclic compounds based on GRUNDMANN’S ketone, which is obtained via ozonolysis of 
cholecalciferol, also known as vitamin D3.[78] Starting from building block 26 (for synthesis see 
chapter 3.1.1.), the first step was the formation of the appropriate enol triflate 34, which was 
already discussed in chapter 3.1.2. (Scheme 12). Based on enol triflate 34, cross-coupling 
attempts were made, to form the desired diene 25.  
 
Scheme 12. Synthesis of diene 25, based on ketone 26 via its enol triflate 34, followed by STILLE or SUZUKI-MIYAURA 
cross-coupling. 
SUZUKI-MIYAURA cross-coupling, using vinylboronic anhydride and K2CO3 as base, gave the 
desired diene 25 in moderate yield (26%). However, the yield could be increased to 77% with 
STILLE cross-coupling conditions, using tributyl(vinyl)tin and LiCl. 
3.2.1.2. Tetracyclic compounds: cycloadditions using typical DIELS-ALDER dienophiles 
To explore the scope of diene 25 towards [4+2] cycloadditions, first, typical DIELS-ALDER 
dienophiles were used. Scheme 13 shows all performed cycloadditions using typical DIELS-
ALDER dienophiles like maleimide and derivatives, maleic anhydride and benzoquinone, 
whereby a the procedure of MAYER et al. was used.[78] Instead of refluxing the reaction mixture, 
the reaction was performed using microwave irradiation to shorten the reaction time. DIELS-
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ALDER reaction between diene 25 and maleimide gave tetracyclic 36 with a good yield of 88%, 
whereby the N-hydroxylated version of maleimide gave 37 in nearly quantitative yields. 
Dienophile 1-(hydroxymethyl)-1H-pyrrole-2,5-dione (41), which was used for the formation of 
DIELS-ALDER adduct 38, was synthesised according to a procedure of TAWNEY et al. in 69% 
yield,[79] and the following cycloaddition went well with an isolated yield of 71%.  
 
Scheme 13. General [4+2] DIELS-ALDER cycloaddition (top) and the isolated DIELS-ALDER adducts (bottom). The 
new stereocenters are marked in red. *Dienophile 41 was synthesised according to literature in 69% yield.[79] 
Cycloaddition of maleic anhydride and diene 25 showed a very good conversion on TLC. 
However, anhydride 39 decomposed immediately during the purification process on SiO2. The 
replacement of the light acidic SiO2 with basic Al2O3 was not successful and 39 decomposed 
again. Nevertheless, fast FCC with neutralised SiO2 (using TEA) gave 39 in 9% isolated yield. 
Organic anhydrides are labile functional groups and can be hydrolysed easily, which explains 
the low yield after purification. However, purifcation was necessary after cycloaddition, since 
1H NMR spectrum of crude 39 showed some impurities. Cycloaddition of diene 25 and p-
benzoquinone gave 40 in 15% isolated yield. A reason for the low yield could be, that the 
MICHAEL acceptor p-benzoquinone is a very reactive component in this reaction,[80-81] which 
can lead to several side products. Unidentifiable side products could also be observed on TLC. 
The stereoconfiguration of the new stereocenters were identified by NOESY spectroscopy. A 
strong coupling between 3b-H and 5a-CH3 as well as a coupling between 3a-H/10a-H and 3b-
H could be observed, resulting in 3aR, 3bS and 10aS configuration for all products (for 
tetracycle 40 5S, 9S and 10R configuration according to IUPAC nomenclature). 
The final step to the target compounds is the deprotection of the alcohol function in the side 
chain. For the TBDMS deprotection three methods were explored on the model compound 36 
(Scheme 14). Fluoride sources are known to cleave silyl ethers. Therefore, the first attempt 
was the usage of TBAF/TEA (Scheme 14, I),[68] whereby the free primary alcohol could be 
isolated in 59% yield.  
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Scheme 14. Attempts for the TBDMS deprotection of model compound 36. 
In another attempt, the use of HF·py and pyridine was tested (Scheme 14, II).[82] The desired 
alcohol could be obtained in excellent yield (96%). Besides fluoride sources, catalytic amounts 
of N-iodosuccinimide (NIS) can cleave silyl ethers as well (Scheme 14, III).[83] The reaction 
proceeded very well, but even though the product was purified thrice with FCC, an NIS impurity 
of 17% (determined by 1H NMR) could not be removed. Hence, the first two attempts were 
used. Scheme 15 demonstrates the deprotected DIELS-ALDER adducts. Besides 42, only dione 
46 could be isolated in very good yields (95%).  
 
Scheme 15. Deprotection of the DIELS-ALDER adducts with methods I, II, III. 
It is noteworthy, that TLC showed successful deprotection attempts, but products 43, 44 and 
45 decomposed during the purification process, although various stationary phases (Al2O3, 
(neutralised) SiO2) were used for FCC. Due to decomposition during the chromatographic 
purification process, it was tried to deprotected diene 25 before the cycloaddition, to possibly 
forego the purification process (Scheme 16).  
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Scheme 16. Deprotection of 25 using TBAF/TEA, resulting in diene 47. 
Alcohol 47 could be synthesised in 73% yield under standard conditions. Scheme 17 illustrates 
the cycloaddition of deprotected diene 47 with, inter alia, maleimide as model compound, 
whereby alcohol 42 could be isolated in moderate yield of 38%. Since deprotection after DIELS-
ALDER reaction resulted in a very good yield of 42 (96%), the attempt using DIELS-ALDER 
reaction after deprotection showed a decrease in the yield. One possible reason can be the 
poor solubility of 47, which means that 47 was not converted completely.  
 
Scheme 17. Attempts for the DIELS-ALDER cycloaddition using deprotected diene 47 and maleimide, N-hydroxy 
maleimide, N-hydroxymethyl maleimide and maleic anhydride as dienophiles. The new stereocenters are marked 
in red. *Dienophile 41 was synthesised according to literature in 69% yield.[79] 
As a result, purification by FCC was crucial in this step. Next to 42, dione 45 could be isolated 
in this way, but only in a poor yield of 8%, probably due to fast hydrolysation. The stereocenters 
at C-3a, C-3b and C-10a could be again identified with NOESY spectroscopy as 3aR, 3bS and 
10aS configurated. The N-hydroxylated imide 43, as well as the N-hydroxymethylated imide 
44 could not be isolated.  
3.2.1.3. Tricyclic compounds: cycloadditions using MICHAEL systems  
After several variations of ring A obtained by DIELS-ALDER cycloadditions with monocyclic 
dienophiles resulting in tetracyclic compounds, the aim was now to form tricyclic compounds, 
whereby these bear open chain fragments of ring A, especially a hydroxy group resembling 3-
OH of the steroidal lead structures. Scheme 18 shows the retrosynthesis of the target molecule 
diol A, which should be formed after deprotection of TBDMS-protected tricycle B. B should be 
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obtained by DIELS-ALDER cycloaddition of diene 25 and aliphatic alkenes bearing alcohol 
functions or precursors thereof, like alcohol 48.  
 
Scheme 18. Retrosynthesis of target compound diol A. 
Since olefinic dienophiles typically need to bear conjugated electron withdrawing groups, e.g. 
carbonyl groups, to undergo successful cycloaddition, the use of an alcohol with a terminal 
olefin was a futile attempt. Therefore, we first tried to introduce an electron withdrawing group 
to transform a plain olefin into a reactive dienophile. 
3.2.1.3.1. Introduction of electron withdrawing elements to obtain reactive dienophiles 
An electron withdrawing group is for example the p-toluenesulfonyl group (tosyl). The 
introduction of the tosyl group to 3-buten-1-ol (48) resulting in the literature-known vinyl sulfone 
50 was performed according to a procedure of CATURLA and NÁJERA.[84] In the presence of 
sodium 4-toluenesulfinate (49) and iodine the desired dienophile 50 could be obtained 
stereoselectively in E-configuration in a moderate yield of 53% (Scheme 19).  
 
Scheme 19. Synthesis of the appropriate vinyl sulfone 50, based on 3-buten-1-ol (48). 
The E-configuration could be a problem for the following cycloaddition since the accessibility 
can be limited for the cycloaddition due to steric hindrance of the big tosyl group. The following 
cycloaddition was performed with the unprotected diene 47, as well as with its TBDMS-
protected version 25, under microwave conditions (Scheme 20). 
 
Scheme 20. Cycloaddition between unprotected diene 47 and TBDMS-protected diene 25, respectively, with vinyl 
sulfone 50 under microwave conditions. 
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Unfortunately, no reaction occurred, and the starting material was left unreacted. There are 
some possible reasons for the failure of this reaction: The E-configuration of dienophile 50, 
and consequently the sterically hindered sulfinate residue, or the introduction of just one 
electron withdrawing group was not enough. Therefore, in further reactions, other dienophiles, 
like MICHAEL systems, were tried, to obtain the target structures.  
3.2.1.3.2 Cycloadditions using MICHAEL systems as dienophiles 
In this chapter, DIELS-ALDER cycloadditions with “naked” MICHAEL systems as dienophiles are 
discussed. The first test reaction was perfomed with cyclohexenone 51 as dienophile (Scheme 
21). Instead of microwave irradiation, the reaction mixture was heated to 100 °C in a pressure 
tube.  
 
Scheme 21. DIELS-ALDER cycloaddition of diene 25 and cyclohexenone 51. 
The desired mass of m/z 430.3267 could be detected via GC/MS analysis, but TLC showed a 
smearing line of spots. After purification by FCC only unidentifiable products were obtained 
and target product 52 could not be isolated. Since these conditions were already too harsh for 
the starting materials, the reaction was not performed again with microwave irradiation.  
The next attempt was the usage of acrolein (53) as dienophile since it would result in the 
desired tricyclic target structure A (Scheme 18). Two diastereomers 54a and 54b were isolated 
with an isomeric ratio of 87:13 (determined via 1H NMR) in a good yield of 89% (Scheme 22). 
It is noteworthy, that both isomers could not be separated by FCC, since they have the same 
Rf value (0.16 in hexanes/EtOAc 98:2). NMR analysis revealed that the wrong constitutional 
isomers were formed. Both isomers have the residue attached to C-6’ and only differ in the 
newly built stereocenter at C-6’. Besides C-6’, the stereocenter at C-5a’ was built. The 
stereoconfiguration at C-5a’ of both isomers could be identified as S configurated since both 
5a’-H show a spatial coupling to the nearest proton of 3a’-CH3. Moreover, no coupling can be 
seen between 5a’-H and 9b’-H. 
The stereocenter at C-7’ in 54a has S configuration as well. 6’-H and 9b’-H form one multiplett, 
whereby this multiplett shows a coupling with 5a’-H. Since 9b’-H is definitely facing to the back, 
the observed coupling is between 5a’-H and 6’-H, resulting in S configuration of C-6’ in 54a. In 
54b, C-6’ is R configurated since no coupling between 5a’-H and 6’-H can be observed. 
Moreover, a (weak) coupling between 6’-H and 9b’-H can be seen. 
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Scheme 22. DIELS-ALDER cycloaddition of diene 25 and acrolein (53), resulting in an inseparable mixture of 54a 
and 54b with an isomeric ratio of 87:13 (determined via 1H NMR). The new stereocenters are marked in red.  
To obtain the desired alcohol function in the western part of the molecule, reduction of 54 with 
LiAlH4 was performed (Scheme 23). The alcohol chain is in this case two carbon atoms shorter 
than the lead 23. But as the necessary dimensions of the molecule to be a potent inhibitor have 
not yet been explored these molecules could give further insight into the binding mode. During 
the work-up process of the reaction, Al(OH)3 precipitated and was consequently dissolved with 
concentrated H2SO4. As a result, the hydroxyl group in the side chain was deprotected and 
diols 55a and 55b were obtained. The mixture was separated by FCC and diol 55a was isolated 
in 81% yield and diol 55b in 7% yield. The actual ratio between both isomers was not 
determined since mixed fractions were obtained and a crude 1H NMR was not measured.  
 
Scheme 23. Reduction of the aldehyde group of regioisomeric mixture 54 with subsequent TBDMS deprotection 
using conc. H2SO4, resulting in the separable compounds 55a and 55b. The stereocenters are marked in red. 
The stereoconfiguration at C-5a’ and C-6’ in both isomers could be identified with NOESY 
spectra and the calculated distances between characteristic protons (Table 1). Starting with 
isomer 55a, a clear spatial coupling can be seen between 5a’-H and the nearest proton of 3a’-
CH3 (Table 1, marked in yellow), whereby no coupling is observable between 5a’-H and 9b’-H 
(Table 1, marked in green), which results in S configuration at C-5a’ (Table 1, 55-I or 55-III). 
For the stereoconfiguration at C-6’, first, the right position of 6’-H had to be identified in within 
the multiplett (2.03 – 1.82 ppm) via HMQC. A clear coupling can be observed between 6’-H 
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and 5a’-H (Table 1, marked in blue), resulting in isomer 55-III with S configuration at C-6’. For 
isomer 55b, 5a’-H shows a spatial coupling to 3a’-CH3 (Table 1, marked in yellow), whereby 
no coupling can be seen between 5a’-H and 9b’-H (Table 1, marked in green), which results 
again in S configuration at C-5a’ (Table 1, 55-I or 55-III). After identification of the location of 
6’-H within the multiplett (1.40 – 1.17 ppm) via HMQC, a clear spatial coupling between 6’-H 
and 9b’-H can be observed. All calculated distances were too large for this strong coupling 
(Table 1, marked in pink), but 55-I would be the likeliest. Moreover, no coupling can be 
observed between 6’-H and 5a’-H (Table 1, marked in blue).  
Table 1. Calculated distances between characteristic protons. For calculation details see chapter 6.1. Materials and 
methods. The distances are indicated in Å. 
 
Compound Protons 5a’-H 6’-H 7’-H 9b’-H 6’-CH2 
55-I 3a’-CH3 2.129 4.955 4.058 3.849 5.243 
 5a’-H - 3.062 2.506 3.687 3.235 
 6’-H - - 2.522 3.845 2.453 
 7’-H - - - 5.252 2.448 
 9b’-H - - - - 5.216 
55-II 3a’-CH3 4.217 5.061 3.346 3.844 4.809 
 5a’-H - 2.278 3.840 2.374 3.442 
 6’-H - - 2.504 4.184 2.444 
 7’-H - - - 5.084 2.473 
 9b’-H - - - - 5.495 
55-III 3a’-CH3 2.144 4.517 3.998 3.849 5.532 
 5a’-H - 2.375 2.461 3.665 3.782 
 6’-H - - 2.406 4.861 2.464 
 7’-H - - - 5.240 3.184 
 9b’-H - - - - 3.595 
55-IV 3a’-CH3 4.189 3.524 5.427 3.820 5.142 
 5a’-H - 3.063 2.735 2.542 2.523 
 6’-H - - 2.485 4.767 2.510 
 7’-H - - - 4.459 2.585 
 9b’-H - - - - 5.055 
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As a result, C-6’ has R configuration (Table 1, 55-I). The determined stereocenters C-6’ and 
C-5a’ in 55a and 55b are in accordance to the analysed stereocenters in the diastereomeric 
mixture of 54. 
Since the hydroxyl chain of 55a and 55b is two carbon atoms too short, the next attempt should 
lead to an extension of this chain, a so-called C-homologation. SNOWDEN and co-workers 
developed a one-carbon JOCIC-type homologation of aldehydes.[85] Based on the mixture of 
aldehydes 54, first, the trichloromethylcarbinols were prepared using a method of AGGARWAL 
and MEREU.[86] In the presence of DBU and CHCl3 the two trichloromethylcarbinols 56a and 
56b could be synthesised and separated by FCC (Scheme 24). The stereocenter at C-6’ in 
56a could be determined as S configurated since a clear coupling between 6’-H and 5a’-H 
could be observed. It could not be analysed which stereoconfiguration at C-1 was formed. The 
stereochemistry at position C-6’ in 56b could not be identified in this step since HMQC spectra 
did not allow the determination of the location of 5a’-H and 9b’-H in their small multiplett (2.44 
– 2.32 ppm). Moreover, the configuration at C-1 could not be identified as in isomer 56a. But 
as the stereoinformation at C-1 will be lost after this reaction, the stereoconfiguration at C-1 
can be neglected.  
 
Scheme 24. Synthesis of trichloromethylcarbinols 56a and 56b starting from regioisomeric mixture 54. 
Now, based on 56a and 56b, C-homologation via a JOCIC-type reaction was attempted using 
LiBH4 and NaOH (Scheme 25).[85] Due to low and with 56b contaminated amount of 56a the 
reaction was first carried out with pure 56b. The desired mass could be detected via GC/MS 
but 57 could not be isolated. However, two related compounds were isolated: alcohol 58, which 
is the protected version of 55b and alcohol 59, which is according to literature a typical side 
product in this reaction.[85]   
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Scheme 25. Results of the JOCIC-type C-homologation of 56b. 
Scheme 26 shows a possible mechanism for the formation of 58 from 56b via a base-mediated 
inversion of the synthesis of the carbinols. With the presence of NaOH, the alcohol function of 
56b will be deprotonated and alcoholate A is formed. A can now undergo elimination of 
trichloromethylcarbanion (-CCl3) by generating aldehyde B. The aldehyde function will be 
reduced by LiBH4 to alcohol 58.  
 
Scheme 26. Possible mechanism for formation of 58 from 56b. 
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Deprotection of 58 using HF·py and pyridine resulted in 55b in 25% yield, which confirms the 
formation of 58. Unfortunately, a sufficent amount of 57 could not be isolated for full 
characterisation and for further reactions. With the formation of 55b the stereochemistry at C-
6’ of 56b could be determined retrospectively as R configurated (Scheme 25).  
3.2.2. Variation of ring A and B – aromatic ring B 
Since the IC50 values of lead structures 23 (∆7-sterol) and 24 (∆5-sterol) have shown, that the 
position of the double bond in ring B is negligible, aromatisation and planarisation of ring B and 
how this modification affects the inhibitory efficacy was of great interest. Scheme 27 
demonstrates the retrosynthesis of phenol 60, bearing an aromatic ring B.  
 
Scheme 27. Retrosynthesis of phenolic tricycle 60 based on central building block 28c. 
Based on phenol 60, the reactivity of the phenolic hydroxyl group should be exploited, and 
various derivatives synthesised. Phenol 60 should be formed via dehydrogenative 
aromatisation of ketone 61, which in turn should be generated via ROBINSON annulation out of 
central building block 28c and methyl vinyl ketone (62). The following studies were part of the 
bachelor thesis of PATRICIA L. SKOWRONEK, which was performed under my supervision.[87]  
3.2.2.1. ROBINSON annulation 
A ROBINSON annulation comprises a MICHAEL addition with subsequent intramolecular Aldol 
condensation. In this case central building block 28c (chapter 3.1.2.) should be added to methyl 
vinyl ketone (62) via 1,4-MICHAEL addition. Scheme 28 shows the mechanism of this type of 
reaction with ketone 28c under basic conditions. 
In the first step, enolate 63 is formed by deprotonation of ketone 28c. Due to the electron 
withdrawing keto group of 28c the protons next to it are acidic, and therefore the deprotonation 
can occur on the left or right side of the ketone. This depends on various aspects, e.g. steric 
hindrance. However, for our purpose the deprotonation should occur at C-4. The formed 
enolate can now attack the MICHAEL system, in our case methyl vinyl ketone (62), in a 1,4-
MICHAEL addition. Keto-enol-tautomerisation of the formed enolate enables the following Aldol 
addition, forming ring B. Dehydration should give ketone 61. 
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Scheme 28. Mechanism of the ROBINSON annulation exemplified by central building block 28c and methyl vinyl 
ketone (62) under basic conditions.  
The ROBINSON annulation can be carried out under basic and acidic conditions. Table 2 shows 
the explored conditions.   
Table 2. Reaction conditions for the ROBINSON annulation between methyl vinyl ketone 62 and central building block 
28c. eEntries were perfomed by PATRICIA SKOWRONEK.[87] 
entry catalyst solvent T [°C] t [h] yield (61) 
1 conc. H2SO4 (20 mol%) toluene 115  17 - 
2e conc. H2SO4 (1.3 eq) toluene 115  17 - 
3e KOH (2 mol%) EtOH 42  18 - 
 
Entry 1 and 2e follows a method of HEATHCOCK et al. using conc. H2SO4 as catalyst.[88] Catalytic 
amount as well as stochiometric amounts were tried, but both conditions did not result in any 
product. BERGMANN et al. described a method using KOH as catalyst,[89] but the product could 
not be identified in this approach either (entry 3e).  
3.2.2.2. Trapping/imitating the enolate 
A possible reason for the failed ROBINSON annulation, is the unsuccessful formation of the 
MICHAEL adduct, which could never be detected by GC/MS analysis. Hence, the idea was to 
trap the initial enolate as a silyl enol ether before the actual MICHAEL addition was performed. 
Scheme 29 depicts the reaction. Based on a method of QUINIO et al., ketone 28c was converted 
to the appropriate silyl enol ether 63 using TMSCl and TEA.[90] The mass of the desired silyl 
enol ether was found by GC/MS, but NMR spectroscopy revealed that the constitutional isomer 
64e was obtained. 
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Scheme 29. Attempt for trapping the enolate as a silyl enol ether 63 resulting in the formation of isomer 64e. 
Figure 10 depicts the COSY spectrum of 64e. The COSY spectrum shows a strong correlation 
between 6’-H and 7’-H and not between 4’-H and 3a’-H. The 7-H protons were assigned via 
4JH,H coupling between 7’-H and 7a’-CH3.  
 
Figure 10. COSY spectrum of silyl enol ether 64e. 
Concerning acidity, both positions 4’-H and 6’-H should be equal, which means the only 
possible reason for the formation of this undesired constitutional isomer is steric hindrance. 
Figure 11 shows a possible conformation of 28c. In this case 6’-H is more accessible than 4’-
H. Consequently, TEA cannot attack properly 4’-H. 
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Figure 11. A possible conformation of central building block 28c. 
Due to the formation of the wrong constitutional isomer 64e the further planned steps could not 
be carried out.  
Another idea was trapping the enolate as an enamine, which then can undergo the MICHAEL 
addition. This type of reaction is called STORK enamine reaction.[91] A benefit of this reaction is 
that no catalyst is needed, which means that this mild condition could reduce possible side 
reactions or decomposition. Using a method from YASUI et al.,[92] pyrrolidine was added to 
ketone 28c and the mixture was heated to reflux. TLC showed that the starting material was 
fully consumed, but crude 1H NMR spectroscopy revealed more than one product. The crude 
product was not purified via FCC, since enamines are labile functional groups. Therefore, 
methyl vinyl ketone was added directly. Unfortunately, TLC showed no significant spots and 
GC/MS analysis revealed that the desired MICHAEL adduct could not be formed with this 
method (Scheme 30).  
 
Scheme 30. Attempted STORK enamine reaction based on ketone 28c. 
Neither a ROBINSON annulation nor attempts trapping or imitate enol 63 (Scheme 28) were 
successful. The fourth and last approach was developed using BREDERECK’S reagent. This 
reagent can be applied for α-aminomethylenation in molecules bearing an acidic methylene 
group. Scheme 31 shows the mechanism. BREDERECK’S reagent has the property to generate 
in situ the strong basic tert-butoxide (tBuO-) and the appropriate iminium ion. A MANNICH 
reaction takes places, whereby after keto-enol-tautomerism of 28c in the presence of tBuO-, 
the corresponding enolate attacks the iminium ion. A β-elimination of dimethylamine leads to 
the enamino ketone 67.[93]  
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Scheme 31. Mechanism using BREDERECK’S reagent giving an enamino ketone 67 and subsequent reactions to 
phenol 70.  
To form the desired aromatic ring B, enaminoketone 67 is converted to exomethylene 
compound 68 using TEA and DIBAL-H, which can now undergo a cyclisation with a β-ketoester 
to the appropriate ketone 69. Oxidation with CuBr2 should then result in phenol 70. 
Using a method of TANINO et al.,[94] BREDERECK’S reagent was added to ketone 28c. After 
preservation of the enaminoketone 67, 2D NMR spectra revealed that again the wrong 
constitutional isomer 71e was synthesised in 46% yield (Scheme 32).  
 
Scheme 32. Use of BREDERECK'S reagent results in the wrong constitutional isomer 71e. 
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Four approaches were tried, but every attempt to synthesise phenols 60 and 70, respectively 
failed. Due to the formation of the wrong constitutional isomers, the synthesis of the desired 
tricycle with ketone 28c is very difficult. These attempts also showed, that the C-6 position of 
ketone 28c is more reactive than C-4. In chapter 3.2.1. several variations of tri- and tetracyclic 
analogues of SH-42 (22) and diols 23 and 24, respectively, were already successful. Therefore, 
the project of an aromatic ring B was closed, and the focus was set on synthesis of seco-
steroidal analogues.   
3.3. Variations of ring A and B – seco-steroidal analogues 
Besides tri- and tetracyclic analogues derived from the lead structures 23 and 24, seco-
steroidal analogues are of high interest. With maintenance of rings C and D and a “broken” 
ring B, ring A should be varied using aromatic and aliphatic residues. These residues should 
be attachted to C-4 or C-5 position of the perhydroindane (rings C and D) unit.   
3.3.1. Seco-steroidal analogues with bridging at C-4 
Starting with the attachment of residues at C-4, Scheme 33 shows the general route to the 
desired seco-steroids. Based on central building block 26, aryl and alkyl residues should be 
attached directly to C-4 using organometallic chemistry (C, Scheme 33, third column). The 
seco-steroids B containing an aryl or alkyl residue as ring A attached via methylene linker 
should be formed from exomethylene compound 72, which should be synthesised from ketone 
26 via methylenation using e.g. WITTIG olefination (Scheme 33, second column). Seco-steroid 
D bearing an aryl residue as ring A attached via an ethylene linker, should be formed from enol 
triflate 34 (for synthesis see chapter 3.1.2.) using SONOGASHIRA cross-coupling reaction 
(Scheme 33, fourth column). The saturated version seco-steroid A should be synthesised from 
aldehyde 73b via WITTIG olefination (Scheme 33, first column). Aldehyde 73b should be formed 
from alkene 72 using hydroboration and subsequent reduction.  
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Scheme 33. Planned routes for the synthesis of seco-steroidal analogues with bridging at C-4 with an aromatic or 
aliphatic ring A. The new generated ring A and the appropriate linkers are marked in pink. 
3.3.1.1. Synthesis of building blocks alkene 72 and aldehyde 73b 
The two further required building blocks alkene 72 and aldehyde 73b were synthesised from 
central building block 26. Scheme 34 shows the synthesis of exomethylene compound 72 
using WITTIG olefination. By the usage of methyltriphenylphosphonium bromide (MePPh3Br) 
and LDA the appropriate ylide is formed, which reacts subsequently with ketone 26. Next to 
triphenylphosphine oxide, the desired terminal olefin 72 is formed in a very good yield of 91%.  
 
Scheme 34. Wittig olefination of 26 resulting in alkene 72. 
Aldehyde 73b was synthesised over two steps starting from terminal olefin 72 (Scheme 35). 
Hydroboration using BH3·THF with subsequent addition of H2O2 and NaOH to form the 
hydroxyl group, gave selectively alcohol 74 with 73% yield. The stereochemistry at C-4 could 
be determined as S configurated since a strong coupling between 4-CH2 and 7a-CH3 could be 
observed in the NOESY spectrum.  
 
Scheme 35. Synthesis of aldehyde 73b via hydroboration and reduction of 72. 
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The final step to aldehyde 73b was performed during the bachelor thesis of DOREEN REUTER 
(née KREMER) based on alcohol 74.[95] Oxidation with DMP gave the desired aldehyde 73b in 
57% yield.  
3.3.1.2. Aromatic residues  
In this chapter all studies towards the introduction of aromatic residues with bridging at C-4 are 
discussed.  
3.3.1.2.1. Directly attached aryl residues to C-4  
To study the effect of the length of the linker of seco-steroids, aromatic residues were directly 
attached to C-4, resulting in 4-arylperhydroindanes. Based on ketone 26 various 
hydroxyphenyl/(hydroxymethyl)phenyl residues were introduced. Scheme 36 shows the 
general retrosynthesis of the target molecules.  
 
Scheme 36. Retrosynthesis of triols with direct linking of the aromatic residues to C-4. 
The desired triols A should be obtained after TBDMS deprotection. The (bis)silylethers B 
should be formed via Br-Li exchange of the TBDMS protected bromophenol/bromo-
benzylalcohol C with subsequent addition to ketone 26.  
First, the phenols and benzyl alcohols were protected (Scheme 37). Six phenols and benzyl 
alcohols were protected using imidazole and TBDMSCl and all silylethers were isolated in good 
yields (70 – 86%), whereby five of them were synthesised during the bachelor thesis of MORITZ 
M. KORNMAYER.[96]  
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Scheme 37. TBDMS protection of phenols and benzylalcohols. 
The following Br-Li exchange of the protected phenols and benzylalcohols using n-BuLi, with 
subsequent addition to ketone 26 are depicted in Scheme 38. The meta substituted bromide 
76 was successfully added to ketone 26 and alcohol 82 was obtained in 64% yield. Para 
substituted bromide 78d could be successfully converted to alcohol 83 in a very good yield of 
89%. The addition of the protected benzyl alcohols 80d (meta substituted) and 81d (para 
substituted) took place in good yields of 81% for alcohol 84 and 69% for alcohol 85. According 
to TLC, Br-Li exchange of the ortho substituted bromides 75d and 79d was successful, but the 
lithiated intermediate did not undergo addition to ketone 26. A possible reason for the failed 
addition could be the steric hindrance between the large TBDMS group and the reactive site 
of the molecule.  
 
Scheme 38. Resulting alcohols 82, 83, 84 and 85 from the addition of the TBDMS protected phenols and 
benzylalcohols. The new stereocenter is marked in red. 
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The configuration of the new stereocenter at C-4 was identified via NOESY. In all four cases a 
clear spatial coupling between the hydroxy group and 7a-CH3 group could be observed, 
resulting in S configuration at C-4. As an example, Figure 12 shows the NOESY spectrum of 
alcohol 83.  
 
Figure 12. NOESY spectrum of alcohol 83. The spatial coupling between 7a-CH3 and OH are marked in red. 
The last step was the deprotection of both TBDMS protected hydroxy groups using HF·py and 
pyridine (Scheme 39). Because of the presence of two TBDMS groups, twice the amount of 
HF·py and pyridine was required. In contrast to the deprotection of the benzyl alcohols 84 and 
85, the deprotection of the meta and para substituted phenols 82 and 83 went smoothly with 
very high yields (97% and quantitative). The deprotection of the benzyl alcohols only 
proceeded in moderate yields (41 and 47%). 
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Scheme 39. TBDMS cleavage of (bis)silylethers. 
It was of chemical interest, which configuration at the former hydroxy stereocenter exists, after 
elimination of the hydroxyl group. Therefore, triethylsilane (TES) in combination with TFA was 
used, which leads to a dehydration of alcohols with subsequent hydrogenation of the formed 
alkene (ionic hydrogenation).[97] Alcohol 83 was used as a model compound for the elimination 
(Scheme 40).  
 
Scheme 40. Elimination of the hydroxyl group at C-4 resulting in arylperhydroindane 90. 
With the presence of TFA the hydroxy group is protonated, and water is eliminated, forming 
an alkene. Simultaneously, TES delivers a hydride, which attacks the double bond. During the 
reaction the stereoinformation at C-4 ist lost temporarily and the stereocenter is then rebuilt 
upon hydride transfer, resulting again in S configuration at C-4. In 83 the aryl residue is facing 
to the back, whereby in the case of 90 the residue is now facing to the front. Additionally, with 
the presence of 5.5 equivalents TFA the aliphatic side chain TBDMS ether was deprotected 
but the phenol remained protected.  
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3.3.1.2.2. Seco-steroids with methylene linker at C-4  
This chapter discusses the synthesis of 4-benzylperhydroindanes containing a methylene 
linker between the aromatic residue and C-4. This part of the project was carried out during 
the bachelor thesis of MORITZ M. KORNMAYER, under my supervision.[96] The idea was an 
extension of the directly linked aromatic residues (see chapter 3.3.1.2.1.) to a methylene group 
as linker. Scheme 41 shows the retrosynthesis of the desired compounds.  
 
Scheme 41. Retrosynthesis of 4-benzylperhydroindanes A bearing a methylene linker from alkene 72. 
The desired diols should be obtained via TBDMS deprotection, whereby the TBDMS protected 
alcohols should be synthesised using SUZUKI-MIYAURA cross-coupling conditions starting from 
exomethylene compound 72 (see chapter 3.3.1.1.) and various aryl bromides (see chapter 
3.3.1.2.1.).  
While in standard SUZUKI-MIYAURA procedures boronic acids as organoboron component are 
used, in this case 9-BBN was used, which should upon hydroboration of olefin 72 form the B-
alkyl-9-BBN intermediate in situ. Due to the steric hindrance of 9-BBN, the anti-MARKOVNIKOV 
product is strongly preferred, and the chances of unwanted side reactions are reduced, inter 
alia because 9-BBN leads to 1:1 stoichiometry of the starting materials. Different catalysts 
([1,1′-bis(diphenylphosphino)-ferrocene]-dichloropalladium(II) (Pd(dppf)Cl2) and tetrakis-
(triphenylphosphine)palladium(0)  (Pd(PPh3)4)) and aryl halides (iodobenzene and 
bromobenzene) were tested, whereby the best result was achieved using bromobenzene with 
Pd(dppf)Cl2 as catalyst. It was also examined, if the phenols and benzyl alcohols had to be 
protected and it became obvious that the use of the TBDMS protected derivatives led to higher 
yields, compared to the unprotected variant. Scheme 42 depicts the isolated cross-coupling 
products. 
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Scheme 42. SUZUKI-MIYAURA cross-coupling products. The new stereocenter is marked in red. 
The ortho substituted bromoarenes (see Scheme 37) did not undergo the cross-coupling. This 
observation is similar to the failed reactions for the introduction of a directly attached aromatic 
residue at C-4 (see chapter 3.3.1.2.1.). This means that the steric hindrance plays a huge role 
in this case as well. The model compound 91d was synthesised in moderate yield of 39%. The 
meta and para substituted TBDMS protected phenols 92d and 93d were synthesised in a similar 
yield (25% and 33%). TBDMS protected benzyl alcohols could be successfully coupled to 72 
as well and (bis)silylethers 94d and 95d were isolated in 13% and 51% yield. The low yield of 
94d can occur from not fully generated 9-alkyl-BNN, because amounts of alkene 72 were also 
isolated during the purification step. The stereocenter at C-4’ was identified as R since a clear 
coupling between 1’’-CH2 and 7a’-CH3 was observed in NOESY spectrum. 
The last step to the final compound was deprotection of the hydroxy groups using HF·py and 
pyridine (Scheme 43).  
 
Scheme 43. Formation of alcohol 96d and diols 97d, 98d, 99d and 100d via TBDMS cleavage. 
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All synthesised cross-coupling products could be successfully TBDMS deprotected, although 
the yields are relatively low (13 – 33%). The alcohol and all diols can now be tested as potential 
inhibitors of DHCR24. 
3.3.1.2.3. Seco-steroids with ethylene linker at C-4  
In the last two chapters the synthesis of seco-steroids with direct linking of an aromatic ring at 
C-4, as well as the introduction of a methylene linker were discussed. To reach the concise 
length of the steroidal structure an ethylene linker is necessary, which results in 4-
(arylethyl)perhydroindanes. 
3.3.1.2.3.1. Introduction of an ethylene linker via SONOGASHIRA cross-coupling 
First, it was tried to introduce an ethylene linker via Sonogashira cross-coupling. Scheme 44 
shows the retrosynthesis of the target compounds 101 and 102. Diol 101 should be obtained 
after hydrogenation and TBDMS cleavage of cross-coupled product 103, which should be 
formed from enol triflate 34 (see chapter 3.1.2.) and 3-hydroxyphenylacetylene (104). Diol 102 
should also be synthesised from 103 by an incomplete hydrogenation of the acetylene using 
for example LINDLAR catalyst followed by deprotection.  
 
Scheme 44. Retrosynthesis of target structures 101 and 102. 
SONOGASHIRA cross-coupling of enol triflate 34 and 3-hydroxyphenylacetylene (104) resulted 
in alkyne 103 in a very good yield of 96% (Scheme 45). It was tried to hydrogenate the triple 
bond without hydrogenating the double bond using LINDLAR catalyst, a lead poisoned Pd-
catalyst, to preferably receive the Z-isomer but no reaction occurred (Scheme 45). Probably 
the catalyst was too mild for the extended conjugated system.  
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Scheme 45. SONOGASHIRA cross-coupling between enol triflate 34 and 3-hydroxyphenylacetylene (104) and 
subsequent hydrogenation attempts. 
For the following simultaneous hydrogenation of double and triple bond, various attempts were 
made since the normal hydrogenation conditions (Pd/C, H2) did not result in the desired 
hydrogenated phenol. The conditions are shown in Table 3. 
Table 3. Hydrogenation conditions of alkyne 103. 
entry catalyst conditions solvent pressure yield (106) 
1 Pd/C (10 wt%) 1.5-18 h, 20 °C EtOAc atm 0% 
2 Pd/C (10 wt%) 1.5-18 h, 23°C EtOAc 20-30 bar 0% 
3 PtO2 (2 mol%) 18 h, 20 °C EtOAc atm n.d. 
4 PtO2 (2 mol%) 18 h, 20 °C EtOAc, AcOH atm n.d. 
5 PtO2 (2 mol%) 18 h, 23-30 °C EtOAc 20-30 bar n.d. 
6 PtO2 (2 mol%) 18 h, 23-30 °C EtOAc, AcOH 20-30 bar n.d. 
 
Entries 1 and 2 show the hydrogenation using Pd/C at atmospheric pressure and at 20-30 bar. 
TLC monitoring revealed that no reaction at all took place and the starting material was left 
unreacted. For entries 3 and 4 platinum(IV)oxide (PtO2) was used, whereby in entry 4 AcOH 
was added in addition, according to a method of SOBOTKA and CHANLEY.[98] In both reactions 
new spots could be detected on TLC, but GC/MS showed a lot of signals of unidentifiable, 
hydrogenated and partially hydrogenated products. The same reaction could be observed at 
20-30 bar (entries 5 and 6) and only unidentifiable products were isolated.  
3.3.1.2.3.2. Introduction of an ethylene linker via WITTIG olefination 
Since the hydrogenation of the Sonogashira cross-coupled product 103 failed, another 
approach was made using WITTIG olefination. Scheme 46 shows the planned route to the 
desired seco-steroidal compound A containing a meta or para substituted phenol. In the lead 
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structures 23 and 24 the hydroxyl group is in meta position. However, by thermal rotation 
around the single bond connecting ring A, this position is not fixed anymore. Therefore, the 
phenolic residue bearing the hydroxyl group in para position was of interest as well as the 
hydroxyl group does not change its position by rotation. While in the SONOGASHIRA reaction 
(chapter 3.3.1.2.3.1.) the variation of starting material was limited, in this case meta and para 
substituted phenols were easily accessible.  
 
Scheme 46. Planned route to diol A via WITTIG olefination between 107 and an appropriate aldehyde C. 
The final compounds A should be formed from TBDMS deprotection, whereby the TBDMS 
protected compounds B should be generated from a WITTIG olefination between bromide 107 
and substituted benzaldehydes C. In this step, the formation of the Z-olefin would be preferred 
since the configuration imitates the steroidal structure.  
Two approaches for the synthesis of bromide 107 starting from primary alcohol 74 (for 
synthesis see chapter 3.3.1.1.) were tried (Scheme 47).  
 
Scheme 47. Attempts for the synthesis of 107 from alcohol 74. 
In the first reaction (Scheme 47, I) a procedure from DANIELS et al.[99] was performed, using 
triphenylphosphine dibromide (Ph3PBr2). TLC showed a much more polar compound (Rf = 
0.32, hexanes/EtOAc 6:4) than the starting material 74 (Rf = 0.76, hexanes/EtOAc 6:4), which 
rather not speaks for the desired bromide 107, and after isolation and purification NMR analysis 
revealed that not the desired compound was synthesised, but that the silylether was 
substituted with bromine. Related substitutions of silylethers using Ph3PBr2 can be found in 
literature.[100] The second attempt was an APPEL reaction (Scheme 47, II), using 
triphenylphosphine (PPh3) and carbon tetrabromide (CBr4). During this reaction, more 
nonpolar compounds than 74 were observed on TLC, but only only unidentifiable aliphatic 
fragments were isolated.  
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Due to the unsuccessful attempts for the synthesis of 107, it was decided to switch the 
substitution pattern and to perform the WITTIG olefination with aldehyde 73b (for synthesis see 
chapter 3.3.1.1.) and the appropriate benzyl bromides. Scheme 48 shows the new route to the 
target structures. 
 
Scheme 48. Retrosynthesis of seco-steroid A based on aldehyde 73b. 
Diols A should be formed via TBDMS deprotection. TBDMS protected olefins B should be 
synthesised via WITTIG olefination using previously described aldehyde 73b (for synthesis see 
chapter 3.3.1.1.) and ylides derived from TBDMS protected benzyl bromide. These studies 
were performed during the bachelor thesis of DOREEN REUTER (née KREMER) under my 
supervision.[95]  
Scheme 49 depicts the synthesis of the desired meta and para hydroxy substituted benzyl 
bromides. Based on m-cresol (108) and p-cresol (109), a two-step synthesis was performed 
(Scheme 49, I) starting with the TBDMS protection of the phenolic function, which resulted in 
95% m-OTBDMS protected 110b and 93% p-OTBDMS protected 111b. To generate the benzyl 
bromides from the protected cresols, radical WOHL-ZIEGLER bromination was used according 
to a published method.[101] Several test reactions were carried out, with variation of the radical 
starter solvent and reaction time, but the best results were obtained using AIBN in CCl4 at 
80 °C. While the m-substituted benzyl bromide 112b was isolated in a low yield of 13%, the p-
substituted benzyl bromide 113b could not be synthesised by this way. A huge problem in this 
reaction was the fast multiple bromination of the protected cresols. Parallel to these reactions, 
a three step route based on 3- and 4-hydroxybenzaldehyde (114 and 115) was tried (Scheme 
49, II). After successful TBDMS protection of the hydroxyl group, the aldehyde function was 
reduced using NaBH4 and primary alcohols 118b and 119b were isolated in good yields of 71% 
and 64%. The last step was an APPEL reaction using PPh3 and CBr4, which resulted in the 
desired benzyl bromides (carried out according to Jones et al.[102]). The m-derivative 112b was 
obtained with 18% yield and the p-derivative 113b in 25% yield. All in all, in both attempts, the 
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bromination steps could only performed in low yields. Probably the conditions were too harsh 
for these molecules. 
 
Scheme 49. Two routes for the synthesis of benzyl bromides 112b and 113b. 
For the following WITTIG olefination, the triphenylphosphonium bromide salts were required. 
Therefore, the benzyl bromides were refluxed in the presence of PPh3 (Scheme 50). Besides 
both benzyl bromides 112b and 113b the commercially available m-methoxy derivative 120 was 
used.  
 
Scheme 50. Synthesis of the triphenylphosphonium bromide salts. 
The triphenylphosponium bromide salt 121b bearing a methoxy group in m-position could be 
isolated with a good yield of 80%. The m-OTBDMS salt (122b) as well as the p-OTBDMS salt 
(123b) could be generated in only poor yields of 19% and 18%. A reason could be, that both 
reactions were performed with only 0.15 mmol due to low amount of isolated 112b and 113b, 
whereby the reaction with m-methoxy derivative was performed with 7.9 mmol. 
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The WITTIG olefination between aldehyde 73b and the synthesised phosphonium salts are 
depicted in Scheme 51. In all three reactions first the ylide was formed using LDA, which could 
be identified by a bright colour change. This visible approval was observed in all three 
reactions. After addition of aldehyde 73b, the colour slowly faded, and all three reactions 
showed a new spot on TLC and the desired mass was found with GC/MS analysis. However, 
purification via FCC gave only the m-methoxylated WITTIG product 124b in 44% isolated yield 
and the m-OTBDMS and p-OTBDMS WITTIG products (125b and 126b) could not be isolated. 
 
Scheme 51. WITTIG olefination of aldehyde 73b and the appropriate benzyl phosphonium bromides. 
Due to lack of time in the bachelor thesis, we focused on the m-methoxylated compound. After 
the successful WITTIG olefination, it was important to identify whether the E- and/or Z- isomer 
was formed. Only one new spot was observed on TLC and the 1H NMR spectrum also showed 
only one set of signals. With the coupling constant 15.8 Hz of the olefinic protons the E-isomer 
was identified (E-isomer: range 11 – 18 Hz, typically 16 Hz; Z-isomers: range: 6 – 14 Hz, 
typically 10 Hz).[103]  All in all it was possible to synthesise the seco-steroid 124b in moderate 
yield (44%) (Scheme 52). The stereochemistry was also verified via NOESY spectroscopy. 
 
Scheme 52. Formation of E-isomer 124b via WITTIG olefination. 
Since only the Z-isomer of 124b would mimic the steroidal structure of the lead structures 23 
and 24, it was not necessary to deprotect the E-isomer. Therefore, the next step was 
hydrogenation of the double bond. Hydrogenation was performed in the presence of Pd/C and 
H2 (Scheme 53). The desired hydrogenated seco-steroid 127b was obtained with 81% yield.  
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Scheme 53. Hydrogenation of 124b resulting in 127b. 
The last steps to the desired diol were TBDMS deprotection and methyl ether cleavage. SINGH 
et al. showed, that BBr3 can cleave methyl ethers, as well as trimethylsilyl (TMS) ethers in one 
step.[104] Although compound 127b contains a TBDMS instead of TMS group, this procedure 
was tried (Scheme 54). The starting material (Rf = 0.96, hexanes/EtOAc 9:1) was fully 
consumed and a new polar spot (Rf = 0.42, hexanes/EtOAc 9:1) appeared, which theoretically 
could be the desired diol regarding the polarity. After purification, 1H NMR spectroscopy 
showed that the diol was not formed, but that the starting material 127b decomposed. No 
aromatic signals could be observed in the 1H NMR spectrum and only aliphatic signals of ring 
C and D as well as the characteristic side chain signals could be seen. A possible reason for 
the decomposition can be the warm-up to 0 °C.  
 
Scheme 54. Attempt for methyl ether and TBDMS cleavage using BBr3. 
Due to limited amount of seco-steroid 127b TBDMS deprotection was now tried first. Methoxy 
groups can act as prodrugs, so if the methyl ether cleavage will fail again, the methoxylated 
compound could be tested. Scheme 55 shows the TBDMS deprotection using HF·py and 
pyridine. The desired alcohol could be obtained in a good yield of 74%.  
 
Scheme 55. TBDMS cleavage of 127b. 
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The following methyl ether cleavage was performed again with BBr3. After addition of BBr3 the 
reaction mixture was first slowly warmed to - 30 °C. At this temperature, a slow progression of 
the reaction could be monitored on TLC. That confirms the consideration why the starting 
material decomposed and that the reagent was too reactive at 0 °C. Scheme 56 shows the 
methyl ether cleavage. The desired diol could be isolated with a yield of 61%.   
 
Scheme 56. Methyl ether cleavage using BBr3, resulting in diol 101. 
3.3.1.2.4. Studies towards the introduction of an amine and ether linker  
A side project of seco-steroidal analogues with bridging at C-4 was the introduction of an amine 
or ether linker. Scheme 57 shows the retrosynthesis of the desired compounds.   
 
Scheme 57. Retrosynthesis of target diols A, bearing an amine or ether linker. 
The target diols A should be formed via deprotection of the phenol and aliphatic side chain. 
Seco-steroids B bearing an amine and ether linker, respectively, should be synthesised from 
alcohol 74 using standard amine and ether synthesis protocols.   
3.3.1.2.4.1. Attempts for the introduction of an ether linker 
Starting with the introduction of an ether linker, first, the aromatic building blocks had to be 
synthesised. For the aromatic building block TBDMS-protected phenyl bromide 76 (for 
synthesis see chapter 3.3.1.2.1.) and mono-TBDMS-protected resorcinol (130e) were used. 
The TBDMS protection was performed according to a procedure of WU et al.,[105] and was 
conducted during PATRICIA SKOWRONEK’S bachelor thesis[87] (Scheme 58).  
 
Scheme 58. Mono-TBDMS protection of resorcinol (129). 
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Phenol 130e was synthesised with a moderate yield of 38%. A popular method for, inter alia, 
etherification is the MITSUNOBU reaction. Scheme 59 shows the mechanism of the MITSUNOBU 
reaction on the example of protected resorcinol 130e and alcohol 74, using the standard 
MITSUNOBU reagents PPh3 and diisopropyl azodicarboxylate (DIAD, 131).  
 
Scheme 59. Mechanism of MITSUNOBU reaction[106] by the example of 130e and 74. 
Nucleophilic attack of PPh3 to DIAD (131) lead to intermediate 132, whereby the negatively 
charged nitrogen acts as base and deprotonates the present phenol 130e. The resulting 
intermediate 133 with the positively charged phosphorus is now attacked by alcohol 74 and 
intermediate 134 is formed. Subsequent elimination of the hydrazine derivative gives 135 
carrying a good leaving group. The lately formed phenolate of 130e attacks the alcohol in α-
position in a SN2 reaction, triphenylphosphine oxide is eliminated and the desired ether 136 is 
formed.[106-107]  
For the etherification, a method of BOXHALL et al. was used.[108] The mass of the desired ether 
136 was obtained by GC/MS analysis, but TLC showed a smearing line and as a consequence 
ether 136 could not be isolated by FCC (Scheme 60).  
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Scheme 60. Result of the MITSUNOBU reaction of 74 and 130e. 
Certainly, a β-elimination led to isolation of alkene 72. A β-elimination can occur in three 
different types: E1, E2 or E1cB reaction, whereby in this case, the mechanism follows the E2 
mechanism. Due to the formation of the good leaving group (LG; here: triphenylphosphine 
oxide in 135, see Scheme 59) and the presence of a base (B), which is in this case the formed 
phenolate of 130e, the E2 elimination takes place and alkene 72 is formed (Scheme 61).  
 
Scheme 61. Example of the E2 elimination. 
Another attempt for the synthesis of 136 was an SN2 reaction via triflate 137 (Scheme 62). A 
method of NAGASAKA et al. was used,[109] but the reaction failed already with the isolation of 
triflate 137 and again, alkene 72 was obtained after β-elimination. 
 
Scheme 62. Attempt towards the synthesis of 137 results in E2 elimination, receiving alkene 72. 
With the formation of 137, a good leaving group was built and consequently the β-elimination 
took place.  
Another approach using Pd-catalysed C-O cross-coupling was tried. This method was 
developed by BUCHWALD and co-workers for the C-O cross-coupling on primary alcohols.[110] 
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In this publication they describe catalytic systems, which provide general and mild conditions 
for a Pd-catalysed C-O cross-coupling. In a previous publication of BUCHWALD and coworkers, 
the synthesis of a methanesulfonate precatalyst 138 is described.[111] As ligand, t-BuBrettPhos 
(140) was used and the catalyst 139 was isolated with 81% yield (Scheme 63).  
 
Scheme 63. Synthesis of catalyst 139 for BUCHWALD-HARTWIG cross-coupling.[111] 
In the presence of catalyst 139, a C-O cross-coupling approach was made, using TBDMS 
protected phenyl bromide 76 and alcohol 74 (Scheme 64). TLC showed no new spot and both 
starting materials were also still visible, but the desired mass could be detected by GC/MS. 
BUCHWALD described a few cases, in which the alcohol and the product had the same Rf value. 
Therefore, the reaction mixture was treated with DMAP, TEA and acetic anhydride to acetylate 
the remaining alcohol 74. However, only the acetylated alcohol was obtained, and no product 
was formed in a sufficient amount for an isolation. After all attempts to synthesise ether 136 
failed, this project was closed at this stage. 
 
Scheme 64. Attempted BUCHWALD-HARTWIG C-O cross-coupling of 76 and 74. 
3.3.1.2.4.2. Attempts for the introduction of an amine linker 
For the formation of an amine linker, TBDMS protected 3-aminophenol 142e had to be 
synthesised (Scheme 65).[112] The protected amine 142e was obtained in a good yield of 57%.  
 
Scheme 65. TBDMS protection of 3-aminophenol (141). 
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For the introduction of an amine linker, a MITSUNOBU reaction was tried. Earlier research in our 
group showed that a primary amine is too inactive to react in this type of reaction.[113] Therefore, 
a strong electron withdrawing group, e.g. 2-nitrobenzenesulfonyl (nosyl, Ns) group, was 
introduced (Scheme 66). A method of MIYAUCHI et al. was used for the activation of amine 
142e.[114] The desired activated amine 143e was obtained with 46% yield. 
 
Scheme 66. Introduction of a nosyl group. 
For the MITSUNOBU reaction of primary alcohol 74 with activated amine 143e, a procedure of 
LEPORE and HE was used (Scheme 67).[115] The reaction proceeded in a similar way to the 
unsuccessful MITSUNOBU etherification. TLC showed a lot of new spots and with GC/MS 
analysis the desired mass was detected, but the product could not be isolated by FCC. 
Probably the amount of the formed secondary amine was too low for isolation. As main side 
product alkene 72 was isolated, which means that a β-elimination took place again and 
prevented the formation of amine 144e. 
 
Scheme 67. Introduction of an amine linker via MITSUNOBU reaction. 
3.3.1.3. Aliphatic residues 
Besides aromatic residues, aliphatic residues should be attached at C-4. These studies are 
discussed in the following chapters. 
3.3.1.3.1. Direct attachted aliphatic residue at C-4  
Starting with the introduction of aliphatic residues, which should be attached directly to C-4, 
Scheme 68 shows the retrosynthesis of the desired triols A. Triols A should be obtained via 
deprotection of the protected alcohols B, which should be generated from cyclohexyl bromides 
C via Br-Li exchange with subsequent addition to central building block ketone 26.  
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Scheme 68. Retrosynthesis of desired triols A based on central building block 26. 
3.3.1.3.1.1. Synthesis of building block 146 
Besides central building block 26, the cyclohexyl bromide building block had to be synthesised. 
For the test reaction, para substituted cyclohexyl bromide 146 was synthesised in one step. 
Starting from 7-oxabicyclo[2.2.1]heptane (145), cyclohexyl bromide 146 was synthesised 
according to a patent in 43% yield (Scheme 69).[116]   
 
Scheme 69. Synthesis of cyclohexyl bromide 146. 
The addition of TMSBr leads to ether cleavage by the attack of the bromide from the less 
hindered side and while the bromide is formed, the alcohol is TMS protected. 
3.3.1.3.1.2. Br-Li exchange of 146 and addition to ketone 26 
For the formation of the seco-steroid, Br-Li exchange of 146 with subsequent addition of the 
lithiated compound to ketone 26 was performed (Scheme 70).  
 
Scheme 70. Br-Li exchange of 146 with subsequent addition to 26. 
TLC of the Br-Li exchange showed that no starting material was left, but more than one spot 
was observed. Nevertheless, ketone 26 was added and after 4 h the reaction was stopped. 
TLC showed again a lot of new spots but no characteristic spot. The desired mass of alcohol 
147 could not be detected via GC/MS analysis. Other approaches for the synthesis of seco-
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steroids with direct attachment of the residue to C-4, were not performed since the seco-
steroids bearing an aromatic residue directly linked to C-4, showed no inhibitory effect on 
DHCR24.  
3.3.1.3.2. Seco-steroids with methylene linker at C-4 
In this chapter the approaches towards the introduction of an aliphatic residue to C-4 
connected with a methylene linker is discussed. Scheme 71 depicts the retrosynthesis of the 
desired alcohols A, which should be generated from TBDMS protected compounds B via 
deprotection. The TBDMS protected seco-steroids should be synthesised using SUZUKI-
MIYAURA cross-coupling of bromocyclohexanes C and terminal alkene 72 (as discussed in 
chapter 3.3.1.2.2.).  
 
Scheme 71. Retrosynthesis of seco-steroids A based on alkene 72. 
For the test reaction, bromide 146 was used. First, a Pd-catalysed method of FU and co-
workers was tried, using Pd(OAc)2 as catalyst, K3PO4·H2O as base and PCy3 as ligand 
(Scheme 72, I).[117] In the first stage of the reaction, terminal alkene 72 was borylated using 9-
BBN, whereby formation of the B-alkyl-9-BBN intermediate could be observed with TLC. The 
actual cross-coupling reaction showed a lot of new spots on TLC, but the desired mass could 
not be detected via GC/MS analysis. The reaction was repeated, with the difference, that the 
particular reaction mixtures were degassed longer. Nevertheless, the desired mass could not 
be found via GC/MS and separation of the spots revealed that no product was formed. 
Moreover, alkene 72 was isolated, which means that the borylation did not proceed 
quantitatively.   
 
Scheme 72. SUZUKI-MIYAURA cross-coupling of alkene 72 with cyclohexyl bromide 146. 
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For the next approach, a procedure of SAITO and FU was used, whereby in this procedure, 
unactivated secondary alkyl halides were cross coupled, using NiCl2·glyme as catalyst and 
trans-N,N’-dimethylcyclohexane-1,2-diamine as ligand (Scheme 72, II).[118] In this case solid 
9-BBN was used, which resulted in a faster borylation, but the following alkyl-alkyl cross-
coupling was not successful. Although the desired mass was detected by GC/MS, TLC showed 
a smearing line of spots and the desired product 148 could not be obtained via FCC 
purification. Alkene 72 was recovered under these conditions as well, which means, that the 
formation of the B-alkyl-9-BBN adduct did not proceed quantitatively, although TLC showed 
no leftover starting material 72. After these attempts, the synthesis of seco-steroids bearing a 
cyclohexyl residue attached via a methylene linker at C-4 were no longer pursued.  
3.3.1.3.3. Seco-steroids with ethylene linker at C-4 
The last chapter of the introduction of aliphatic residues discusses the introduction of 
cyclohexyl residues via an ethylene linker. With this linker, the correct dimension of the 
steroidal structure will be achieved. Scheme 73 demonstrates the retrosynthesis of the desired 
target diols 149 and 151. Z-Olefin 149 should be synthesised via TBDMS and methyl ether 
cleavage of 150 if the Z-isomer of 150 was formed. Olefin 150 should be synthesised using an 
olefination method like WITTIG olefination from aldehyde 73b and bromide 152. The latter 
should be synthesised from of 3-methoxycyclohexane-carboxylic acid (153) in two steps. Since 
the synthesis of building block 107 was not successful (see chapter 3.3.1.2.3.), the reaction 
should be performed with aldehyde 73b. Besides the Z-configurated diol 149, its saturated form 
151 should be generated via hydrogenation and subsequent TBDMS and methyl ether 
cleavage of 150, whereby the E/Z configuration of the starting olefin is negligible in this step. 
 
Scheme 73. Retrosynthesis of target diols 149 and 151, which should be synthesised from aldehyde 73b and 3-
methoxycyclohexanecarboxylic acid (153). 
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3.3.1.3.3.1. Synthesis of building blocks 152a and 152b 
The synthesis of the required aliphatic building block 152 is shown in Scheme 74. Based on 
commercially available cis/trans mixture of 3-methoxycyclohexanecarboxylic acid (153), the 
first step was the reduction of the carboxylic acid group to an alcohol function using 
dimethylsulfide borane according to a patent.[119] The reaction should occur at - 78 °C, but at 
this temperature no reaction was monitored on TLC. Therefore, the reaction was slowly 
warmed to 0 °C and gas evolution could be observed. With the ceasing of gas evolution, TLC 
showed that the starting material was fully consumed, and the reduction was finished. Next, 
the crude cis/trans mixture of alcohol 154 was brominated under APPEL conditions.[99] 
 
Scheme 74. Two step synthesis of cyclohexylmethyl bromide trans-152a and cis-152b from 3-methoxycyclo-
hexanecarboxylic acid (153) (cis/trans assignment was performed retrospectively from trans-158 and cis-160). 
With the formation of the bromides 152, the cis/trans isomers could be separated via FCC and 
racemic trans-isomer 152a was obtained in a moderate yield of 41% and racemic cis-isomer 
152b with 40%. It is noteworthy, that at this stage the cis/trans assignment was not possible 
and could only be performed retrospectively. 
3.3.1.3.3.2. WITTIG olefination 
The first attempt for the olefination was a WITTIG olefination, whereby E and Z isomers can be 
formed. For the synthesis of the appropriate phosphonium bromide salts, the racemic bromides 
trans-152a and cis-152b and PPh3 were dissolved in toluene and heated to reflux. When only 
triphenylphosphine oxide and the starting material could be isolated, toluene was replaced by 
acetonitrile. For trans-152a the desired phosphonium bromide trans-155 could be isolated, but 
in the case of isomer cis-152b only the mass of the phosphonium bromide salt cis-156 could 
be found, but the product could not be isolated and only triphenylphosphine oxide was obtained 
(Scheme 75).  
 
Scheme 75. Formation of the triphenylphosphonium bromide salts from cyclohexylmethyl bromides trans-152a and 
cis-152b (cis/trans assignment was performed retrospectively from trans-158 and cis-160). 
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Consequently, the following WITTIG olefination was only performed with phosphonium bromide 
trans-155 (Scheme 76). The reaction was performed with LDA as base to generate the 
appropriate ylide.  
 
Scheme 76. Attempted WITTIG olefination of 73b and trans-155. 
The formation of the ylide was confirmed by the colour change from colourless to deep orange. 
However, the desired olefin 150 could not be synthesised using WITTIG conditions and only 
unidentifiable products were isolated.   
3.3.1.3.3.3. JULIA-KOCIENSKI olefination  
An alternative to WITTIG olefination is the JULIA-KOCIENSKI olefination, a modified version of 
the JULIA olefination in which alkenes can be generated from alkylsulfonyl benzothiazole and 
aldehydes. The JULIA-KOCIENSKI olefination predicts a high E selectivity which is in this case 
not the favoured configuration. Nevertheless, this type of olefination was tried. Starting from 
racemic bromides trans-152a and cis-152b, the bromide was substituted with 
mercaptobenzothiazole in an SN2 reaction, resulting in trans-157 and cis-159 
(stereoconfiguration determined retrospectively), followed by oxidation of the thioether moiety 
using m-CPBA to receive the racemic JULIA-KOCIENSKI reagents trans-158 and cis-160 in 91% 
and quantitative yield, respectively (Scheme 77). 
 
Scheme 77. Synthesis of JULIA-KOCIENSKI reagents trans-158 and cis-160 from trans-152a and cis-152b (cis/trans 
assignment was performed retrospectively from trans-158 and cis-160). 
In this stage, both stereocenters of the methoxycyclohexylmethyl residue could be clearly 
identified via NOESY spectroscopy. Figure 13 shows the NOESY spectrum of sulfonyl trans-
158. At 400 MHz 3’-H and 1’-CH2 appear together as one multiplett, but measurement with 
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600 MHz resulted in a split up of the signals and the couplings could be analysed separately. 
No spatial coupling between 3’-H and 1’-H could be seen, which means that both protons are 
trans to one another. Consequently, both residues, the methoxy group and the methyl sulfonyl 
group are in trans position to each other as well.  
 
Figure 13. NOESY spectrum of racemic trans-158. 
Figure 14 shows the NOESY spectrum of sulfonyl cis-160. Upon the measurement at 
400 MHz, one proton of C-2’ and 1’-H appeared together in a multiplett. Therefore, the NOESY 
was measured again with 800 MHz and the signals split up to a duplet for 2’-H and a multiplett 
for 1’-H. A coupling between 3’-H and 1’-H can be clearly seen. As a result, the methoxy group 
and the methyl sulfonyl residue are in cis position to each other. 
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Figure 14. NOESY spectrum of racemic cis-160. 
After successful synthesis of both JULIA-KOCIENSKI reagents, the olefination was performed, 
using aldehyde 73b. Table 4 shows the used conditions and results towards the olefination. 
The first two entries show the attempts using sulfonyl compound cis-160. In entry 1 NaHMDS 
(pKa = 29.5[69]) was used as base. The desired mass could not be detected by GC/MS and no 
characteristic spot was observed on TLC. Consequently, FCC did not result in the desired 
olefin. The exchange of NaHMDS with the stronger base LDA (pKa = 35.7[69]) did also not 
result in the desired olefin 150 (entry 2). Entries 3 and 4 shows the results using sulfonyl 
compound trans-158. With the use of NaHMDS the desired mass was detected by GC/MS and 
TLC showed a new characteristic spot, but the product could not be isolated (entry 3). NMR 
spectroscopy showed olefinic peaks, but also aromatic peaks, which could be derived from 
sulfonyl reagent trans-158. The exchange of NaHMDS with LDA gave the desired product with 
69% yield (entry 4). 
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Table 4. Attempts for the JULIA-KOCIENSKI olefination of trans-158 and cis-160, respectively, with aldehyde 73b. 
 
entry reagent base yield (150) 
1 cis-160 NaHMDS 0% 
2 cis-160 LDA 0% 
3 trans-158 NaHMDS traces 
4 trans-158 LDA 69% 
 
NMR spectroscopy showed only aliphatic signals as well as the characteristic olefinic signals, 
which split of as E/Z isomers in a ratio of 56:44 (determined via 1H NMR spectroscopy). Due 
to the racemic mixture of trans-158, four diastereomers can be generated in total. A closer look 
at the 1H NMR showed that four methoxy groups are present, which means that all four isomers 
were formed. Also, 13C NMR shows, that more than two isomers were isolated. GC/MS 
chromatogram of 150 confirmed the assumption of the formation of all four diastereomers 
(Figure 15). 
 
Figure 15. Left: Methoxy group signals in the 1H NMR spectrum of 150. Right: section of the GC/MS chromatogram 
detecting the four isomeric signals of 150. 
Based on the 1H NMR, the E/Z ratio is 55:45, but the ratio between the four isomers could not 
be determined, since a lot of signals come together in a multiplett. Integration of the 
chromatogram revealed a ratio of 4:5:43:48 of the four isomers. Due to the identical mass of 
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the isomers, it cannot be specified which diastereomere belongs to which signals. However, 
with the E/Z ratio and the ratio of the four isomers detected via GC/MS analysis, it is clear, that 
one E- and one Z-isomer were preferably formed than the diastereomeric version of them. The 
four isomers could not be separated and therefore the mixture was used for the next steps 
(Scheme 78). 
 
Scheme 78. JULIA-KOCIENSKI olefination of 73b and racemic mixture of sulfonyl trans-158 resulted in the four 
diastereomers. *E/Z ratio determined via 1H NMR. 
For biological testing, the Z-isomers were preferred, since they mimic the steroidal structure 
best. Due to impossible separation of the four diastereomeres with our options the mixture was 
used. First, the TBDMS group was cleaved using HF·py and pyridine. Using FCC, two fractions 
were isolated, whereby the first fraction showed only three methoxy groups signal in the 1H 
NMR spectrum and moreover the E/Z ratio had changed to 71:29 (Scheme 79).  
The second fraction exposed to be one Z-isomer, which is in accordance to the observation of 
the 1H NMR spectrum of the first fraction. Since the residue can rotate, the distances of the 
sterecenters’ protons cannot be measured and consequently the stereoconfiguration of the 
isomer cannot be determined. The mixture of the three isomers was isolated in 53% yield and 
the Z-isomer in 16% yield.  
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Scheme 79. TBDMS cleavage of 150 resulting in two fractions. *E/Z ratio determined via 1H NMR. 
To cleave the methyl ether, a procedure from BHATT et al. was used.[120] In the presence of NaI 
and SiCl4 the phenol of E/Z mixture 161 was deprotected and E/Z mixture 149 could be 
obtained in 33% yield (Scheme 80). Unfortunately, the amount of Z-161 was too low to perform 
methyl ether cleavage.  
After methyl ether cleavage, the E/Z ratio was 59:41 (determined via 1H NMR) and NMR 
spectra showed only two sets of signals, which means that one E-isomer was separated. 
Nevertheless, the amount of 149 was so low, that the fraction with the separated E-isomer 
could not be isolated. However, this isomer is not desired anyway, as the E-isomer does not 
mimic the orginal steroidal scaffold. Nevertheless, the inhibitory effect on the cholesterol 
biosynthesis of the diastereomeric E/Z mixture 161 and the separated Z-isomer of 161 as well 
as diastereomeric E/Z mixture of diol 149 was analysed.  
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Scheme 80. Methylether cleavage of diastereomeric mixture 161. *E/Z ratio determined via 1H NMR. 
For the removal of the double bond, the diastereomeric E/Z mixture of 150 was hydrogenated 
using Pd/C and H2, followed by TBDMS cleavage with HF·py and pyridine, resulting in the 
diastereomeric mixture 162 in 52% yield over two steps (Scheme 81).  
 
Scheme 81. Hydrogenation and TBDMS cleavage of diastereomeric mixture 150.  
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NMR spectra show two products, but the ratio could not be determined since the signals of 
each diastereomer appear together in a multiplett.  
Methylether cleavage using NaI and SiCl4 led to the final compound 151 as inseparable 
diastereomeric mixture in 31% yield. The inhibitory effect of 151 was also tested on the 
cholesterol biosynthesis (Scheme 82).  
 
Scheme 82. Methylether cleavage of diastereomeric mixture 162. 
The ratio between both products could not be determined in this step as well, since the signals 
of each diastereomer comes in a multiplett.  
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3.3.2. Seco-steroidal analogues with bridging at C-5 
Besides bridging at C-4, seco-steroids with bridging on C-5 were of high interest. Therefore, 
central building block 28c, which was already discussed in chapter 3.1.2., was required 
(Scheme 83).  
 
Scheme 83. Planned route for the synthesis of seco-steroidal analogues with bridging at C-5. Ring A should be 
aromatic or aliphatic (marked in pink). 
3.3.2.1. Aromatic residue  
In this chapter, the introduction of a phenol is discussed. Scheme 84 shows the retrosynthesis 
of the target compounds 163 and 165. 
 
Scheme 84. Retrosynthesis of seco-steroid 163, based on central building block 28c. 
Diol 163 should be obtained after dehydration with subsequent hydrogenation and double 
TBDMS cleavage. The protected alcohol 164 should be generate via Br-Li exchange of 78d 
(for synthesis see chapter 3.3.1.2.1.) with subsequent addition to ketone 28c. Moreover, triol 
165 should be obtained via deprotection of 164. 
Starting with the Br-Li exchange of 78d and the following addition to ketone 28c, this reaction 
proceeds identical to the addition shown in chapter 3.3.1.2.1. (Scheme 85). TLC showed two 
new spots. Alcohol 164a (Rf = 0.55, hexanes/EtOAc 9:1) and its diastereomer 164b (Rf = 0.26, 
hexanes/EtOAc 9:1) were separated and isolated by FCC in < 2% and 44% yield, respectively. 
In solution, both diastereomers undergo dehydration very fast, which can be observed during 
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the NMR measurement. Consequently, it was not possible to determine the stereoconfi-
guration at C-5. 
 
Scheme 85. Br-Li exchange of 78d and following nucleophilic addition of ketone 28c. 
Alcohols 164a and 164b should be deprotected in order to get the desired triol 165. Starting 
with 164b, the phenol and the primary alcohol were deprotected, using HF·py and pyridine. 
TLC showed a clear new polar spot, but 1H NMR did not show the desired compound 165. 
Besides the deprotection, an elimination took place and compound 166, bearing a ∆5 double 
bond, was obtained in 67% yield (Scheme 86).  
 
Scheme 86. Results of the attempt to deprotect 164b, resulting in 166. 
In the 1H NMR spectrum the characteristic olefinic signal of 6’-H around 5.92 – 5.85 ppm can 
be seen. 4’-H and 7’-H appear as a multiplett, which makes the determination of the double 
bond position difficult. The position of the 7’-H protons in the multiplett were assigned via 2D 
HMBC spectrum, observing a 4JH,H coupling between 7a-CH3 and 7’-H. Thus, COSY spectrum 
revelead, that 6’-H shows a clear 3JH,H coupling to one of the 7’-H protons (Figure 16). The 
position of the double bond is in accordance to the attempts of trapping and imitating the enol 
in chapter 3.2.2.2. describing the attempts of the formation of an aromatic ring B.  
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Figure 16. COSY spectrum of 166. 
Based on 164a and 164b the hydroxy group at C-5’ should be eliminated to get the desired 
diol. During dehydration, loss of the stereoinformation at C-5’ occurs, which means, that it does 
not matter if the reaction is performed with 164a or 164b (Scheme 87).  
 
Scheme 87. Dehydration, ionic hydrogenation and TBDMS cleavage of 164b resulting in diastereomers 163a and 
163b. 
Successful dehydration with subsequent hydrogenation using TES/TFA was confirmed by 
GC/MS analysis and the product was used without further purification. The crude (bis)silylether 
was then TBDMS deprotected using HF·py and pyridine. TLC showed two new spots and 163a 
(Rf = 0.63, hexanes/EtOAc 7:3) and 163b (Rf = 0.30, hexanes/EtOAc 7:3) could be separated 
and isolated by FCC. The stereocenter at C-5’ in 163a could be determined as R configurated, 
since a clear spatial coupling between 5’-H and 7a’-CH3 could be observed in the NOESY 
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spectrum. The formed stereocenter in 163b could not be identified via NOESY spectroscopy 
since important signals like 3a’-H are located under a multiplett, but crystals of diastereomer 
163b could be obtained and the structure in the solid state was determined by X-ray structure 
analysis (Figure 17).  
 
Figure 17. Mercury depiction of the structure of 163b in the crystalline state. 
The phenol at C-5 is facing to the front and consequently 5-H to the back, resulting in S 
configuration.  
3.3.2.2. Aliphatic and open chained residues 
In this chapter the introduction of cyclohexanol and open chained residue at C-5 is discussed. 
3.3.2.2.1. Introduction of a cyclohexanol 
For the introduction of a cyclohexanol at C-5 position organometallic chemistry was used. 
Scheme 88 shows the retrosynthesis of the desired seco-steroidal diol 167. 
 
Scheme 88. Retrosynthesis of seco-steroid 167 based on central building block 28c. 
The desired diol 167 should be formed via dehydration and hydrogenation, followed by 
deprotection of alcohol 168. Alcohol 168 should be obtained via nucleophilic addition of 
bromide 146 (for synthesis see chapter 3.3.1.3.1.1.) and ketone 28c, using organometallic 
chemistry.  
The first approach was a Br-Li exchange of the bromide followed by addition of the lithiated 
intermediate to ketone 28c, which is depicted in Scheme 89.  
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Scheme 89. Results of Br-Li exchange of 146 with subsequent nucleophilic addition to 28c. 
Br-Li exchange showed a lot of new spots on TLC and the starting material was consumed 
completely. Therefore, ketone 28c was added and after 1 h TLC showed already a lot of spots. 
After, in total, 3 h, nothing has changed according to TLC and GC/MS analysis showed not the 
desired mass. Probably the desired Br-Li exchange did not take place. A possible reason can 
be, that the silyl ether was cleaved. The reaction was performed again, now using 3 equivalents 
of t-BuLi, but the reaction proceeded in the same way.  
Therefore, another approach was tried. GRIGNARD reagents (RMgX) are a central tool for the 
formation of a C-C bond in the organic chemistry.[121] Scheme 90 depicts the attempted 
GRIGNARD reaction of 146 and ketone 28c. 
 
Scheme 90. Attempted GRIGNARD reaction of 146 with 28c. 
To activate Mg, dibromoethane was added,[122] since a layer of unreactive Mg(OH)2 or MgO2 
can lead to the inactivation of the magnesium metal. The use of LiCl has an accelerating effect 
on the Br-Mg exchange.[123] Nevertheless, the GRIGNARD formation showed no reaction on 
TLC. The starting material 146 seems to be untouched at room temperature. Therefore, the 
reaction was heated to 50 °C, but no reaction occurred. Ketone 28c was added and the reaction 
mixture was stirred overnight, but both starting materials left unreacted. The reaction was 
repeated, and heated to 70 °C, but nothing happened.  
Besides GRIGNARD reagents, organozinc reagents have become a powerful tool in 
organometal chemistry.[124] In this case, Zn was used instead of Mg (Scheme 91). 
Unfortunately, the reaction was not successful and desired seco-steroid 168 could not be 
obtained. As in the attempt of the GRIGNARD reaction, the organozinc reagent could not be 
formed. A possible reason can be, that bromide 146 is too inactive for this reaction. After these 
unsuccessful attempts, the introduction of cyclohexanol to C-5 was no longer pursued. 
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Scheme 91. Attempted organozinc reaction of 146 with 28c. 
3.3.2.2.2. Introduction of an open chained residue 
Scheme 92 illustrates the retrosynthesis of the open chained residue. Desired diol 169 should 
be formed via hydrogenation and subsequent TBDMS deprotection of alkyne 170. Alkyne 170 
should be generated from central building block 28c via triflation, followed by SONOGASHIRA 
cross-coupling. Furthermore, diol 171 should be generated via deprotection of 170 since the 
rigid alkyne structure mimics the length of the lead structures. 
 
Scheme 92. Retrosynthesis of diols 169 and 171. 
Starting from ketone 28c, enol triflate 172 was synthesised, using phenyltriflimide and 
NaHMDS, in 53% yield (Scheme 93). The double bond was formed selectively in ∆5-position, 
which is in accordance to the studies towards the synthesis of an aromatic ring B (see chapter 
3.2.2.). 
 
Scheme 93. Synthesis of enol triflate 172. 
With enol triflate 172, SONOGASHIRA cross-coupling with but-3-yn-1-ol (173) was performed 
(Scheme 94). The resulting alkyne 170 was used without further purification. 
Results and Discussion 
 
  
 
  
 73 
 
 
Scheme 94. SONOGASHIRA cross-coupling between 172 and but-3-yn-1-ol (173). 
Scheme 95 depicts the deprotection of the alcohol group using HF·py and pyridine. Diol 171 
was obtained in a good yield of 86% over both steps. 
 
Scheme 95. TBDMS cleavage of 170 using HF·py and pyridine, resulting in diol 171. *Yield is based on starting 
material 172 over two steps. 
In the next step, hydrogenation of 170 was performed to receive the saturated version of 171. 
Scheme 96 shows the hydrogenation with subsequent deprotection.   
 
Scheme 96. Hydrogenation of 170 with subsequent TBDMS cleavage resulting in 169. *Yield is based on starting 
material 172 over three steps. 
Diol 169 could be obtained in 21% over three steps. Unfortunately, the stereocenter at C-5 
could not be determined since the 5-H split up in a multiplett with other protons. Moreover, 
various crystallisation attempts of the oil did not result in measurable crystals.  
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3.4. Studies towards seco-steroids with a “broken” ring C 
A side project of this thesis was the study towards the variation of ring C for the synthesis of 
further seco-steroidal structures. This chapter was developed in the bachelor thesis of ANNA J. 
STEINMETZ, which was carried out under my supervision.[125] 
3.4.1. Retrosynthesis of seco-steroidal diol 174a 
In Scheme 97 the retrosynthesis of diol 174a is shown. Diol 174a should be obtained via 
TBDMS cleavage and dehydration with subsequent hydrogenation of alcohol 175a, which 
should be formed via Br-Li exchange of bromotetralin 176a, with subsequent addition to ketone 
177a.  
 
Scheme 97. Retrosynthesis of 174a, based on bromotetralone 178 and norcamphor (179). 
Bromide 176a should be formed via reduction of the keto group of bromotetralone 178 and 
TBDMS protection of the formed alcohol group. Building block 177a should be synthesised 
over five steps from norcamphor (179). 
3.4.2. Synthesis of building block 177a 
The first two steps of the five-step synthesis of ketone 177a are literature-known and followed 
a procedure of BURNELL AND WU.[126] The steps are depicted in Scheme 98. The first step is a 
BAYER-VILLIGER oxidation of racemic norcamphor (179) to lactone 180a, using m-CPBA as 
oxidising agent. Lactone 180a could be isolated in a good yield of 80%.   
 
Scheme 98. BAYER-VILLIGER oxidation of racemic norcamphor (179), followed by C-methylation resulting in racemic 
181a. 
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Diastereoselective mono-methylation of 180a using methyl iodide (MeI) and LDA gave 
methylated lactone 181a in a good yield of 77%. Instead of the highly toxic solvent HMPA, THF 
was used. With the methylation a new stereocenter was built. Using NOESY spectroscopy as 
identification method for the new stereocenter, a coupling between 4-H and 5-H was very weak 
and would therefore speak for the trans derivative. The distances of the methyl group to 4-H, 
5-H, 6-H and 8-H were determined (Table 5).  
Table 5. Distances of the methyl group 4-CH3 to certain protons in DH-AS-2a. 8-H shows the distances to the 
nearest proton of the CH2 group. 
 
Configuration 4-H 5-H 6-H 8-H 
cis  2.431 Å 2.505 Å 4.885 Å 2.059 Å 
trans 2.448 Å 2.496 Å 2.113 Å 4.752 Å 
 
Figure 18 shows the NOESY spectrum of 181a. Looking at the measured distances, it makes 
no difference looking at their spatial coupling, since the distance in the cis isomer (2.431 Å) is 
nearly the same as in the trans isomer (2.448 Å). The crucial factor of the determination of the 
stereoconfiguration are the couplings between the methyl group and 6-H and the methyl group 
and 8-H since the distances in cis and trans are completely different. There is no spatial 
coupling between the methyl group and 6-H, but a strong coupling between methyl group and 
8-H, resulting in the cis isomer.  
This is in accordance to the study of FUKUMOTO et al., saying that the methylation takes place 
from the less hindered side, resulting in this isomer.[127] Additionally the specific rotation was 
measured, resulting in racemic cis methylated lactone 181a was obtained. 
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Figure 18. NOESY spectrum of 181a. 
According to FUKUMOTO et al., the reduction of the ester of lactone 181a was performed, using 
LiAlH4. A strong reducing agent is needed here, because of the stable ester. Reduction 
resulted in ring opening of the lactone, obtaining diol 182a (Scheme 99).  
 
Scheme 99. Reductive ring opening of 181a. 
Since the stereochemistry is not affected by the ring opening and reduction, the relative 
configuration is maintained and the racemic mixture of 182a was obtained. A clear coupling 
between 3-H and 2’-H could be observed via NOESY spectroscopy. Unfortunately, the 
stereochemistry at C-3 and C-2’ is not the same as in the lead structures, but since the aim of 
this project was to find a route to this type of seco-steroid with variation on ring C, the 
stereoconfiguration was initially neglected.  
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The following mono-TBDMS protection is depicted in Scheme 100. Two products were 
isolated, the mono-protected silyl ether 183aa and the double-protected silyl ether 183ba.  
 
Scheme 100. TBDMS protection of primary hydroxyl group of 182a. 
A possible reason for the double TBDMS protection can be the used amount of 2 equivalents 
of TBDMSCl. Lowering the amount could lead to more mono-deprotected product. 
Nevertheless, the formation of both isomers is in accordance with the literature.[128]  
For the final step to building block 177a, the secondary alcohol group was oxidised using DMP 
(Scheme 101). The desired ketone could be isolated in a very good yield of 88% as a racemic 
mixture. 
 
Scheme 101. Oxidation of remaining hydroxyl group of 183aa using DMP. 
3.4.3. Synthesis of building block 176a 
The second building block 176a was synthesised from bromotetralone 178, following a 
procedure of TSCHAEN et al. for the reduction of the keto group.[129] Scheme 102 depicts the 
reduction, followed by the protection of the formed alcohol group. 
 
Scheme 102. Reduction of bromotetralone 178, followed by TBDMS protection of the hydroxyl group. 
The reduction using NaBH4 gave racemate 184a in quantitative yield. The TBDMS protection 
of the resulting alcohol group gave racemic 176a in a good yield of 66%.  
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3.4.4. Nucleophilic addition of metalated 176a to 177a 
To receive the seco-steroidal structure, building block 176a should be attached to 177a. 
Therefore, a Br-Li exchange of 176a using n-BuLi, followed by addition to ketone 177a was 
performed (Scheme 103).  
 
Scheme 103. Nucleophilic addition of lithiated 176a to 177a. 
The Br-Li exchange was monitored via TLC and a complete exchange could not be observed, 
although more n-BuLi was added. Nevertheless, the crude lithiated product was directly 
reacted with ketone 177a and the desired product 175a was isolated with a low yield of 21%. 
Thereby a new stereocenter was built, but the stereocenters could not be identified in this step. 
The final step was the dehydration (TFA) of the tertiary alcohol of 175a with subsequent ionic 
hydrogenation (TES) of the double bond[97] and deprotection of both TBDMS groups (Scheme 
104).   
 
Scheme 104. Synthesis of 174a via dehydration with subsequent hydrogenation of 175a. 
The usage of TFA also leads to the deprotection of both alcohols. For a complete deprotection, 
the reaction mixture was treated with conc. H2SO4 before workup. The desired diol 174a could 
be isolated, but only in a poor yield of 22%. TLC showed a lot of other spots, which speaks for 
still incomplete deprotection or decomposed fragments.  
Unfortunately, the stereochemistry could not be determined with NOESY spectroscopy and no 
X-ray crystal structure could be measured, due to the oily aggregate condition of the product. 
Scheme 105 shows the eight possible formed isomers and the four racemates, respectively.  
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Scheme 105. Eight possible isomers of 174a. 
With the knowledge of the stereochemistry of both racemic building blocks 177a and 176a, 
obviously the final product occurs as a racemate as well. Certainly, which diastereomers, 
where formed could not be determined. The racemic character was confirmed by the 
measurement of the optical rotation. HPLC chromatogram showed four signals in a ratio of 
2:3:12:83, but an assignment to individual isomers was not possible.  
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4. Biological Testing 
The herein synthesised test compounds and some intermediates were tested regarding to their 
microbial effect using agar diffusion assay and cytotoxicity using MTT assay. Furthermore, 
their activity towards cholesterol biosynthesis was examined with the usage of a developed 
assay from our group.[130]  
4.1. Agar diffusion assay 
In the agar diffusion assay, the antimicrobial effect of the test compounds was analysed on 
various model germs, which are listed in Table 6. Compounds which inhibit the growth of 
microorganisms impede the growth of various germs on medium containing agar resulting in 
inhibition zones. Their diameters give a statement about the qualitative existence of a microbial 
effect. A quantitative assertion cannot be made, since the sizes of the inhibition zones are 
dependent on the diffusion of every single compound on the aqueous medium. Clotrimazole 
was used for the antimycotic effect and tetracycline·HCl for the antibacterial effect as reference 
substances. In chapter 6.4.1. the detailed procedure for the agar diffusion assay is described. 
Table 6. Used model germs in agar diffusion tests. 
Model germ DSM number species 
Escherichia coli 426 gram-negative bacteria 
Pseudomonas marginalis 7527 gram-negative bacteria 
Straphylococcus equorum 20675 gram-positive bacteria 
Streptococcus entericus 14446 gram-positive bacteria 
Yarrowia lipolytica 1345 yeast 
Saccharomyces cerevisiae 1333 yeast 
 
Table 7 shows the results of the agar diffusion test. The diameters of the inhibition zones were 
measured in mm and are indicated as “total inhibition” (t.i.) or “growth inhibition” (g.i.). If no 
antimicrobial activity is shown, the field is marked with a dash (-) and not tested substances 
are labelled with “not tested” (n.t.). 
None of the herein tested compounds showed an antimicrobial effect towards the model 
germs.  
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Table 7. Results of the agar diffusion test.  
compound gram-negative bacteria gram-positive bacteria yeast 
 
   
 
  
reference substances 
clotrimazole n.t. n.t. n.t. n.t. 30 TH 27 TH 
tetracycline·HCl 34 TH 35 TH 38 TH 34 TH n.t. n.t. 
tri- and tetracyclic compounds 
55a - - - - - - 
55b - - - - - - 
42 - - - - - - 
45 - - - - - - 
46 - - - - - - 
seco-steroids 
86 - - - - - - 
87 - - - - - - 
88 - - - - - - 
89 - - - - - - 
96d - - - - - - 
97d - - - - - - 
98d - - - - - - 
99d - - - - - - 
100d - - - - - - 
129 - - - - - - 
101 - - - - - - 
161 - - - - - - 
Z-161 - - - - - - 
149 - - - - - - 
162 - - - - - - 
151 - - - - - - 
166 - - - - - - 
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163a - - - - - - 
163b - - - - - - 
174a - - - - - - 
other compounds / intermediates 
171 - - - - - - 
169 - - - - - - 
39 - - - - - - 
37 - - - - - - 
38 - - - - - - 
 
4.2. MTT assay 
Besides the antimicrobial aspect, the cytotoxic activity of these compounds was tested, using 
a standard MTT method of MOSMANN (for procedure see chapter 6.4.2.).[131] This assay is 
based on the reduction of the soluble yellow coloured tetrazolium salt 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazoliumbromide (MTT, 185) to the insoluble blue coloured formazan (186) 
(Scheme 106).  
 
Scheme 106. Reduction of MTT (185) to formazan (186). 
This reduction can only occur in vivo, since the reducing agents are NADH and NADPH, 
respectively. Photometric measurement can determine the amount of the formed formazan 
(186), which correlates with the cell viability. HL-60 cells were used, and Triton X-100 was 
included as positive control. With this assay, potential cytotoxic substances can be identified 
via determined IC50 values, but no statement about the underlying mode of action can be made.   
The IC50 value of cisplatin was determined with this assay resulting in 5 µM and is used as 
reference for the interpretation of the test results. Compounds with a comparable or lower 
value are considered as toxic (for example compound 166 with an IC50 value of 7.3 µM). It is 
noteworthy, that the IC50 values can vary depending on the cell line. Table 8 shows the results. 
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Table 8. Results of the MTT assay. 
Compound IC50 [µM]  Compound IC50 [µM] 
tri and tetracycles  seco-steroids 
55a 33  86 45 
55b 14  87 > 50 
42 > 50  88 > 50 
45 10  89 > 50 
46 > 50  96d 29 
other compounds / intermediates  97d 20 
171 > 50  98d 20 
169 19  99d 11 
39 > 50  100d 27 
37 12  129 30 
38 17  101 39 
   161 29 
   Z-161 28 
   149 19 
   162 38 
   151 > 50 
   166 7.3 
   163a 42 
   163b 19 
   174a 46 
 
Ten compounds resulted in IC50 values above 50 µM and thus, they are considered as non-
toxic. All other tested compounds showed IC50 values greater than 5 µM and are therefore also 
considered as not significantly toxic (compared to reference substance cisplatin). A huge 
difference in cytotoxicity was noticed between the tetracycles 42 and 45. The exchange of the 
nitrogen atom in 42 with an oxygen atom in 45 shows an increase in toxicity. The introduction 
of an aliphatic chain at C-5 showed that the unsaturated diol 171, bearing a double and a triple 
bond, has a higher IC50 value (> 50 µM) than its saturated version 169 with an IC50 value of 
19 µM. The opposite could be observed in the seco-steroids bearing an aromatic residue at C-
5. The unsaturated seco-steroid 166, bearing a double bond in ∆5 position has a very low IC50 
value of 7.3 µM and is therefore considered as toxic. Its saturated versions diastereomers 163a 
Biological Testing 
 
  
 
  
 84 
 
and 163b show higher IC50 values than 166, whereby 163a has the highest with 42 µM (Figure 
19).   
 
Figure 19. Structures and IC50 values of tetracycles 42 and 45 (top), diols 171 and 169 (middle) and seco-
steroids 166, 163a and 163b (bottom). 
Moreover, it is interesting to see, that 86, 87, 88, 89 bearing a directly linked aromatic residue 
at C-4 are all non-toxic with IC50 values of ≥ 45 µM, and with the introduction of a methylene or 
ethylene linker cytotoxicity of the compounds increases up to 11 µM (99d) (Figure 20). 
 
Figure 20. Structure of seco-steroids with attachment of aromatic residues at C-4. 
Regarding to the cholesterol biosynthesis, the application as inhibitors can be positively 
evaluated, since the compounds are considered as not (significantly) toxic (except seco-steroid 
166, IC50 = 7.3 µM).  
4.3. Cholesterol biosynthesis assay 
The inhibitory effect of the synthesised steroid-like analogues towards the cholesterol 
biosynthesis was analysed using an assay developed in our group, whereby inhibitors of the 
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post sqalene part can be identified and classified (for more details see chapter 6.4.3.).[130, 132] 
Table 9 shows the tested compounds and the inhibited enzyme in the cholesterol biosynthesis.  
Table 9. Qualitative results towards the efficacy of the synthesised compounds as inhibitor of cholesterol 
biosynthesis. 
Compound inhibited enzyme  Compound inhibited enzyme 
tri and tetracycles  seco-steroids 
55a -  86 - 
55b DHCR24 (low)  87 - 
42 -  88 - 
45 -  89 - 
46 -  96d - 
other compounds / intermediates  97d C5 desaturase 
171 -  98d - 
169 C5 desaturase  99d - 
39 -  100d - 
37 -  129 - 
38 -  101 - 
   161 - 
   Z-161 - 
   149 - 
   162 - 
   151 - 
   166 - 
   163a - 
   163b - 
   174a - 
 
Only three of the compounds showed an inhibitory effect on cholesterol biosynthesis (Figure 
21). Tricycle 55b showed a weak inhibition of DHCR24. Compared to lead structures 23 and 
24, ring A is eliminated and replaced with CH2-OH at C-7’. 55b has a structure similar to 
chemotype III inhibitors, like the lead structures of this thesis. Although, the chain is two carbon 
atoms too short and also attached at C-6’ instead of C-7’, it showed a slight inhibitory effect 
towards DHCR24.  
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Figure 21. Top: Structure of chemotype III. Middle: Lead structures SH-42 (22) and its related diols 23 and 24.[43] 
Bottom: Structures of 55b and its diastereomer 55a. 
Its diastereomer 55a, in which the chain is attached to C-7’, showed no effect on cholesterol 
biosynthesis.  
Furthermore, diols 169 and 97d inhibited the enzyme lathosterol oxidase (sterol C5 desaturase, 
SC5D) (Figure 22). This enzyme catalyses the conversion of lathosterol to 7-
dehydrocholesterol.[133] Known inhibitors of lathosterol oxidase belong to chemotype I, e.g. 
lathosterol side chain amides like MGI-21 (21).[66]    
 
Figure 22. Top: Lathosterol oxidase inhibitors: Lathosterol side chain amides (chemotype I) and MGI-21 (21).[66] 
Bottom: Structures of 97d and 169. 
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No similarity between the chemotype I structure, and the structures of 97d / 169 can be 
observed. Instead of the amide in the side chain, these structures carry a hydroxyl chain, which 
is present in chemotype III structures like lead structures 23 and 24 and its esterified version 
SH-42 (22), which are DHCR24 inhibitors.[43]  
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5. Summary and Conclusion 
The aim of this thesis was to synthesise steroid analogues, based on lead structures 23 and 
24, which are very potent and selective inhibitors of the enzyme DHCR24 in cholesterol 
biosynthesis with IC50 values of 0.1 nM and 2.5 nM, respectively. Structure variations of these 
compounds were, hitherto, exclusively performed regarding the side chain of ring D starting 
from steroidal building blocks. In order to learn more about structure-activity relationships in 
this class of DHCR24 inhibitors, and possibly improve activity, the synthesis of tri- and tetracylic 
steroid-like compounds, as well as seco-steroidal compounds was the focus of this project. 
Scheme 107 depicts an overview of the synthesis of central building blocks 26 and 28c. The 
literature-known synthesis of 26 started with the ozonolysis of ergocalciferol (27) with 
subsequent reductive work-up leading to INHOFFEN-LYTHGOE diol (29) in 71% yield.[67] To 
maintain the primary hydroxy group in the side chain, which is a crucial functional group for the 
DHCR24 inhibitors, it was TBDMS protected and the remaining secondary hydroxyl group was 
oxidised using DMP to receive central building block 26 in 91% yield.  
 
Scheme 107. Overview of the synthesis of central building blocks 26 and 28c. The failed attempts are marked in 
grey. 
Based on ketone 26 its constitutional isomer 28c was synthesised. Due to the failed attempt of 
a SHAPIRO reaction (Scheme 107, marked in grey), which should provide alkene 32c via a 
tosylhydrazone with subsequent deprotonation, alkene 32c was obtained via enol triflate 34. 
STILLE-type hydride transfer of 34 with tributylvinyltin did not result in the desired alkene 
(Scheme 107, marked in grey), but Pd-catalysed hydride transfer using formic acid gave 
alkene 32c in a very good yield of 81%. After regioselective hydroboration of alkene 34c, the 
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three isomers 35a, 35b and 35c were isolated. Only isomers 35a and 35c were of interest, 
since these have the required hydroxyl group attached at C-5. After oxidation using DMP, the 
desired central building block 28c could be isolated in very good yields of 97% and 99%, 
respectively.  
Scheme 108 depicts an overview of the syntheses of tetracyclic steroid-like analogues of the 
lead structures containing a modified ring A. Based on central building block 26, the desired 
diene 25 was synthesised via the appropriate enol triflate 34, which is already known from the 
synthesis of ketone 28c. SUZUKI-MIYAURA cross-coupling between enol triflate 34 and 
vinylboronic acid did result in the desired diene 25 in only 26% yield (Scheme 108, marked in 
grey), but the usage of STILLE cross-coupling conditions increased the yield to 77%.  
 
Scheme 108. Overview of the syntheses of tetracyclic steroid analogues based on central building block 26. Failed 
attempts are marked grey. The newly built ring A is marked in pink. *Dienophile 41 was synthesised according to 
literature in 69% yield.[79]  
Diene 25 smoothly underwent DIELS-ALDER cycloaddition with various dienophiles, e.g. 
maleimide and derivatives, maleic anhydride, and benzoquinone, and resulted in tetracycles 
36, 37, 38, 39 and 40 in 9 – 97% yield. The low yields of 39 (9%) and 40 (15%) can be explained 
by decomposition during the chromatographic purification step, although various stationary 
phases, e.g. SiO2, Al2O3 or neutralised SiO2 were tested. For the final TBDMS deprotection, 
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three methods (I – III) were explored, whereby method II turned out as the best deprotection 
method, but overall, only tetracycles 42 and 46 could be isolated in very good yields (95 and 
96%). Even though the other desired deprotected products could be confirmed via GC/MS, the 
purification step led again to decomposition of the product. Purification was necessary in this 
step, since the reagents could not be removed in another way. A different option, to evade the 
purification step was deprotecting diene 25 before cycloaddition. In the presence of TBAF and 
TEA diene 47 was obtained in 73% yield. Subsequent cycloaddition with maleimide led to the 
tetracycle 42 in 38% yield, which is much lower than via the other pathway (96%). However, 
dione 45 could now be isolated, even if only in a poor yield of 8%. Hydroxylated diones 43 and 
44 could not be obtained via this route, too. One possible reason for the low yields using 
already deprotected diene 47 could be its bad solubility, which resulted in an incomplete 
cycloaddition.  
Scheme 109 shows the attempts for the synthesis of tricycles. Vinyl sulfone 50 was 
synthesised according to literature in 53% yield.[84] Unfortunately, the target tricycle could not 
be isolated. The use of cyclohexenone as dienophile did also not lead to the desired tricycle 
52. Cycloaddition between diene 25 and acrolein (53) resulted in an inseparable mixture of 
isomers 54a and 54b in 87:13 ratio. The configuration of the newly built stereocenters at C-5a’ 
and C-6’ could be defined in this step (for 54a: 5a’S, 6’S; 54b: 5a’S, 6’R). The aldehyde function 
was reduced to the hydroxyl group using LiAlH4, and the TBDMS group was cleaved using 
conc. H2SO4. Diols 55a and 55b were isolated in 81% and 7% yield.   
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Scheme 109. Overview of the synthesis of tricyclic compounds via DIELS-ALDER cycloaddition. The failed attempts 
are marked in grey. The attached aliphatic residue is marked in pink.  
Since the hydroxymethyl chain in 55a/55b is two carbon atoms too short to fit with the geometry 
of the lead compounds, C-homologation was performed using DBU and CHCl3. Instead of a 
regioisomeric mixture of two trichloromethylcarbinols, diastereomers 56a with 15% and 56b 
with 13% yield were isolated, whereby both residues are attached to the C-6’ position. The 
following JOCIC-type reaction was performed only with pure 56b, as only a low amount of pure 
56a could be obtained by FCC. The desired C-homologated product 57 could be detected via 
GC/MS, but not isolated. Instead, 59 and 58 were isolated, whereby 59 is a typical side product 
in this reaction, and 58 is the protected version of 55b. Probably 58 was formed via a base-
mediated inversion of the synthesis of the carbinols. Deprotection also led to 55b.  
Another aim of the synthesis of tricyclic compounds was the formation of an aromatic ring B 
(60) (Scheme 110), since in the lead structures ∆7-sterol 23 and ∆5-sterol 24 the exact position 
of the double bond in ring B seems to be less important for the potenty of enzyme inhibitory 
potency. Based on central building block 28c, the first approach was a ROBINSON annulation 
with methyl vinyl ketone using acidic or basic conditions (Scheme 110, marked in pink).  
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Scheme 110. Overview of the attempts for the formation of an aromatic ring B. Attempted ROBINSON annulation is 
marked in pink. Attempts of trapping/imitating the enolate is marked in blue and the use of BREDERECK’S reagent is 
marked in petrol.  
Unfortunately, these attempts did not result in the desired product 61 and only decomposition 
products were obtained. It was assumed that the MICHAEL adduct was not formed and the idea 
was to trap or imitate the enolate which should attack the methyl vinyl ketone (62) (Scheme 
110, marked in blue). Silyl enol ether 64e and pyrrolidine enamine 65 should be synthesised to 
receive the desired structure A. Nevertheless, the products B, bearing the double bond at the 
wrong position were obtained (only 64e was isolated), which means that the following MICHAEL 
addition to methyl vinyl ketone will not lead to the desired MICHAEL adduct.  
Another approach was the usage of BREDERECK’S reagent (66) (Scheme 110, marked in 
petrol). This can be applied for α-aminomethylenation in molecules bearing an acidic 
methylene group to receive, after subsequent treatment with TEA and DIBAL-H, 69 as a 
precursor of a phenolic ring. However, instead of enaminoketone 63e, its regioisomer 64e was 
isolated in 46% yield. After these attempts, it became clear, that the C-6 position of ketone 28c 
is more acidic and accessible than position C-4. At this point, the project of the formation of an 
aromatic ring B based on central building block 28c, was stopped.  
Besides tri- and tetracyclic analogues of the steroidal lead structures, also seco-steroidal 
analogues were of high interest. Scheme 111 depicts an overview of the syntheses of seco-
steroids consisting of rings C and D and an aromatic residue at C-4.  
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Scheme 111. Overview of the introduction of an aromatic residue at C-4 position of building blocks consisting of 
ring C and D: Direct linking is marked in pink, introduction of a methylene linker is marked in blue and introduction 
of an ethylene linker is marked in petrol. Failed attempts are marked in grey. 
Starting with the directly linked residues (Scheme 111, marked in pink), Br-Li exchange of 
TBDMS protected phenol and benzylalcohol units with subsequent addition to central building 
block 26 resulted in 4-arylperhydroindanes. While meta- and para-substituted aryllithium 
compounds did undergo the addition, ortho-substituted residues left unreacted, probably due 
to steric hindrance. Tertiary alcohols 82, 83, 84 and 85 could be isolated in good yields of 64 
– 89%, whereby the new stereocenter at C-4’ is S configurated. The following double TBDMS 
deprotection using HF·py and pyridine resulted in the desired structures, triols 86, 87, 88 and 
89. It was of interest which stereoconfiguration at C-4’ is formed after deoxygenation. This was 
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examined by the example of 83 using TFA and TES. The resulting compound 90 had S 
configuration at C-4, like 83, but this time the aryl residue is facing to the front.  
The studies towards seco-steroids with a methylene linker giving 4-benzylperhydroindanes 
(Scheme 111, marked in blue) were performed with exomethylene compound 72, which was 
synthesised from central building block 26 via WITTIG olefination. To generate the borylated 
compound for cross-coupling, 72 was treated with 9-BBN to form the B-alkyl-9-BBN 
intermediate. Various TBDMS protected bromophenols/-benzylalcohols were coupled via 
SUZUKI-MIYAURA-type cross-coupling. Besides the “naked” phenyl 91d, the meta- and para-
substituted phenyls/benzyls 92d, 93d, 94d and 95d were isolated in yields ranging from 13 to 
51%. Ortho-substituted phenol and benzylalcohol could not be obtained with this procedure, 
probably due to steric hindrance. The low yields are the results of incomplete formation of the 
B-alkyl-9-BBN intermediate. The following deprotection gave the target compounds 96d, 97d, 
98d, 99d and 100d in 13 – 33 %.  
To receive ring B seco-analogues of the lead structures with correct distance betweens rings 
A and C, an ethylene linker resulting in 4-arylethylperhydroindanes was introduced (Scheme 
111, marked in green). First, a SONOGASHIRA cross-coupling between enol triflate 34, which is 
formed from ketone 26, and 3-hydroxyphenylacetylene (104) was performed, resulting in 
alkyne 103. Hydrogenation attempts did not give the desired seco-steroid and only 
unidentifiable and (half)hydrogenated compounds were isolated. Therefore, another attempt 
was tried based on aldehyde 73b, which was synthesised from alkene 72 via hydroboration 
and subsequent oxidation with DMP. Besides phosphonium bromide 121b, m-OTBDMS and 
p-OTBDMS protected phosphonium bromides were synthesised, but only 121b gave the 
desired seco-steroid 124b as E-isomer in 44% yield via WITTIG olefination. It was also tried to 
convert alcohol 74 to 107, but the attempts were unsuccessful (Scheme 111, marked in grey). 
Nevertheless, the isolated E-isomer 124b was hydrogenated to seco-steroid 127b, since the E-
isomer would not comply with the shape of the lead structures. The last steps were the 
deprotections of the alcohol functions. After TBDMS deprotection using HF·py and pyridine 
and subsequent methyl ether cleavage with BBr3, the desired seco-steroid 101 was obtained.  
Besides an ethylene linker, attempts for the synthesis of isosteric ether and amine linkers were 
made (Scheme 112, marked in petrol). For the preparation of an ether linker starting from 
alcohol 74 MITSUNOBU as well as BUCHWALD-HARTWIG reaction was tried. The mass of the 
desired ether 136 was found in the MITSUNOBU reaction, but the BUCHWALD-HARTWIG reaction 
was unsuccessful. Unfortunately, the product could not be isolated in a sufficent amount. For 
the amine linker, MITSUNOBU reaction with N-nosyl derivative 143e was tried as well, but also 
in this case, only traces of the desired product 144e were found by GC/MS. 
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Besides aromatic residues, aliphatic residues bearing hydroxyl groups were attached to the C-
4 position of central building block 26 (Scheme 112). The introduction of a cyclohexanol unit 
with direct attachment to C-4 (Scheme 112, marked in blue), was attempted via Br-Li exchange 
of 146 and subsequent addition to ketone 26. Unfortunately, this did not result in the desired 
product 148. Other attempts were not tried, as the corresponding directly linked compounds 
bearing aromatic residues did not show any effect on cholesterol biosynthesis. For the 
introduction of a methylene linker (Scheme 112, marked in turquoise), two methods based on 
alkene 72 were tried. First, bromide 146 was tried to couple to exomethylene compound 72 via 
B-alkyl-9-BBN derivative in a SUZUKI-MIYAURA cross-coupling, but the desired product 148 
could not be obtained. The second approach was for inactivated secondary alkyl halides using 
NiCl2, but also this attempt did not lead to the desired product.  
For the introduction of a cyclohexanol unit (resembling ring A) with an ethylene linker (Scheme 
112, marked in purple) aldehyde 73b was used. The WITTIG reagents 155 and 156 were 
synthesised via three steps, whereby 156 was only obtained in traces and therefore the 
following WITTIG olefination could not be performed. Olefination using 155 did not result in the 
desired product 150. The next attempt was a JULIA-KOCIENSKI olefination. The racemic JULIA 
reagents 158 and 160 were synthesised from the cis/trans mixture of 3-
methoxycyclohexanecarboxylic acid via four steps. Only 158 underwent the JULIA-KOCIENSKI 
olefination and seco-steroid 150 was obtained as an E/Z mixture (ratio 55:45, determined via 
1H NMR) of four isomers (ratio 4:5:43:38, determined via GC/MS) in 69% yield. The four 
isomers could not be separated by FCC. The E/Z mixture of the four isomers was TBDMS 
deprotected using HF·py and pyridine, whereby after this step one Z-isomer (161) could be 
separated from the mixture of two E-isomers and one Z-isomer (ratio 71:29, determined via 1H 
NMR). Unfortunately, it could not be identified which Z-isomer was isolated. Since the isolated 
amount of Z-161 was too low for methyl ether cleavage, its biological activity was tested as a 
potential prodrug. Methyl ether cleavage of the E/Z mixture 161 was performed using NaI and 
SiCl4 and 149 was isolated in 33% yield with an E/Z ratio of 59:41, which means, that one E-
isomer was not deprotected or isolated.  
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Scheme 112. Overview of the introduction of aliphatic residues at C-4. Introduction of an amine/ether linker is 
marked in petrol. Attempts for direct linking are marked in blue and introduction of a methylene linker is marked in 
turquois. Introduction of an ethylene linker is marked in lilac. 
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Additionally, the E/Z mixture 150 was hydrogenated and TBDMS deprotected to receive 162, 
a mixture of two diastereomers, in 52% yield after two steps. Methyl ether cleavage resulted 
in the mixture of two diols 151 in 31% yield. 
Besides seco-steroids with bridging at C-4, residues resembling ring A of the steroidal lead 
compounds were attached at C-5 of ring C and D building blocks. For this purpose, the 5-
ketoperhydroindane 28c was used (Scheme 113).  
 
Scheme 113. Overview of the syntheses of seco-steroids with ring A equivalents attached to C-5. Introduction of 
an aliphatic chain is marked in pink. Introduction of an aryl residue is marked in blue and the attempts of attaching 
a cyclohexyl residue to C-5 is marked in petrol.  
An aliphatic chain was introduced via SONOGASHIRA cross-coupling (Scheme 113, marked in 
pink). The appropriate enol triflate 172 of ketone 28c was cross coupled with but-3-yn-1-ol 
(173) to give alkyne 170. Since the presence of the alkyne group lead to an overall molecule 
geometry similar to the lead structures, the alkyne was TBDMS deprotected to give diol 171 in 
86% yield over two steps. Additionally, the triple and double bond in 170 were hydrogenated 
using PtO2 and after TBDMS deprotection, diol 169 was obtained in 11% yield over three steps 
based on 172. The introduction of a cyclohexanol residue, which would mimic the complete 
ring A of steroids, faced some difficulties (Scheme 113, marked in petrol). Organometallic 
reactions were tried, e.g. Br-Li exchange with subsequent addition to ketone 28c, GRIGNARD 
reaction using Mg/LiCl and organozinc reaction. However, all three approaches did not result 
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in the desired seco-steroid 168, whereby it is noteworthy that already the formation of the alkyl-
Li/MgX/ZnX was not successful and ketone 28c was recovered.  
The attachment of a phenol unit as ring A equivalent was performed using bromoarene 78d 
(Scheme 113, marked in blue). Br-Li exchange with subsequent addition to 28c resulted in a 
separable mixture of alcohols 164a and 164b in < 2% and 44% yield, respectively, whereby 
the stereoconfiguration at C-5 could not be determined. Since in further reactions removal of 
the generated tertiary hydroxyl group under loss of stereoinformation at C-5 was intended, this 
isomeric mixture can in principle be used for the next step. But as isomer 164b was isolated 
with 44% yield, the following reactions were performed only with this isomer. First, we tried to 
isolate the TBDMS deprotected version of 164b to obtain the triol 165. However, the isolated 
product turned out to be the dehydrated version 166 in a good yield of 67%. To get rid of the 
olefinic double bond, 164b was dehydrated and hydrogenated simultaneously with TES/TFA, 
and subsequent TBDMS deprotection gave the separable mixture of diols 163a and 163b in 
41% and 18% yield, respectively.  
Scheme 114 depicts the studies towards seco-steroids with an open ring C and an aromatic 
ring B. The ring D building block 177a was synthesised in a five step synthesis. Starting from 
racemic norcamphor (179), BAYER-VILLIGER oxidation led to lactone 180a in 80% yield. C-
monomethylation gave pure 181a in 77% yield. Reductive ring opening gave racemic diol 182a 
in 87% yield, and the following TBDMS protection gave a mixture of mono-protected 183aa 
and double-protected 183ba. The mono-protected alcohol was oxidised with DMP to ketone 
177a in 88% yield. The ring A and B building block 176a was synthesised from 6-bromo-2-
tetralone (178), which was first reduced to racemic tetralol 184a in quantitative yield. The 
following TBDMS protection gave 176a in 66% yield. The bromoarene 176a was added to the 
ketone 177a via Br-Li exchange and seco-steroid 175a could be isolated in 21% yield. The 
tertiary alcohol and TBDMS groups were removed simultaneously with TES and an excess 
TFA and 174a was obtained in 22% yield as a racemic mixture of stereoisomers. The 
configuration of the single components of 174a could not be identified with our methods, but all 
in all eight possible isomers (4 racemates) can be formed. This mixture was subjected to 
testing as potential inhibitor of DHCR24.    
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Scheme 114. Overview of the studies towards seco-steroidal analogues with an open ring C and an aromatic ring 
B. 
All test compounds were tested regarding their antimicrobial/antibiotic effect in an agar 
diffusion assay, as well as their cytotoxicity using an MTT assay. None of the compounds 
showed an antimicrobial/antibiotic effect or were considered as strong cytotoxic (except 166 
with an IC50 = 7.3 µM). The biological activity towards cholesterol biosynthesis was tested as 
well, whereby 55b showed a low inhibitory effect on DHCR24, and 169 and 97d on lathosterol 
oxidase. Tricycle 55b has a related structure to lead structures 23 and 24, which are in the 
class of chemotype III inhibitors. Diols 169 and 97d have no structural similarities to lathosterol 
oxidase inhibitors like MGI-21 (21), since their side chains do not contain an amide function. 
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Unfortunately, the other synthesised tri/tetracyclic and seco-steroid analogues of lead 
structures 23 and 24 did not lead to an inhibitory effect on the cholesterol biosynthesis.  
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6. Experimental Part 
6.1. Materials and methods 
General conditions 
All oxygen- and moisture-sensitive reactions were carried out in oven-dried glassware under 
nitrogen atmosphere using Schlenk-technique. Anhydrous solvents and reagents were 
transferred through syringes under nitrogen. 
Reagents and solvents 
Solvents used for anhydrous reactions were dried by standard methods of distillation over 
drying agents. DCM was dried over molecular sieve (3 Å) after distillation. THF was distilled 
over sodium and benzophenone. All other solvents and reagents were obtained from 
commercial sources (abcr, Acros, Fluka, Merck, Sigma-Aldrich or TCI in the qualities puriss., 
p.a., or purum) and used without further purification. 
Chromatography 
Thin layer chromatography (TLC) for qualitative reaction and fraction controls was performed 
using pre-coated polyester sheets polygram SIL G/UV254 with SiO2 coating (0.2 mm, 
40 x 80 mm) by Macherey-Nagel. As visualisation method CAM stain (ceric ammonium 
molybdate) with subsequent heating was used. Flash column chromatography (FCC) was 
carried out using SiO2 60 (particle size 40 – 63 μm) by Merck. 
Analytical data 
Melting points were measured in single determination on a Büchi Melting Point B-540 device 
and are stated in °C. 
Values for specific rotation [α] were measured at 23 °C at a wavelength of λ = 589 nm (Na-D-
line) using a Perkin Elmer 241 Polarimeter instrument. All samples were dissolved in 
chloroform (layer thickness l = 10 cm), the concentration is stated in g/100 mL. 
All NMR spectra were recorded at room temperature using JNM-Eclipse 400 (400 MHz), JNM-
Eclipse 500 (500 MHz), Avance III HD 400 MHz Bruker Biospin (400 MHz) and Avance III HD 
500 MHz Bruker Biospin (500 MHz) mit CryoProbe™ Prodigy through the NMR-division of the 
Department of Pharmacy of the LMU. Chemical shifts δ are reported as δ-values in ppm (parts 
per million) and refer to the deuterated solvent peak. Coupling constants (J) of protons are 
stated in Hz. The signal multiplicities are defined using the following abbreviations: s (singlet), 
d (doublet), dd (double doublet), dt (double triplet), t (triplet), q (quartet), p (pentet), ddd 
(doublet of doublet of doublets), tdd (triplet of doublet of doublets), dtd (doublet of triplet of 
doublets) and m (multiplet). The signal assignment was carried out using HMQC, HMBC, 
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COSY and DEPT spectra. All spectra were evaluated using MestReNova by Mestrelab 
Research S.L. 
Infrared spectra were measured on a JASCO FT/IR-4100 infrared spectrometer, using a 
Smiths Detection DuraSamp IR II Diamond ATR sensor for detection. The measured 
wavenumbers ṽ are reported in cm-1.  
High resolution mass spectra (HRMS) were recorded on a Jeol Mstation 700 or JMS GCmate 
II Jeol instrument for electron ionisation (EI). Electrospray ionisation (ESI) was measured on a 
Thermo Finnigan LTQ-FT. All measurements were performed by the mass spectroscopy 
service of the LMU. The mass is reported in m/z units with the mass of the molecular ion. 
Gas chromatography (GC) for the determination of purities was performed on a Varian 3800 
gas chromatograph coupled to a Saturn 2200 ion trap from Varian (Darmstadt, Germany). The 
auto sampler was from CTC Analytics (Zwingen, Switzerland) and the split/splitless injector 
was a Varian 1177 (Darmstadt, Germany). Instrument control and data analysis were carried 
out with Varian Workstation 6.9 SP1 software. A VF-5-ms capillary column of 30 m length, 0.25 
mm i.d. and 0.25 μm film thickness was used at a constant flow rate of 1.4 mL/min. Carrier gas 
was helium 99.999% from Air Liquide (Düsseldorf, Germany). The inlet temperature was kept 
at 300 °C and injection volume was 1 μL with splitless time 1.0 min. The initial column 
temperature was 50 °C and was held for 1.0 min. Then temperature was ramped up to 250 °C 
with 50 °C/min. Then the sterols were eluted at a rate of 5 °C/min until 310 °C (hold time 3 
min). Total run time was 20 min. Transfer line temperature was 300 °C and the ion trap 
temperature was 150 °C. The ion trap was operated with electron ionization (EI) at 70 eV in 
scan mode (m/z 50 - 650) with a solvent delay of 6.3 min.  
HPLC analytical measurements for determination of the purities of the products were carried 
out detecting at 191 nm, 210 nm, 250 nm and 254 nm using the following methods: 
Method a: 
Column: Agilent Poroshell 120®, EC-C18 2.7µm (3.0 x 100 mm) 
Flow rate: 0.5 mL/min 
Eluent: MeCN/H2O 40:60 + 0.1% formic acid  
Method b: 
Column: InfinityLab Poroshell 120®, EC-C18 2.7 µm (3.0 x 100 mm) 
Flow rate: 0.5 mL/min 
Eluent: MeCN/H2O 50:50 + 0.1% formic acid  
Method c: 
Column: Zorbax Eclipse Plus®, C18 5.0 µm (4.6 x 150 mm) 
Flow rate: 0.5 mL/min 
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Eluent: MeCN/H2O 70:30 + 0.1% formic acid  
Method d: 
Column: Agilent Poroshell 120®, EC-C18 2.7 µm (3.0 x 100 mm) 
Flow rate: 1.0 mL/min 
Eluent: MeCN/H2O 90:10  
Method e: 
Column: InfinityLab Poroshell 120®, EC-C18 2.7 µm (3.0 x 100 mm) 
Flow rate: 0.5 mL/min 
Eluent: MeCN/MeOH 90:10  
Method f: 
Column: Zorbax Eclipse Plus®, C18 5.0 µm (4.6 x 150 mm) 
Flow rate: 0.5 mL/min 
Eluent: MeCN/H2O 95:5  
 
The X-ray intensity data were measured on a Bruker D8 Venture TXS system equipped with a 
multilayer mirror monochromator and a Mo Kα rotating anode X-ray tube (λ = 0.71073 Å). The 
frames were integrated with the Bruker SAINT software package. Data were corrected for 
absorption effects using the Multi-Scan method (SADABS). The structure was solved and 
refined using the Bruker SHELXTL Software Package.  
To explore the minima of the ground state potential energy surface of 55a and 55b the program 
package “Conformational Search” of Macro Model (S. Schrödinger Release 2019-2: 
MacroModel, Schrödinger, LLC, New York, NY, 2019) was used. The conformational search 
was conducted from a guessed structure with the “Torsional Sampling MCMM” method with 
100 steps per rotatable bond and a maximum atom deviation cutoff of 0.5 Å in the MMFF force 
field. In total 100 structures within a window of a maximum of 5 kcal/mol from the lowest found 
MMFF energy were saved. The distances between characteristic atoms of the lowest energy 
structure are shown in Table 1. All other found structures are only single bond rotamers, 
showing that the presented ring conformation is the only stable conformation in a range of 
5 kcal/mol. 
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6.2. Synthetic procedures and analytical data 
6.2.1. General procedures for synthesis 
General procedure 1 (GP1): TBDMS protection (1) 
In an oven-dried two-necked Schlenk flask the appropriate alcohol/phenol (1.00 eq) was 
dissolved in dry DCM to receive a concentration of 0.1 mmol/mL. The solution was cooled to 
0 °C and TBDMSCl (1.10 eq), DMAP (10 mol%) and TEA (3.00 eq) were sequentially added. 
The reaction mixture was slowly warmed to rt and stirred for 13 h. The reaction mixture was 
quenched with water and extracted with DCM (3 x). The combined organic layers were dried 
over Na2SO4, filtered and the solvent was removed in vacuo. The crude product was purified 
via FCC (SiO2).  
General procedure 2 (GP2): TBDMS protection (2) 
In an oven-dried flask the appropriate alcohol/phenol (1.00 eq) was dissolved in dry DCM to 
receive a concentration of 0.1 mmol/mL and imidazole (1.10 eq) and TBDMSCl (1.10 eq) were 
sequentially added. The reaction mixture was stirred at rt for 18 h. The reaction was stopped 
with water and extracted with DCM (3 x). The combined organic layers were dried over 
Na2SO4, filtered and the solvent was removed in vacuo. The crude product was purified via 
FCC (SiO2).  
General procedure 3 (GP3): DESS-MARTIN oxidation 
In an oven-dried flask the appropriate alcohol (1.00 eq) was dissolved in dry DCM to receive a 
concentration of 0.1 mmol/mL. DMP (1.50 eq) was added and the reaction mixture was stirred 
at rt for 3 h. The reaction mixture was diluted with Et2O (13.0 mL pro 1.00 mmol alcohol), water 
(13.0 mL pro 1.00 mmol alcohol) and an excess of Na2S2O3 and the suspension was stirred 
for additional 30 min. The two layers were separated, and the aq. phase was extracted with 
EtOAc (3 x). The combined organic layers were dried over Na2SO4, filtered and the solvent 
was removed in vacuo. The product was purified via FCC (SiO2). 
General procedure 4 (GP4): Hydroboration with BH3·THF and oxidation 
In an oven-dried two-necked Schlenk flask the appropriate alkene (1.00 eq) was dissolved in 
dry THF to receive a concentration of 0.1 mmol/mL and the solution was cooled to 0 °C. 
BH3·THF (1M in THF, 3.00 eq) was added dropwise and the reaction mixture was warmed to 
rt and stirred for 2 h. The reaction mixture was cooled to 0 °C and aq. 1M NaOH (12.0 mL per 
1.00 mmol alkene) and 30% (w/w) H2O2 (12.0 mL per 1.00 mmol alkene) were added and the 
resulting mixture was stirred at rt for 18 h. The two layers were separated, and the aq. phase 
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was extracted with DCM (3 x). The combined organic layers were dried over Na2SO4, filtered 
and the solvent was removed in vacuo. The crude product was purified via FCC (SiO2). 
General procedure 5 (GP5): DIELS-ALDER cycloaddition 
The DIELS-ALDER reactions were carried out in the microwave or in a pressure tube. In an 
oven-dried pressure/microwave tube diene 25 (1.00 eq) was dissolved in dry toluene to receive 
a concentration of 0.1 mmol/mL and the appropriate dienophile (1.00 eq) was added. When 
using a pressure tube, reaction mixture was heated to 100 °C for 2 h. When using microwave 
conditions, the used parameters are indicated in the appropriate approach. The solvent was 
removed in vacuo and the crude product was purified via FCC (SiO2). 
General procedure 6 (GP6): Br-Li exchange and nucleophilic addition  
In an oven-dried two-necked Schlenk flask the appropriate aryl bromide (1.10 eq) was 
dissolved in dry THF to receive a concentration of 0.3 mmol/mL. The solution was cooled to 
- 78 °C and n-BuLi (1.20 eq) was added. The reaction mixture was stirred for 1 h at - 78 °C. 
The organolithium species was used without further purification. 
Ketone 26/28c (1.00 eq) was dissolved in dry THF to receive a concentration of 0.3 mmol/mL 
and this solution was added to the solution of the organolithium species at - 78 °C and stirred 
for additional 1 h. The reaction was stopped with sat. aq. NH4Cl solution, allowed to warm to rt 
and the layers were separated. The aq. layer was extracted with EtOAc (3 x) and the combined 
organic layers were washed with brine, dried over Na2SO4, filtered and the solvent was 
removed in vacuo. The title compound was purified via FCC (SiO2).  
General procedure 7 (GP7): SUZUKI-MIYAURA cross-coupling  
In an oven-dried two-necked Schlenk flask alkene 72 (1.00 eq) was dissolved in dry THF to 
receive a concentration of 0.3 mmol/mL and cooled to 0 °C. 9-BBN (0.5M in THF, 1.10 eq) was 
added and the mixture was warmed up slowly to rt and then stirred for 2 h to give a solution of 
the appropriate B-alkyl-9-BBN. 
The aryl bromide (1.00 eq) and Pd(PPh3)4 (3 mol%) were dissolved in dry THF to receive a 
concentration of 0.3M and added to the degassed B-alkyl-9-BBN solution and aq. 2M NaOH 
(40.0 µL per 1.00 mmol alkene) was added. The mixture was refluxed for 12 h. The reaction 
mixture was diluted with water and the aq. phase was extracted with hexanes (3 x), washed 
with brine, dried over Na2SO4, filtered and the crude product was purified via FCC (SiO2). 
General procedure 8 (GP8): Dehydration and ionic hydrogenation 
In an oven-dried flask the appropriate tertiary alcohol (1.00 eq), TFA (5.50 eq) and TES 
(2.50 eq) were dissolved in dry DCM to receive a concentration of 0.1 mmol of tertiary alcohol 
Experimental Part 
 
  
 
  
 106 
 
per mL and stirred for 2 h at rt. The reaction mixture was quenched with sat. aq. NaHCO3 
solution and the aq. phase was extracted with DCM (3 x). The combined organic layers were 
washed with water, dried over Na2SO4, filtered and the solvent was removed in vacuo. The 
compounds were used without further purification.  
General procedure 9 (GP9): TBDMS deprotection  
In an oven-dried flask the appropriate TBDMS-protected alcohol/phenol (1.00 eq), HF·pyr 
(~30% pyridine, ~70% HF, 2.20 eq per TBDMS group), pyridine (2.30 eq per TBDMS group) 
were dissolved in EtOAc to receive a concentration of 0.1 mmol/mL. The reaction mixture was 
stirred at rt for 18 h. The reaction was stopped with methoxytrimethylsilane (35.0 eq) and stirred 
for additional 40 min. The solvent was removed in vacuo and the crude product was purfied 
via FCC (SiO2). 
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6.2.2. Procedures and data for building blocks bearing ring C and D 
(1R,3aR,4S,7aR)-1-((S)-1-Hydroxypropan-2-yl)-7a-methyloctahydro-1H-inden-4-ol 
(Inhoffen-Lythgoe-Diol, 29)[67-68] 
 
 
 
C13H24O2 
M = 212.33 g/mol 
Ergocalciferol (27, 5.00 g, 13.0 mmol, 1.00 eq) was dissolved in methanol p.a. (500 mL) and 
dry pyridine (5.00 mL) was added. The reaction mixture was cooled to - 78 °C. Ozone was 
passed through the reaction mixture (flow rate 60 L/h, 50 Hz). After 2 h a grey-blue colour 
appeared, and the ozone flow was discontinued, and the reaction mixture was purged with N2 
to remove the remaining dissolved ozone for 10 min. The solution was warmed to 0 °C and 
NaBH4 (8.50 g, 225 mmol, 18.0 eq) was added portionwise over a period of 1 h. The reaction 
mixture was allowed to warm up to rt overnight. The reaction was quenched with 1M aq. HCl 
(100 mL), concentrated in vacuo (~ 100 mL) and the residue was extracted with EtOAc (3 x 
200 mL). The organic layers were dried over Na2SO4, filtered and the solvent was removed in 
vacuo. The title compound was purified via FCC (hexanes/EtOAc 7:3) and isolated as white 
crystalline solid (1.73 g, 8.15 mmol, 65%).  
 
Rf = 0.21 (hexanes/EtOAc 7:3). 
mp: 113 °C. 
[𝛂]𝑫
𝟐𝟑: + 36.3 (c = 0.11, CHCl3). 
1H NMR (500 MHz, chloroform-d) δ/ppm = 4.08 (t, J = 2.8 Hz, 1H, 4-H), 3.63 (dt, J = 10.4, 3.8 
Hz, 1H, 1’-H), 3.40 – 3.34 (m, 1H, 1’-H), 2.01 – 1.95 (m, 1H, 7-H), 1.88 – 1.76 (m, 3H, 2, 5, 6-
H), 1.60 – 1.51 (m, 2H, 3, 2’-H), 1.51 – 1.40 (m, 3H, 3, 5, 6-H), 1.38 – 1.29 (m, 4H, 2, 3a, 4-
OH, 1’-OH), 1.21 – 1.12 (m, 2H, 1, 7-H), 1.02 (d, J = 6.7 Hz, 3H, 2’-CH3), 0.95 (s, 3H, 7a-CH3). 
13C NMR (126 MHz, chloroform-d) δ/ppm = 69.4 (C-4), 67.9 (C-2’), 53.1 (C-1), 52.51 (C-3a), 
42.0 (C-7a), 40.4 (C-7), 38.4 (C-1’), 33.7 (C-5), 26.8 (C-2), 22.7 (C-3), 17.6 (C-6), 16.8 (1’-
CH3), 13.7 (7a-CH3). 
IR (ATR): ṽ/cm-1 = 3957, 3809, 3792, 3348, 3271, 3271, 2930, 2864, 2359, 1714, 1699, 1473, 
1458, 1439, 1382, 1358, 1181, 1161, 1066, 1030, 987, 957, 940, 727, 626, 603, 571. 
HRMS (EI): m/z calculated for C12H21O2 [M-CH3]˙⁺ 197.1542; found 197.1532. 
Purity (GC): > 95% (scan mode m/z 50-650 (EI 70 eV)) 
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(1R,3aR,4S,7aR)-1-((S)-1-((tert-Butyldimethylsilyl)oxy)propan-2-yl)-7a-
methyloctahydro-1H-inden-4-ol (30) 
 
 
 
 
C19H38O2Si 
M = 326.59 g/mol 
Alcohol 30 was synthesised according to GP1, using diol 29 (200 mg, 0.942 mmol, 1.00 eq). 
The title compound was purified via FCC (hexanes/EtOAc 8:2) and isolated as colourless oil 
(309 mg, 0.946 mmol, quantitative). 
 
Rf = 0.51 (hexanes/EtOAc 8:2). 
[𝛂]𝑫
𝟐𝟑: + 29.8 (c = 0.12, CHCl3). 
1H NMR (500 MHz, chloroform-d) δ/ppm = 4.07 (d, J = 3.1 Hz, 1H, 4-OH), 3.57 (dd, J = 9.6, 
3.3 Hz, 1H, 1’-H), 3.26 (dd, J = 9.6, 7.3 Hz, 1H, 1’-H), 1.99 (dt, J = 12.7, 3.1 Hz, 1H, 7-H), 1.87 
– 1.74 (m, 3H, 2, 5, 6-H), 1.61 – 1.38 (m, 5H, 3, 5, 6, 2’-H), 1.36 – 1.25 (m, 3H, 2, 3a-H, 4-OH), 
1.19 – 1.07 (m, 2H 1, 7-H), 0.96 (d, J = 6.5 Hz, 3H, 2’-CH3), 0.93 (s, 3H, 7a-CH3), 0.88 (s, 9H, 
SiC(CH3)3), 0.02 (s, 6H, Si(CH3)2). 
13C NMR (126 MHz, chloroform-d) δ/ppm = 69.4 (C-4), 67.9 (C-2’), 53.3 (C-1), 52.5 (C-3a), 
42.0 (C-7a), 40.4 (C-7), 38.7 (C-1’), 33.8 (C-5), 26.8 (C-2), 26.11 (SiC(CH3)3), 22.8(C-3), 18.5 
(SiC(CH3)3), 17.6 (C-6), 16.9 (1’-CH3), 13.8 (7a-CH3), -5.2 (Si(CH3)2), -5.3 (Si(CH3)2). 
IR (ATR): ṽ/cm-1 = 3769, 3677, 3414, 2928, 2856, 1471, 1388, 1360, 1251, 1091, 1061, 1033, 
1005, 989, 942, 833, 812, 773, 723, 692, 664, 620. 
HRMS (EI): m/z calculated for C19H38O2Si [M]˙⁺ 326.2636; found 326.2628. 
Purity (GC): 94% (scan mode m/z 50-650 (EI 70 eV)). 
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(1R,3aR,7aR)-1-((S)-1-((tert-Butyldimethylsilyl)oxy)propan-2-yl)-7a-methyloctahydro-
4H-inden-4-one (26) 
 
 
 
 
 
 
C19H36O2Si 
M = 324.58 g/mol 
Ketone 26 was synthesised according to GP3, using alcohol 30 (1.12 g, 3.43 mmol, 1.00 eq). 
The title compound was purified via FCC (hexanes/EtOAc 9:1) and isolated as colourless oil 
(1.01 g, 3.11 mmol, 91%). 
 
Rf = 0.40 (hexanes/EtOAc 9:1). 
[𝛂]𝑫
𝟐𝟑: + 1.0 (c = 0.11, CHCl3). 
1H NMR (500 MHz, chloroform-d) δ/ppm = 3.56 (dd, J = 9.6, 2.7 Hz, 1H, 1’-H), 3.35 – 3.28 (m, 
1H, 1’-H), 2.48 – 2.39 (m, 1H, 3a-H), 2.32 – 2.17 (m, 2H, 5-H), 2.11 (ddd, J = 13.1, 4.7, 2.4 Hz, 
1H, 7-H), 2.01 (dddt, J = 14.4, 7.3, 4.8, 2.3 Hz, 1H, 6-H), 1.95 – 1.81 (m, 2H, 2, 6-H), 1.74 (dtd, 
J = 13.3, 11.8, 6.2 Hz, 1H, 3-H), 1.64 – 1.46 (m, 4H, 1, 3, 7, 2’-H), 1.39 – 1.29 (m, 1H, 2-H), 
1.02 (d, J = 6.0 Hz, 3H, 2’-CH3), 0.89 (s, 9H, SiC(CH3)3), 0.64 (s, 3H, 7a-CH3), 0.03 (s, 6H, 
Si(CH3)2). 
13C NMR (126 MHz, chloroform-d) δ/ppm = 212.1 (C-4), 67.7 (C-2’), 61.9 (C-3a), 53.3 (C-1), 
50.1 (C-7a), 41.1 (C-5), 39.0 (C-7), 38.8 (C-1’), 27.1 (C-2), 26.1 (SiC(CH3)3), 24.2 (C-6), 19.4 
(C-3), 18.5 (SiC(CH3)3), 17.2 (1’-CH3), 12.7 (7a-CH3), -5.2 (Si(CH3)2), -5.3 (Si(CH3)2). 
IR (ATR): ṽ/cm-1 = 3892, 3803, 2954, 2929, 2889, 2856, 1715, 1471, 1458, 1384, 1361, 1307, 
1250, 1218, 1186, 1091, 1057, 1038, 1005, 940, 834, 773, 679, 662, 563. 
HRMS (EI): m/z calculated for C19H36O2Si [M]˙⁺ 324.2479; found 324.2464. 
Purity (HPLC): > 95 % (λ = 191 nm) (method d).     
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(1R,3aR,7aR)-1-((S)-1-((tert-Butyldimethylsilyl)oxy)propan-2-yl)-7a-methyl-2,3,3a,6,7,7a-
hexahydro-1H-inden-4-yl trifluoromethanesulfonate (34) 
 
  
 
 
 
C20H35F3O4SSi 
M = 456.64 g/mol 
A solution of ketone 26 (106 mg, 0.327 mmol, 1.00 eq) in dry THF (15.0 mL) was added 
dropwise to NaHMDS (2M in THF, 0.410 mL, 0.820 mmol, 2.50 eq) at - 78 °C. After 1 h N-
phenyl-bis(trifluoromethansulfonimide) (280 mg, 0.784 mmol, 2.40 eq) was added and stirred 
for additonal 20 min. The reaction mixture was warmed up to rt and stirred for additional 2 h. 
The reaction was stopped with water (15.0 mL) and the organic solvent was removed in vacuo. 
The aq. residue was extracted with hexanes (3 x 20.0 mL). The combined organic layers were 
washed with water (30.0 mL), dried over Na2SO4, filtered and the solvent was removed in 
vacuo. The title compound was purified via FCC (hexanes/EtOAc 9:1) and isolated as 
colourless oil (135 mg, 0.297 mmol, 91%). 
 
Rf = 0.81 (hexanes/EtOAc 9:1). 
[𝛂]𝑫
𝟐𝟑: + 16.8 (c = 0.10, CHCl3). 
1H NMR (500 MHz, chloroform-d) δ/ppm = 5.58 (q, J = 3.6 Hz, 1H, 5-H), 3.56 (dd, J = 9.7, 3.3 
Hz, 1H, 1’-H), 3.31 (dd, J = 9.7, 6.9 Hz, 1H, 1’-H), 2.51 – 2.44 (m, 1H, 3a-H), 2.34 – 2.28 (m, 
2H, 6-H), 2.02 – 1.91 (m, 2H, 2-H, 2, 7-H), 1.82 – 1.75 (m, 1H, 3-H), 1.62 – 1.34 (m, 5H, 1, 2, 
3, 7, 2’-H), 1.01 (d, J = 6.6 Hz, 3H, 2’-CH3), 0.89 (s, 9H, SiC(CH3)3), 0.77 (s, 3H, 7a-CH3), 0.03 
(s, 6H, Si(CH3)2). 
13C NMR (126 MHz, chloroform-d) δ/ppm = 150.0 (C-4), 118.7 (q, JC-F = 320.3 Hz, CF3) 116.3 
(C-5), 67.7 (C-1‘), 50.9 (C-1), 50.1 (C-3a), 45.5 (C-7a), 39.2 (C-2’), 34.9 (C-7), 27.9 (C-2), 26.1 
(SiC(CH3)3), 24.0 (C-6), 21.8 (C-3), 18.5 (SiC(CH3)3), 17.2 (2’-CH3), 11.6 (7a-CH3), -5.2 
(Si(CH3)2), -5.3 (Si(CH3)2).   
IR (ATR): ṽ/cm-1 = 3909, 3861, 2954, 2929, 2857, 1676, 1471, 1445, 1417, 1361, 1314, 1246, 
1205, 1142, 1099, 1002, 899, 870, 857, 834, 812, 774, 631, 604, 567. 
HRMS (EI): m/z calculated for C20H35F3O4SSi [M]˙⁺ 456.1972; found 456.1970. 
Purity (HPLC): > 95 % (λ = 210 nm) (method d). 
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tert-Butyldimethyl((S)-2-((1R,3aS,7aS)-7a-methyl-2,3,3a,6,7,7a-hexahydro-1H-inden-1-
yl)propoxy)silane (32c) 
  
 
 
 
C19H36OSi 
M = 308.58 g/mol 
To a solution of enol triflate 34 (3.04 g, 6.69 mmol, 1.0 eq) in dry THF (50.0 mL) DIPEA 
(4.83 mL, 27.7 mmol, 4.15 eq) and formic acid (0.78 mL, 20.1 mmol, 3.00 eq) were added and 
the solution was degassed before Pd(OAc)2 (15.0 mg, 0.067 mmol, 1.00 mol%) and PPh3 
(35.0 mg, 0.134 mmol, 2.00 mol%) were added. The reaction mixture was stirred at rt for 18 h.  
EtOAc (50.0 mL) was added and the organic phase was washed with brine (40.0 mL), dried 
over Na2SO4, filtered and the solvent was removed in vacuo. The crude product was purified 
via FCC (hexanes/EtOAc 99:1) and olefin 32c was obtained as colourless oil (1.81 g, 
5.61 mmol, 84%). 
 
Rf = 0.88 (hexanes/EtOAc 99:1). 
[𝛂]𝑫
𝟐𝟑: + 60.8 (c = 0.12, CHCl3). 
1H NMR (400 MHz, chloroform-d) δ/ppm = 5.66 – 5.52 (m, 2H, 4’-H, 5’-H), 3.60 (dd, J = 9.6, 
3.4 Hz, 1H, 1-H), 3.30 – 3.23 (m, 1H, 1-H), 2.13 – 1.94 (m, 3H, 3a’, 6’-H), 1.99 (dt, J = 12.7, 
4.1 Hz, 1H, 7’-H), 1.86 (dtd, J = 13.0, 9.4, 6.5 Hz, 1H, 2’-H), 1.68 – 1.53 (m, 2H, 3’, 2-H), 1.51 
– 1.32 (m, 2H, 2’, 7’-H), 1.30 – 1.14 (m, 2H, 1’, 3’-H), 1.02 (d, J = 6.5 Hz, 3H, 2-CH3), 0.89 (s, 
9H, SiC(CH3)3), 0.70 (s, 3H, 7a’-CH3), 0.03 (s, 6H, Si(CH3)2). 
13C NMR (126 MHz, chloroform-d) δ/ppm = 128.5 (C-4’), 126.7 (C-5’), 68.1 (C-1), 51.2 (C-1’), 
48.5 (C-3a’), 42.0 (C-7a’), 39.6 (C-2), 36.7 (C-7’), 28.1 (C-2’), 26.2 (SiC(CH3)3), 25.2 (C-3’), 
24.6 (C-6’), 18.6 (SiC(CH3)3), 17.2 (2-CH3), 11.2 (7a’-CH3) -5.2 (Si(CH3)2), -5.2 (Si(CH3)2).   
IR (ATR): ṽ/cm-1 = 3825, 3742, 3689, 3019, 2950, 2928, 2875, 2857, 1639, 1471, 1458, 1388, 
1361, 1251, 1127, 1085, 1030, 1005, 939, 833, 812, 772, 702, 675, 620, 562. 
HRMS (EI): m/z calculated for C18H33OSi [M]˙⁺ 293.2301; found 293.2295. 
Purity (HPLC): > 95% (λ = 210 nm), > 95% (λ = 191 nm) (method f). 
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(1R,3aS,5R,7aS)-1-((S)-1-((tert-Butyldimethylsilyl)oxy)propan-2-yl)-7a-methyloctahydro-
1H-inden-5-ol (35a), (1R,3aR,4R,7aR)-1-((S)-1-((tert-Butyldimethylsilyl)oxy)propan-2-yl)-
7a-methyloctahydro-1H-inden-4-ol (35b) and (1R,3aS,5S,7aS)-1-((S)-1-((tert-
Butyldimethylsilyl)-oxy)propan-2-yl)-7a-methyloctahydro-1H-inden-5-ol (35c)  
 
 
 
 
C19H38O2Si 
M = 326.59 g/mol 
The title compounds were synthesised according to GP4, using olefin 32c (1.80 g, 5.80 mmol, 
1.00 eq). The alcohols were purified and separated via FCC (hexanes/EtOAc 8:2) and alcohol 
35a was obtained as white solid (831 mg, 2.55 mmol, 44%), alcohol 35b as white solid 
(273 mg, 0.838 mmol, 14%) and alcohol 35c as white solid (150.3 mg, 0.460 mmol, 8%).  
 
Analytical data of alcohol 35a: 
Rf = 0.39 (hexanes/EtOAc 8:2). 
mp: 98 °C. 
[𝛂]𝑫
𝟐𝟑: + 32.6 (c = 0.10, CHCl3). 
1H NMR (500 MHz, chloroform-d) δ/ppm = 4.06 (p, J = 2.9 Hz, 1H, 5-H), 3.58 (dd, J = 9.6, 3.3 
Hz, 1H, 1’-H), 3.26 (dd, J = 9.6, 7.5 Hz, 1H, 1’-H), 1.83 – 1.45 (m, 10H, 2, 3, 3a, 4, 6, 7, 2’-H), 
1.37 (bs, 1H, 5-OH), 1.31 – 1.20 (m, 2H, 1, 2-H), 1.16 – 1.04 (m, 1H, 3-H), 0.99 (d, J = 6.5 Hz, 
3H, 2’-CH3), 0.89 (s, 9H, SiC(CH3)3), 0.66 (s, 3H, 7a-CH3), 0.03 (s, 3H, Si(CH3)2), 0.02 (s, 3H, 
Si(CH3)2). 
13C NMR (126 MHz, chloroform-d) δ/ppm = 68.1 (C-1’), 66.7 (C-5), 52.6 (C-1), 42.4 (C-7a), 
42.2 (C-3a), 39.3 (C-2’), 34.6 (C-7), 33.5 (C-4), 29.3 (C-6), 27.4 (C-2), 26.6 (C-3), 26.1 
(SiC(CH3)3), 18.5 (SiC(CH3)3), 17.1 (2’-CH3), 10.3 (7a-CH3), -5.2 (Si(CH3)2), -5.2 (Si(CH3)2). 
IR (ATR): ṽ/cm-1 = 3882, 3626, 3286, 2928, 2889, 2855, 2364, 2345, 1473, 1460, 1407, 1352, 
1333, 1252, 1197, 1093, 1022, 997, 976, 937, 920, 833, 812, 770, 742, 700, 656, 585, 566. 
HRMS (EI): m/z calculated for C19H37O2Si [M-H]˙⁺ 325.2557; found 325.2572. 
Purity (GC): > 95% (scan mode m/z 50-650 (EI 70 eV)). 
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Analytical data of alcohol 35b: 
Rf = 0.33 (hexanes/EtOAc 8:2). 
mp: 77 °C. 
[𝛂]𝑫
𝟐𝟑: + 9.4 (c = 0.07, CHCl3). 
1H NMR (400 MHz, chloroform-d) δ/ppm = 3.57 (ddd, J = 10.8, 6.7, 4.0 Hz, 2H, 4, 1’-H), 3.26 
(dd, J = 9.6, 7.4 Hz, 1H, 1’-H), 2.04 – 1.95 (m, 1H, 5-H), 1.91 – 1.76 (m, 3H, 2, 3, 7-H), 1.67 – 
1.46 (m, 3H, 6, 2’-H), 1.38 – 1.17 (m, 5H, 1, 2, 3, 3a, OH), 1.15 – 1.03 (m, 2H, 5, 7-H), 0.98 (d, 
J = 6.5 Hz, 3H, 2’-CH3), 0.89 (s, 9H, SiC(CH3)3), 0.68 (s, 3H, 7a-CH3), 0.02 (s, 3H, Si(CH3)2), 
0.02 (s, 3H, Si(CH3)2). 
13C NMR (126 MHz, chloroform-d) δ/ppm = 71.3 (C-4), 67.9 (C-1‘), 57.1 (C-3a), 53.2 (C-1), 
44.9 (C-7a), 39.2 (C-7), 38.8 (C-2’), 36.1 (C-5), 27.5 (C-2), 26.1 (SiC(CH3)3), 23.8 (C-3), 21.9 
(C-6), 18.5 (SiC(CH3)3), 16.9 (2’-CH3), 12.2 (7a-CH3), -5.2 (Si(CH3)2), -5.2 (Si(CH3)2). 
IR (ATR): ṽ/cm-1 = 3293, 2927, 2855, 1471, 1459, 1386, 1360, 1251, 1097, 1069, 1030, 1017, 
1005, 954, 832, 812, 769, 719, 667. 
HRMS (EI): m/z calculated for C19H37O2Si [M]˙⁺ 326.2636; found 326.2641. 
Purity (GC): > 95% (scan mode m/z 50-650 (EI 70 eV)). 
 
Analytical data of alcohol 35c: 
Rf = 0.28 (hexanes/EtOAc 8:2). 
mp: 83 °C. 
[𝛂]𝑫
𝟐𝟑: + 38.1 (c = 0.07, CHCl3). 
1H NMR (400 MHz, chloroform-d) δ/ppm = 3.68 – 3.53 (m, 2H, 5, 1’-H), 3.25 (dd, J = 9.6, 7.3 
Hz, 1H, 1’-H), 1.92 (dt, J = 13.1, 3.6 Hz, 1H, 7-H), 1.86 – 1.73 (m, 3H, 3, 6-H), 1.57 – 1.43 (m, 
3H, 4, 2’-H, OH), 1.37 – 1.08 (m, 7H, 1, 2, 3a, 4, 6, 7-H), 0.98 (d, J = 6.5 Hz, 3H, 2’-CH3), 0.89 
(s, 9H, SiC(CH3)3), 0.72 (s, 3H, 7a-CH3), 0.02 (s, 6H, Si(CH3)2). 
13C NMR (101 MHz, chloroform-d) δ/ppm = 76.8 (C-5), 71.9 (C-1’), 67.9 (C-1), 52.0 (C-3a), 
48.6 (C-7a), 42.1 (C-2’), 39.2 (C-7), 37.5 (C-6), 35.3 (C-3), 31.7 (C-2), 28.3 (SiC(CH3)3), 26.1 
(C-4), 18.5 (SiC(CH3)3), 17.0 (2’-CH3), 11.4 (7a-CH3), -5.2 (Si(CH3)2), -5.2 (Si(CH3)2). 
IR (ATR): ṽ/cm-1 = 3304, 2928, 2856, 1471, 1359, 1249, 1104, 1088, 1056, 1027, 1004, 957, 
883, 858, 833, 812, 772, 702, 665. 
HRMS (EI): m/z calculated for C19H38O2Si [M]˙⁺ 326.2636; found 326.2630. 
Experimental Part 
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Purity (GC): > 95% (scan mode m/z 50-650 (EI 70 eV)). 
 
  
Experimental Part 
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(1R,3aS,7aS)-1-((S)-1-((tert-Butyldimethylsilyl)oxy)propan-2-yl)-7a-methyloctahydro-
5H-inden-5-one (28c) 
 
 
 
 
 
 
C19H36O2Si 
M = 324.58 g/mol 
Ketone 28c was synthesised according to GP3, using alcohol 35a (888 mg, 2.72 mmol, 
1.00 eq). The title compound was purified via FCC (hexanes/EtOAc 9:1) and isolated as white 
solid (872 mg, 2.69 mmol, 99%). 
 
Rf = 0.63 (hexanes/EtOAc 9:1). 
mp: 60 °C. 
[𝛂]𝑫
𝟐𝟑: + 41.8 (c = 0.11, CHCl3). 
1H NMR (500 MHz, chloroform-d) δ/ppm = 3.58 (dd, J = 9.6, 3.3 Hz, 1H, 1’-H), 3.30 (dd, J = 
9.6, 7.1 Hz, 1H, 1’-H), 2.45 – 2.37 (m, 1H, 6-H), 2.35 – 2.23 (m, 3H, 4, 7-H), 2.16 (ddd, J = 
13.1, 7.0, 2.0 Hz, 1H, 4-H), 1.93 (dtd, J = 13.3, 9.5, 6.3 Hz, 1H, 3-H), 1.85 – 1.76 (m, 1H, 3a-
H), 1.67 – 1.52 (m, 3H, 2, 6, 2’-H), 1.50 – 1.41 (m, 1H, 3-H), 1.31 – 1.21 (m, 2H, 1, 2-H), 1.01 
(d, J = 6.6 Hz, 3H, 2’-CH3), 0.92 (s, 3H, 7a-CH3), 0.89 (s, 9H, Si-C(CH3)3), 0.03 (s, 6H, 
Si(CH3)2). 
13C NMR (126 MHz, chloroform-d) δ/ppm = 212.4 (C-5), 67.7 (C-1’), 51.5 (C-1), 49.9 (C-3a), 
42.9 (C-7), 42.0 (C-7a), 39.0 (C-2’), 37.7 (C-4 or C-6), 37.7 (C-4 or C-6), 28.7 (C-3), 26.7 (C-
2), 26.1 (SiC(CH3)3), 18.5 (SiC(CH3)3), 17.1 (2’-CH3), 10.8 (7a-CH3), -5.2 (Si(CH3)2), -5.3 
(Si(CH3)2). 
IR (ATR): ṽ/cm-1 = 3384, 2946, 2928, 2896, 2857, 1717, 1470, 1412, 1361, 1250, 1226, 1200, 
1144, 1081, 1045, 1017, 1005, 992, 962, 939, 915, 856, 835, 813, 772, 749, 701, 681, 664, 
619, 574. 
HRMS (EI): m/z calculated for C15H27O2Si [M]˙⁺ 267.1780; found 267.1773. 
Purity (HPLC): 83% (λ = 191 nm), > 95% (λ = 210 nm) (method f).    
Experimental Part 
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1R,3aS,7aS)-1-((S)-1-((tert-Butyldimethylsilyl)oxy)propan-2-yl)-7a-methyl-2,3,3a,4,7,7a-
hexahydro-1H-inden-5-yl trifluoromethanesulfonate (172) 
 
 
 
C20H35F3O4SSi 
M = 456.64 g/mol 
A solution of 28c (350 mg, 1.08 mmol, 1.0 eq) in dry THF (20.0 mL) was added dropwise to 
NaHMDS (1M in THF, 2.70 mL, 2.70 mmol, 2.50 eq) at - 78 °C. After 1 h N-phenyl-
bis(trifluoromethansulfonimide) (925 mg, 2.59 mmol, 2.40 eq) was added and stirred for 
additonal 20 min. The reaction mixture was warmed up to rt and stirred for 2 h. The reaction 
was stopped with water (25.0 mL) and the organic solvent was removed in vacuo. The aq. 
residue was extracted with hexanes (3 x 25.0 mL). The combined organic layers were washed 
with water (30.0 mL), dried over Na2SO4, filtered and the solvent was removed in vacuo. The 
title product was purified via FCC (hexanes/EtOAc 95:5) and isolated as colourless oil (260 mg, 
0.569 mmol, 53%). 
 
Rf = 0.54 (hexanes/EtOAc 95:5). 
[𝜶]𝑫
𝟐𝟑: + 34.1 (c = 0.04, CHCl3). 
1H NMR (400 MHz, chloroform-d) δ/ppm = 5.66 (dt, J = 5.7, 2.1 Hz, 1H, 6-H), 3.57 (dd, J = 9.6, 
3.3 Hz, 1H, 1’-H), 3.31 (dd, J = 9.7, 6.8 Hz, 1H, 1’-H), 2.40 – 2.25 (m, 2H, 4, 7-H), 2.23 – 2.06 
(m, 2H, 4, 7-H), 1.99 – 1.68 (m, 3H, 2, 3, 3a-H), 1.60 – 1.51 (m, 1H, 2’-H), 1.47 – 1.18 (m, 3H, 
1, 2, 3 -H), 0.99 (d, J = 6.6 Hz, 3H, 2’-CH3), 0.89 (s, 9H, SiC(CH3)3), 0.72 (d, J = 0.7 Hz, 3H, 
7a-CH3), 0.03 (s, 6H, Si(CH3)2). 
13C NMR (101 MHz, chloroform-d) δ/ppm = 148.8 (C-5), 120.3 (q, JC-F = 320.2 Hz, CF3), 118.5 
(C-6), 67.7 (C-1’), 51.6 (C-1), 46.3 (C-3a), 41.1 (C-7a), 38.8 (C-2’), 38.7 (C-7), 30.8 (C-4), 28.4 
(C-2 or 3), 26.1 (C-2 or 3), 26.1 (SiC(CH3)3), 18.5 (SiC(CH3)3), 16.8 (2’-CH3), 11.2 (7a-CH3), -
5.2 (Si(CH3)2), -5.3 (Si(CH3)2). 
IR (ATR): ṽ/cm-1 = 2955, 2929, 2886, 2857, 1472, 1416, 1245, 1206, 1142, 1078, 1044, 1017, 
968, 906, 886, 854, 833, 774, 733, 665. 
HRMS (EI): m/z calculated for C20H35O4F3SSi [M]˙⁺ 456.1972; found 456.1978. 
Purity (HPLC): 90% (λ = 210 nm), 81% (λ = 250 nm) (method e). 
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tert-Butyldimethyl((S)-2-((1R,3aR,7aR)-7a-methyl-4-vinyl-2,3,3a,6,7,7a-hexahydro-1H-
inden-1-yl)propoxy)silane (25) 
 
 
 
 
 
C21H38OSi 
M = 334.62 g/mol 
Enol triflate 34 (1.00 g, 2.20 mmol, 1.00 eq) was dissolved in dry THF (20.0 mL) and 
tributyl(vinyl)tin (0.770 mL, 2.60 mmol, 1.20 eq) and LiCl (466 mg, 11.0 mmol, 5.00 eq) were 
added. The suspension was degassed before Pd(PPh3)4 (127 mg, 0.110 mmol, 5.00 mol%) 
was added and the reaction mixture was stirred at 80 °C for 3 h. The reaction was stopped 
with water (10.0 mL) and the organic solvent was removed in vacuo. The aq. residue was 
extracted with hexanes (3 x 30.0 mL) and the combined organic layers were dried over 
Na2SO4, filtered and concentrated in vacuo. The title compound was purified via FCC 
(hexanes/EtOAc 99:1) and isolated as colourless oil (591 mg, 1.70 mmol, 77%). 
 
Rf = 0.40 (hexanes/EtOAc 99:1). 
[𝛂]𝑫
𝟐𝟑: + 31.9 (c = 0.06, CHCl3). 
1H NMR (400 MHz, chloroform-d) δ/ppm = 6.20 (ddt, J = 17.7, 11.2, 0.9 Hz, 1H, 1’’-H), 5.70 – 
5.67 (m, 1H, 5’-H), 5.22 – 5.17 (m, 1H, 2’’-H), 4.87 – 4.82 (m, 1H, 2’’-H), 3.61 (dd, J = 9.6, 3.4 
Hz, 1H, 1-H), 3.28 (dd, J = 9.6, 7.4 Hz, 1H, 1-H), 2.28 – 2.18 (m, 3H, 3a’, 6’-H), 2.04 – 1.86 
(m, 3H, 2’, 3’, 7’-H), 1.62 – 1.52 (m, 1H, 2-H), 1.46 – 1.35 (m, 3H, 2’, 3’, 7’-H), 1.30 – 1.21 (m, 
1H, 1’-H), 1.04 (d, J = 6.6 Hz, 3H, 2-CH3), 0.90 (s, 9H, SiC(CH3)3), 0.70 (s, 3H, 7a’-CH3), 0.04 
(s, 3H, Si(CH3)2), 0.04 (s, 3H, Si(CH3)2). 
13C NMR (126 MHz, chloroform-d) δ/ppm = 138.9 (C-1’’), 138.2 (C-4’), 126.1 (C-5’), 111.6 (C-
2’’), 68.0 (C-1), 50.7 (C-1’), 49.7 (C-3a’), 43.02 (C-7a’), 39.5 (C-2), 35.9 (C-7’), 28.3 (C-2’), 
26.1 (SiC(CH3)3), 24.9 (C-6’), 24.3 (C-3’), 18.6 (SiC(CH3)3), 17.3 (2-CH3), 11.5 (7a’-CH3), -5.2 
(Si(CH3)2), -5.2 (Si(CH3)2). 
IR (ATR): ṽ/cm-1 = 2952, 2926, 2857, 1471, 1385, 1361, 1251, 1127, 1085, 1032, 1024, 1004, 
833, 808, 773, 664, 586. 
HRMS (EI): m/z calculated for C21H38OSi [M]˙⁺ 334.2686; found 334.2689. 
Purity (HPLC): > 95% (λ = 210 nm), > 95% (λ = 254 nm) (method d).  
Experimental Part 
 
  
 
  
 118 
 
(S)-2-((1R,3aR,7aR)-7a-Methyl-4-vinyl-2,3,3a,6,7,7a-hexahydro-1H-inden-1-yl)propan-1-
ol (47) 
 
 
 
 
C15H24O 
M = 220.36 g/mol 
In an oven-dried flask diene 25 (630 mg, 1.88 mmol, 1.00 eq) was dissolved in dry THF 
(5.00 mL). TBAF (1M in THF, 2.82 mL, 2.82 mmol, 1.50 eq) and TEA (0.525 mL, 3.77 mmol, 
2.00 eq) were added and the resulting reaction mixture was stirred at rt for 18 h. The reaction 
was stopped with water (5.00 mL) and the aq. phase was extracted with EtOAc (3 x 7.00 mL). 
The combined organic layers were dried over Na2SO4, filtered and the solvent was removed 
in vacuo. The title compound was purfied via FCC (hexanes/EtOAc 7:3) and isolated as 
viscous, colourless oil (303 mg, 1.38 mmol, 73%). 
 
Rf = 0.48 (hexanes/EtOAc 7:3). 
[𝜶]𝑫
𝟐𝟑: + 16.7 (c = 0.04, CHCl3). 
1H NMR (400 MHz, chloroform-d) δ/ppm = 6.19 (ddt, J = 17.7, 11.2, 1.0 Hz, 1H, 1’’-H), 5.69 (q, 
J = 3.5 Hz, 1H, 5’-H), 5.19 (dd, J = 17.7, 1.6 Hz, 1H, 2’’-H), 4.84 (dd, J = 11.2, 1.6 Hz, 1H, 2’’-
H), 3.66 (dd, J = 10.6, 3.2 Hz, 1H, 1’-H), 3.40 (dd, J = 10.5, 6.9 Hz, 1H, 1’-H), 2.31 – 2.13 (m, 
3H, 3a’, 6’-H), 2.04 – 1.91 (m, 3H, 2’, 3’, 7’-H), 1.67 – 1.55 (m, 1H, 2-H), 1.48 – 1.36 (m, 3H, 
2’, 3’, 7’-H), 1.34 – 1.26 (m, 2H, 1’-H, OH), 1.09 (d, J = 6.7 Hz, 3H, 2-CH3), 0.71 (s, 3H, 7a’-
CH3). 
13C NMR (101 MHz, chloroform-d) δ/ppm = 138.9 (C-1’’), 138.1 (C-4’), 126.0 (C-5’), 111.7 (C-
2’’), 68.1 (C-1), 50.4 (C-1’), 49.7 (C-3a’), 42.9 (C-7a’), 39.2 (C-2), 35.9 (C-7’), 28.3 (C-2’ or 3’), 
24.9 (C-6’), 24.2 (C-2’ or 3’), 17.1 (2-CH3), 11.4 (7a’-CH3). 
IR (ATR): ṽ/cm-1 = 3324, 2949, 2874, 1445, 1378, 1038, 983, 889.   
HRMS (EI): m/z calculated for C15H24O [M]˙⁺ 220.1822; found 220.1820. 
Purity (HPLC): > 95% (λ = 210 nm), > 95% (λ = 254 nm) (method c).   
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tert-Butyldimethyl((S)-2-((1R,3aS,7aR)-7a-methyl-4-methyleneoctahydro-1H-inden-1-
yl)propoxy)silane (72) 
 
 
 
 
C20H38OSi 
M = 322.61 g/mol 
Methyltriphenylphosphonium bromide (2.41 g, 6.75 mmol, 1.50 eq) was dissolved in dry THF 
(30.0 mL) and the solution was cooled to 0 °C. LDA (2M in THF, 4.50 mL, 9.00 mmol, 2.00 eq) 
was added and the mixture was stirred for 30 min. A solution of ketone 26 (1.46 g, 4.50 mmol, 
1.00 eq) in dry THF (10.0 mL) was added and the reaction mixture was slowly warmed up to 
rt and stirred for 18 h. The reaction was diluted with water (20.0 mL) and the mixture was 
extracted with EtOAc (3 x 40.0 mL). The combined organic layers were dried over Na2SO4, 
filtered and the solvent was removed in vacuo. The title compound was purified via FCC 
(hexanes/toluene 9:1) and obtained as colourless oil (980 mg, 3.04 mmol, 68%). 
 
Rf = 0.30 (hexanes/toluene 9:1). 
[𝛂]𝑫
𝟐𝟑: + 59.8 (c = 0.11, CHCl3). 
1H NMR (400 MHz, chloroform-d) δ/ppm = 4.74 (q, J = 1.9 Hz, 1H, 1’’-H), 4.46 (q, J = 2.0 Hz, 
1H, 1’’-H), 3.60 (dd, J = 9.6, 3.4 Hz, 1H, 1-H), 3.27 (dd, J = 9.6, 7.4 Hz, 1H, 1-H), 2.30 – 2.23 
(m, 1H, 5’-H), 2.04 – 1.97 (m, 1H, 7’-H), 1.96 – 1.89 (m, 2H, 3a’, 5’-H), 1.88 – 1.81 (m, 1H, 3’-
H), 1.66 – 1.47 (m, 5H, 2, 2’, 6’-H), 1.37 – 1.23 (m, 3H, 1’, 3’, 7’-H), 1.01 (d, J = 6.5 Hz, 3H, 2-
CH3), 0.90 (s, 9H, SiC(CH3)3), 0.57 (d, J = 0.6 Hz, 3H, 7a’-CH3), 0.04 (s, 3H, Si(CH3)2), 0.04 
(s, 3H, Si(CH3)2). 
13C NMR (101 MHz, chloroform-d) δ/ppm = 149.7 (C-4’), 105.2 (C-1’’), 68.0 (C-1), 55.2 (C-3a’), 
53.1 (C-1’), 45.3 (C-7a’), 40.2 (C-7’), 39.5 (C-2), 35.6 (C-5’), 27.3 (C-3’), 26.1 (SiC(CH3)3), 23.9 
(C-6’), 22.6 (C-2’), 18.6 (SiC(CH3)3), 17.2 (2-CH3), 12.0 (7a’-CH3), -5.2 (Si(CH3)2), -5.2 
(Si(CH3)2). 
IR (ATR): ṽ/cm-1 = 3076, 2950, 2927, 2855, 1650, 1471, 1252, 1088, 1030, 1004, 884, 833, 
773, 665.  
HRMS (EI): m/z calculated for C20H38OSi [M]˙⁺ 322.2686; found 322.2689. 
Purity (GC): > 95% (scan mode m/z 50-650 (EI 70 eV)).  
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((1R,3aS,4S,7aR)-1-((S)-1-((tert-Butyldimethylsilyl)oxy)propan-2-yl)-7a-
methyloctahydro-1H-inden-4-yl)methanol (74) 
 
 
 
 
 
C20H40O2Si 
M = 340.62 g/mol 
Alcohol 74 was synthesised according to GP4, using olefin 72 (688 mg, 2.13 mmol, 1.00 eq). 
The title compound was purified via FCC (hexanes/EtOAc 8:2) and isolated as white solid 
(526 mg, 1.54 mmol, 72%). 
 
Rf = 0.37 (hexanes/EtOAc 8:2). 
mp: 86°C. 
[𝛂]𝑫
𝟐𝟑: + 64.4 (c = 0.11, CHCl3). 
1H NMR (500 MHz, chloroform-d) δ/ppm = 3.72 (ddd, J = 10.3, 3.1, 1.2 Hz, 1H, 4-CH2), 3.66 
(t, J = 10.0 Hz, 1H, 4-CH2), 3.57 (dd, J = 9.6, 3.3 Hz, 1H, 1’-H), 3.25 (dd, J = 9.6, 7.4 Hz, 1H, 
1’-H), 1.96 – 1.90 (m, 2H, 4, 6-H), 1.90 – 1.85 (m, 1H, 5-H), 1.82 – 1.74 (m, 1H, 3-H), 1.58 – 
1.41 (m, 5H, 2, 3a, 7, 2’-H), 1.37 – 1.29 (m, 1H, 5-H), 1.27 – 1.19 (m, 2H, 3-H, OH), 1.17 – 
1.08 (m, 2H, 1, 6-H), 0.95 (d, J = 6.5 Hz, 3H, 2’-CH3), 0.89 (s, 9H, SiC(CH3)3), 0.64 (s, 3H, 7a-
CH3), 0.02 (s, 3H, Si(CH3)2), 0.02 (s, 3H, Si(CH3)2). 
13C NMR (126 MHz, chloroform-d) δ/ppm = 67.9 (C-1’), 61.7 (4-CH2), 53.5 (C-1), 51.6 (C-3a), 
42.2 (C-7a), 40.9 (C-4), 40.7 (C-6), 39.2 (C-2’), 28.1 (C-5), 26.9 (C-3), 26.1 (SiC(CH3)3), 23.8 
(C-2), 18.5 (SiC(CH3)3), 18.3 (C-7), 16.9 (2’-CH3), 13.6 (7a-CH3), -5.2 (Si(CH3)2), -5.2 
(Si(CH3)2). 
IR (ATR): ṽ/cm-1 = 3298, 2945, 2928, 2854, 1471, 1250, 1087, 1019, 908, 859, 844, 833, 733, 
734, 663. 
HRMS (EI): m/z calculated for C20H40O2Si [M]˙⁺ 340.2792; found 340.2791. 
Purity (GC): > 95% (scan mode m/z 50-650 (EI 70 eV)). 
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(1R,3aS,4S,7aR)-1-((S)-1-((tert-Butyldimethylsilyl)oxy)propan-2-yl)-7a-methyloctahydro-
1H-indene-4-carbaldehyde (73b) 
 
 
   C20H38O2Si 
M = 338.60 g/mol 
Aldehyde 73b was synthesised according to GP3 using alcohol 74 (465 mg, 1.37 mmol, 
1.00 eq). The title compound was purified via FCC (hexanes/EtOAc 85:15) and isolated as a 
colourless oil (265 mg, 0.783 mmol, 57%). 
 
Rf = 0.90 (hexanes/EtOAc 85:15). 
[𝜶]𝑫
𝟐𝟑: + 94.9 (c = 0.05, CHCl3). 
1H NMR (400 MHz, chloroform-d) δ/ppm = 10.03 (s, 1H, CHO), 3.57 (dd, J = 9.6, 3.3 Hz, 1H, 
1’-H), 3.29 (dd, J = 9.6, 7.0 Hz, 1H, 1’-H), 2.52 – 2.46 (m, 1H, 4-H), 2.28 (dd, J = 13.7, 3.3 Hz, 
1H, 2-H or 5-H), 1.96 (dt, J = 13.3, 3.5 Hz, 1H, 7-H), 1.93 – 1.87 (m, 1H, 2-H or 5-H), 1.87 – 
1.80 (m, 1H, 1-H), 1.80 – 1.69 (m, 2H, 3-H or 6-H), 1.48 (ddq, J = 13.5, 6.7, 3.7 Hz, 3H, 2´´-H, 
3-H or 6-H), 1.38 – 1.30 (m, 1H, 2-H or 5-H), 1.30 – 1.09 (m, 3H, 3a-H, 7-H), 0.97 (d, J = 6.6 
Hz, 3H, 2’-CH3), 0.89 (s, 9H, SiC(CH3)3), 0.63 (s, 3H, 7a-CH3), 0.03 (s, 3H, Si(CH3)2), 0.03 (s, 
3H, Si(CH3)2). 
13C NMR (101 MHz, chloroform-d) δ/ppm = 205.0 (CHO), 67.9 (C-1’), 52.9 (C-3a), 51.2 (C-1), 
48.7 (C-4), 42.9 (C-7a), 40.1 (C-7), 39.1 (C-2’), 26.9 (C-2 or C-5), 26.1 (SiC(CH3)3), 25.2 (C-2 
or C-5), 23.2 (C-3 or C-6), 19.1 (C-3 or C-6), 18.5 (SiC(CH3)3), 17.1 (2’-CH3), 12.7 (7a-CH3), -
5.2 (Si(CH3)2) , -5.3 (Si(CH3)2). 
IR (ATR): ṽ/cm-1 = 2951, 2930, 2855, 2736, 2363, 1716, 1472, 1462, 1388, 1361, 1250, 1187, 
1124, 1088, 1058, 1035, 1006, 981, 938, 915, 894, 833, 814, 773, 733, 705, 666. 
HRMS (EI): m/z calculated for C20H38O2Si [M]˙⁺ 338.2641; found 338.2632. 
Purity (GC): 86% (scan mode m/z 50-650 (EI 70 eV)).  
  
Experimental Part 
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6.2.3. Procedures and data for tri/tetracycles (chapter 3.2.) 
(3aR,3bS,5aR,6R,8aR,10aS)-6-((S)-1-((tert-Butyldimethylsilyl)oxy)propan-2-yl)-5a-
methyl-3b,4,5,5a,6,7,8,8a,10,10a-decahydroindeno[5,4-e]isoindole-1,3(2H,3aH)-dione 
(36) 
 
 
 
C25H41NO3Si 
M = 431.69 g/mol 
Tetracycle 36 was synthesised according to GP5 (microwave conditions: 125 °C, 5 min, 6 bar, 
300 W), using diene 25 (52.7 mg, 0.157 mmol, 1.00 eq) and maleimide (15.3 mg, 0.157 mmol, 
1.00 eq). The title compound was purified via FCC (hexanes/EtOAc 8:2) and isolated as white 
crystalline solid (60.0 mg, 0.139 mmol, 89%).  
 
Rf = 0.26 (hexanes/EtOAc 8:2). 
mp: 205 °C. 
[𝛂]𝑫
𝟐𝟑: + 105.5 (c = 0.08, CHCl3). 
1H NMR (500 MHz, chloroform-d) δ/ppm = 8.21 (s, 1H, NH), 5.46 – 5.40 (m, 1H, 9-H), 3.57 
(dd, J = 9.7, 2.7 Hz, 1H, 1’-H), 3.28 (dd, J = 9.6, 6.6 Hz, 1H, 1’-H), 3.13 (ddd, J = 8.7, 7.2, 1.5 
Hz, 1H, 10a-H), 3.08 (dd, J = 8.8, 6.0 Hz, 1H, 3a-H), 2.70 (ddt, J = 15.1, 7.2, 1.1 Hz, 1H, 10-
H), 2.41 – 2.25 (m, 3H, 3b, 4, 8a-H), 2.16 – 2.08 (m, 1H, 10-H), 2.01 – 1.94 (m, 1H, 5-H), 1.94 
– 1.86 (m, 1H, 7-H or 8-H), 1.79 – 1.71 (m, 1H, 4-H), 1.61 – 1.53 (m, 1H, 7-H or 8-H), 1.50 – 
1.27 (m, 5H, 5, 6, 7, 8, 2’-H), 0.98 (d, J = 5.9 Hz, 3H, 2’-CH3), 0.89 (s, 9H, SiC(CH3)3), 0.52 (s, 
3H, 5a-CH3), 0.02 (s, 6H, Si(CH3)2). 
13C NMR (126 MHz, chloroform-d) δ/ppm = 180.5 (C-1), 178.6 (C-3), 144.9 (C-8b), 116.5 (C-
9), 67.8 (C-1’), 52.7 (C-6), 48.8 (C-8a), 44.7 (C-3a), 42.9 (C-5a), 41.7 (C-10a), 39.6 (C-2’), 
36.4 (C-5), 34.8 (C-3b), 28.6 (C-7 or C-8), 26.1 (SiC(CH3)3), 23.9 (C-10), 23.2 (C-4), 21.9 (C-
7 or C-8), 18.5 (5a-CH3 or SiC(CH3)3), 18.5 (5a-CH3 or SiC(CH3)3), 16.9 (2’-CH3), -5.2 
(Si(CH3)2), -5.2 (Si(CH3)2). 
IR (ATR): ṽ/cm-1 = 3837, 3801, 3225, 2956, 2928, 2855, 1747, 1699, 1461, 1441, 1378, 1354, 
1328, 1254, 1198, 1184, 1163, 1093, 999, 938, 858, 833, 812, 773, 742, 687, 665, 635, 559. 
HRMS (EI): m/z calculated for C25H41NO3Si [M]˙⁺ 431.2850; found 431.2853. 
Purity (HPLC): > 95% (λ = 210 nm), > 95% (λ = 254 nm) (method d).  
Experimental Part 
 
  
 
  
 123 
 
(3aR,3bS,5aR,6R,8aR,10aS)-6-((S)-1-((tert-Butyldimethylsilyl)oxy)propan-2-yl)-5a-
methyl-3b,4,5,5a,6,7,8,8a,10,10a-decahydro-1H-cyclopenta[5,6]naphtho[1,2-c]furan-
1,3(3aH)-dione (39) 
 
 
 
   
C25H40O4Si 
M = 432.68 g/mol 
Tetracycle 39 was synthesised according to GP5 (microwave conditions: 125 °C, 5 min, 6 bar, 
300 W), using diene 25 (109 mg, 0.326 mmol, 1.00 eq) and maleic anhydride (31.9 mg, 
0.326 mmol, 1.00 eq). The title compound was purified via FCC (SiO2, neutralised with TEA, 
hexanes/EtOAc 8:2) and isolated as white crystalline solid (12.9 mg, 0.029 mmol, 9%).  
 
Rf = 0.50 (hexanes/EtOAc 8:2). 
mp: 207 °C. 
[𝛂]𝑫
𝟐𝟑: + 104.9 (c = 0.03, CHCl3). 
1H NMR (400 MHz, chloroform-d) δ/ppm = 5.51 (dd, J = 7.1, 2.9 Hz, 1H, 9-H), 3.57 (dd, J = 
9.7, 2.6 Hz, 1H, 1’-H), 3.40 (ddd, J = 9.7, 7.1, 1.7 Hz, 1H, 10a-H), 3.30 (td, J = 9.4, 6.4 Hz, 2H, 
3a, 1’-H), 2.80 – 2.67 (m, 1H, 10-H), 2.44 – 2.15 (m, 3H, 3b, 8a, 10-H), 2.05 – 1.97 (m, 1H, 5-
H), 1.96 – 1.86 (m, 1H, 4, 7 or 8-H), 1.77 (dt, J = 12.8, 5.7 Hz, 1H, 4, 7 or 8-H), 1.65 – 1.27 (m, 
6H, 4, 5, 6, 7, 8, 2’-H), 0.98 (d, J = 5.9 Hz, 3H, 2’-CH3), 0.89 (s, 9H, SiC(CH3)3), 0.53 (s, 3H, 
5a-CH3), 0.03 (s, 3H, Si(CH3)2), 0.03 (s, 3H, Si(CH3)2). 
13C NMR (101 MHz, chloroform-d) δ/ppm = 174.7 (C-1), 171.9 (C-3), 145.6 (C-8b), 117.0 (C-
9), 67.7 (C-1’), 52.8 (C-6), 48.8 (C-8a), 44.4 (C-3a), 42.9 (C-5a), 41.1 (C-10a), 39.5 (C-2’), 
36.1 (C-5), 34.4 (C-3b), 28.5 (C-4, 7 or 8), 26.1 (SiC(CH3)3), 24.1 (C-10), 23.1 (C-4, 7 or 8), 
21.9 (C-4, 7 or 8), 18.6 (5a-CH3), 18.5 (SiC(CH3)3), 16.9 (2’-CH3), -5.2 (Si(CH3)2), -5.3 
(Si(CH3)2). 
IR (ATR): ṽ/cm-1 = 3348, 2954, 2854, 1765, 1632, 1413, 1247, 1187, 1092, 1024, 954, 923, 
832, 773, 699. 
HRMS (EI): m/z calculated for C25H40O4Si [M]˙⁺ 432.2696; found 432.2694. 
Purity (HPLC): > 95% (λ = 191 nm), > 95% (λ = 210 nm) (method f). 
Experimental Part 
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(5aR,6R,8aR)-6-((S)-1-((tert-Butyldimethylsilyl)oxy)propan-2-yl)-2-hydroxy-5a-methyl-
3b,4,5,5a,6,7,8,8a,10,10a-decahydroindeno[5,4-e]isoindole-1,3(2H,3aH)-dione (37) 
 
 
 
 
 
C25H41NO4Si 
M = 447.69 g/mol 
Tetracycle 37 was synthesised according to GP5 (microwave conditions: 125 °C, 5 min, 6 bar, 
300 W), using diene 25 (150 mg, 0.448 mmol, 1.00 eq) and N-hydroxy maleimide (50.7 mg, 
0.448 mmol, 1.00 eq). The title compound was purified via FCC (hexanes/EtOAc 5:5) and 
isolated as white solid (196 mg, 0.438 mmol, 97%).  
 
Rf = 0.48 (hexanes/EtOAc 5:5). 
mp: 167 °C. 
[𝛂]𝑫
𝟐𝟑: + 95.0 (c = 0.03, CHCl3). 
1H NMR (500 MHz, chloroform-d) δ/ppm = 5.38 (dq, J = 7.4, 2.4 Hz, 1H, H-9), 3.57 (dd, J = 
9.7, 2.9 Hz, 1H, 1’-H), 3.28 (dd, J = 9.6, 6.7 Hz, 1H, 1’-H), 3.11 – 3.02 (m, 2H, 3a, 10a-H), 2.71 
(ddd, J = 16.0, 7.0, 1.5 Hz, 1H, 10-H), 2.38 – 2.27 (m, 3H, 8a, 3b-H, 4, 7 or 8-H), 2.18 – 2.11 
(m, 1H, 10-H), 1.97 (dd, J = 13.9, 6.8 Hz, 1H, 5-H), 1.93 – 1.86 (m, 1H, 4, 7 or 8-H), 1.76 (dt, 
J = 12.5, 4.6 Hz, 1H, 4, 7 or 8-H), 1.59 – 1.52 (m, 1H, 4, 7 or 8-H), 1.50 – 1.40 (m, 3H, 5, 6, 2’-
H), 1.40 – 1.24 (m, 3H, OH, 4, 7 or 8-H), 0.98 (d, J = 6.0 Hz, 3H, 2’-CH3), 0.89 (s, 9H, 
SiC(CH3)3), 0.51 (s, 3H, 5a-CH3), 0.03 (s, 3H, Si(CH3)2), 0.03 (s, 3H, Si(CH3)2). 
13C NMR (101 MHz, chloroform-d) δ/ppm = 174.6 (C-1), 172.9 (C-3), 144.8 (C-8b), 116.2 (C-
9), 67.8 (C-1’), 52.7 (C-6), 48.7 (C-8a), 42.9 (C-5a), 41.0 (C-3a), 39.6 (C-2’), 37.7 (C-10a), 
36.3 (C-5), 34.8 (C-3b), 28.5 (C-4, 7 or 8), 26.1 (SiC(CH3)3), 23.8 (C-10), 23.2 (C-4, 7 or 8), 
21.9 (C-4, 7 or 8), 18.5 (SiC(CH3)3), 18.5 (5a-CH3), 16.9 (2’-CH3), -5.2 (Si(CH3)2), -5.2 
(Si(CH3)2).  
IR (ATR): ṽ/cm-1 = 2929, 2855, 1770, 1699, 1681, 1515, 1469, 1436, 1362, 1315, 1256, 1218, 
1182, 1093, 1076, 1060, 1019, 1005, 938, 852, 835, 812, 773, 714, 663, 603, 577, 567. 
HRMS (EI): m/z calculated for C25H41NO3Si [M]˙⁺ 431.2850; found 431.2832. 
Purity (HPLC): 93% (λ = 191 nm), > 95% (λ = 210 nm) (method f).   
Experimental Part 
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1-(Hydroxymethyl)-1H-pyrrole-2,5-dione (41)[79] 
 
 
 
 
 
C5H5NO3 
M = 127.09 g/mol 
Maleimide (200 mg, 2.06 mmol, 1.00 eq) was added to a mixture of formaldehyde (37% 
solution, 500 µL) and 5% aq. NaOH solution (0.010 mL) was added. Maleimide had dissolved 
within a few seconds and an exothermic reaction proceeded. After 30 sec a white solid has 
formed, which was filtrated and washed with ice cold EtOH (10.0 mL) and Et2O (10.0 mL). The 
title compound was obtained as white solid (181 mg, 1.43 mmol, 69%). 
 
Rf = 0.32 (hexanes/EtOAc 6:4). 
mp: 99 °C. 
1H NMR (400 MHz, chloroform-d) δ/ppm = 6.77 (s, 2H, 3, 4-H), 5.08 (d, J = 7.8 Hz, 2H, N-
CH2), 3.18 (t, J = 7.9 Hz, 1H, OH). 
13C NMR (101 MHz, chloroform-d) δ/ppm = 170.3 (C-2, 5), 134.8 (C-3, 4), 61.2 (N-CH2). 
IR (ATR): ṽ/cm-1 = 3092, 1698, 1357, 1325, 1165, 1036, 911, 840, 757, 694, 657. 
HRMS (EI): m/z calculated for C5H4NO3 [M]˙⁺ 126.0191; found 126.0176. 
Purity (HPLC): > 95% (λ = 210 nm), > 95% (λ = 254 nm) (method c).   
  
Experimental Part 
 
  
 
  
 126 
 
(5aR,6R,8aR)-6-((S)-1-((tert-Butyldimethylsilyl)oxy)propan-2-yl)-2-(hydroxymethyl)-5a-
methyl-3b,4,5,5a,6,7,8,8a,10,10a-decahydroindeno[5,4-e]isoindole-1,3(2H,3aH)-dione 
(38) 
 
 
 
 
 
C26H43NO4Si 
M = 461.72 g/mol 
Tetracycle 38 was synthesised according to GP5 (microwave conditions: 125 °C, 5 min, 6 bar, 
300 W), using diene 25 (123 mg, 0.368 mmol, 1.00 eq) and 41 (46.7 mg, 0.368 mmol, 1.00 eq). 
The title compound was purified via FCC (hexanes/EtOAc 6:4) and isolated as white oily solid 
(121 mg, 0.262 mmol, 71%).  
 
Rf = 0.46 (hexanes/EtOAc 6:4). 
[𝛂]𝑫
𝟐𝟑: + 102.0 (c = 0.05, CHCl3). 
1H NMR (400 MHz, chloroform-d) δ/ppm = 5.43 – 5.34 (m, 1H, 9-H), 4.95 (d, J = 8.2 Hz, 2H, 
N-CH2), 3.56 (dd, J = 9.6, 2.6 Hz, 1H, 1’-H), 3.28 (dd, J = 9.6, 6.5 Hz, 1H, 1’-H), 3.21 (t, J = 8.1 
Hz, 1H, OH), 3.15 – 3.04 (m, 2H, 3a, 10a-H), 2.76 – 2.68 (m, 1H, 10-H), 2.40 – 2.28 (m, 3H, 
4, 8a, 3b-H), 2.19 – 2.10 (m, 1H, 10-H), 1.97 (dd, J = 15.0, 6.5 Hz, 1H, 5-H), 1.92 – 1.84 (m, 
1H, 8-H), 1.82 – 1.74 (m, 1H, 4-H), 1.59 – 1.23 (m, 6H, 5, 6, 7, 8, 2’-H), 0.98 (d, J = 5.9 Hz, 
3H, 2’-CH3), 0.89 (s, 9H, Si-C(CH3)3), 0.51 (s, 3H, 5a-CH3), 0.02 (s, 6H, Si(CH3)2). 
13C NMR (101 MHz, chloroform-d) δ/ppm = 179.9 (C-1), 178.1 (C-3), 144.9 (C-8b), 116.4 (C-
9), 67.8 (C-1’), 62.6 (N-CH2), 52.7 (C-6), 48.7 (C-8a), 43.7 (C-3a), 42.9 (C-5a), 40.5 (C-10a), 
39.6 (C-2’), 36.4 (C-5), 34.8 (C-3b), 28.5 (C-8), 26.1 (Si-C(CH3)3), 23.9 (C-10), 23.3 (C-4), 21.9 
(C-7), 18.5 (Si-C(CH3)3), 18.5 (5a-CH3), 16.9 (1’-CH3), -5.2 (Si(CH3)2), -5.2 (Si(CH3)2). 
IR (ATR): ṽ/cm-1 = 2927, 2854, 1766, 1719, 1695, 1468, 1425, 1358, 1253, 1205, 1091, 1069, 
1048, 1005, 977, 852, 834, 773, 639, 591. 
HRMS (EI): m/z calculated for C25H41NO3Si [M-CH2OH]˙⁺ 431.2850; found 431.2853. 
Purity (HPLC): > 95% (λ = 210 nm) (method c). 
 
 
Experimental Part 
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(5S,9S,10R,13R,14R,17R)-17-((S)-1-((tert-Butyldimethylsilyl)oxy)propan-2-yl)-13-methyl-
6,9,10,11,12,13,14,15,16,17-decahydro-1H-cyclopenta[a]phenanthrene-1,4(5H)-dione 
(40) 
 
 
 
 
  
C27H42O3Si 
M = 442.72 g/mol 
Tetracycle 40 was synthesised according to GP5 (microwave conditions: 125 °C, 2.5 h, 6 bar, 
300 W), using diene 25 (303 mg, 0.906 mmol, 1.0 eq) and p-benzochinone (98 mg, 0.91 mmol, 
1.0 eq). The title compound was purified via FCC (hexanes/EtOAc 95:5) and isolated as orange 
solid (62 mg, 0.14 mmol, 15%).  
 
Rf = 0.17 (hexanes/EtOAc 95:5). 
mp: 147 °C. 
[𝛂]𝑫
𝟐𝟑: + 170.4 (c = 0.04, CHCl3). 
1H NMR (400 MHz, chloroform-d) δ/ppm = 6.57 (d, J = 10.2 Hz, 1H, 3-H), 6.50 (dd, J = 10.3, 
1.3 Hz, 1H, 2-H), 5.07 (t, J = 3.1 Hz, 1H, 7-H), 3.59 (dd, J = 9.7, 3.1 Hz, 1H, 1’-H), 3.29 (dd, J 
= 9.6, 6.8 Hz, 1H, 1’-H), 3.25 – 3.20 (m, 2H, 5, 10-H), 2.63 – 2.51 (m, 2H, 11, 14-H), 2.50 – 
2.37 (m, 2H, 6, 9-H), 2.21 – 2.08 (m, 1H, 6-H), 1.90 (ddt, J = 21.0, 14.3, 9.1 Hz, 2H, 12, 15-H), 
1.77 – 1.67 (m, 1H, 16-H), 1.58 – 1.24 (m, 6H, 11, 12, 15, 16, 17, 2’-H), 0.98 (d, J = 6.1 Hz, 
3H, 2’-CH3), 0.89 (s, 9H, SiC(CH3)3), 0.69 (s, 3H, 13-CH3), 0.03 (s, 3H, Si(CH3)2), 0.03 (s, 3H, 
Si(CH3)2). 
13C NMR (101 MHz, chloroform-d) δ/ppm = 201.7 (C-1), 199.7 (C-4), 141.9 (C-8), 141.1 (C-3), 
137.2 (C-2), 114.6 (C-7), 67.8 (C-1’), 53.6 (C-17), 50.9 (C-5), 50.2 (C-10), 48.9 (C-14), 41.9 
(C-13), 39.5 (C-2’), 37.5 (C-12), 36.4 (C-9), 28.4 (C-15), 27.3 (C-6), 26.1 (SiC(CH3)3), 24.2 (C-
11), 23.0 (C-16), 18.9 (13-CH3), 18.5 (SiC(CH3)3), 16.9 (2’-CH3), -5.2 (Si(CH3)2), -5.2 
(Si(CH3)2). 
IR (ATR): ṽ/cm-1 = 2954, 2929, 2879, 2856, 2358, 1681, 1600, 1471, 1438, 1382, 1360, 1341, 
1251, 1184, 1091, 1006, 977, 939, 858, 834, 816, 774, 691, 667. 
HRMS (EI): m/z calculated for C27H42O3Si [M]˙⁺ 442.2897; found 442.2901.  
Purity (HPLC): 93% (λ = 210 nm) (method e). 
Experimental Part 
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 (3aR,3bS,5aR,6R,8aR,10aS)-6-((S)-1-Hydroxypropan-2-yl)-5a-methyl-
3b,4,5,5a,6,7,8,8a,10,10a-decahydroindeno[5,4-e]isoindole-1,3(2H,3aH)-dione (42) 
 
 
 
 
 
 
 
C19H27NO3 
M = 317.43 g/mol 
Alcohol 42 was synthesised according to GP9, using tetracycle 36 (45.3 mg, 0.105 mmol, 
1.00 eq). The title compound was purified via FCC (hexanes/EtOAc 5:5) and obtained as white 
solid (32 mg, 0.101 mmol, 96%). 
 
Rf = 0.34 (hexanes/EtOAc 5:5). 
mp: 170 °C. 
[𝛂]𝑫
𝟐𝟑: + 126.1 (c = 0.05, CHCl3).  
1H NMR (400 MHz, chloroform-d) δ/ppm = 8.22 (s, 1H, NH), 5.44 (dq, J = 7.7, 2.7 Hz, 1H, 9-
H), 3.64 (dd, J = 10.5, 2.8 Hz, 1H, 1’-H), 3.37 (dd, J = 10.5, 6.3 Hz, 1H, 1’-H), 3.18 – 3.05 (m, 
2H, 3a, 10a-H), 2.70 (ddt, J = 15.1, 7.2, 1.2 Hz, 1H, 10-H), 2.44 – 2.25 (m, 3H, 3b, 4, 8a-H), 
2.17 – 2.06 (m, 1H, 10-H), 2.03 – 1.87 (m, 2H, 5-H), 1.82 – 1.71 (m, 1H, 4-H), 1.64 – 1.27 (m, 
5H, 6, 7, 8, 2’-H), 1.03 (d, J = 6.1 Hz, 3H, 2’-CH3), 0.53 (s, 3H, 5a-CH3). 
13C NMR (101 MHz, chloroform-d) δ/ppm = 180.4 (C-1), 178.5 (C-2), 144.7 (C-8b), 116.6 (C-
9), 67.8 (C-1’), 52.6 (C-6), 48.8 (C-8a), 44.7 (C-3a), 43.0 (C-5a), 41.7 (C-10a), 39.3 (C-2’), 
36.4 (C-5), 34.8 (C-3b), 28.6 (C-7 or C-8), 23.9 (C-10), 23.2 (C-4), 21.9 (C-7 or C-8), 18.4 (5a-
CH3), 16.7 (2’-CH3). 
IR (ATR): ṽ/cm-1 = 2924, 1770, 1702, 1467, 1436, 1354, 1199, 1103, 1044, 1031, 985, 824, 
793, 638, 564. 
HRMS (EI): m/z calculated for C19H27NO3 [M]˙⁺ 317.1986; found 317.1988. 
Purity (HPLC): > 95% (λ = 191 nm), 92% (λ = 210 nm) (method f). 
  
Experimental Part 
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(5S,9S,10R,13R,14R,17R)-17-((S)-1-Hydroxypropan-2-yl)-13-methyl-
6,9,10,11,12,13,14,15,16,17-decahydro-1H-cyclopenta[a]phenanthrene-1,4(5H)-dione 
(46) 
 
 
 
 
 
C21H28O3 
M = 328.45 g/mol 
Alcohol 46 was synthesised according to GP9, using tetracycle 40 (53.0 mg, 0.120 mmol, 
1.00 eq). The title compound was purified via FCC (hexanes/EtOAc 4:6) and isolated as 
orange oily solid (37.4 mg, 0.114 mmol, 95%). 
 
Rf = 0.52 (hexanes/EtOAc 5:5). 
[𝛂]𝑫
𝟐𝟑: + 246.6 (c = 0.05, CHCl3). 
1H NMR (400 MHz, chloroform-d) δ/ppm = 6.57 (d, J = 10.3 Hz, 1H, 2 or 3-H), 6.51 (dd, J = 
10.3, 1.3 Hz, 1H, 2 or 3-H), 5.08 (t, J = 3.1 Hz, 1H, 7-H), 3.66 (dd, J = 10.5, 3.1 Hz, 1H, 1’-H), 
3.39 (dd, J = 10.5, 6.6 Hz, 1H, 1’-H), 3.28 – 3.21 (m, 2H, 5, 10-H), 2.64 – 2.51 (m, 2H, 14-H, 
11, 15 or 16-H), 2.50 – 2.38 (m, 2H, 6, 9-H), 2.23 – 2.10 (m, 1H, 6-H), 2.00 – 1.89 (m, 3H, 12-
H, 11, 15 or 16-H), 1.80 – 1.69 (m, 1H, 11, 15 or 16-H), 1.60 – 1.25 (m, 5H, 11, 15, 16, 17, 2’-
H), 1.05 (d, J = 6.4 Hz, 3H, 2’-CH3), 0.71 (s, 3H, 13-CH3). 
13C NMR (101 MHz, chloroform-d) δ/ppm = 201.7 (C-1 or 4), 199.7 (C-1 or 4), 141.7 (C-8), 
141.1 (C-2 or 3), 137.2 (C-2 or 3), 114.8 (C-7), 67.9 (C-1’), 53.4 (C-17), 50.9 (C-5 or 10), 50.2 
(C-5 or 10), 48.9 (C-14), 41.9 (C-13), 39.3 (C-2’), 37.5 (C-12), 36.4 (C-9), 28.4 (C-11, 15 or 
16), 27.3 (C-6), 24.2 (C-11, 15 or 16), 22.9 (C-11, 15 or 16), 18.9 (13-CH3), 16.6 (2’-CH3). 
IR (ATR): ṽ/cm-1 = 2940, 2875, 2361, 1682, 1600, 1468, 1441, 1379, 1341, 1262, 1179, 1088, 
1072, 1039, 997, 982, 948, 901, 873, 848, 749, 728. 
HRMS (EI): m/z calculated for C21H28O3 [M]˙⁺ 328.2033; found 328.2033.  
Purity (HPLC): > 95% (λ = 210 nm), 90% (λ = 254 nm) (method c).   
 
 
Experimental Part 
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(3aR,3bS,5aR,6R,8aR,10aS)-6-((S)-1-Hydroxypropan-2-yl)-5a-methyl-
3b,4,5,5a,6,7,8,8a,10,10a-decahydro-1H-cyclopenta[5,6]naphtho[1,2-c]furan-1,3(3aH)-
dione (45) 
 
 
 
 
 
C19H26NO4 
M = 318.41 g/mol 
Alcohol 45 was synthesised according to GP5 (microwave conditions: 125 °C, 8 min, 6 bar, 
300 W), using diene 47 (60.0 mg, 0.272 mmol, 1.00 eq) and maleic anhydride (26.7 mg, 
0.272 mmol, 1.00 eq). The title compound was purified via FCC (hexanes/EtOAc 5:5) and 
isolated as white solid (6.60 mg, 0.0207 mmol, 8%). 
 
Rf = 0.31 (hexanes/EtOAc 50:50). 
mp: 178 °C. 
[𝛂]𝑫
𝟐𝟑: + 47.2 (c = 0.13, CHCl3).  
1H NMR (500 MHz, chloroform-d) δ/ppm = 5.52 (dt, J = 7.3, 2.8 Hz, 1H, 9-H), 3.65 (dd, J = 
10.5, 2.9 Hz, 1H, 1’-H), 3.42 – 3.37 (m, 2H, 10a, 1’-H), 3.32 (dd, J = 9.6, 6.4 Hz, 1H, 3a-H), 
2.80 – 2.72 (m, 1H, 10-H), 2.44 – 2.32 (m, 1H, 3b-H), 2.31 – 2.15 (m, 1H, 4, 7 or 8-H), 2.02 
(ddd, J = 14.3, 7.9, 1.4 Hz, 1H, 5-H), 1.99 – 1.91 (m, 1H, 4, 7 or 8-H), 1.78 (dt, J = 13.3, 5.9 
Hz, 1H 4, 7 or 8-H), 1.67 – 1.47 (m, 5H, 5, 6, 10, 2’-H, 4, 7 or 8-H), 1.44 – 1.32 (m, 2H, 4, 7 or 
8-H), 1.04 (d, J = 6.2 Hz, 3H, 2’-CH3), 0.55 (s, 3H, 5a-CH3). 
13C NMR (126 MHz, chloroform-d) δ/ppm = 174.7 (C-1), 171.9 (C-3), 145.4 (C-8b), 117.2 (C-
9), 67.8 (C-1’), 52.6 (C-6), 48.8 (C-8a), 44.4 (C-3a), 42.9 (C-5a), 41.0 (C-10a), 39.3 (C-2’), 
36.1 (C-5), 34.3 (C-3b), 28.5 (C-4, 7 or 8), 24.1 (C-10), 23.1 (C-4, 7 or 8), 21.8 (C-4, 7 or 8), 
18.5 (5a-CH3), 16.7 (2’-CH3). 
IR (ATR): ṽ/cm-1 = 2956, 2163, 1776, 1592, 1468, 1442, 1250, 1025, 959, 821, 686. 
HRMS (EI): calculated for C19H26O4 [M]˙⁺ 318.1826; found 318.1843.  
Purity (HPLC): 77% (λ = 191 nm), > 95% (λ = 210 nm) (method f). 
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4-Tosylbut-3-en-1-ol (50)[84] 
 
 
 
 
C11H14O3S 
M = 226.29 g/mol 
A suspension of 3-buten-1-ol (48, 0.477 mL, 5.55 mmol, 1.00 eq), sodium p-toluenesulfinate 
(1.98 g, 11.1 mmol, 2.00 eq) and iodine (1.69 g, 6.66 mmol, 1.20 eq) in methanol (50.0 mL) 
was stirred for 2 d at rt. The solvent was removed in vacuo and the resulting residue was 
dissolved in EtOAc (50.0 mL) and washed with aq. 0.2M Na2S2O3 (30.0 mL). The organic layer 
was decanted and aq. 3M NaOH (20.0 mL) was added and stirred for 1 d. The organic layer 
was separated, washed with brine (3 x 30 mL), dried over Na2SO4 and the solvent was 
removed in vacuo. The title compound was purified via FCC (hexanes/EtOAc 2:8) and isolated 
as yellowish oil (664 mg, 2.93 mmol, 53%).  
 
Rf = 0.52 (hexanes/EtOAc 2:8). 
1H NMR (400 MHz, chloroform-d) δ/ppm = 7.80 – 7.74 (m, 1H, 3’, 5’-H), 7.36 – 7.31 (m, 1H, 
2’, 6’-H), 6.97 (dt, J = 15.2, 6.9 Hz, 1H, 3-H), 6.43 (dt, J = 15.2, 1.5 Hz, 1H, 4-H), 3.78 (t, J = 
6.2 Hz, 2H, 1-H), 2.53 – 2.45 (m, 2H, 2-H), 2.43 (s, 3H, 4’-CH3). 
13C NMR (101 MHz, chloroform-d) δ/ppm = 144.5 (C-4’), 142.8 (C-3), 137.6 (C-1’), 132.9 (C-
4), 130.1 (C-2’, 6’), 127.9 (C-3’, 5’), 60.6 (C-1), 34.6 (C-2), 21.8 (4’-CH3). 
IR (ATR): ṽ/cm-1 = 3498, 2924, 2884, 1632, 1596, 1402, 1314, 1301, 1282, 1138, 1085, 1044, 
963, 913, 809, 776, 729, 704, 657.   
HRMS (EI): m/z calculated for C11H13O3S [M]˙⁺ 225.0583; found 225.0579. 
Purity (HPLC): > 95% (λ = 210 nm), > 95% (λ = 254 nm) (method c).    
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(3R,3aR,5aS,6S,9bR)-3-((S)-1-((tert-Butyldimethylsilyl)oxy)propan-2-yl)-3a-methyl-
2,3,3a,4,5,5a,6,7,8,9b-decahydro-1H-cyclopenta[a]naphthalene-6-carbaldehyde (54a) 
and (3R,3aR,5aS,6R,9bR)-3-((S)-1-((tert-Butyldimethylsilyl)oxy)propan-2-yl)-3a-methyl-
2,3,3a,4,5,5a,6,7,8,9b-decahydro-1H-cyclopenta[a]naphthalene-6-carbaldehyde (54b)  
 
 
 
 
 
C24H42O2Si 
M = 390.68 g/mol 
The inseparable mixture of aldehydes 54a and 54b were synthesised according to GP5, using 
diene 25 (217 mg, 0.622 mmol, 1.00 eq) and acrolein (53, 41.6 µL, 0.622 mmol, 1.00 eq). The 
title compounds were purified via FCC (hexanes/EtOAc 98:2) and isolated as a white oily solid 
(224 mg, 0.553 mmol, 89%) in an isomeric ratio of 87:13 (determined via 1H NMR).  
 
Rf = 0.16 (hexanes/EtOAc 98:2). 
[𝛂]𝑫
𝟐𝟑: + 30.0 (c = 0.04, CHCl3). 
1H NMR (800 MHz, chloroform-d) δ/ppm = 9.82 (d, J = 2.8 Hz, 1H, a-1-H), 9.65 (d, J = 3.7 Hz, 
0.14H, b-1-H), 5.26 – 5.24 (m, 1H, a-9’-H), 5.24 – 5.22 (m, 0.15H, b-9’-H), 3.60 – 3.57 (m, 
1.23H, a/b-1’’-H), 3.30 – 3.26 (m, 1.16H, a/b-1’’-H), 2.64 – 2.59 (m, 1H, a-5a’-H), 2.57 – 2.52 
(m, 0.10H, b-5a’-H), 2.48 – 2.43 (m, 2H, a-6’, a-9b’-H), 2.37 – 2.34 (m, 0.10H, b-9b’-H), 2.28 
– 2.23 (m, 0.12H, b-8’-H), 2.19 – 2.10 (m, 3.52H, b-6’, a-8’-H, a/b-CH2), 1.93 – 1.87 (m, 2.50H, 
a-4’, b-3’, b-7’-H, a/b-CH2), 1.86 – 1.74 (m, 3.60H, a-5’, a-7’, b-4’, b-7’-H, a/b-CH2), 1.69 – 
1.64 (m, 0.12H, b-7’-H), 1.63 – 1.58 (m, 1.76H, a-4’-H, a/b-CH2), 1.57 – 1.53 (m, 1H, a-5’-H), 
1.51 – 1.45 (m, 1.3H, a-2’’-H), 1.39 – 1.29 (m, 4.1H, a-3’, b-2’’-H, a/b-CH2), 0.97 (dd, J = 10.9, 
6.6 Hz, 3.92H, a/b-2’’-CH3), 0.90 – 0.88 (m, 12H, a/b-SiC(CH3)3), 0.77 (s, 0.48H, b-3a’-CH3), 
0.74 (s, 3H, a-3a’-CH3), 0.03 – 0.02 (m, 8H, a/b-Si(CH3)2). 
13C NMR (201 MHz, chloroform-d) δ/ppm = 206.3 (a-C-1), 205.8 (b-C-1), 140.4 (b-C-9a’), 
140.1 (a-C-9a’), 119.4 (a-C-9’), 118.9 (b-C-9’), 67.8 (b-C-1’’), 67.8 (a-C-1’’), 54.1 (b-C-3’), 53.8 
(a-C-3’), 52.7 (b-C-6’), 49.5 (a-C-9b’), 49.2 (a-C-6’), 48.8 (b-C-9b’), 42.0 (a-C-3a’), 41.7 (b-C-
3a’), 39.5 (a-C-2’’), 39.4 (b-C-2’’), 37.5 (a-C-4’), 37.4 (b-C-4’), 36.3 (a-C-5a’), 35.1 (b-C-5a’), 
28.4 (a-CH2), 28.3 (b-CH2), 26.1 (a/b-SiC(CH3)3), 25.9 (b-CH2), 25.4 (a-7’-H), 25.2 (a-5’-H), 
24.6 (b-8’-H), 23.9 (b-CH2), 23.7 (b-7’-H), 23.4 (a-CH2), 22.6 (a-8’-H), 18.9 (a-3a’-CH3), 18.8 
(b-3a’-CH3), 18.5 (a/b-SiC(CH3)3), 16.9 (a-2’’-CH3), 16.8 (b-2’’-CH3), -5.2 (a/b-Si(CH3)2), -5.2 
(a/b-Si(CH3)2). 
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IR (ATR): ṽ/cm-1 = 3393, 2928, 2856, 2359, 1716, 1471, 1462, 1386, 1361, 1250, 1188, 1083, 
1029, 1004, 940, 832, 814, 773, 667. 
HRMS (EI): m/z calculated for C24H42O2Si [M]˙⁺ 390.2948; found 390.2944. 
Purity (GC): > 95% (scan mode m/z 50-650 (EI 70 eV)). 
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(S)-2-((3R,3aR,5aS,6S,9bR)-6-(Hydroxymethyl)-3a-methyl-2,3,3a,4,5,5a,6,7,8,9b-
decahydro-1H-cyclopenta[a]naphthalen-3-yl)propan-1-ol (55a) and (S)-2-
((3R,3aR,5aS,6R,9bR)-6-(hydroxymethyl)-3a-methyl-2,3,3a,4,5,5a,6,7,8,9b-decahydro-
1H-cyclopenta[a]naphthalen-3-yl)propan-1-ol (55b) 
 
 
 
 
 
 
C18H30O2 
M = 278.44 g/mol 
A solution of the inseparable mixture of aldehydes 54a and 54b (100 mg, 0.256 mmol, 1.00 eq) 
in dry THF (3.00 mL) was added to a mixture of LiAlH4 (10.7 mg, 0.282 mmol, 1.10 eq) in dry 
THF (5.00 mL) at 0 °C. After 1.5 h the reaction mixture was diluted with water (5.00 mL), conc. 
H2SO4 was added dropwise until the precipitate was dissolved and stirred for additional 30 min. 
The layers were separated, and the aq. phase was extracted with EtOAc (3 x 10.0 mL). The 
combined organic layers were washed with sat. aq. NaHCO3 solution (5.00 mL), dried over 
Na2SO4, filtered and the solvent was removed in vacuo. The title products were separated and 
purified via FCC (hexanes/EtOAc 5:5), whereby 55a was obtained as white solid (57.7 mg, 
0.207 mmol, 81%) and diol 55b was isolated as colourless oil (5.10 mg, 0.0183 mmol, 7%). 
 
Analytical data of diol 55a: 
Rf = 0.33 (hexanes/EtOAc 5:5). 
mp: 136 °C.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
[𝛂]𝑫
𝟐𝟑: + 76.0 (c = 0.05, CHCl3). 
1H NMR (400 MHz, chloroform-d) δ/ppm = 5.18 (q, J = 3.1 Hz, 1H, 9’-H), 3.72 – 3.61 (m, 2H, 
1, 6’-CH2), 3.56 (dd, J = 10.6, 8.8 Hz, 1H, 6’-CH2), 3.38 (dd, J = 10.6, 6.7 Hz, 1H, 1-H), 2.60 – 
2.50 (m, 1H, 5a’-H), 2.37 – 2.26 (m, 1H, 9b’-H), 2.11 – 2.04 (m, 2H, 8’-H, 1’, 2’ or 5’-H), 2.03 – 
1.82 (m, 4H, 2, 4’, 6’-H, 1’, 2’ or 5’-H), 1.78 – 1.66 (m, 2H, 7’-H), 1.61 – 1.45 (m, 3H, 4’-H, 1’, 
2’ or 5’-H), 1.45 – 1.28 (m, 4H, 3’, 8’-H, 1’, 2’ or 5’-H), 1.02 (d, J = 6.7 Hz, 3H, 2-CH3), 0.74 (s, 
3H, 3a’-CH3). 
13C NMR (101 MHz, chloroform-d) δ/ppm = 139.9 (C-9a’), 118.7 (C-9’), 67.9 (C-1), 61.3 (7’-
CH2), 53.6 (C-3’), 49.2 (C-9b’), 41.8 (C-3a’), 39.3 (C-2), 38.6 (C-6’), 37.7 (C-4’), 37.2 (C-5a’), 
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28.4 (C-1’, 2’ or 5’), 25.4 (C-1’, 2’ or 5’), 25.1 (C-1’, 2’ or 5’), 23.4 (C-7’), 21.9 (C-8’), 18.9 (3a’-
CH3), 16.6 (2-CH3). 
IR (ATR): ṽ/cm-1 = 3269, 2947, 2873, 2363, 1464, 1379, 1261, 1122, 1076, 1036, 985, 951, 
902, 826, 667. 
HRMS (EI): m/z calculated for C18H30O2 [M]˙⁺ 278.2240; found 278.2239. 
Purity (GC): > 95% (scan mode m/z 50-650 (EI 70 eV)).  
 
Analytical data of diol 55b: 
Rf = 0.46 (hexanes/EtOAc 5:5). 
[𝛂]𝑫
𝟐𝟑: + 33.9 (c = 0.16, MeOH). 
1H NMR (400 MHz, chloroform-d) δ/ppm = 5.22 (t, J = 3.3 Hz, 1H, 9’-H), 3.76 (dd, J = 10.7, 3.5 
Hz, 1H, 6’-CH2), 3.65 (dd, J = 10.5, 3.3 Hz, 1H, 1-H), 3.55 (dd, J = 10.7, 6.3 Hz, 1H, 6’-CH2), 
3.39 (dd, J = 10.5, 6.7 Hz, 1H, 1-H), 2.38 (d, J = 11.1 Hz, 1H, 9b’-H), 2.25 – 2.06 (m, 3H, 5a’, 
8’-H), 1.96 – 1.73 (m, 5H, 4’, 7’-H, 1’, 2’ or 5’-H), 1.65 – 1.42 (m, 3H, 2, 4’, 7’-H), 1.40 – 1.17 
(m, 5H, 3’, 6’-H, 1’, 2’ or 5’-H), 1.03 (d, J = 6.7 Hz, 3H, 2-CH3), 0.75 (s, 3H, 3a’-CH3). 
13C NMR (101 MHz, chloroform-d) δ/ppm = 141.7 (C-9a’), 119.2 (C-9’), 67.9 (C-1), 66.2 (6’-
CH2), 53.8 (C-3’), 49.1 (C-9b’), 41.6 (C-6’), 41.5 (C-3a’), 39.2 (C-2), 37.7 (C-4’), 36.9 (C-5a’), 
28.4 (C-1’, 2’ or 5’), 26.7 (C-7’), 25.5 (C-8’), 24.8 (C-1’, 2’ or 5’), 24.0 (C-1’, 2’ or 5’), 18.7 (3a’-
CH3), 16.6 (2-CH3). 
IR (ATR): ṽ/cm-1 = 3325, 2936, 2871, 2361, 1611, 1564, 1550, 1511, 1483, 1344, 1245, 1125, 
986, 813, 751. 
HRMS (EI): m/z calculated for C18H30O2 [M]˙⁺ 278.2240; found 278.2242. 
Purity (GC): 94% (scan mode m/z 50-650 (EI 70 eV)). 
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1-((3R,3aR,5aS,6S,9bR)-3-((S)-1-((tert-Butyldimethylsilyl)oxy)propan-2-yl)-3a-methyl-
2,3,3a,4,5,5a,6,7,8,9b-decahydro-1H-cyclopenta[a]naphthalen-6-yl)-2,2,2-trichloroethan-
1-ol (56a) and 1-((3R,3aR,5aS,9bR)-3-((S)-1-((tert-butyldimethylsilyl)oxy)propan-2-yl)-
3a-methyl-2,3,3a,4,5,5a,6,7,8,9b-decahydro-1H-cyclopenta[a]naphthalen-6-yl)-2,2,2-
trichloroethan-1-ol (56b)  
 
C25H43Cl3O2Si 
M = 510.05 g/mol 
To the inseparable mixture of aldehydes 54a/54b (146 mg, 0.361 mmol, 1.00 eq) chloroform 
(57.7 µL, 0.722 mmol, 2.00 eq) and DBU (53.9 µL, 0.361 mmol, 1.00 eq) were added. The 
reaction mixture was stirred at rt for 17 h. The reaction mixture was diluted with DCM (5.00 mL) 
and sat. aq. NH4Cl (5.00 mL) was added. The layers were separated, and the aq. layer was 
extracted with DCM (3 x 10.0 mL). The combined organic layers were dried over Na2SO4, 
filtered and the solvent was removed in vacuo. The title compounds were purified and 
separated via FCC (hexanes/CHCl3 4:6) and 56a was isolated as white solid (71.0 mg, 
0.135 mmol, 15%) and 56b as light yellow solid (64.0 mg, 0.122 mmol, 13%). 
 
Analytical data of trichloromethylcarbinol derivate 56a: 
Rf: 0.41 (hexanes/CHCl3 40:60). 
mp: 54 °C. 
[𝛂]𝑫
𝟐𝟑: + 12.4 (c = 0.06, CHCl3). 
1H NMR (500 MHz, chloroform-d) δ/ppm = 5.21 (dt, J = 31.5, 3.1 Hz, 1H, 9’-H), 4.09 (dd, J = 
5.1, 3.7 Hz, 1H, 1-H), 3.59 (dd, J = 9.6, 3.4 Hz, 1H, 1’’-H), 3.26 (ddd, J = 9.6, 7.3, 4.1 Hz, 1H, 
1’’-H), 2.84 (d, J = 5.1 Hz, 1H, OH), 2.52 (tq, J = 10.1, 2.9 Hz, 1H, 5a’-H), 2.33 (m, 2H, 9b’-H, 
1’, 2’, 5’, 7’ or 8’-H), 2.20 – 2.01 (m, 3H, 7’-H, 1’, 2’, 5’ or 8’-H), 1.93 – 1.71 (m, 4H, 4’, 6’, 7’-H, 
1’, 2’, 5’ or 8’-H), 1.64 – 1.57 (m, 1H, 4’-H), 1.52 – 1.45 (m, 1H, 2’’-H), 1.41 – 1.18 (m, 5H, 3’-
H, 1’, 2’, 5’ or 8’-H), 0.97 (dd, J = 6.7, 1.5 Hz, 3H, 2’’-CH3), 0.89 (s, 9H, SiC(CH3)3), 0.78 (s, 
3H, 3a’-CH3), 0.03 (s, 3H, Si(CH3)2), 0.03 (s, 3H, Si(CH3)2). 
13C NMR (101 MHz, chloroform-d) δ/ppm = 142.3 (C-9a’), 118.9 (C-9’), 104.6 (C-2), 87.3 (C-
1), 67.9 (C-1’’), 54.1 (C-3’), 49.2 (C-9b’), 41.8 (C-6’), 41.2 (C-3a’), 39.5 (C-2’’), 37.9 (C-4’), 37.8 
(C-5a’), 31.7 (C-7’), 28.4 (C-1’, 2’, 5’ or 8’), 27.9 (C-1’, 2’, 5’ or 8’), 26.1 (SiC(CH3)3), 25.9 (C-
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1’, 2’, 5’ or 8’), 24.2 (C-1’, 2’, 5’ or 8’), 18.9 (3a’-CH3), 18.5 (SiC(CH3)3), 16.8 (2’’-CH3), -5.2 
(Si(CH3)2), -5.2 (Si(CH3)2). 
IR (ATR): ṽ/cm-1 = 2952, 2928, 2856, 2361, 1715, 1470, 1462, 1386, 1361, 1253, 1085, 1038, 
1005, 939, 908, 833, 809, 772, 733, 667. 
HRMS (EI): m/z calculated for C25H43Cl3O2Si [M]˙⁺ 508.2092; found 508.2077. 
Purity (GC): 94% (scan mode m/z 50-650 (EI 70 eV)). 
 
Analytical data of trichloromethylcarbinol derivate 56b: 
Rf: 0.33 (hexanes/CHCl3 40:60). 
mp: 65 °C. 
[𝛂]𝑫
𝟐𝟑: + 12.5 (c = 0.06, CHCl3). 
1H NMR (500 MHz, chloroform-d) δ/ppm = 5.27 (t, J = 3.3 Hz, 1H, 9’-H), 4.29 (dd, J = 6.7, 1.2 
Hz, 1H, 1-H), 3.59 (dd, J = 9.6, 3.3 Hz, 1H, 1’’-H), 3.27 (dd, J = 9.7, 7.3 Hz, 1H, 1’’-H), 2.69 
(dd, J = 6.7, 0.6 Hz, 1H, OH), 2.44 – 2.32 (m, 2H, 5a’, 9b’-H), 2.25 – 2.17 (m, 2H, 7’-H, 1’, 2’, 
5’ or 8’-H), 2.16 – 2.07 (m, 1H, 1’, 2’, 5’ or 8’-H), 2.04 – 1.97 (m, 1H, 6’-H), 1.93 – 1.84 (m, 2H, 
4’-H, 2’’-H), 1.83 – 1.76 (m, 2H, 1’, 2’, 5’ or 8’-H), 1.70 – 1.57 (m, 2H, 4’, 7’-H), 1.49 (m, 1H, 1’, 
2’, 5’ or 8’-H), 1.40 – 1.24 (m, 4H, 3’-H, 1’, 2’, 5’ or 8’-H), 0.97 (d, J = 6.5 Hz, 3H, 2’’-CH3), 0.89 
(s, 9H, SiC(CH3)3), 0.77 (s, 3H, 3a’-CH3), 0.03 (s, 3H, Si(CH3)2), 0.03 (s, 3H, Si(CH3)2). 
13C NMR (101 MHz, chloroform-d) δ/ppm = 141.7 (C-9a’), 119.7 (C-9’), 104.8 (C-2), 82.2 (C-
1), 67.8 (C-1’’), 54.1 (C-3’), 49.4 (C-9b’), 41.5 (C-3a’), 40.7 (C-6’), 39.5 (C-2’’), 38.6 (C-5a’), 
37.8 (C-4’), 28.4 (C-1’, 2’, 5’ or 8’), 26.1 (SiC(CH3)3), 25.8 (C-1’, 2’, 5’ or 8’), 25.5 (C-1’, 2’, 5’ 
or 8’), 24.1 (C-1’, 2’, 5’ or 8’), 23.2 (C-7’), 18.8 (3a’-CH3), 18.5 (SiC(CH3)3), 16.8 (2’’-CH3), -5.2 
(Si(CH3)2), -5.2 (Si(CH3)2). 
IR (ATR) ṽ/cm-1 = 2928, 2856, 2359, 1707, 1462, 1385, 1361, 1251, 1083, 1005, 938, 910, 
833, 807, 773, 732, 669. 
HRMS (EI): m/z calculated for C25H43Cl3O2Si [M]˙⁺ 508.2092; found 508.2077. 
Purity (GC): > 95% (scan mode m/z 50-650 (EI 70 eV)). 
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tert-Butyldimethyl((S)-2-((1R,3aS,7aS)-7a-methyl-5-((trimethylsilyl)oxy)-2,3,3a,4,7,7a-
hexahydro-1H-inden-1-yl)propoxy)silane (64e) 
 
 
 
C22H44O2Si2  
M = 396.76 g/mol  
In an oven dried flask ketone 28c (150 mg, 0.462 mmol, 1.00 eq) was dissolved in dry 
THF (3.00 mL) and TEA (0.155 mL, 1.10 mmol, 1.50 eq) and TMSCl (90.0 mg, 0.830 mmol, 
3.8 eq) were added dropwise at 0°C. The reaction mixture was stirred for 4.5 d at 70 °C. The 
reaction mixture was cooled to rt and the reaction was diluted with hexanes (10.0 mL). The 
organic layer was washed with sat. aq. NaHCO3 solution (3 x 10.0 mL), dried over Na2SO4, 
filtered and the solvent was removed in vacuo. The title compound was purified via FCC 
(hexanes/EtOAc 95:5) and silyl enol ether 64e was obtained as a colourless oil (78.8 mg, 
0.199 mmol, 43%). 
 
Rf = 0.95 (hexanes/EtOAc 95:5). 
[𝛂]𝑫
𝟐𝟑:  + 64.6 (c = 0.11, CHCl3). 
1H NMR (500 MHz, chloroform-d) δ/ppm = 4.77 (d, J = 6.0 Hz, 1H, 6’-H), 3.59 (d, J = 13.0 Hz, 
1H, 1-H), 3.26 (dd, J = 9.6, 7.4 Hz, 1H, 1-H), 2.12 (dd, J = 16.2, 5.7 Hz, 1H, 7’-H), 2.03 – 1.98 
(m, 1H, 4’-H), 1.98 – 1.93 (m, 1H, 7’-H), 1.88 – 1.82 (m, 1H, 2’-H), 1.82 – 1.76 (m, 1H, 4’-H), 
1.75 – 1.67 (m, 1H, 3a’-H), 1.67 – 1.62 (m, 1H, 3’-H), 1.56 – 1.49 (m, 1H, 2-H), 1.40 – 1.31 (m, 
1H, 2’-H), 1.28 – 1.21 (m, 1H, 1’-H), 1.21 – 1.15 (m, 1H, 3’-H), 0.99 (d, J = 6.6 Hz, 3H, 2-CH3), 
0.89 (s, 9H, SiC(CH3)3), 0.68 (s, 3H, 7a’-CH3), 0.17 (s, 9H, Si(CH3)3), 0.03 (s, 6H, Si(CH3)2). 
13C NMR (126 MHz, chloroform-d) δ/ppm = 149.8 (C-5’), 104.2 (C-6’), 68.0 (C-1), 52.2 (C-1’), 
46.3 (C-3a’), 41.3 (C-7a’), 39.1 (C-7’), 33.1 (C-4’), 28.5 (C-2’), 26.6 (C-3’), 26.1 (SiC(CH3)3), 
18.5 (SiC(CH3)3), 16.7 (2-CH3), 11.2 (7a’-CH3), 0.5 (Si(CH3)3), -5.2 (Si(CH3)2), -5.2 (Si(CH3)2). 
IR (ATR): ṽ/cm-1 = 3747, 2956, 2930, 2857, 1661, 1471, 1250, 1188, 1089, 1031, 1003, 968, 
898, 835, 773, 665. 
HRMS (EI): m/z calculated for C22H44O2Si2 [M]˙⁺ 396.2874; found 396.2891.  
Purity (HPLC): > 95% (λ = 210 nm), > 95% (λ = 250 nm) (method e).   
Experimental Part 
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(1R,3aS,7aS)-1-((S)-1-((tert-Butyldimethylsilyl)oxy)propan-2-yl)-6-
((dimethylamino)methylene)-7a-methyloctahydro-5H-inden-5-one (71e) 
 
 
 
C22H41NO2Si 
M = 379.66 g/mol 
In an oven dried flask ketone 28c (100 mg, 0.308 mmol, 1.00 eq) was dissolved in dry DMF 
(3.00 mL). BREDERECK’S reagent (0.318 mL, 1.54 mmol, 5.00 eq) was added dropwise and the 
reaction was heated to 100 °C for 2 h. The reaction mixture was cooled to rt and concentrated 
under reduced pressure. The residue was dissolved in DCM (10.0 mL), washed with water 
(3 x 5.00 mL) and the aq. layer was extracted with DCM (3 x 10.0 mL). All combined organic 
layers were dried over Na2SO4, filtered and the solvent was removed in vacuo. The title 
compound was purified via FCC (EtOAc/ MeOH/TEA 94:5:1) gave enaminone 71e as a 
colourless oil (107 mg, 0.283 mmol, 46%). 
 
Rf = 0.37 (EtOAc/ MeOH/TEA 94:5:1). 
[𝛂]𝑫
𝟐𝟑:  - 119.4 (c = 0.12, CHCl3). 
1H NMR (500 MHz, chloroform-d) δ/ppm = 7.51 (s, 1H, 6-CH), 3.61 (dd, J = 9.6, 3.4 Hz, 1H, 
1’-H), 3.30 (dd, J = 9.7, 7.3 Hz, 1H, 1’-H), 3.07 (s, 6H, N(CH3)2), 2.96 (d, J = 13.9 Hz, 1H, 7-
H), 2.42 – 2.39 (m, 1H, 7-H), 2.38 (d, J = 5.5 Hz, 1H, 4-H), 2.09 (dd, J = 18.2, 13.3 Hz, 1H, 4-
H), 1.87 (dddd, J = 9.7, 6.8, 3.2, 1.7 Hz, 1H, 2-H), 1.81 (tdd, J = 13.2, 7.0, 3.9 Hz, 1H, 3a-H), 
1.73 – 1.67 (m, 1H, 3-H), 1.58 (ddp, J = 9.7, 6.4, 3.3 Hz, 1H, 2’-H), 1.44 – 1.36 (m, 1H, 1-H), 
1.36 – 1.31 (m, 1H, 2-H), 1.22 – 1.14 (m, 1H, 3-H), 1.03 (d, J = 6.6 Hz, 3H, 2’-CH3), 0.89 (s, 
9H, SiC(CH3)3), 0.71 (d, J = 0.7 Hz, 3H, 7a-CH3), 0.03 (s, 3H, Si(CH3)2), 0.03 (s, 3H, Si(CH3)2). 
13C NMR (126 MHz, chloroform-d) δ/ppm = 198.1 (C-5), 152.8 (6-CH), 102.9 (C-6), 67.9 (C-
1’), 52.9 (C-1), 45.1 (C-3a), 43.66 (N(CH3)2), 41.6 (C-7a), 40.8 (C-7), 40.3 (C-4), 38.9 (C-2’), 
28.3 (C-2), 27.2 (C-3), 26.1 (SiC(CH3)3), 18.5 (SiC(CH3)3), 16.8 (2’-CH3), 11.5 (7a-CH3), -5.2 
(Si(CH3)2), -5.3 (Si(CH3)2). 
IR (ATR): ṽ/cm-1 = 2953, 2928, 2856, 1644, 1544, 1470, 1424, 1372, 1322, 1270, 1249, 1212, 
1125, 1084, 1030, 970, 939, 917, 834, 773, 730, 664, 614, 598.  
HRMS (EI): m/z calculated for C22H41NO2Si [M]˙⁺ 379.2901; found 379.2900. 
Purity (HPLC): > 95% (λ = 210 nm), > 95% (λ = 250 nm) (method e).    
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6.2.4. Procedures and data for seco-steroids with bridging at C-4 (chapter 3.3.1.) 
(2-Bromophenoxy)(tert-butyl)dimethylsilane (75d) 
 
 
 
 
C12H19BrOSI 
M = 286.04 g/mol 
Aryl bromide 75d was synthesized according to GP2, using 2-bromophenol (508 mg, 
2.92 mmol, 1.00 eq). The title compound was purified via FCC (hexanes/EtOAc 95:5) and 
isolated as colourless oil (601 mg, 2.09 mmol, 72%).  
 
Rf = 0.80 (hexanes/EtOAc 95:5).  
1H NMR (500 MHz, chloroform-d) δ/ppm = 7.51 (dd, J = 7.9, 1.7 Hz, 1H, 3-H), 7.16 (ddd, J = 
8.0, 7.3, 1.7 Hz, 1H, 5-H), 6.91 – 6.78 (m, 2H, 4-H, 6-H), 1.05 (s, 9H, SiC(CH3)3), 0.25 (s, 6H, 
Si(CH3)2). 
13C NMR (101 MHz, chloroform-d) δ/ppm = 152.6 (C-1), 133.4 (C-3), 128.2 (C-5), 122.4 (C-4), 
120.3 (C-6), 115.4 (C-2), 25.8 (SiC(CH3)3), 18.4 (SiC(CH3)3), -4.2 (Si(CH3)2). 
IR (ATR): ṽ/cm-1 = 2930, 2886, 2859, 1583, 1475, 1440, 1391, 1362, 1282, 1252, 1156, 1121, 
1047, 1030, 912, 837, 823, 780, 749, 708, 670.  
HRMS (EI): m/z calculated for C12H19BrOSi [M]˙⁺ 286.0383; found 286.0379. 
Purity (HPLC): > 95% (λ = 210 nm), > 95% (λ = 254 nm) (method d). 
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(3-Bromophenoxy)(tert-butyl)dimethylsilane (76) 
 
 
 
 
C12H19BrOSi 
M = 286.04 g/mol 
Aryl bromide 76 was synthesized according to GP2 using 3-bromophenol (307 µL, 2.89 mmol, 
1.00 eq). The title compound was purified via FCC (hexanes/EtOAc 95:5) and isolated as 
colourless oil (711 mg, 2.48 mmol, 85%).  
 
Rf = 0.70 (hexanes/toluene 95:5). 
1H NMR (400 MHz, chloroform-d) δ/ppm = 7.13 – 7.04 (m, 2H, 2-H, 5-H)), 7.01 (ddd, J = 2.3, 
1.4, 0.8 Hz, 1H, 6-H), 6.81 – 6.73 (m, 1H, 4-H), 0.98 (s, 9H, SiC(CH3)3), 0.20 (s, 6H, Si(CH3)2). 
13C NMR (101 MHz, chloroform-d) δ/ppm = 156.7 (C-1), 130.6 (C-5), 124.6 (C-2), 123.7 (C-6), 
122.6 (C-3), 118.9 (C-4), 25.8 (SiC(CH3)3), 18.3 (SiC(CH3)3), -4.3 (Si(CH3)2). 
IR (ATR): ṽ/cm-1 = 2956, 2930, 2886, 2859, 1588, 1567, 1472, 1422, 1391, 1362, 1294, 1268, 
1253, 1238, 1158, 108, 1062, 1007, 99, 925, 882, 862, 837, 825, 810, 773, 738, 681.  
HRMS (EI): m/z calculated for C12H19BrOSi [M]˙⁺ 286.0383; found 286.0379. 
Purity (HPLC): > 95% (λ = 210 nm), > 95% (λ = 254 nm) (method d).   
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(4-Bromophenoxy)(tert-butyl)dimethylsilane (78d) 
 
 
 
 
C12H19BrOSi 
M = 286.04 g/mol 
Aryl bromide 78d was synthesized according to GP2, using 4-bromophenol (499 mg, 
2.88 mmol, 1.00 eq). The title compound was purified via FCC (hexanes/EtOAc 95:5) and 
isolated as colourless oil (647 mg, 2.25 mmol, 78%).  
 
Rf = 0.83 (hexanes/EtOAc 95:5). 
1H NMR (400 MHz, chloroform-d) δ/ppm = 7.36 – 7.28 (m, 2H, 3-H, 5-H), 6.76 – 6.67 (m, 2H, 
2-H, 6-H), 0.97 (s, 9H, SiC(CH3)3), 0.18 (s, 6H, Si(CH3)2). 
13C NMR (101 MHz, chloroform-d) δ/ppm = 154.9 (C-1), 132.3 (C-3, C-5), 121.9 (C-2, C-6), 
113.6 (C-4), 25.6 (SiC(CH3)3), 18.2 (SiC(CH3)3), -4.5 (Si(CH3)2). 
IR (ATR): ṽ/cm-1 = 2956, 2930, 2887, 2360, 2341, 1876, 1586, 1485, 1472, 1464, 1391, 1362, 
1252, 1164, 1094, 1070, 1007, 906, 838, 825, 803, 779, 725, 700, 670.  
HRMS (EI): m/z calculated for C12H19BrOSi [M]˙⁺ 286.0383; found 286.0382. 
Purity (HPLC): > 95% (λ = 210 nm), > 95% (λ = 254 nm) (method d). 
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((2-Bromobenzyl)oxy)(tert-butyl)dimethylsilane (79d) 
 
 
 
 
 
C13H21BrOSi 
M = 300.05 g/mol 
Aryl bromide 79d was synthesized according to GP2, using 2-bromobenzyl alcohol (495 mg, 
2.65 mmol, 1.00 eq). The title compound was purified via FCC (hexanes/EtOAc 95:5) and 
isolated as colourless oil (620 mg, 2.06 mmol, 78%).  
 
Rf = 0.55 (hexanes/toluene 95:5).   
1H NMR (400 MHz, methylene chloride-d2) δ/ppm =  7.56 (ddt, J = 7.8, 1.9, 1.0 Hz, 1H, 3-H or 
6-H), 7.51 (dd, J = 7.9, 1.2 Hz, 1H, 3-H or 6-H), 7.34 (td, J = 7.5, 1.2 Hz, 1H, 5-H), 7.13 (dddt, 
J = 8.0, 7.5, 1.6, 0.7 Hz, 1H, 4-H), 4.75 (d, J = 1.0 Hz, 2H, 1-CH2), 0.97 (s, 9H, SiC(CH3)3), 
0.14 (s, 6H, Si(CH3)2). 
13C NMR (101 MHz, methylene chloride-d2) δ/ppm = 141.0 (C-1), 132.6 (C-3 or C-6), 128.8 (C-
4), 128.3 (C-3 or C-6), 127.9 (C-5), 121.6 (C-2), 65.2 (1-CH2), 26.3 (SiC(CH3)3), 18.9 
(SiC(CH3)3), -5.1 (Si(CH3)2). 
IR (ATR): ṽ/cm-1 = 3070, 2955, 2929, 2885, 2857, 2360, 2341, 1594, 1570, 1471, 1464, 1443, 
1406, 1390, 1254, 1203, 1119, 1095, 1043, 1025, 1006, 939, 834, 815, 775, 745, 673.  
HRMS (EI): m/z calculated for C12H18BrOSi [M]˙⁺ 285.0305; found 285.0319. 
Purity (HPLC): > 95% (λ = 191 nm), > 95% (λ = 210 nm), > 95% (λ = 254 nm) (method f).   
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((3-Bromobenzyl)oxy)(tert-butyl)dimethylsilane (80d) 
 
  
 
 
 
C13H21BrOSi 
M = 300.05 g/mol 
Aryl bromide 80d was synthesized according to GP2, using 3-bromobenzyl alcohol (504 mg, 
2.69 mmol, 1.00 eq). The title compound was purified via FCC (hexanes/EtOAc 95:5) and 
isolated as colourless oil (628 mg, 2.09 mmol, 78%).  
 
Rf = 0.44 (hexanes/toluene 95:5).  
1H NMR (400 MHz, methylene chloride-d2) δ/ppm = 7.49 (ddt, J = 2.2, 1.4, 0.7 Hz, 1H, 2-H), 
7.38 (dddd, J = 7.7, 2.7, 1.3, 0.6 Hz, 1H, 4-H), 7.26 (dtt, J = 7.7, 1.5, 0.8 Hz, 1H, 6-H), 7.21 (t, 
J = 7.7 Hz, 1H, 5-H), 4.71 (q, J = 0.8 Hz, 2H, 1-CH2), 0.95 (s, 9H, SiC(CH3)3), 0.11 (s, 6H, 
Si(CH3)2). 
13C NMR (101 MHz, methylene chloride-d2) δ/ppm = 144.7 (C-1), 130.5 (C-4 or C-5), 130.4 (C-
4 or C-5), 129.6 (C-2), 125.2 (C-6), 122.8 (C-3), 64.7 (1-CH2), 26.2 (SiC(CH3)3), 18.8 
(SiC(CH3)3, -5.1 (Si(CH3)2). 
IR (ATR): ṽ/cm-1 = 2954, 2929, 2885, 2857, 2361, 2342, 1599, 1572, 1472, 1462, 1428, 1404, 
1390, 1367, 1254, 1198, 1194, 1078, 1067, 1006, 939, 833, 814, 773, 630, 666.  
HRMS (EI): m/z calculated for C13H21BrOSi [M]˙⁺ 300.0540; found 300.0383. 
Purity (HPLC): > 95% (λ = 191 nm), > 95% (λ = 210 nm) (method f). 
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((4-Bromobenzyl)oxy)(tert-butyl)dimethylsilane (81d) 
 
 
 
 
 
C13H21BrOSi 
M = 300.05 g/mol 
Aryl bromide 81d was synthesized according to GP2, using 4-bromobenzyl alcohol (514 mg, 
2.75 mmol, 1.00 eq). The title compound was purified via FCC (hexanes/EtOAc 95:5) and 
isolated as colourless oil (578 mg, 1.92 mmol, 70%).  
 
Rf = 0.38 (hexanes/toluene 95:5).  
1H NMR (400 MHz, methylene chloride-d2) δ/ppm = 7.55 – 7.38 (m, 2H, 3-H, 5-H), 7.29 – 7.15 
(m, 2H, 2-H, 6-H), 4.68 (d, J = 0.9 Hz, 2H, 1-CH2), 0.94 (s, 9H, SiC(CH3)3), 0.10 (s, 6H, 
Si(CH3)2). 
13C NMR (101 MHz, methylene chloride-d2) δ/ppm = 141.3 (C-1), 131.7 (C-3, C-5), 128.4 (C-
2, C-6), 120.9 (C-4), 64.8 (1-CH2), 26.2 (SiC(CH3)3), 18.8 (SiC(CH3)3), -5.1 (Si(CH3)2). 
IR (ATR): ṽ/cm-1 = 2954, 2929, 2885, 2857, 2360, 2342, 1895, 1594, 1486, 1472, 1462, 1406, 
1390, 1370, 1296, 1255 1203, 1114, 1084, 1070, 1011, 938, 835, 814, 796, 774, 668.  
HRMS (EI): m/z calculated for C13H20BrOSi [M]˙⁺ 299.0461; found 299.0461. 
Purity (HPLC): > 95% (λ = 210 nm), > 95% (λ = 254 nm) (method d). 
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(1R,3aR,4S,7aR)-4-(3-((tert-Butyldimethylsilyl)oxy)phenyl)-1-((S)-1-((tert-
butyldimethylsilyl)oxy)propan-2-yl)-7a-methyloctahydro-1H-inden-4-ol (82) 
 
 
 
 
 
 
 
C31H56O3Si2 
M = 532.96 g/mol 
Alcohol 82 was synthesised according to GP6 using silyl ether 76 (180 mg, 0.627 mmol, 
1.10 eq) and ketone 26 (184 mg, 0.568 mmol, 1.00 eq). The title compound was purified via 
FCC (hexanes/EtOAc 9:1) and isolated as colourless oil (195 mg, 0.366 mmol, 64%).  
 
Rf = 0.48 (hexanes/EtOAc 9:1). 
[𝛂]𝑫
𝟐𝟑: + 48.8 (c = 0.04, CHCl3). 
1H NMR (400 MHz, chloroform-d) δ/ppm = 7.17 (t, J = 7.9 Hz, 1H, 5’’-H), 7.00 (ddd, J = 7.8, 
1.9, 1.0 Hz, 1H, 6’’-H), 6.94 (t, J = 2.1 Hz, 1H, 2’’-H), 6.68 (ddd, J = 8.0, 2.4, 1.0 Hz, 1H, 4’’-
H), 3.56 (dd, J = 9.6, 3.4 Hz, 1H, 1’-H), 3.27 (dd, J = 9.6, 7.2 Hz, 1H, 1’-H), 2.11 – 2.04 (m, 1H, 
2, 3, 5, 6 or 7-H), 2.02 – 1.92 (m, 1H, 2, 3, 5, 6-H), 1.76 – 1.65 (m, 4H, 3a-H, 2, 3, 5, 6 or 7-H), 
1.63 – 1.51 (m, 2H, 2’-H, 2, 3, 5, 6-H), 1.47 (s, 1H, OH), 1.35 – 1.18 (m, 4H, 2, 3, 5, 6 or 7-H), 
1.04 (s, 3H, 7a-CH3), 1.01 (d, J = 6.5 Hz, 3H, 2’-CH3), 0.98 (s, 9H, SiC(CH3)3), 0.89 (s, 9H, 
SiC(CH3)3), 0.19 (s, 6H, Si(CH3)2), 0.02 (s, 6H, Si(CH3)2). 
13C NMR (101 MHz, chloroform-d) δ/ppm = 155.7 (C-3’’), 150.8 (C-1’’), 129.0 (C-5’’), 117.9 (C-
4’’) 117.7 (C-6’’), 116.8 (C-2’’), 76.3 (C-4), 67.8 (C-1’), 56.3 (C-3a), 53.5 (C-1), 43.1 (C-7a), 
40.9 (C-2, 3, 5, 6 or 7), 40.3 (C-2, 3, 5, 6 or 7), 38.7 (C-2’), 26.3 (C-2, 3, 5, 6 or 7), 26.1 
(SiC(CH3)3), 25.9 (SiC(CH3)3), 20.4 (C-2, 3, 5, 6 or 7), 19.6 (C-2, 3, 5, 6 or 7), 18.5 (SiC(CH3)3), 
18.4 (SiC(CH3)3), 16.9 (2’-CH3), 13.5 (7a-CH3), -4.2 (Si(CH3)2), -4.2 (Si(CH3)2), -5.2 (Si(CH3)2), 
-5.2 (Si(CH3)2). 
IR (ATR): ṽ/cm-1 = 2951, 2928, 2857, 2357, 1600, 1583, 1482, 1471, 1462, 1427, 1388, 1361, 
1272, 1251, 1184, 1125, 1089, 1036, 1004, 986, 941, 918, 830, 814, 774, 731, 698, 667. 
HRMS (EI): m/z calculated for C31H56O3Si2 [M]˙⁺ 532.3768; found 532.3771. 
Purity (HPLC): > 95% (λ = 210 nm), > 95% (λ = 250 nm) (method e).   
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 (1R,3aR,4S,7aR)-4-(4-((tert-Butyldimethylsilyl)oxy)phenyl)-1-((S)-1-((tert-
butyldimethylsilyl)oxy)propan-2-yl)-7a-methyloctahydro-1H-inden-4-ol (83) 
  
C31H56O3Si2 
M = 532.96 g/mol 
Alcohol 83 was synthesised according to GP6 using silylether 78d (159 mg, 0.553 mmol, 
1.10 eq) and ketone 26 (164 mg, 0.505 mmol, 1.00 eq). The title compound was purified via 
FCC (hexanes/EtOAc 9:1) and isolated as white solid (239 mg, 0.448 mmol, 89%).  
 
Rf = 0.40 (hexanes/EtOAc 9:1). 
mp: 72 °C. 
[𝛂]𝑫
𝟐𝟑: + 35.4 (c = 0.03, CHCl3). 
1H NMR (400 MHz, methylene chloride-d2) δ/ppm = 7.30 – 7.25 (m, 2H, 2’’, 6’’-H), 6.80 – 6.74 
(m, 2H, 3’’, 5’’-H), 3.57 (dd, J = 9.6, 3.3 Hz, 1H, 1’-H), 3.28 (dd, J = 9.6, 7.1 Hz, 1H, 1’-H), 2.05 
(dt, J = 12.6, 3.3 Hz, 1H, 6-H), 1.94 (tt, J = 13.3, 4.3 Hz, 1H, 2 or 3-H), 1.78 – 1.63 (m, 4H, 3a, 
5, 7-H), 1.61 – 1.53 (m, 2H, 2’-H, 2 or 3-H), 1.50 (s, 1H, OH), 1.34 – 1.17 (m, 5H, 1, 6, 7-H, 2 
or 3-H), 1.03 (s, 3H, 7a-CH3), 1.01 (d, J = 6.6 Hz, 3H, 2’-CH3), 0.98 (s, 9H, Si(CH3)3), 0.89 (s, 
9H, Si(CH3)3), 0.19 (s, 6H, Si(CH3)2), 0.02 (s, 6H, Si(CH3)2). 
13C NMR (126 MHz, methylene chloride-d2) δ/ppm = 154.5 (C-4’’), 142.6 (C-1’’), 126.2 (C-2’’, 
C-6’’), 119.8 (C-3’’, C-5’’), 76.4 (C-4), 68.2 (C-1’), 56.8 (C-3a), 53.9 (C-7a), 43.6 (C-5), 41.5 
(C-6), 40.7 (C-2’), 39.2 (C-7), 26.7 (SiC(CH3)3), 26.3 (SiC(CH3)3), 26.0 (C-2 or C-3), 20.9 (C-2 
or C-3), 20.1 (SiC(CH3)3), 18.6 (SiC(CH3)3), 17.1 (2’-CH3), 13.7 (7a-CH3), -4.2 (Si(CH3)2), -5.1 
(Si(CH3)2), -5.2 (Si(CH3)2). 
IR (ATR): ṽ/cm-1 = 3579, 2928, 2886, 2856, 2359, 1607, 1505, 1471, 1445, 1387, 1361, 1252, 
1215, 1175, 1144, 1080, 1025, 1004, 986, 970, 916, 833, 811, 772, 713, 666. 
HRMS (EI): m/z calculated for C31H56O3Si2 [M]˙⁺ 532.3763; found 532.3763. 
Purity (HPLC): > 95% (λ = 210 nm) (method f).  
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(1R,3aR,4S,7aR)-4-(3-(((tert-Butyldimethylsilyl)oxy)methyl)phenyl)-1-((S)-1-((tert-
butyldimethylsilyl)oxy)propan-2-yl)-7a-methyloctahydro-1H-inden-4-ol (84) 
 
 
 
 
 
C32H58O3Si2 
M = 546.98 g/mol 
Alcohol 84 was synthesised according to GP6 using silylether 80d (190 mg, 0.631 mmol, 
1.10 eq) and ketone 26 (186 mg, 0.573 mmol, 1.00 eq). The title compound was purified via 
FCC (hexanes/EtOAc 9:1) and isolated as white, oily solid (253 mg, 0.463 mmol, 81%).  
 
Rf = 0.50 (hexanes/EtOAc 9:1). 
[𝛂]𝑫
𝟐𝟑: + 17.9 (c = 0.05, CHCl3). 
1H NMR (500 MHz, chloroform-d) δ/ppm = 7.39 (t, J = 1.7 Hz, 1H, 2’’-H), 7.33 (dt, J = 7.9, 1.6 
Hz, 1H, 6’’-H), 7.28 (t, J = 7.6 Hz, 1H, 5’’-H), 7.17 (dt, J = 7.5, 1.5 Hz, 1H, 4’’-H), 4.75 (s, 2H, 
3’’-CH2),  3.56 (dd, J = 9.6, 3.4 Hz, 1H, 1’-H), 3.28 (dd, J = 9.6, 7.0 Hz, 1H, 1’-H), 2.08 (dt, J = 
12.8, 3.4 Hz, 1H, 2, 3, 5 or 6-H), 2.04 – 1.93 (m, 1H, OH), 1.74 (dq, J = 9.1, 4.8, 3.8 Hz, 3H, 
3a, 7-H), 1.71 – 1.67 (m, 1H, 2, 3, 5 or 6-H), 1.63 – 1.50 (m, 3H, 2’-H, 2, 3, 5 or 6-H), 1.34 – 
1.17 (m, 5H, 1-H, 2, 3, 5 or 6-H), 1.05 (s, 3H, 7a-CH3), 1.02 (d, J = 6.5 Hz, 3H, 2’-CH3), 0.94 
(s, 9H, SiC(CH3)3), 0.89 (s, 9H, SiC(CH3)3), 0.09 (s, 3H, Si(CH3)2), 0.09 (s, 3H, Si(CH3)2), 0.03 
(s, 6H, Si(CH3)2). 
13C NMR (126 MHz, chloroform-d) δ/ppm = 149.0 (C-1’’), 141.3 (C-3’’), 128.1 (C-6’’), 124.2 (C-
4’’), 123.3 (C-5’’), 122.5 (C-2’’), 76.5 (C-4), 67.8 (C-1’), 65.4 (3’’-CH2), 56.2 (C-3a), 53.5 (C-1), 
43.1 (C-7a), 41.1 (C-7), 40.3 (C-2, 3, 5 or 6), 38.7 (C-2’), 26.3 (C-2, 3, 5 or 6), 26.1 (SiC(CH3)3), 
26.1 (SiC(CH3)3), 20.4 (C-2, 3, 5 or 6), 19.6 (C-2, 3, 5 or 6), 18.6 (SiC(CH3)3), 18.5 (SiC(CH3)3), 
16.9 (2’-CH3), 13.5 (7a-CH3), -5.0 (Si(CH3)2), -5.2 (Si(CH3)2), -5.2 (Si(CH3)2). 
IR (ATR): ṽ/cm-1 = 2950, 2928, 2856, 2359, 2342, 1606, 1471, 1385, 1375, 1360, 1333, 1281, 
1251, 1180, 1144, 1069, 1033, 1003, 985, 938, 891, 833, 814, 769, 701, 667. 
HRMS (EI): m/z calculated for C32H59O3Si2 [M]˙⁺ 547.3997; found 547.3988. 
Purity (HPLC): > 95% (λ = 210 nm) (method e).    
Experimental Part 
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(1R,3aR,4S,7aR)-4-(4-(((tert-Butyldimethylsilyl)oxy)methyl)phenyl)-1-((S)-1-((tert-
butyldimethylsilyl)oxy)propan-2-yl)-7a-methyloctahydro-1H-inden-4-ol (85) 
 
 
 
 
 
 
 
C32H58O3Si2 
M = 546.98 g/mol 
Alcohol 85 was synthesised according to GP6 using silylether 81d (180 mg, 0.597 mmol, 
1.10 eq) and ketone 26 (177 mg, 0.545 mmol, 1.00 eq). The title compound was purified via 
FCC (hexanes/EtOAc 9:1) and isolated as white solid (206 mg, 0.377 mmol, 69%).  
 
Rf = 0.45 (hexanes/EtOAc 9:1). 
mp: 88 °C. 
[𝛂]𝑫
𝟐𝟑: + 17.5 (c = 0.04, CHCl3). 
1H NMR (400 MHz, methylene chloride-d2) δ/ppm = 7.43 – 7.37 (m, 2H, 2’’, 6’’-H), 7.29 – 7.24 
(m, 2H, 3’’, 5’’-H), 4.70 (d, J = 0.8 Hz, 2H, 4’’-CH2), 3.60 – 3.54 (m, 1H, 1’-H), 3.32 – 3.25 (m, 
1H, 1’-H), 2.07 (dt, J = 12.7, 3.3 Hz, 1H, 7-H), 1.97 (ddt, J = 17.5, 9.1, 4.4 Hz, 1H, 6-H), 1.80 
– 1.66 (m, 4H, 3a, 5, 2-H), 1.62 – 1.48 (m, 3H, 6, 2’-H, OH), 1.37 – 1.19 (m, 5H, 1, 2, 3, 7-H), 
1.06 – 1.04 (m, 3H, 7a-CH3), 1.02 (d, J = 6.6 Hz, 3H, 2’-CH3), 0.94 (s, 9H, SiC(CH3)3), 0.89 (s, 
9H, SiC(CH3)3), 0.10 (s, 6H, Si(CH3)2), 0.03 (s, 6H, Si(CH3)2). 
13C NMR (101 MHz, methylene chloride-d2) δ/ppm = 148.5 (C-1’’), 139.9 (C-4’’), 126.5 (C-3’’, 
C-5’’), 124.9 (C-2’’, C-6’’), 76.6 (C-4), 68.2 (C-1’), 65.3 (4’’-CH2), 56.6 (C-3a), 53.9 (C-1), 43.5 
(C-7a), 41.6 (C-5), 40.7 (C-7), 39.2 (C-2’), 26.8 (C-2), 26.3 (SiC(CH3)3), 20.8 (C-3), 20.0 (C-6), 
18.8 (SiC(CH3)3), 17.2 (SiC(CH3)3), 13.7 (2’-CH3), -5.0 (7a-CH3), -5.1 (Si(CH3)2), -5.2 
(Si(CH3)2). 
IR (ATR): ṽ/cm-1 = 3573, 2948, 2928, 2893, 2855, 2360, 1508, 1470, 1377, 1315, 1252, 1219, 
1145, 1116, 1076, 1020, 1004, 985, 971, 938, 859, 832, 815, 802, 772, 751, 721, 666. 
HRMS (EI): m/z calculated for C32H57O3Si2 [M]˙⁺ 545.3840; found 545.3840. 
Purity (HPLC): > 95% (λ = 210 nm) (method a). 
Experimental Part 
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(1R,3aR,4S,7aR)-4-(3-Hydroxyphenyl)-1-((S)-1-hydroxypropan-2-yl)-7a-
methyloctahydro-1H-inden-4-ol (86) 
 
C19H28O3 
M = 304.43 g/mol 
Triol 86 was synthesised according to GP9, using alcohol 82 (46.0 mg, 0.0863 mmol, 1.00 eq). 
The title compound was purified via FCC (hexanes/EtOAc 6:4) and isolated as white solid 
(25.5 mg, 0.0838 mmol, 97%). 
 
Rf = 0.21 (hexanes/EtOAc 6:4). 
mp: 203 °C. 
[𝛂]𝑫
𝟐𝟑: + 22.6 (c = 0.06, MeOH). 
1H NMR (400 MHz, DMSO-d6) δ/ppm = 9.09 (s, 1H, 3’’-OH), 7.03 (t, J = 7.8 Hz, 1H, 5’’-H), 6.88 
– 6.84 (m, 1H, 2’’-H), 6.81 (dt, J = 7.8, 1.3 Hz, 1H, 6’’-H), 6.53 (ddd, J = 7.9, 2.4, 0.9 Hz, 1H 
4’’-H), 4.35 (s, 1H, 4-OH), 4.20 (dd, J = 5.7, 4.8 Hz, 1H, 1’-OH), 3.37 (dq, J = 10.3, 4.0, 3.6 Hz, 
1H, 1’-H), 3.10 – 2.99 (m, 1H, 1’-H), 1.94 (d, J = 13.0 Hz, 2H, 2, 3, 5, 6 or 7-H), 1.67 – 1.19 (m, 
9H, 3a, 2’-H, 2, 3, 5, 6 or 7-H), 1.18 – 1.05 (m, 2H, 1-H, 2, 3, 5, 6 or 7-H), 0.98 (s, 3H, 7a-CH3), 
0.95 (d, J = 6.5 Hz, 3H, 2’-CH3). 
13C NMR (101 MHz, DMSO-d6) δ/ppm = 156.8 (C-3’’), 151.8 (C-1’’), 128.4 (C-5’’), 115.5 (C-
6’’), 112.4 (C-4’’), 112.2 (C-2’’), 74.4 (C-4), 65.6 (C-1’), 56.1 (C-3a), 53.0 (C-1), 42.4 (C-7a), 
40.0 (C-2, 3, 5, 6 or 7), 39.9 (C-2, 3, 5, 6 or 7), 38.2 (C-2’), 25.9 (C-2, 3, 5, 6 or 7), 20.1 (C-2, 
3, 5, 6 or 7), 19.2 (C-2, 3, 5, 6 or 7), 16.8 (2’-CH3), 13.4 (7a-CH3). 
IR (ATR): ṽ/cm-1 = 3539, 3473, 3140, 2943, 2928, 2885, 2859, 2359, 1591, 1445, 1395, 1374, 
1337, 1285, 1264, 1226, 1190, 1153, 1108, 1087, 1071, 1032, 1022, 1002, 981, 941, 886, 859, 
846, 786, 763, 715, 699, 661. 
HRMS (EI): m/z calculated for C19H28O3 [M]˙⁺ 304.2033; found 304.2033. 
Purity (HPLC): > 95% (λ = 210 nm) (method a).  
Experimental Part 
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(1R,3aR,4S,7aR)-4-(4-Hydroxyphenyl)-1-((S)-1-hydroxypropan-2-yl)-7a-
methyloctahydro-1H-inden-4-ol (87) 
 
C19H28O3 
M = 304.43 g/mol 
Triol 87 was synthesised according to GP9, using alcohol 83 (42.0 mg, 0.0788 mmol, 1.00 eq). 
The title compound was purified via FCC (hexanes/EtOAc 6:4) and isolated as white solid 
(24.0 mg, 0.0788 mmol, quantitative). 
 
Rf = 0.22 (hexanes/EtOAc 6:4). 
mp: 212 °C. 
[𝛂]𝑫
𝟐𝟑: + 103.5 (c = 0.06, CHCl3). 
1H NMR (400 MHz, DMSO-d6) δ/ppm = 9.06 (s, 1H, 4’’-OH), 7.21 – 7.16 (m, 2H, 2’’-H), 6.67 – 
6.61 (m, 2H, 3’’-H), 4.25 (s, 1H, 4-OH), 4.20 (t, J = 5.2 Hz, 1H, 1’-OH), 3.37 (dq, J = 10.3, 4.1, 
3.6 Hz, 1H, 1’-H), 3.04 (dt, J = 10.3, 6.5 Hz, 1H, 1’-H), 1.96 – 1.83 (m, 2H, 2, 3, 5, 6 or 7-H), 
1.67 – 1.19 (m, 9H, 3a, 2’-H, 2, 3, 5, 6 or 7-H), 1.16 – 1.06 (m, 2H, 1-H, 2, 3, 5, 6 or 7-H), 0.97 
(s, 3H, 7a-CH3), 0.94 (d, J = 6.5 Hz, 3H, 2’-CH3). 
13C NMR (101 MHz, DMSO-d6) δ/ppm = 155.1 (C-4’’), 140.5 (C-1’’), 125.8 (C-2’’), 114.2 (C-
3’’), 74.1 (C-4), 65.6 (C-1’), 56.4 (C-3a), 53.1 (C-1), 42.5 (C-7a), 40.3 (C-2, 3, 5, 6 or 7), 40.1 
(C-2, 3, 5, 6 or 7), 38.2 (C-2’), 25.9 (C-2, 3, 5, 6 or 7), 20.2 (C-2, 3, 5, 6 or 7), 19.3 (C-2, 3, 5, 
6 or 7), 16.8 (2’-CH3), 13.4 (7a-CH3). 
IR (ATR): ṽ/cm-1 = 3399, 3124, 3021, 2956, 2934, 2891, 2360, 1616, 1596, 1517, 1454, 1377, 
1336, 1300, 1249, 1211, 1178, 1161, 1081, 1038, 1020, 1001, 962, 933, 856, 826, 789, 771. 
HRMS (EI): m/z calculated for C19H28O3 [M]˙⁺ 304.2033; found 304.2026. 
Purity (HPLC): > 95% (λ = 210 nm) (method a).   
 
 
Experimental Part 
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(1R,3aR,4S,7aR)-4-(4-(Hydroxymethyl)phenyl)-1-((S)-1-hydroxypropan-2-yl)-7a-
methyloctahydro-1H-inden-4-ol (89) 
 
 
 
 
 
 
C20H30O3 
M = 318.46 g/mol 
Triol 89 was synthesised according to GP9, using alcohol 85 (50 mg, 0.0914 mmol, 1.00 eq). 
The title compound was purified via FCC (hexanes/EtOAc 4:6) and isolated as white solid 
(13.6 mg, 0.0427 mmol, 47%). 
 
Rf = 0.24 (hexanes/EtOAc 4:6). 
mp: 167 °C. 
[𝛂]𝑫
𝟐𝟑: + 22.7 (c = 0.03, CHCl3). 
1H NMR (400 MHz, DMSO-d6) δ/ppm = 7.38 – 7.34 (m, 2H, 2’’, 6’’-H), 7.22 – 7.18 (m, 2H, 3’’, 
5’’-H), 5.05 (t, J = 5.7 Hz, 1H, 4’’-CH2-OH), 4.46 – 4.40 (m, 3H, 4’’-CH2, 4-OH), 4.21 (t, J = 5.3 
Hz, 1H, 1’-OH), 3.37 (dt, J = 8.7, 3.9 Hz, 1H, 1’-H), 3.04 (dt, J = 10.3, 6.5 Hz, 1H, 1’-H), 1.93 
(t, J = 13.6 Hz, 2H, 7-H, 2, 3, 5 or 6-H), 1.71 – 1.54 (m, 4H, 2, 3, 5 or 6-H), 1.50 – 1.22 (m, 5H, 
7-H, 2’-H, 2, 3, 5 or 6-H), 1.18 – 1.07 (m, 2H, 1-H, 2, 3, 5 or 6-H), 0.99 (s, 3H, 7a-CH3), 0.95 
(d, J = 6.5 Hz, 3H, 2’-CH3).  
13C NMR (101 MHz, DMSO-d6) δ/ppm = 148.5 (C-1’’), 139.6 (C-4’’), 125.8 (C-3’’, 5’’), 124.5 
(C-2’’, 6’’), 74.5 (C-4), 65.5 (C-1’), 62.8 (4’’-CH2), 56.1 (C-3a), 52.9 (C-1), 42.5 (C-7a), 40.2 (C-
2, 3, 5 or 6), 39.9 (C-7), 38.2 (C-2’), 25.9 (C-2, 3, 5 or 6), 20.1 (C-2, 3, 5 or 6), 19.2 (C-2, 3, 5 
or 6), 16.8 (2’-CH3), 13.4 (7a-CH3). 
IR (ATR): ṽ/cm-1 = 3607, 3453, 3253, 2868, 2933, 2359, 1511, 1455, 1403, 1375, 1300, 1261, 
1235, 1215, 1187, 1159, 1115, 1083, 1049, 1017, 999, 986, 959, 930, 902, 856, 829, 793, 772. 
HRMS (EI): m/z calculated for C20H30O3 [M]˙⁺ 318.2189; found 318.2185. 
Purity (HPLC): > 95% (λ = 210 nm) (method a). 
 
  
Experimental Part 
 
  
 
  
 153 
 
(1R,3aR,4S,7aR)-4-(3-(Hydroxymethyl)phenyl)-1-((S)-1-hydroxypropan-2-yl)-7a-
methyloctahydro-1H-inden-4-ol (88) 
 
 
 
 
 
 
 
C20H30O3 
M = 318.46 g/mol 
Triol 88 was synthesised according to GP9, using alcohol 84 (168 mg, 0.307 mmol, 1.00 eq). 
The title compound was purified via FCC (hexanes/EtOAc 5:5) and isolated as white solid 
(40.0 mg, 0.126 mmol, 41%). 
 
Rf = 0.23 (hexanes/EtOAc 50:50). 
mp: 58 °C. 
[𝛂]𝑫
𝟐𝟑: + 3.0 (c = 0.17, CHCl3). 
1H NMR (400 MHz, methanol-d4) δ/ppm = 7.43 (d, J = 2.0 Hz, 1H, 6’’-H), 7.35 (dt, J = 7.8, 1.5 
Hz, 1H, 2’’-H), 7.27 (t, J = 7.6 Hz, 1H, 5’’-H), 7.17 (dt, J = 7.6, 1.4 Hz, 1H, 4’’-H), 4.60 (s, 2H, 
3’’-CH2), 3.56 (dd, J = 10.6, 3.2 Hz, 1H, 1’-H), 3.25 (dd, J = 10.6, 7.1 Hz, 1H, 1’-H), 2.13 – 1.98 
(m, 2H, 5, 6-H), 1.84 – 1.66 (m, 4H, 7-H, 2 or 3-H, OH), 1.61 – 1.48 (m, 2H, 5 or 6-H, 2’-H), 
1.43 – 1.21 (m, 6H, 1, 2, 3-H, 5 or 6-H, 2 x OH), 1.09 (s, 3H,  7a-CH3), 1.06 (d, J = 6.6 Hz, 3H, 
2’-CH3). 
13C NMR (101 MHz, methanol-d4) δ/ppm = 150.9 (C-1’’), 142.2 (C-3’’), 128.9 (C-5’’), 125.8 (C-
4’’), 124.9 (C-2’’), 124.5 (C-6’’), 77.2 (C-4), 67.8 (C-1’), 65.6 (3’’-CH2), 57.5 (C-3a), 54.7 (C-1), 
44.2 (C-7a), 42.0 (C-7), 41.7 (C-5 or 6), 39.8 (C-2’), 27.4 (C-2 or 3), 21.3 (C-2 or 3), 20.6 (C-5 
or 6), 17.2 (2’-CH3), 13.9 (7a-CH3). 
IR (ATR): ṽ/cm-1 = 2928, 1603, 1507, 1471, 1255, 1083, 913, 833, 812, 773. 
HRMS (EI): m/z calculated for C20H30O3 [M]˙⁺ 318.2189; found 318.2184. 
Purity (HPLC): > 95% (λ = 210 nm) (method a). 
  
Experimental Part 
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(S)-2-((1R,3aS,4S,7aS)-4-(4-((tert-Butyldimethylsilyl)oxy)phenyl)-7a-methyloctahydro-
1H-inden-1-yl)propan-1-ol (90) 
 
C25H42O2Si 
M = 402.69 g/mol 
Alcohol 90 was synthesised according to GP8 using alcohol 83 (102 mg, 0.191 mmol, 1.00 eq). 
The title compound was purified via FCC (hexanes/EtOAc 9:1) and isolated as white, oily solid 
(22.0 mg, 0.0546 mmol, 29%). 
 
Rf = 0.20 (hexanes/EtOAc 9:1). 
[𝛂]𝑫
𝟐𝟑: + 16.7 (c = 0.03, CHCl3). 
1H NMR (400 MHz, chloroform-d) δ/ppm = 7.17 – 7.11 (m, 2H, 2’’, 6’’-H), 6.78 – 6.64 (m, 2H, 
3’’, 5’’-H), 3.60 (dd, J = 10.5, 3.2 Hz, 1H, 1-H), 3.34 (dd, J = 10.5, 6.8 Hz, 1H, 1-H), 3.11 (t, J 
= 5.5 Hz, 1H, 4’-H), 2.32 – 2.21 (m, 1H, 5’-H), 2.01 (tt, J = 14.2, 13.0, 5.6 Hz, 2H, 6’, 7’-H), 
1.84 – 1.61 (m, 4H, 3a’, 5’, 6’-H, 2’ or 3’-H), 1.56 – 1.39 (m, 1H, 2-H), 1.31 – 1.13 (m, 5H, 1’, 
7’-H, 2’ or 3’-H), 1.00 (d, J = 6.5 Hz, 3H, 2-CH3), 0.97 (s, 9H, SiC(CH3)3), 0.38 (s, 3H, 7a’-CH3), 
0.18 (s, 3H, Si(CH3)2), 0.18 (s, 3H, Si(CH3)2). 
13C NMR (101 MHz, chloroform-d) δ/ppm = 153.2 (C-4‘‘), 136.8 (C-1‘‘), 130.1 (C-2‘‘, 6‘‘), 119.1 
(C-3‘‘, 5‘‘), 68.1 (C-1), 53.3 (C-1‘), 51.9 (C-3a‘), 42.6 (C-7a’), 41.0 (C-7’), 39.4 (C-4’), 38.6 (C-
2), 29.9 (C-5’), 26.8 (C-2’ or 3’), 25.9 (SiC(CH3)3), 25.8 (C-2’ or 3’), 20.6 (C-6’), 18.4 
(SiC(CH3)3), 16.9 (2-CH3), 12.3 (7a’-CH3), -4.3 (Si(CH3)2). 
IR (ATR): ṽ/cm-1 = 2958, 2925, 2852, 1731, 1704, 1512, 1457, 1368, 1109, 1037, 1024, 1012, 
939, 813, 785, 723. 
HRMS (EI): m/z calculated for C25H42O2Si [M]˙⁺ 402.2949; found 402.2951. 
Purity (HPLC): n.d. 
 
Experimental Part 
 
  
 
  
 155 
 
((S)-2-((1R,3aS,4R,7aS)-4-Benzyl-7a-methyloctahydro-1H-inden-1-yl)propoxy)(tert-
butyl)dimethylsilane (91d) 
 
 
 
 
 
 
C26H44OSi 
M = 400.72 g/mol  
Silyl ether 91d was synthesised according to GP7, using alkene 72 (33.0 mg, 0.102 mmol, 
1.10 eq) and bromobenzene (14.6 mg, 0.0930 mmol, 1.00 eq). The title compound was 
purified via FCC (hexanes/toluene 9:1) and isolated as a colourless oil (14.6 mg, 0.0364 mmol, 
39%).  
 
Rf = 0.55 (hexanes/toluene 9:1).  
[𝛂]𝑫
𝟐𝟑: + 37.0 (c = 0.07, CHCl3). 
1H NMR (400 MHz, methylene chloride-d2) δ/ppm = 7.32 – 7.05 (m, 5H, 2’’, 3’’, 4’’, 5’’, 6’’-H), 
3.61 (dd, J = 9.6, 3.3 Hz, 1H, 1-H), 3.29 (ddd, J = 9.6, 7.3, 0.9 Hz, 1H, 1-H), 2.83 – 2.73 (m, 
1H, 4’-CH2), 2.48 (dd, J = 13.4, 11.4 Hz, 1H, 4’-CH2), 2.03 – 1.92 (m, 2H, 4’, 7’-H), 1.89 – 1.79 
(m, 1H, 2’, 3’, 5’ or 6’-H), 1.76 – 1.42 (m, 7H, 2, 3a’, 7’-H, 2’, 3’, 5’ or 6’-H), 1.35 – 1.14 (m, 4H, 
1’-H, 2’, 3’, 5’ or 6’-H), 0.99 (dd, J = 6.6, 0.9 Hz, 3H, 2-CH3), 0.90 (s, 9H, SiC(CH3)3), 0.86 (s, 
3H, 7a’-CH3), 0.04 (s, 6H, Si(CH3)2). 
13C NMR (101 MHz, methylene chloride-d2) δ/ppm = 144.5 (C-1’’), 129.6 (C-2’’, C-6’’), 128.7 
(C-3’’, C-5’’), 125.9 (C-4’’), 68.3 (C-1), 54.4 (C-1’), 53.1 (C-3a’), 42.9 (C-7a’), 41.4 (C-7’), 40.2 
(C-4’), 39.5 (C-2), 35.1 (4’-CH2), 29.3 (C-5’), 27.4 (C-3’), 26.3 (SiC(CH3)3), 24.4 (C-6’), 18.8 
(SiC(CH3)3), 18.6 (C-2’), 17.2 (2-CH3), 14.1 (7a’-CH3), -5.1 (Si(CH3)2), -5.2 (Si(CH3)2). 
IR (ATR): ṽ/cm-1 = 2978, 2856, 1602, 1495, 1470, 1385, 1251, 1120, 1095, 1056, 1032, 1007, 
961, 834, 811, 767, 738, 699, 665. 
HRMS (EI): m/z calculated for C28H44OSi [M]˙⁺ 400.3156; found 400.3163. 
Purity (GC): 84% (scan mode m/z 50-650 (EI 70 eV)). 
 
 
Experimental Part 
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tert-Butyl((S)-2-((1R,3aS,4R,7aS)-4-(3-((tert-butyldimethylsilyl)oxy)benzyl)-7a-
methyloctahydro-1H-inden-1-yl)propoxy)dimethylsilane (92d) 
 
 
 
 
 
C32H58O2Si2 
M = 530.40 g/mol 
Silylether 92d was synthesised according to GP7, using alkene 72 (245 mg, 0.759 mmol, 
1.00 eq) and aryl bromide 76 (218 mg, 0.759 mmol, 1.00 eq). The title compound was purified 
via FCC (hexanes/toluene 95:5) and isolated as a colourless oil (102 mg, 0.192 mmol, 25%).  
 
Rf = 0.22 (hexanes/toluene 95:5).  
[𝛂]𝑫
𝟐𝟑: + 27.1 (c = 0.06, CHCl3). 
1H NMR (400 MHz, methylene chloride-d2) δ/ppm 7.15 – 7.06 (m, 1H, 5’’-H), 6.74 (dt, J = 7.7, 
1.4 Hz, 1H, 6’’-H), 6.66 – 6.60 (m, 2H, 2’’-H, 4’’-H), 3.60 (dd, J = 9.6, 3.3 Hz, 1H, 1-H), 3.28 
(dd, J = 9.6, 7.3 Hz, 1H, 1-H), 2.74 (dd, J = 13.8, 2.7 Hz, 1H, 4’-CH2), 2.43 (dd, J = 13.4, 11.3 
Hz, 1H, 4’-CH2), 2.00 – 1.89 (m, 2H, 4’, 7’-H), 1.89 – 1.78 (m, 1H, 2’, 3’, 5’ or 6’-H), 1.74 – 1.39 
(m, 7H, 2, 7’-H, 2’, 3’, 5’ or 6’-H), 1.34 – 1.10 (m, 4H, 1’, 3a’-H, 2’, 3’, 5’ or 6’-H), 1.00 – 0.97 
(m, 12H, 2-CH3, SiC(CH3)3), 0.90 (s, 9H, SiC(CH3)3), 0.85 (s, 3H, 7a’-CH3), 0.18 (s, 6H, 
Si(CH3)2), 0.04 (s, 6H, Si(CH3)2). 
13C NMR (101 MHz, methylene chloride-d2) δ/ppm = 156.1 (C-3’’), 146.1 (C-1’’), 129.5 (C-5’’), 
122.6 (C-6’’), 121.4 (C-2’’), 117.6 (C-4’’), 68.3 (C-1), 54.4 (C-1’), 53.0 (C-3a’), 42.9 (C-7a’), 
41.4 (C-7’), 40.1 (C-4’), 39.5 (4’-CH2), 35.1 (C-2), 29.4 (2’, 3’, 5’ or 6’-H), 27.4 (2’, 3’, 5’ or 6’-
H), 26.3 (SiC(CH3)3), 26.0 (SiC(CH3)3), 24.4 (2’, 3’, 5’ or 6’-H), 18.8 (SiC(CH3)3), 18.7 
(SiC(CH3)3), 18.6 (2’, 3’, 5’ or 6’-H), 17.2 (2-CH3), 14.1 (7a’-CH3), -4.1 (Si(CH3)2), -5.1 
(Si(CH3)2), -5.2 (Si(CH3)2). 
IR (ATR): ṽ/cm-1 = 2927, 2856, 1602, 1585, 1471, 1362, 1273, 1252, 1157, 1089, 1004, 982, 
958, 835, 775, 696, 665.  
HRMS (EI): m/z calculated for C32H58O2Si2 [M]˙⁺ 530.3970; found 530.3966. 
Purity (HPLC): 87% (λ = 191 nm) (method f).   
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tert-Butyl((S)-2-((1R,3aS,4R,7aS)-4-(4-((tert-butyldimethylsilyl)oxy)benzyl)-7a-
methyloctahydro-1H-inden-1-yl)propoxy)dimethylsilane (93d) 
 
 
 
 
 
 
C32H58O2Si2 
M = 530.40 g/mol 
Silylether 93d was synthesised according to GP7, using alkene 72 (260 mg, 0.806 mmol, 
1.00 eq) and bromide 78d (218 mg, 0.759 mmol, 1.00 eq). The title compound was purified via 
FCC (hexanes/toluene 95:5) and isolated as a colourless oil (139 mg, 0.262 mmol, 33%).  
 
Rf = 0.30 (hexanes/toluene 95:5).  
[𝛂]𝑫
𝟐𝟑: + 18.3 (c = 0.05, CHCl3). 
1H NMR (400 MHz, methylene chloride-d2) δ/ppm = 7.02 – 6.94 (m, 2H, 2’’, 6’’-H), 6.75 – 6.69 
(m, 2H, 3’’, 5’’-H), 3.60 (dd, J = 9.6, 3.3 Hz, 1H, 1-H), 3.28 (dd, J = 9.6, 7.3 Hz, 1H, 1-H), 2.74 
– 2.67 (m, 1H, 4’-CH2), 2.41 (dd, J = 13.6, 11.4 Hz, 1H, 4’-CH2), 2.00 – 1.90 (m, 2H, 4’, 7’-H), 
1.87 – 1.78 (m, 1H, 2’, 3’, 5’ or 6’-H), 1.72 – 1.40 (m, 7H, 2, 3a’, 7’-H, 2’, 3’, 5’ or 6’-H), 1.31 – 
1.10 (m, 4H, 1’-H, 2’, 3’, 5’ or 6’-H), 1.01 – 0.96 (m, 12H, 2-CH3, SiC(CH3)3), 0.89 (s, 9H, 
SiC(CH3)3), 0.84 (s, 3H, 7a’-CH3), 0.17 (s, 6H, Si(CH3)2), 0.04 (s, 6H, Si(CH3)2). 
13C NMR (101 MHz, methylene chloride-d2) δ/ppm = 153.9 (C-4’’), 137.1 (C-1’’), 130.3 (C-2’’, 
6’’), 120.2 (C-3’’, 5’’), 68.3 (C-1), 54.4 (C-1’), 53.1 (C-3a’), 42.9 (C-7a’), 41.4 (C-7’), 40.3 (C-
4’), 39.5 (C-1’), 34.3 (4’-CH2), 29.3 (C-2’, 3’, 5’ or 6’), 27.4 (C-2’, 3’, 5’ or 6’), 26.3 (SiC(CH3)3), 
26.0 (SiC(CH3)3), 24.4 (C-2’, 3’, 5’ or 6’), 18.8 (SiC(CH3)3), 18.6 (SiC(CH3)3), 18.6 (C-2’, 3’, 5’ 
or 6’), 17.2 (2-CH3), 14.1 (7a’-CH3), -4.2 (Si(CH3)2), -5.1 (Si(CH3)2), -5.2 (Si(CH3)2). 
IR (ATR): ṽ/cm-1 = 2926, 2856, 2361, 1608, 1509, 1471, 1387, 1253, 1167, 1094, 1007, 912, 
834, 800, 772, 677.  
HRMS (EI): m/z calculated for C32H58O2Si2 [M]˙⁺ 530.3970; found 530.3976. 
Purity (HPLC): > 95% (λ = 210 nm) (method d). 
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tert-Butyl((S)-2-((1R,3aS,4R,7aS)-4-(3-(((tert-butyldimethylsilyl)oxy)methyl)benzyl)-7a-
methyloctahydro-1H-inden-1-yl)propoxy)dimethylsilane (94d) 
 
 
 
 
 
C33H60O2Si2 
M = 544,41 g/mol 
Silylether 94d was synthesised according to GP7, using alkene 72 (156 mg, 0.484 mmol, 
1.00 eq) and benzyl bromide 80d (146 mg, 0.484 mmol, 1.00 eq). The title compound was 
purified via FCC (hexanes/toluene 95:5) and isolated as a colourless oil (35.1 mg, 
0.0644 mmol, 13%).  
 
Rf = 0.20 (hexanes/toluene 95:5).  
[𝛂]𝑫
𝟐𝟑: + 55.6 (c = 0.006, CHCl3). 
1H NMR (400 MHz, methylene chloride-d2) δ/ppm = 7.24 – 7.18 (m, 1H, 5’’-H), 7.13 – 7.09 (m, 
2H, 2’’, 4’’-H), 7.02 (d, J = 7.5 Hz, 1H, 6’’-H), 4.70 (s, 2H, 3’’-CH2), 3.61 (dd, J = 9.6, 3.4 Hz, 
1H, 1-H), 3.29 (dd, J = 9.6, 7.3 Hz, 1H, 1-H), 2.79 (d, J = 13.3 Hz, 1H, 4’-CH2), 2.48 (dd, J = 
13.4, 11.4 Hz, 1H, 4’-CH2), 2.01 – 1.93 (m, 2H, 4’, 7’-H), 1.90 – 1.78 (m, 1H, 2’, 3’, 5’ or 6’-H), 
1.74 – 1.40 (m, 7H, 2, 3a’-H, 2’, 3’, 5’ or 6’-H), 1.35 – 1.09 (m, 4H, 1’, 7’-H, 2’, 3’, 5’ or 6’-H), 
0.98 (d, J = 6.5 Hz, 3H, 2-CH3), 0.94 (s, 9H, SiC(CH3)3), 0.90 (s, 9H, SiC(CH3)3), 0.86 (s, 3H, 
7a’-CH3), 0.10 (s, 6H, Si(CH3)2), 0.05 – 0.03 (m, 6H, Si(CH3)2). 
13C NMR (101 MHz, methylene chloride-d2) δ/ppm = 144.4 (C-1’’), 141.9 (C-3’’), 128.5 (C-5’’), 
128.1 (C-6’’), 127.5 (C-2’’), 123.9 (C-4’’), 68.3 (C-1), 65.5 (3’’-CH2), 54.4 (C-1’), 53.1 (C-3a’), 
42.9 (C-7a’), 41.4 (C-7’), 40.3 (C-4’), 39.5 (C-2), 35.1 (4’-CH2), 29.3 (C-2’, 3’, 5’ or 6’), 27.4 (C-
2’, 3’, 5’ or 6’), 26.3 (SiC(CH3)3), 26.3 (SiC(CH3)3), 24.4 (C-2’, 3’, 5’ or 6’), 18.8 (SiC(CH3)3), 
18.8 (SiC(CH3)3), 18.6 (C-2’, 3’, 5’ or 6’), 17.2 (2-CH3), 14.1 (7a’-CH3), -5.0 (Si(CH3)2), -5.1 
(Si(CH3)2), -5.2 (Si(CH3)2). 
IR (ATR): ṽ/cm-1 = 2951, 2928, 2856, 2361, 2341, 1609, 1472, 1462, 1446, 1388, 1361, 1252, 
1157, 1080, 1033, 1006, 965, 138, 919, 833, 814, 773, 702, 666.  
HRMS (EI): m/z calculated for C32H57O2Si2 [M]˙⁺ 529.3892; found 529.3872. 
Purity (HPLC): 85% (λ = 210 nm) (method f).   
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tert-Butyl((S)-2-((1R,3aS,4R,7aS)-4-(4-(((tert-butyldimethylsilyl)oxy)methyl)benzyl)-7a-
methyloctahydro-1H-inden-1-yl)propoxy)dimethylsilane (95d) 
 
 
 
 
 
C33H60O2Si2 
M = 544.41 g/mol 
Silylether 95d was synthesised according to GP7, using alkene 72 (249 mg, 0.772 mmol, 
1.0 eq) and benzyl bromide 81d (233 mg, 0.772 mmol, 1.00 eq). The title compound was 
purified via FCC (hexanes/toluene 7:3) and isolated as a colourless oil (243 mg, 0.261 mmol, 
57%).  
 
Rf = 0.09 (hexanes/toluene 7:3).  
[𝛂]𝑫
𝟐𝟑: + 100.0 (c = 0.07, CHCl3). 
1H NMR (400 MHz, methylene chloride-d2) δ/ppm = 7.23 – 7.17 (m, 2H, 3’’, 5’’-H), 7.12 – 7.07 
(m, 2H, 2’’, 6’’-H), 4.68 (s, 2H, 4’’-CH2), 3.61 (dd, J = 9.6, 3.3 Hz, 1H, 1-H), 3.32 – 3.26 (m, 1H, 
1-H), 2.78 (d, J = 13.5 Hz, 1H, 4’-CH2), 2.48 (dd, J = 13.4, 11.4 Hz, 1H, 4’-CH2), 2.01 – 1.93 
(m, 2H, 4’, 7’-H), 1.89 – 1.78 (m, 1H, 2’, 3’, 5’ or 6’-H), 1.75 – 1.36 (m, 7H, 2, 3a’-H, 2’, 3’, 5’ or 
6’-H), 1.37 – 1.12 (m, 4H, 1’, 7’-H, 2’, 3’, 5’ or 6’-H), 0.98 (d, J = 6.6 Hz, 3H, 2-CH3), 0.93 (s, 
9H, SiC(CH3)3), 0.90 (s, 9H, SiC(CH3)3), 0.86 (s, 3H, 7a’-CH3), 0.10 (s, 6H, Si(CH3)2), 0.04 (s, 
3H, Si(CH3)2), 0.04 (s, 3H, Si(CH3)2). 
13C NMR (101 MHz, methylene chloride-d2) δ/ppm = 143.1 (C-1’’), 139.2 (C-4’’), 129.4 (C-2’’, 
6’’), 126.7 (C-3’’, 5’’), 68.3 (C-1), 65.4 (4’’-CH2), 54.4 (C-1’), 53.1 (C-3a’), 42.9 (C-7a’), 41.4 (C-
7’), 40.3 (C-4’), 39.5 (C-2), 34.8 (4’-CH2), 29.3 (C-2’, 3’, 5’ or 6’), 27.4 (C-2’, 3’, 5’ or 6’), 26.3 
(SiC(CH3)3), 24.4 (C-2’, 3’, 5’ or 6’), 18.9 (SiC(CH3)3), 18.8 (SiC(CH3)3), 18.6 (C-2’, 3’, 5’ or 6’), 
17.2 (2-CH3), 14.1 (7a’-CH3), -5.0 (Si(CH3)2), -5.1 (Si(CH3)2), -5.2 (Si(CH3)2). 
IR (ATR): ṽ/cm-1 = 2951, 2927, 2856, 2361, 2341, 1514, 1472, 1462, 1388, 1376, 1361, 1251, 
1215, 1177, 1086, 1033, 1020, 1006, 944, 939, 833, 814, 773, 699, 667.  
HRMS (EI): m/z calculated for C32H57O2Si2 [M]˙⁺ 529.3892; found 529.3885. 
Purity (HPLC): 85% (λ = 210 nm) (method f).   
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(S)-2-((1R,3aS,4R,7aS)-4-Benzyl-7a-methyloctahydro-1H-inden-1-yl)propan-1-ol (96d) 
 
 
 
 
 
 
C20H30O 
M =286.23 g/mol 
Alcohol 96d was synthesised according to GP9 using silylether 91d (35.1 mg, 0.0876 mmol, 
1.00 eq). The title compound was purified via FCC (hexanes/EtOAc 85:15) and isolated as a 
colourless oil (16.3 mg, 0.0569 mmol, 65%). 
 
Rf = 0.25 (hexanes/EtOAc 85:15).  
[𝛂]𝑫
𝟐𝟑:  + 41.0 (c = 0.18, CHCl3). 
1H NMR (400 MHz, methylene chloride-d2) δ/ppm = 7.28 – 7.12 (m, 5H, 2’’, 3’’, 4’’, 5’’, 6’’-H), 
3.65 – 3.57 (m, 1H, 1-H), 3.38 – 3.28 (m, 1H, 1-H), 2.79 (d, J = 13.6 Hz, 1H, 4’-CH2), 2.48 (dd, 
J = 13.4, 11.4 Hz, 2H, 4’-CH2), 2.01 – 1.95 (m, 2H, 4’, 7’-H), 1.90 – 1.81 (m, 1H, 2’, 3’, 5’ or 6’-
H), 1.75 – 1.41 (m, 7H, 2, 3a’-H, 2’, 3’, 5’ or 6’-H), 1.36 – 1.13 (m, 4H, 1’, 7’-H, 2’, 3’, 5’ or 6’-
H), 1.02 (d, J = 6.7 Hz, 3H, 2-CH3), 0.87 (s, 3H, 7a’-CH3). 
13C NMR (101 MHz, methylene chloride-d2) δ/ppm = 144.5 (C-1’’), 129.5 (C-2’’, 6’’), 128.7 (C-
3’’, 5’’), 125.9 (C-4’’), 68.2 (C-1), 54.2 (C-1’), 53.1 (C-3a’), 42.9 (C-7a’), 41.4 (C-7’), 40.2 (C-
4’), 39.3 (C-2), 35.1 (4’-CH2), 29.3 (C-2’, 3’, 5’ or 6’), 27.4 (C-2’, 3’, 5’ or 6’), 24.4 (C-2’, 3’, 5’ 
or 6’), 18.6 (C-2’, 3’, 5’ or 6’), 16.9 (2-CH3), 14.0 (7a’-CH3). 
IR (ATR): ṽ/cm-1 = 3329, 3062, 3025, 2922, 2870, 2360, 2341, 1603, 1494, 1542, 1378, 1274, 
1233, 1181, 1117, 1088, 1032, 1002, 982, 956, 931, 909, 867, 779, 740, 699.  
HRMS (EI): m/z calculated for C20H30O [M]˙⁺ 286.2291; found 286.2293.  
Purity (HPLC): 92% (λ = 210 nm) (method c). 
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3-(((1R,3aS,4R,7aS)-1-((S)-1-Hydroxypropan-2-yl)-7a-methyloctahydro-1H-inden-4-
yl)methyl)phenol (97d) 
 
 
 
 
 
 
C20H30O2 
M = 302.22 g/mol 
Diol 97d was synthesised according to GP9 using silylether 92d (163 mg, 0.256 mmol, 1.00 eq). 
The title compound was purified via FCC (hexanes/EtOAc 7:3) and isolated as a white 
crystalline solid (25.4 mg, 0.0840 mmol, 33%). 
 
Rf = 0.36 (hexanes/EtOAc 70:30).  
mp: 147 °C. 
[𝛂]𝑫
𝟐𝟑:  + 54.6 (c = 0.07, CHCl3). 
1H NMR (400 MHz, methanol-d4) δ/ppm = 7.08 – 7.02 (m, 1H, 5-H), 6.63 – 6.55 (m, 3H, 2, 4, 
6-H), 3.60 (dd, J = 10.6, 3.2 Hz, 1H, 1’’-H), 3.28 (dd, J = 10.6, 7.1 Hz, 1H, 1’’-H), 2.74 (dd, J = 
13.4, 2.6 Hz, 1H, 4’-CH2), 2.44 (dd, J = 13.3, 11.4 Hz, 1H, 4’-CH2), 2.05 – 1.96 (m, 2H, 4’, 7’-
H), 1.95 – 1.86 (m, 1H, 2’, 3’, 5’ or 6’-H), 1.82 – 1.29 (m, 8H, 3a’, 2’’-H, 2’, 3’, 5’ or 6’-H), 1.27 
– 1.15 (m, 3H, 1’, 7’-H, 2’, 3’, 5’ or 6’-H), 1.04 (d, J = 6.6 Hz, 3H, 2’’-CH3), 0.90 (s, 3H, 7a’-
CH3). 
13C NMR (101 MHz, methanol-d4) δ/ppm = 158.3 (C-3), 146.4 (C-1), 130.1 (C-5), 121.3 (C-2), 
116.8 (C-6), 113.4 (C-4), 67.9 (C-1’’), 55.0 (C-1’), 53.9 (C-3a’), 43.5 (C-7a’), 42.2 (C-7’), 40.9 
(C-4’), 40.0 (C-2’’), 35.7 (4’-CH2), 29.9 (C-2’, 3’, 5’ or 6’), 27.9 (C-2’, 3’, 5’ or 6’), 24.9 (C-2’, 3’, 
5’ or 6’), 19.0 (C-2’, 3’, 5’ or 6’), 17.2 (2’’-CH3), 14.2 (7a’-CH3).  
IR (ATR): ṽ/cm-1 = 3436, 3169, 2928, 2874, 2355, 1728, 1616, 1588, 1499, 1444, 1367, 1268, 
1251, 1180, 1157, 1116, 1083, 1027, 999, 970, 948, 938, 928, 875, 804, 786, 773, 763, 694, 
678.  
HRMS (EI): m/z calculated for C20H30O2 [M]˙⁺ 302.2240; found 302.2239.  
Purity (HPLC): > 95% (λ = 191 nm), > 95% (λ = 210 nm) (method c).   
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4-(((1R,3aS,4R,7aS)-1-((S)-1-Hydroxypropan-2-yl)-7a-methyloctahydro-1H-inden-4-
yl)methyl)phenol (98d) 
 
 
 
 
 
 
C20H30O2 
M = 302.22 g/mol 
Diol 98d was synthesised according to GP9 using silylether 93d (250 mg, 0.471 mmol, 1.00 eq). 
The title compound was purified via FCC (hexanes/EtOAc 7:3) and isolated as a white 
crystalline solid (18.0 mg, 0.0595 mmol, 13%). 
 
Rf = 0.33 (hexanes/EtOAc 7:3). 
mp: 130°C. 
[𝛂]𝑫
𝟐𝟑:  + 100.0 (c = 0.06, CHCl3). 
1H NMR (400 MHz, methylene chloride-d2) δ/ppm = 7.03 – 6.95 (m, 2H, 2, 6-H), 6.75 – 6.68 
(m, 2H, 3, 5-H), 4.89 (s, 1H, 4-OH), 3.62 (dd, J = 10.3, 3.2 Hz, 1H, 1’’-H), 3.33 (dd, J = 10.5, 
7.0 Hz, 1H, 1’’-H), 2.74 – 2.68 (m, 1H, 4’-CH2), 2.41 (dd, J = 13.6, 11.4 Hz, 1H, 4’-CH2), 2.00 
– 1.88 (m, 2H, 4’, 7’-H), 1.87 – 1.78 (m, 1H, 2’, 3’, 5’ or 6’-H), 1.74 – 1.26 (m, 8H, 3a’, 2’’-H, 2’, 
3’, 5’ or 6’-H), 1.23 – 1.10 (m, 3H, 1’, 7’-H, 2’, 3’, 5’ or 6’-H), 1.01 (d, J = 6.6 Hz, 3H, 2’’-CH3), 
0.85 (s, 3H, 7a’-CH3). 
13C NMR (101 MHz, methylene chloride-d2) δ/ppm = 154.2 (C-4), 136.4 (C-1), 130.5 (C-2, 6), 
115.4 (C-3, 5) , 68.3 (C-1’’), 54.2 (C-1’), 53.1 (C-3a’), 42.9 (C-7a’), 41.4 (C-7’), 40.3 (C-4’), 39.2 
(C-2’’), 34.1 (4-CH2), 29.2 (C-2’, 3’, 5’ or 6’), 27.4 (C-2’, 3’, 5’ or 6’), 24.3 (C-2’, 3’, 5’ or 6’), 18.6 
(C-2’, 3’, 5’ or 6’), 16.9 (2’’-CH3), 14.0 (7a’-CH3). 
IR (ATR): ṽ/cm-1 = 3839, 3854, 3802, 3736, 3690, 3676, 3650, 3630, 3386, 2926, 1734, 1717, 
1700, 1684, 1654, 1636, 1616, 1596, 1559, 1540, 1514, 1457, 1375, 1238, 1174, 1099, 1020, 
994, 931, 872, 840, 833, 792.  
HRMS (EI): m/z calculated for C20H30O2 [M]˙⁺ 302.2240; found 302.2239.  
Purity (HPLC): > 95% (λ = 210 nm) (method c). 
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(S)-2-((1R,3aS,4R,7aS)-4-(3-(Hydroxymethyl)benzyl)-7a-methyloctahydro-1H-inden-1-
yl)propan-1-ol (99d) 
 
 
 
 
 
 
 
C21H32O2 
M = 316.24 g/mol 
Diol 99d was synthesised according to GP9 using silylether 94d (250 mg, 0.459 mmol, 1.00 eq). 
The title compound was purified via FCC (hexanes/EtOAc 7:3) and isolated as a white 
crystalline solid (43.0 mg, 0.136 mmol, 30%). 
 
Rf = 0.20 (hexanes/EtOAc 7:3).  
mp: 141 °C. 
[𝛂]𝑫
𝟐𝟑:  + 44.7 (c = 0.05, CHCl3). 
1H NMR (400 MHz, methylene chloride-d2) δ/ppm = 7.28 – 7.22 (m, 1H, 5’’-H), 7.16 – 7.12 (m, 
2H, 2’’, 4’’-H), 7.09 – 7.05 (m, 1H, 6’’-H), 4.63 (s, 2H, 3’’-CH2), 3.61 (dd, J = 10.5, 3.3 Hz, 1H, 
1-H), 3.37 – 3.31 (m, 1H, 1-H), 2.83 – 2.75 (m, 1H, 4’-CH2), 2.50 (dd, J = 13.4, 11.4 Hz, 1H, 
4’-CH2), 2.02 – 1.94 (m, 2H, 4’, 7’-H), 1.91 – 1.80 (m, 1H, 2’, 3’, 5’ or 6’-H), 1.78 – 1.40 (m, 8H, 
2, 3a’-H, 2’, 3’, 5’ or 6’-H), 1.38 – 1.13 (m, 3H, 1’, 7’-H, 2’, 3’, 5’ or 6’-H), 1.02 (d, J = 6.6 Hz, 
3H, 2-CH3), 0.86 (s, 3H, 7a’-CH3). 
13C NMR (101 MHz, methylene chloride-d2) δ/ppm = 144.7 (C-1’’), 141.7 (C-3’’), 128.8 (C-6’’), 
128.8 (C-5’’), 128.1 (C-2’’), 124.6 (C-4’’), 68.2 (C-1), 65.7 (3’’-CH2), 54.2 (C-1’), 53.1 (C-3a’), 
42.9 (C-7a’), 41.3 (C-7’), 40.2 (C-4’), 39.2 (C-2), 35.1 (4’-CH2), 29.2 (C-2’, 3’, 5’ or 6’), 27.4 (C-
2’, 3’, 5’ or 6’), 24.4 (C-2’, 3’, 5’ or 6’), 18.6 (C-2’, 3’, 5’ or 6’), 16.9 (2-CH3), 14.0 (7a’-CH3). 
IR (ATR): ṽ/cm-1 = 3903, 3854, 3839, 3822, 3802, 3751, 3736, 3712, 3690, 3676, 3650, 3630, 
3576, 3337, 2922, 2869, 2360, 1868, 1792, 1772, 1734, 1706, 1684, 1654, 1636, 1608, 1559, 
1540, 1522 , 1508, 1489, 1473, 1458, 1363, 1220, 1155, 1089, 1034, 1003, 982, 891, 788, 
754, 746, 703.  
HRMS (EI): m/z calculated for C21H32O2 [M]˙⁺ 316.2397; found 316.2396.  
Purity (HPLC): > 95% (λ = 210 nm), > 95% (λ = 254 nm) (method c). 
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(S)-2-((1R,3aS,4R,7aS)-4-(4-(Hydroxymethyl)benzyl)-7a-methyloctahydro-1H-inden-1-
yl)propan-1-ol (100d) 
 
 
 
 
 
 
C21H32O2 
M = 316.24 g/mol 
Diol 100d was synthesised according to GP9 using silylether 95d (243 mg, 0.446 mmol, 
1.00 eq). The title compound was purified via FCC (hexanes/EtOAc 7:3) and isolated as a 
white crystalline solid (27.9 mg, 0.0882 mmol, 20%). 
 
Rf = 0.20 (hexanes/EtOAc 7:3).  
mp: 146 °C. 
[𝛂]𝑫
𝟐𝟑: + 61.3 (c = 0.05, CHCl3). 
1H NMR (400 MHz, methylene chloride-d2) δ/ppm = 7.29 – 7.23 (m, 2H, 3’’, 5’’-H), 7.16 – 7.10 
(m, 2H, 2’’, 6’’-H), 4.61 (d, J = 4.5 Hz, 2H, 4’’-CH2), 3.65 – 3.57 (m, 1H, 1-H), 3.37 – 3.29 (m, 
1H, 1-H), 2.79 (dd, J = 14.2, 2.3 Hz, 1H, 4’-CH2), 2.49 (dd, J = 13.4, 11.4 Hz, 1H, 4’-CH2), 2.01 
– 1.93 (m, 2H, 4’, 7’-H), 1.90 – 1.80 (m, 1H, 2’, 3’, 5’ or 6’-H), 1.77 – 1.28 (m, 8H, 2, 3a’-H, 2’, 
3’, 5’ or 6’-H), 1.26 – 1.13 (m, 3H, 1’, 7’-H, 2’, 3’, 5’ or 6’-H), 1.02 (d, J = 6.6 Hz, 3H, 2-CH3), 
0.86 (s, 3H, 7a’-CH3). 
13C NMR (101 MHz, methylene chloride-d2) δ/ppm = 143.8 (C-1’’), 138.9 (C-4’’), 129.7 (C-2’’, 
6’’), 127.5 (C-3’’, 5’’), 68.2 (C-1), 65.5 (4’’-CH2), 54.2 (C-1’), 53.1 (C-3a’), 42.9 (C-7a’), 41.3 (C-
7’), 40.2 (C-4’), 39.2 (C-2), 34.8 (4’-CH2), 29.2 (C-2’, 3’, 5’ or 6’), 27.4 (C-2’, 3’, 5’ or 6’), 24.4 
(C-2’, 3’, 5’ or 6’), 18.6 (C-2’, 3’, 5’ or 6’), 16.9 (2-CH3), 14.0 (7a’-CH3).  
IR (ATR): ṽ/cm-1 = 3903, 3854,  3839, 3822, 3802, 3751, 3736, 3712, 3690, 3676, 3650, 3630, 
3568, 3220, 2928, 2360, 1868, 1830, 1792, 1772, 1734, 1717, 1700, 1684, 1670, 1654, 1636, 
1616, 1576, 1559, 1540, 1508, 1490, 1458, 1418, 1375, 1174, 103, 1002, 846, 794.  
HRMS (EI): m/z calculated for C21H32O2 [M]˙⁺ 316.2397; found 316.2395.  
Purity (HPLC): > 95% (λ = 210 nm) (method c). 
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3-(((1R,3aR,7aR)-1-((S)-1-((tert-Butyldimethylsilyl)oxy)propan-2-yl)-7a-methyl-
2,3,3a,6,7,7a-hexahydro-1H-inden-4-yl)ethynyl)phenol (103) 
 
 
 
 
 
 
 
  C27H40O2Si 
M = 424.70 g/mol 
Diol 103 was synthesised via three steps. For SONOGASHIRA cross-coupling enol triflate 34 
(411 mg, 0.900 mmol, 1.00 eq) was dissolved in dry THF (8.00 mL) and 3-
hydroxyphenylacetylen (104, 118 µL, 1.08 mmol, 1.20 eq), TEA (0.314 mL, 2.25 mmol, 
2.50 eq) and CuI (34.3 mg, 0.180 mmol, 20 mol%) were added under N2 counterflow. After 
purging the solution with N2, PdCl2(PPh3)2 (63.3 mg, 0.0900 mmol, 10 mol%) was added and 
the reaction mixture was stirred for 1.5 h. The reaction was stopped with sat. aq. NH4Cl 
(10.0 mL) and the aq. phase was extracted with DCM (3 x 15.0 mL). The combined organic 
layers were dried over Na2SO4, filtered and the solvent was removed in vacuo. The title 
compound was purified via FCC (hexanes/EtOAc 9:1) and isolated as light yellow oil (367 mg, 
0.864 mmol, 96%).  
 
Rf = 0.27 (hexanes/EtOAc 9:1). 
[𝜶]𝑫
𝟐𝟑: + 23.7 (c = 0.04, CHCl3). 
1H NMR (400 MHz, chloroform-d) δ/ppm = 7.15 (t, J = 7.9 Hz, 1H, 5-H), 6.98 (dt, J = 7.7, 1.2 
Hz, 1H, 4-H), 6.87 (dd, J = 2.6, 1.4 Hz, 1H, 2-H), 6.78 – 6.71 (m, 1H, 6-H), 6.07 (q, J = 3.3 Hz, 
1H, 5’’-H), 4.89 (s, 1H, OH), 3.61 (dd, J = 9.7, 3.4 Hz, 1H, 1’’’-H), 3.29 (dd, J = 9.7, 7.4 Hz, 1H, 
1’’’-H), 2.30 – 2.18 (m, 3H, 3a’’-H, 2’’, 3’’ or 6’’-H), 2.06 – 1.97 (m, 1H, 7’’-H), 1.95 – 1.82 (m, 
2H, 2’’, 3’’ or 6’’-H), 1.67 – 1.56 (m, 1H, 2’’’-H), 1.54 – 1.38 (m, 3H, 7’’-H, 2’’, 3’’ or 6’’-H), 1.35 
– 1.22 (m, 1H, 1’’-H), 1.03 (d, J = 6.5 Hz, 3H, 2’’’-CH3), 0.90 (s, 9H, SiC(CH3)3), 0.74 (s, 3H, 
7a’’-CH3), 0.05 (s, 3H, Si(CH3)2), 0.05 (s, 3H, Si(CH3)2). 
13C NMR (101 MHz, chloroform-d) δ/ppm = 155.4 (C-1), 134.5 (C-5’’), 129.6 (C-5), 125.3 (C-
3), 124.3 (C-4), 122.3 (C-4’’), 118.2 (C-2), 115.3 (C-6), 89.9 (C-1’), 87.8 (C-2’), 67.9 (C-1’’’), 
51.4 (C-1’’), 49.9 (C-3a’’), 42.1 (C-7a’’), 39.5 (C-2’’’), 35.9 (C-7’’), 27.6 (C-2’’, 3’’ or 6’’), 26.1 
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(SiC(CH3)3), 25.4 (C-2’’, 3’’ or 6’’), 24.3 (C-2’’, 3’’ or 6’’), 18.5 (SiC(CH3)3), 17.1 (2’’’-CH3), 11.4 
(7a’’-CH3), -5.2 (Si(CH3)2), -5.2 (Si(CH3)2). 
IR (ATR): ṽ/cm-1 = 2953, 2928, 1708, 1590, 1577, 1471, 1442, 1375, 1250, 1083, 1041, 1003, 
934, 909, 832, 774, 731, 685. 
HRMS (EI): m/z calculated for C27H40O2Si [M]˙⁺ 424.2792; found 424.2790. 
Purity (HPLC): > 95% (λ = 210 nm), > 95% (λ = 250 nm) (method e).   
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3-(tert-Butyldimethylsilyloxy)toluene (110b) 
 
 
                    
C13H22OSi 
M = 222.40 g/mol 
Silylether 110b was synthesised according to GP2 using m-cresol (108, 1.00 g, 9.25 mmol, 
1.00 eq) The title compound was purified via FCC (hexanes/EtOAc 8:2) and isolated as a 
colourless oil (1.95 g, 8.77 mmol, 95%). 
 
Rf = 0.92 (hexanes/EtOAc 8:2). 
1H NMR (400 MHz, chloroform-d) δ/ppm = 6.90 (t, J = 7.7 Hz, 1H, 5-H), 6.57 (d, J = 8.7 Hz, 
1H, 4-H), 6.45 (m, 2H, 2, 6-H), 2.11 (s, 3H, 3-CH3), 0.79 (s, 9H, SiC(CH3)3), 0.00 (s, 6H, 
Si(CH3)2). 
13C NMR (101 MHz, chloroform-d) δ/ppm = 155.6 (C-1), 139.4 (C-3), 129.0 (C-5), 122.1 (C-4), 
120.9 (C-2 or C-6), 117.0 (C-2 or C-6), 25.7 (SiC(CH3)3), 21.4 (3-CH3), 18.2 (SiC(CH3)3), -4.4 
(Si(CH3)2). 
IR (ATR): ṽ/cm-1 = 3854, 3750, 3650, 3032, 2957, 2930, 2896, 2859, 2360, 2342, 1748, 1604, 
1586, 1488, 1472, 1463, 1407, 1390, 1362, 1277, 1252, 1158, 1084, 1005, 954, 886, 835, 778, 
690, 664. 
HRMS (EI): m/z calculated for C13H22OSi [M]˙⁺ 222.1440; found 222.1431. 
Purity (HPLC): > 95% (λ = 191 nm), > 95% (λ = 210 nm) (method d).   
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4-(tert-Butyldimethylsilyloxy)toluene (111b) 
 
 
                        
C13H22OSi 
M = 222.40 g/mol 
Silylether 111b was synthesised according to GP2 using p-cresol (109, 1.00 g, 9.25 mmol, 
1.00 eq) The title compound was purified via FCC (hexanes/EtOAc 8:2) and isolated as a 
colourless oil (1.92 g, 8.63 mmol, 93%). 
 
Rf = 0.88 (hexanes/EtOAc 8:2). 
1H NMR (400 MHz, chloroform-d) δ/ppm = 7.04 – 7.01 (m, 2H, 3, 5-H), 6.74 (d, J = 8.4 Hz, 2H, 
2, 6-H), 2.28 (s, 3H, 4-CH3), 0.99 (s, 9H, SiC(CH3)3), 0.19 (s, 6H, Si(CH3)2). 
13C NMR (101 MHz, chloroform-d) δ/ppm = 153.3 (C-1), 130.4 (C-4), 129.8 (C-3,5), 119.8 (C-
2,6), 25.7 (SiC(CH3)3), 20.6 (4-CH3), 18.2 (SiC(CH3)3), -4.4 (Si(CH3)2). 
IR (ATR): ṽ/cm-1 = 3751, 3650, 3029, 2957, 2930, 2887, 2859, 2361, 2342, 1870, 1613, 1582, 
1508, 1472, 1463, 1390, 1362, 1260, 1168, 1103, 1042, 1007, 911, 836, 822, 811, 778, 689. 
HRMS (EI): m/z calculated for C13H22OSi [M]˙⁺ 222.1440; found 222.1432. 
Purity (HPLC): > 95% (λ = 191 nm), > 95% (λ = 210 nm) (method d).   
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3-((tert-Butyldimethylsilyl)oxy)benzaldehyde (116b) 
 
 
 
 
 
     C13H20O2Si 
M = 236.39 g/mol 
Benzaldehyde 116b was synthesised according to GP2 using 3-hydroxybenzaldehyde (114, 
1.00 g, 8.19 mmol, 1.00 eq). The title compound was purified via FCC (hexanes/EtOAc 5:5) 
and isolated as a colourless oil (1.49 g, 6.30 mmol, 77%). 
 
Rf = 0.89 (hexanes/EtOAc 5:5). 
1H NMR (400 MHz, chloroform-d) δ/ppm = 9.95 (s, 1H, CHO), 7.47 (dt, J = 7.6, 1.2 Hz, 1H, 6-
H), 7.40 (t, J = 7.8 Hz, 1H, 5-H), 7.33 (dd, J = 2.6, 1.5 Hz, 1H, 2-H), 7.11 (ddt, J = 7.7, 2.1, 0.6 
Hz, 1H, 4-H), 1.00 (d, J = 0.6 Hz, 9H, SiC(CH3)3), 0.22 (s, 6H, Si(CH3)2). 
13C NMR (101 MHz, chloroform-d) δ/ppm = 192.1 (CHO), 156.4 (C-3), 137.9 (C-1), 130.1 (C-
5), 126.6 (C-4), 123.6 (C-6), 119.9 (C-2), 25.6 (SiC(CH3)3), 18.2 (SiC(CH3)3), -4.4 (Si(CH3)2). 
IR (ATR): ṽ/cm-1 = 2956, 2931, 2887, 2859, 2725, 2360, 2342, 1702, 1597, 1583, 1482, 1472, 
1464, 1445, 1387, 1363, 1311, 1277, 1254, 1166, 1144, 1078, 1002, 981, 966, 939, 798, 780, 
729, 705, 684, 667. 
HRMS (EI): m/z calculated for C13H20O2Si [M]˙⁺ 236.1233; found 236.1240. 
Purity (HPLC): > 95% (λ = 210 nm) (method d).   
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(3-((tert-Butyldimethylsilyl)oxy)phenyl)methanol (118b) 
 
 
     
  C13H22O2Si 
M = 238.40 g/mol 
A solution of aldehyde 116b (1.48 g, 6.26 mmol, 1.00 eq) in MeOH (50.0 mL) was cooled to 
0 °C and NaBH4 (355 mg, 9.39 mmol, 1.50 eq) was added. The reaction mixture was warmed 
up to rt and stirred for 1 h. The solvent was removed in vacuo and the residue was redissolved 
in EtOAc (100 mL) and washed with water (100 mL) and brine (100 mL). The organic layer 
was dried over Na2SO4, filtered and concentrated under reduced pressure. The title compound 
was purified via FCC (hexanes/EtOAc 8:2) to give alcohol 118b as a colourless oil (1.06 g, 
4.45 mmol, 71%). 
 
Rf = 0.47 (hexanes/EtOAc 8:2). 
1H NMR (400 MHz, chloroform-d) δ/ppm = 7.21 (t, J = 7.8 Hz, 1H, 5-H), 6.94 (ddq, J = 7.6, 1.6, 
0.8 Hz, 1H, 6-H), 6.88 – 6.84 (m, 1H, 2-H), 6.80 – 6.74 (m, 1H, 4-H), 4.64 (d, J = 5.8 Hz, 2H, 
CH2-OH), 1.64 (t, J = 6.0 Hz, 1H, OH), 0.99 (s, 9H, SiC(CH3)3), 0.20 (s, 6H, Si(CH3)2). 
13C NMR (101 MHz, chloroform-d) δ/ppm = 155.9 (C-3), 142.5 (C-1), 129.5 (C-5), 119.8 (C-6), 
119.3 (C-2), 118.6 (C-4), 65.2 (CH2OH), 25.7 (SiC(CH3)3), 18.2 (SiC(CH3)3), -4.4 (Si(CH3)2). 
IR (ATR): ṽ/cm-1 = 3612, 2956, 2930, 2887, 2858, 2362, 1604, 1587, 1486, 1472, 1463, 1442, 
1390, 1362, 1275, 1252, 1153, 1003, 954, 835, 778, 692, 665. 
HRMS (EI): m/z calculated for C13H22O2Si [M]˙⁺ 238.1389; found 238.1381. 
Purity (HPLC): > 95% (λ = 191 nm), > 95% (λ = 254 nm) (method d).   
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(3-(Bromomethyl)phenoxy)(tert-butyl)dimethylsilane (112b)[102] 
 
 
 
                        C13H21BrOSi 
M = 301.30 g/mol 
To a suspension of alcohol 118b (876 mg, 3.67 mmol, 1.00 eq) and PPh3 (2.44 g, 7.35 mmol, 
2.00 eq) in DCM (80.0 mL), CBr4 (1.95 g, 7.35 mmol, 2.00 eq) was added portionwise at 0 °C 
and the reaction mixture was allowed to warm up to rt and stirred for 3 h. The solvent was 
removed in vacuo and the crude product was purified via FCC (hexanes/EtOAc 95:5 → 8:2). 
Benzyl bromide 112b was obtained as a colourless oil (201 mg, 0.667 mmol, 18%). 
 
Rf = 0.83 (hexanes/EtOAc 9:1). 
1H NMR (400 MHz, chloroform-d) δ/ppm = 7.19 (t, J = 7.9 Hz, 1H, 5-H), 6.98 (ddd, J = 7.6, 2.0, 
1.1 Hz, 1H, 4-H), 6.88 (t, J = 2.0 Hz, 1H, 2-H), 6.77 (ddd, J = 8.2, 2.5, 1.0 Hz, 1H, 6-H), 4.44 
(s, 2H, 3-CH2), 1.00 (s, 9H, SiC(CH3)3), 0.21 (s, 6H, Si(CH3)2). 
13C NMR (101 MHz, chloroform-d) δ/ppm = 155.9 (C-1), 139.2 (C-3), 129.7 (C-5), 121.9 (C-4), 
120.8 (C-2), 120.2 (C-6), 33.4 (3-CH2), 25.7 (SiC(CH3)3), 18.2 (SiC(CH3)3), -4.4 (Si(CH3)2). 
IR (ATR): ṽ/cm-1 = 2958, 2930, 2886, 2858, 2362, 1715, 1602, 1586, 1486, 1472, 1463, 1442, 
1390, 1362, 1278, 1253, 1214, 1158, 1079, 1003, 978, 939, 835, 778, 723, 692, 665. 
HRMS (EI): m/z calculated for C13H21OBrSi [M]˙⁺ 300.0545; found 300.0535. 
 Purity (HPLC): 82% (λ = 191 nm), 87% (λ = 210 nm), 85% (λ = 254 nm) (method d). 
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4-((tert-Butyldimethylsilyl)oxy)benzaldehyde (117b) 
 
 
 
            
 
  C13H20O2Si 
M = 236.39 g/mol 
Benzaldehyde 117b was synthesised according to GP2 using 4-hydroxybenzaldehyde (115, 
1.00 g, 8.19 mmol, 1.00 eq). The title compound was purified via FCC (hexanes/EtOAc 8:2) 
and isolated as a white oily solid (1.66 g, 7.02 mmol, 86%). 
 
Rf = 0.70 (hexanes/EtOAc 8:2). 
1H NMR (400 MHz, chloroform-d) δ/ppm = 9.89 (s, 1H, CHO), 7.82 – 7.75 (m, 2H, 2, 6-H), 
6.98 – 6.90 (m, 2H, 3, 5-H), 0.99 (s, 9H, SiC(CH3)3), 0.25 (s, 6H, Si(CH3)2). 
13C NMR (101 MHz, chloroform-d) δ/ppm = 190.9 (CHO), 161.5 (C-4), 131.9 (C-2, 6), 130.4 
(C-1), 120.5 (C-3, 5) , 25.6 (SiC(CH3)3), 18.3 (SiC(CH3)3), -4.3 (Si(CH3)2). 
IR (ATR): ṽ/cm-1 = 2955, 2931, 2858, 2833, 1697, 1596, 1575, 1507, 1471, 1463, 1445, 1421, 
1391, 1362, 1256, 1210, 1154, 1101, 1006, 938, 903, 836, 797, 780, 702, 666. 
HRMS (EI): m/z calculated for C13H20O2Si [M]˙⁺ 236.1233; found 236.1223. 
Purity (HPLC): 76% (λ = 191 nm), 90% (λ = 210 nm), 84% (λ = 254 nm) (method d).   
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(4-((tert-Butyldimethylsilyl)oxy)phenyl)methanol (119b) 
 
 
 
      C13H22O2Si 
M = 238.40 g/mol 
A solution of aldehyde 117b (1.00 g, 4.23 mmol, 1.00 eq) in MeOH (50.0 mL) was cooled to 
0 °C and NaBH4 (240 mg, 6.35 mmol, 1.50 eq) was added. After stirring the mixture at rt for 
1 h, the solvent was removed under reduced pressure. The residue was redissolved in EtOAc 
(100 mL) and washed with water (100 mL) and brine (100 mL). The organic layer was dried 
over Na2SO4, filtered and the solvent was removed in vacuo. The crude product was purified 
via FCC (hexanes/EtOAc 8:2) to give alcohol 119b as a colourless oil (640 mg, 2.68 mmol, 
64%). 
 
Rf = 0.36 (hexanes/EtOAc 8:2). 
1H NMR (400 MHz, chloroform-d) δ/ppm = 7.25 – 7.19 (m, 2H, 2, 6-H), 6.85 – 6.78 (m, 2H, 3, 
5-H), 4.61 (d, J = 5.8 Hz, 2H, 1-CH2), 1.56 (s, 1H, OH), 0.98 (s, 9H, SiC(CH3)3), 0.19 (s, 6H, 
Si(CH3)2). 
13C NMR (101 MHz, chloroform-d) δ/ppm = 155.3 (C-4), 133.7 (C-1), 128.6 (C-2, 6), 120.2 (C-
3, 5), 65.2 (1-CH2), 25.7 (SiC(CH3)3), 18.2 (SiC(CH3)3), -4.4 (Si(CH3)2). 
IR (ATR): ṽ/cm-1 = 3032, 2956, 2929, 2885, 2858, 1609, 1582, 1509, 1471, 1463, 1409, 1390, 
1362, 1250, 1166, 1102, 1006, 909, 834, 812, 777, 731, 689, 654. 
HRMS (EI): m/z calculated for C13H22O2Si [M]˙⁺ 238.1389; found 238.1380. 
Purity (HPLC): > 95% (λ = 191 nm), > 95% (λ = 210 nm), > 95% (λ = 254 nm) (method d).  
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(4-(Bromomethyl)phenoxy)(tert-butyl)dimethylsilane (113b) 
 
 
            C13H21BrOSi 
M = 301.30 g/mol 
To a suspension of alcohol 119b (640 mg, 2.68 mmol, 1.00 eq) and PPh3 (1.42 g, 5.37 mmol, 
2.00 eq) in DCM (60.0 mL) at 0 °C, CBr4 (1.78 g, 5.37 mmol, 2.00 eq) was added. The reaction 
was warmed up to rt over 90 minutes, concentrated under reduced pressure and purified via 
FCC (hexanes/EtOAc 95:5) to give benzyl bromide 113b as a colourless oil (198 mg, 
0.656 mmol, 25%). 
 
Rf = 0.82 (hexanes/EtOAc 95:5). 
1H NMR (400 MHz, chloroform-d) δ/ppm = 7.30 – 7.21 (m, 2H, 2, 6-H), 6.79 (d, J = 8.5 Hz, 2H, 
3, 5-H), 4.49 (s, 2H, 4-CH2), 0.98 (s, 9H, SiC(CH3)3), 0.20 (s, 6H, Si(CH3)2). 
13C NMR (101 MHz, chloroform-d) δ/ppm = 155.9 (C-1), 130.5 (C-4), 130.4 (C-3, 5), 120.3 (C-
2, 6), 34.0 (4-CH2), 25.6 (SiC(CH3)3), 18.2 (SiC(CH3)3), -4.4 (Si(CH3)2). 
IR (ATR): ṽ/cm-1 = 3790, 3683, 3662, 2926, 2854, 1960, 1729, 1691, 1658, 1641, 1598, 1579, 
1548, 1529, 1513, 1462, 1387, 1360, 1288, 1254, 1191, 1155, 1084, 1051, 1002, 965, 833, 
771, 714, 688, 666. 
HRMS (EI): m/z calculated for C13H21OBrSi [M]˙⁺ 300.0539; found 300.0532 
Purity (GC): > 95% (scan mode m/z 50-650 (EI 70 eV)).  
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tert-Butyl((S)-2-((1R,3aS,4R,7aS)-4-((E)-3-methoxystyryl)-7a-methyloctahydro-1H-
inden-1-yl)propoxy)dimethylsilane (124b) 
 
 
  
   
    
 
 
 C28H46O2Si 
M = 442.76 g/mol 
PPh3 (1.58 g, 5.97 mmol, 1.20 eq) was added to a stirred solution of 3-methoxybenzylbromide 
(120, 1.00 g, 4.97 mmol, 1.00 eq) in toluene (40.0 mL) and the reaction mixture was refluxed 
for 12 h. After completion of the reaction, the reaction mixture was cooled to 0 °C and the 
resulting phosphonium salt 121b precipitate was collected by filtration, dried and used without 
further purification.  
A flame-dried round bottom flask was charged with the crude (3-methoxybenzyl)triphenyl-
phosphonium bromide (121b, 714 mg, 1.54 mmol, 1.20 eq) in dry THF (60.0 mL) and the 
solution was cooled to 0 °C. LDA (2M in THF, 0.96 mL, 1.90 mmol, 1.50 eq) was added and 
the mixture was stirred for 30 min at 0 °C. A solution of aldehyde 73b (435 g, 1.28 mmol, 
1.00 eq) in dry THF (15.0 mL) was added and the reaction mixture was slowly warmed to rt 
and stirred for 17 h. The reaction was diluted with water (50.0 mL) and the mixture was 
extracted with EtOAc (3 x 30.0 mL). The combined organic layers were dried over Na2SO4, 
filtered and the solvent was removed in vacuo. The crude product was purified via FCC 
(hexanes/toluene 8:2) and led to olefin 124b as a colourless oil (248 mg, 0.560 mmol, 44%). 
 
Rf = 0.37 (hexanes/toluene 8:2). 
[𝜶]𝑫
𝟐𝟑: + 9.6 (c = 0.06, CHCl3). 
1H NMR (400 MHz, chloroform-d) δ/ppm = 7.20 (t, J = 7.9 Hz, 1H, 5’’-H), 6.93 (dt, J = 7.7, 1.4 
Hz, 1H, 6’’-H), 6.87 (dd, J = 2.6, 1.6 Hz, 1H, 2’’-H), 6.75 – 6.72 (m, 1H, 4’’-H), 6.31 (d, J = 15.8 
Hz, 1H, 1’’-CH), 6.03 (dd, J = 15.8, 8.2 Hz, 1H, 4’-CH), 3.81 (s, 3H, OCH3), 3.58 (ddd, J = 9.6, 
4.4, 3.3 Hz, 1H, 1-H), 3.26 (ddd, J = 9.6, 7.5, 4.4 Hz, 1H, 1-H), 2.20 – 2.10 (m, 1H, 4’-H), 1.96 
(td, J = 9.0, 4.4 Hz, 1H, 7’-H), 1.75 (qq, J = 7.0, 3.5 Hz, 3H, 2’, 5’-H), 1.56 (tddt, J = 13.1, 9.8, 
7.0, 3.6 Hz, 4H, 3’, 6’-H), 1.22 – 1.08 (m, 5H, 2, 1’, 2’, 3a’, 7’-H), 1.01 (d, J = 6.6 Hz, 3H, 2-
CH3), 0.89 (d, J = 1.2 Hz, 9H, SiC(CH3)3), 0.75 (s, 3H, 7a’-CH3), 0.03 (s, 6H, Si(CH3)2). 
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13C NMR (101 MHz, chloroform-d) δ/ppm = 159.8 (C-3’’), 139.6 (C-1’’), 136.1 (4’-CH), 129.4 
(C-5’’), 127.9 (C-1’’), 118.6 (C-6’’), 112.3 (C-2’’), 111.3 (C-4’’), 67.9 (C-1), 55.2 (OCH3), 54.5 
(C-3a’), 52.9 (C-2), 42.8 (C-7a’), 41.3 (C-4’), 39.8 (C-7’), 39.0 (C-1’), 33.1 (C-5’), 27.0 (C-2’), 
26.0 (SiC(CH3)3), 25.3 (C-3’ or 6’), 21.8 (C-3’ or 6’), 18.4 (SiC(CH3)3), 17.0 (2-CH3), 11.9 (7a’-
CH3), -5.3 (Si(CH3)2), -5.4 (Si(CH3)2). 
IR (ATR): ṽ/cm-1 = 3790, 3697, 3662, 2956, 2928, 2857, 1970, 1729, 1711, 1691, 1665, 1641, 
1608, 1549, 1509, 1470, 1390, 1362, 1254, 1231, 1202, 1168, 1092, 1006, 909, 836, 779, 691. 
HRMS (EI): m/z calculated for C28H46O2Si [M]˙⁺ 442.3267; found 442.3258. 
Purity (GC): 71% (scan mode m/z 50-650 (EI 70 eV)).  
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tert-Butyl((S)-2-((1R,3aS,4R,7aS)-4-(3-methoxyphenethyl)-7a-methyloctahydro-1H-
inden-1-yl)propoxy)dimethylsilane (127b) 
 
 
 
 
       C28H48O2Si 
M = 444.78 g/mol 
To a solution of olefin 124b (248 mg, 0.560 mmol, 1.00 eq) palladium on carbon (10% Pd/C, 
24.8 mg, 0.0230 mmol, 10 wt%) was added. The flask was filled with H2 and stirred at rt for 
18 h. The Pd/C catalyst was removed by filtration with a celite pad and the resulting filtrate was 
concentrated under reduced pressure. The crude product was purified via FCC (hexanes 
100% → hexanes/EtOAc 75:25) to give silylether 127b as a colourless oil (202 mg, 0.454 mmol, 
81%). 
 
Rf = 0.46 (hexanes 100%). 
[𝜶]𝑫
𝟐𝟑 = + 2.5 (c = 0.08, CHCl3). 
1H NMR (400 MHz, chloroform-d) δ/ppm = 7.19 (ddd, J = 7.6, 6.7, 2.1 Hz, 1H, 5’’-H), 6.77 (dt, 
J = 7.5, 1.2 Hz, 1H, 6’’-H), 6.72 (dd, J = 6.7, 1.1 Hz, 2H, 2’’, 4’’-H), 3.80 (s, 3H, OCH3), 3.59 
(dd, J = 9.6, 3.4 Hz, 1H, 1-H), 3.24 (dd, J = 9.6, 7.6 Hz, 1H, 1-H), 2.67 (ddd, J = 13.4, 11.3, 5.1 
Hz, 1H, 1’’-CH2), 2.45 (ddd, J = 13.5, 11.0, 5.7 Hz, 1H, 1’’-CH2), 1.97 – 1.91 (m, 1H, 4’-CH2), 
1.87 (dd, J = 12.9, 3.3 Hz, 1H, 5’-H), 1.81 – 1.62 (m, 3H, 2’, 3’ or 6’, 7’-H), 1.60 – 1.41 (m, 4H, 
1’, 3’ or ‘6-H), 1.41 – 1.17 (m, 4H, 4’, 5’, 7’-H), 1.17 – 1.05 (m, 3H, 2’, 3a’-H, 4’-CH2), 1.00 (d, 
J = 6.5 Hz, 3H, 2-CH3), 0.89 (s, 9H, SiC(CH3)2), 0.68 (s, 3H, 7a’-CH3), 0.03 (s, 3H, Si(CH3)2), 
0.03 (s, 3H, Si(CH3)2). 
13C NMR (101 MHz, chloroform-d) δ/ppm = 159.73 (C-3’’), 145.3 (C-1’’), 129.3 (C-5’’), 120.9 
(C-6’’), 114.3 (C-2’’), 110.9 (C-4’’), 68.1 (C-1), 55.5 (C-3a’), 55.3 (OCH3), 53.2 (C-2), 43.3 (C-
7a’), 40.2 (4’-CH2), 39.2 (C-1’), 37.1 (C-7’), 36.4 (C-4’), 33.3 (1’’-CH2), 32.4 (C-5’), 27.4 (C-2’), 
26.1 (SiC(CH3)3), 25.0 (C-3’ or 6’), 22.4 (C-3’ or 6’), 18.5 (SiC(CH3)3), 17.1 (2-CH3), 12.1 (7a’-
CH3), -5.2 (Si(CH3)2), -5.2 (Si(CH3)2). 
IR (ATR): ṽ/cm-1 = 2926, 2855, 2215, 1601, 1584, 1488, 1462, 1387, 1360, 1255, 1152, 1083, 
1041, 1004, 972, 938, 833, 812, 772, 713, 694, 666. 
HRMS (EI): m/z calculated for C28H48O2Si [M]˙⁺ 444.3424; found 444.3419. 
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Purity (GC): > 95% (scan mode m/z 50-650 (EI 70 eV)).   
Experimental Part 
 
  
 
  
 179 
 
(S)-2-((1R,3aS,4R,7aS)-4-(3-Methoxyphenethyl)-7a-methyloctahydro-1H-inden-1-
yl)propan-1-ol (128) 
 
C22H34O2 
M = 330.51 g/mol 
Alcohol 128 was synthesised according to GP9 using silylether 127b (47.0 mg, 0.106 mmol, 
1.00 eq). The title compound was purified via FCC (hexanes/EtOAc 9:1) and isolated as 
colourless oil (26.0 mg, 0.0787 mmol, 74%). 
 
Rf = 0.17 (hexanes/EtOAc 9:1).  
[𝜶]𝑫
𝟐𝟑: + 15.7 (c = 0.03, CHCl3). 
1H NMR (400 MHz, chloroform-d) δ/ppm = 7.23 – 7.14 (m, 1H, 5’’-H), 6.81 – 6.75 (m, 1H, 6’’-
H), 6.74 – 6.70 (m, 2H, 2’’, 4’’-H), 3.80 (m, 3H, OCH3), 3.68 – 3.60 (m, 1H, 1-H), 3.41 – 3.29 
(m, 1H, 1-H), 2.72 – 2.60 (m, 1H, 1’’-CH2), 2.50 – 2.39 (m, 1H, 1’’-CH2), 1.97 – 1.84 (m, 2H, 
7’-H, 2’, 3’, 5’ or 6’-H), 1.83 – 1.65 (m, 4H, 4’-CH2, 2’, 3’, 5’ or 6’-H), 1.61 – 1.43 (m, 3H, 2, 1’-
H, 2’, 3’, 5’ or 6’-H), 1.37 – 1.19 (m, 5H, 4’-CH2, 2’, 3’, 5’ or 6’-H), 1.17 – 1.09 (m, 3H, 3a’, 7’-
H, 2’, 3’, 5’ or 6’-H), 1.05 (d, J = 6.6 Hz, 3H, 2-CH3), 0.69 (s, 3H, 7a’-CH3). 
13C NMR (101 MHz, chloroform-d) δ/ppm = 159.7 (C-3’’), 145.2 (C-1’’), 129.3 (C-5’’), 120.9 (C-
6’’), 114.3 (C-2’’), 110.9 (C-4’’), 68.2 (C-1), 55.5 (C-3a’), 55.3 (OCH3), 52.9 (C-1’), 43.3 (C-7a’), 
40.2 (C-7’), 38.9 (C-2), 37.0 (4’-CH2), 36.4 (C-4’), 33.3 (1’’-CH2), 32.4 (C-2’, 3’, 5’ or 6’), 27.4 
(C-2’, 3’, 5’ or 6’), 24.9 (C-2’, 3’, 5’ or 6’), 22.4 (C-2’, 3’, 5’ or 6’), 16.9 (2-CH3), 12.1 (7a’-CH3). 
IR (ATR): ṽ/cm-1 = 2922, 2854, 1727, 1601, 1584, 1488, 1454, 1438, 1378, 1259, 1164, 1152, 
1044, 983, 909, 871, 775, 733, 694. 
HRMS (EI): m/z calculated for C22H34O2 [M]˙⁺ 330.2559; found 330.2551. 
Purity (GC): > 95% (scan mode m/z 50-650 (EI 70 eV)). 
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3-(2-((1R,3aS,4R,7aS)-1-((S)-1-Hydroxypropan-2-yl)-7a-methyloctahydro-1H-inden-4-
yl)ethyl)phenol (101) 
 
C21H32O2 
M = 316.49 g/mol 
Alcohol 128 (13.0 mg, 0.0393 mmol, 1.00 eq) was dissolved in dry DCM (1.00 mL) and cooled 
to - 78 °C. BBr3 (1M in DCM, 0.118 mL, 0.118 mmol, 3.00 eq) was added dropwise. The 
reaction mixture was stirred at - 78 °C for 16 h. The reaction was stopped with brine (3.00 mL), 
allowed to warm up to rt and stirred for 1 h. The solution was neutralised with NaHCO3 and the 
aq. layer was extracted with EtOAc (3 x 5.00 mL). The title compound was purified via FCC 
(hexanes/EtOAc 7:3) and isolated as colourless oil (7.60 mg, 0.0240 mmol, 61%).  
 
Rf = 0.30 (hexanes/EtOAc 7:3).  
[𝜶]𝑫
𝟐𝟑: + 17.1 (c = 0.02, CHCl3). 
1H NMR (500 MHz, chloroform-d) δ/ppm = 7.16 – 7.10 (m, 1H, 5-H), 6.75 (tt, J = 7.5, 1.2 Hz, 
1H, 6-H), 6.68 – 6.60 (m, 2H, 2, 4-H), 4.80 (s, 1H, OH), 3.67 – 3.60 (m, 1H, 1’’-H), 3.40 – 3.33 
(m, 1H, 1’’-H), 2.68 – 2.59 (m, 1H, 1-CH2), 2.46 – 2.34 (m, 1H, 1-CH2), 1.95 – 1.84 (m, 2H, 7’-
H, 2’, 3’, 5’ or 6’-H), 1.82 – 1.63 (m, 4H, 4’’-CH2, 2’, 3’, 5’ or 6’-H), 1.61 – 1.46 (m, 5H, 1’, 2’’-H, 
2’, 3’, 5’ or 6’-H), 1.41 – 1.15 (m, 6H, 3a’, 4’-H, 2’, 3’, 5’ or 6’-H), 1.05 (d, J = 6.7 Hz, 3H, 2’’-
CH3), 0.69 (s, 3H, 7a’-CH3). 
13C NMR (126 MHz, chloroform-d) δ/ppm = 155.7 (C-3), 145.5 (C-1), 129.6 (C-5), 120.9 (C-6), 
115.3 (C-2), 112.6 (C-4), 68.3 (C-2’’), 55.5 (C-3a’), 52.9 (C-1’), 43.3 (C-7a’), 40.2 (C-7’), 38.9 
(C-2’’), 36.9 (C-2’, 3’, 5’ or 6’), 36.4 (C-4’), 33.1 (1’’-CH2), 32.4 (C-2’, 3’, 5’ or 6’), 27.4 (C-2’, 3’, 
5’ or 6’), 24.9 (4’-CH2), 22.4 (C-2’, 3’, 5’ or 6’), 16.9 (2’’-CH3), 12.1 (7a’-CH3). 
IR (ATR): ṽ/cm-1 = 3312, 3183, 2936, 1588, 1549, 1512, 1484, 1334, 1251, 1119, 998, 884, 
812. 
HRMS (EI): m/z calculated for C21H32O2 [M]˙⁺ 316.2397; found 316.2394. 
Purity (GC): > 95% (scan mode m/z 50-650 (EI 70 eV)).   
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3-((tert-Butyldimethylsilyl)oxy)phenol (130e)[105] 
 
 
 
 
 
C12H20O2Si  
M = 224.38 g/mol 
To a solution of resorcinol (129, 100 mg, 0.908 mmol, 1.00 eq) in dry THF (10.0 mL) at 0 °C, 
imidazole (92.7 mg, 1.36 mmol, 1.50 eq) and TBDMSCl (151 mg, 0.999 mmol, 1.10 eq) was 
added. The reaction mixture was warmed to rt and stirred for 48 h. The solution was filtered, 
and the filtrate was concentrated in vacuo. The title compound was purified via FCC 
(hexanes/EtOAc 95:5) and isolated as a light brown oil (76 mg, 0.34 mmol, 38%). 
 
Rf = 0.19 (hexanes/EtOAc 95:5). 
1H NMR (400 MHz, chloroform-d) δ/ppm = 7.07 (t, J = 8.1 Hz, 1H, 5-H), 6.43 (dd, J = 8.2, 2.3 
Hz, 2H, 4-H and 6-H), 6.35 (t, J = 2.3 Hz, 1H, 2-H), 4.82 (s, 1H, OH), 0.98 (s, 9H, SiC(CH3)3), 
0.20 (s, 6H, Si(CH3)2). 
13C NMR (101 MHz, chloroform-d) δ/ppm = 157.1 (C-3), 156.7 (C-1), 130.1 (C-5), 112.9 (C-6), 
108.6 (C-4), 107.7 (C-2), 25.8 (SiC(CH3)3), 18.3 (SiC(CH3)3), -4.3 (Si(CH3)2). 
IR (ATR): ṽ/cm-1 = 2957, 2930, 2885, 2858, 1591, 1490, 1472, 1293, 1254, 1166, 1144, 1074, 
979, 835, 780, 686, 663. 
HRMS (EI): m/z calculated for C12H20O2Si [M]˙⁺ 224.1227; found 224.1231. 
Purity (HPLC): > 95% (λ = 210 nm), > 95% (λ = 254 nm) (method c).    
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3-((tert-Butyldimethylsilyl)oxy)aniline (142e)[112] 
 
 
 
C12H21NOSi  
M = 223.39 g/mol 
Aniline 142e was synthesised according to GP1, using 3-aminophenol (141, 101 mg, 
0.926 mmol, 1.00 eq). The title compound was purified via FCC (hexanes/EtOAc 8:2) and 
isolated as brown oil (117 mg, 0.524 mmol, 57%). 
 
Rf = 0.47 (hexanes/EtOAc 8:2). 
1H NMR (400 MHz, chloroform-d) δ/ppm = 6.99 (t, J = 8.0 Hz, 1H, 5-H), 6.30 (ddd, J = 7.9, 2.2, 
0.9 Hz, 1H, 4-H), 6.26 (ddd, J = 8.0, 2.3, 0.9 Hz, 1H, 6-H), 6.20 (t, J = 2.2 Hz, 1H, 2-H), 3.59 
(s, 2H, NH2), 0.98 (s, 9H, SiC(CH3)3), 0.19 (s, 6H, Si(CH3)2). 
13C NMR (101 MHz, chloroform-d) δ/ppm = 156.8 (C-1), 147.8 (C-3), 130.0 (C-5), 110.6 (C-6), 
108.6 (C-4), 107.3 (C-2), 25.8 (SiC(CH3)3), 18.3 (SiC(CH3)3), -4.3 (Si(CH3)2). 
IR (ATR): ṽ/cm-1 = 2955, 2929, 2857, 1620, 1597, 1491, 1461, 1311, 1284, 1253, 1191, 1154, 
978, 836, 779, 686, 664. 
HRMS (EI): m/z calculated for C12H21NOSi [M]˙⁺ 223.1387; found 223.1368. 
Purity (HPLC): > 95% (λ = 210 nm), > 95% (λ = 254 nm) (method c).    
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N-(3-((tert-Butyldimethylsilyl)oxy)phenyl)-2-nitrobenzenesulfonamide (143e) 
 
 
 
 
C18H24N2O5SSi  
M = 408.54 g/mol 
Aniline 142e (280 mg, 1.25 mmol, 1.00 eq) was dissolved in dry DCM (5.00 mL) and the solution 
was cooled to 0°C. TEA (0.524 mL, 3.76 mmol, 3.00 eq) and a solution of 2-
nitrobenzenesulfonyl chloride (278 mg, 1.25 mmol, 1.50 eq) in dry DCM (5.00 mL) was added 
dropwise. The reaction mixture was warmed up to rt and stirred for 16 h. The organic layer 
was washed with water (5.00 mL) and the aqueous layer was extracted with DCM (3 x 
10.0 mL). The combined organic layers were dried over Na2SO4, filtered and the solvent was 
removed in vacuo. The crude product was purified via FCC (hexanes/EtOAc 7:3) and the title 
compound 143e was obtained as a light brown solid (232 mg, 0.568 mmol, 45%). 
 
Rf = 0.57 (hexanes/EtOAc 7:3). 
mp: 100°C.  
1H NMR (500 MHz, chloroform-d) δ/ppm = 7.84 (dd, J = 7.9, 1.4 Hz, 2H, 3-H and 6-H), 7.63 
(dtd, J = 55.7, 7.7, 1.3 Hz, 2H, 4-H and 5-H), 7.18 (s, 1H, NH), 7.10 (t, J = 8.1 Hz, 1H, 5'-H), 
6.77 (ddd, J = 8.0, 2.1, 1.0 Hz, 1H, 6'-H), 6.73 (t, J = 2.2 Hz, 1H, 2'-H), 6.65 (ddd, J = 8.2, 2.4, 
1.0 Hz, 1H, 4'-H), 0.93 (s, 9H, SiC(CH3)3), 0.13 (s, 6H, Si(CH3)2). 
13C NMR (126 MHz, chloroform-d) δ/ppm = 156.6 (C-3'), 148.4 (C-2), 136.6 (C-1'), 134.08 (C-
4), 132.6 (C-5), 132.3 (C-1), 132.1 (C-6), 130.2 (C-5'), 125.4 (C-3), 118.6 (C-4'), 116.1 (C-6'), 
115.1 (C-2'), 25.7(SiC(CH3)3), 18.3 (SiC(CH3)3, -4.3 (Si(CH3)2). 
IR (ATR): ṽ/cm-1 = 3289, 2951, 2931, 2857, 1599, 1541, 1499, 1467, 1395, 1370, 1339, 1260, 
1153, 1125, 1058, 994, 902, 835, 777, 719, 688, 653, 583, 556. 
HRMS (EI): m/z calculated for C18H24N2O5SSi [M]˙⁺ 408.11807; found 408.11371. 
Purity (HPLC): > 95% (λ = 210 nm), > 95% (λ = 254 nm) (method c).   
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(((1R,4R)-4-Bromocyclohexyl)oxy)trimethylsilane (146) 
 
 
 
 
C9H19BrOSi 
M = 251.24 g/mol 
TMSBr (1.54 mL, 11.7 mmol, 1.20 eq) was added dropwise to a solution of 7-
oxabicyclo[2.2.1]heptane (145, 975 mg, 9.93 mmol, 1.00 eq) in dry DCM (18 mL) and the 
resulting mixture was stirred at rt for 18 h. The solvent was removed in vacuo and the crude 
product was purified via FCC (hexanes/EtOAc 7:3). Silylether 146 was isolated as colourless 
oil (1.06 g, 4.22 mmol, 43%). 
 
Rf = 0.90 (hexanes/EtOAc 7:3).  
1H NMR (400 MHz, chloroform-d) δ/ppm = 4.18 – 4.07 (m, 1H, 4-H), 3.70 (tt, J = 8.6, 3.8 Hz, 
1H, 1-H), 2.32 – 2.22 (m, 2H, 3, 5-H), 1.93 – 1.84 (m, 2H, 2, 6-H), 1.84 – 1.76 (m, 2H, 3, 5-H), 
1.42 (m, 2H, 2, 6-H), 0.10 (s, 9H, Si(CH3)3). 
13C NMR (101 MHz, chloroform-d) δ/ppm = 68.6 (C-1), 51.9 (C-2), 34.6 (C-2, 3, 5, 6), 0.3 
(Si(CH3)3). 
IR (ATR): ṽ/cm-1 = 2948, 2863, 2360, 1454, 1439, 1376, 1335, 1249, 1086, 1042, 1011, 875, 
835, 788, 746, 697, 673.  
HRMS (EI): m/z calculated for C9H18BrOSi [M]˙⁺ 249.0310; found 249.0303. 
Purity (GC): > 95% (scan mode m/z 50-650 (EI 70 eV)).  
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(1R,3R)-1-(Bromomethyl)-3-methoxycyclohexane / (1S,3S)-1-(bromomethyl)-3-
methoxycyclohexane (152a) and (1S,3R)-1-(bromomethyl)-3-methoxycyclohexane / 
(1R,3S)-1-(bromomethyl)-3-methoxycyclohexane (152b) 
 
 
 
 
 
C8H15BrO 
M = 207.11 g/mol 
Racemic bromides 152a and 152b were synthesised over two steps. To a solution of cis/trans 
mixture of 3-methoxycyclohexanecarboxylic acid (153, 844 mg, 5.17 mmol, 1.00 eq) in dry 
THF (30.0 mL), dimethyl sulfide borane (2M in THF, 3.36 mL, 6.73 mmol, 1.30 eq) was added 
dropwise at - 78 °C and the mixture was stirred for 5 h at 0°C. The reaction was stopped with 
aq. sat. NaHCO3 solution (20.0 mL) and the mixture was extracted with EtOAc (3 x 30.0 mL). 
The combined organic layers were dried over Na2SO4, filtered and concentrated in vacuo to 
give (3-methoxycyclohexyl)methanol (154) as a colourless oil (746 mg, 5.17 mmol, 
quantitative). Alcohol 154 was used without further purification. 
 
Rf = 0.20 (DCM/MeOH 99:1).  
HRMS (EI): m/z calculated for C8H16O2 [M]˙⁺ 144.1144; found 144.1143. 
 
To a suspension of crude alcohol 154 (746 mg, 5.17 mmol, 1.00 eq) and PPh3 (2.74 g, 
10.3 mmol, 2.00 eq) in DCM (50.0 mL) at 0 °C, CBr4 (3.43 g, 10.3 mmol, 2.00 eq) was added. 
The reaction was warmed up to rt and after 2 h the solvent was removed in vacuo and the title 
compounds were separated and purified via FCC (hexanes/EtOAc 97:3) and 152a (436 mg, 
2.11 mmol, 41%) and 152b (421 mg, 2.03 mmol, 39%) were both obtained as light yellow oil.   
 
Analytical data of 152a*: 
Rf = 0.29 (hexanes/EtOAc 97:3). 
1H NMR (400 MHz, chloroform-d) δ/ppm = 3.54 (p, J = 3.2 Hz, 1H, 3-H), 3.32 – 3.28 (m, 5H, 
OCH3, 1-CH2), 2.07 – 1.95 (m, 2H, 1, 2-H), 1.90 – 1.77 (m, 2H, 4, 6-H), 1.68 – 1.47 (m, 2H, 5-
H), 1.35 – 1.25 (m, 1H, 4-H), 1.20 (tt, J = 12.3, 2.5 Hz, 1H, 2-H), 1.08 (tdd, J = 12.5, 11.0, 4.0 
Hz, 1H, 6-H). 
13C NMR (101 MHz, chloroform-d) δ/ppm = 75.1 (C-3), 55.8 (OCH3), 41.0 (1-CH2), 34.9 (C-2), 
34.2 (C-1), 31.1 (C-6), 29.3 (C-4), 19.9 (C-8). 
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IR (ATR): ṽ/cm-1 = 2929, 2858, 2821, 1738, 1445, 1363, 1250, 1233, 1083, 965, 944, 886, 
807, 685. 
HRMS (EI): m/z calculated for C8H14BrO [M-H]˙⁺ 205.0234; found 205.0220. 
Purity (GC): > 95% (scan mode m/z 50-650 (EI 70 eV)).  
 
Analytical data of 152b*: 
Rf = 0.20 (hexanes/EtOAc 97:3). 
1H NMR (400 MHz, chloroform-d) δ/ppm = 3.36 (s, 3H, OCH3), 3.31 (dd, J = 6.3, 1.5 Hz, 2H, 
1-CH2), 3.14 (tt, J = 10.8, 4.2 Hz, 1H, H-3), 2.23 (dtt, J = 11.9, 4.1, 2.0 Hz, 1H, 2-H), 2.08 – 
2.00 (m, 1H, 4-H), 1.87 – 1.78 (m, 2H, 5, 6-H), 1.74 – 1.63 (m, 1H, 1-H), 1.33 – 1.20 (m, 1H, 
5-H), 1.16 – 1.03 (m, 1H, 4-H), 1.01 – 0.88 (m, 2H, 2, 6-H). 
13C NMR (101 MHz, chloroform-d) δ/ppm = 78.9 (C-3), 55.9 (OCH3), 39.8 (1-CH2), 38.9 (C-1), 
37.2 (C-2), 31.8 (C-4), 31.1 (C-6), 23.6 (C-5). 
IR (ATR): ṽ/cm-1 = 2929, 2857, 2821, 1463, 1450, 1373, 1276, 1232, 1166, 1110, 1088, 976, 
923. 
HRMS (EI): m/z calculated for C8H14BrO [M-H]˙⁺ 205.0234; found 205.0220. 
Purity (GC): 92% (scan mode m/z 50-650 (EI 70 eV)). 
 
*The cis/trans identification was performed retrospectively from 158 and 160, respectively.   
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2-((((1R,3R)-3-Methoxycyclohexyl)methyl)thio)benzo[d]thiazole and 2-((((1S,3S)-3-
methoxycyclohexyl)methyl)thio)benzo[d]thiazole (157) 
 
 
 
 
C15H19NOS2 
M = 293.44 g/mol 
To a solution of bromide 152a (400 mg, 1.93 mmol, 1.00 eq) and 2-mercaptobenzthiazole 
(388 mg, 2.32 mmol, 1.20 eq) in DCM (32.0 mL) at 0 °C TEA (0.538 mL, 3.86 mmol, 2.00 eq) 
was added and the reaction mixture was stirred at rt for 17 h. The reaction was stopped with 
water (20.0 mL) and the extracted with DCM (3 x 35.0 mL). The combined organic layers were 
washed with water (50.0 mL), brine (50.0 mL) and then dried over Na2SO4, filtered and the 
solvent was removed in vacuo. The title compound was purified via FCC (hexanes/EtOAc 9:1) 
and isolated as colourless oil (172 mg, 0.586 mmol, 30%). 
 
Rf = 0.40 (hexanes/EtOAc 90:10). 
1H NMR (400 MHz, chloroform-d) δ/ppm = 7.85 (ddd, J = 8.2, 1.2, 0.6 Hz, 1H, 4-H), 7.74 (ddd, 
J = 7.9, 1.3, 0.6 Hz, 1H, 7-H), 7.40 (ddd, J = 8.3, 7.3, 1.3 Hz, 1H, 5-H), 7.31 – 7.25 (m, 1H, 6-
H), 3.57 – 3.52 (m, 1H, 3’-H), 3.32 – 3.26 (m, 5H, OCH3, 1’-CH2), 2.18 – 2.06 (m, 2H, 1’, 2’-H), 
1.94 – 1.80 (m, 2H, 4’, 6’-H), 1.69 – 1.49 (m, 3H, 4’, 5’-H), 1.41 – 1.31 (m, 1H, 2’-H), 1.19 – 
1.08 (m, 1H, 6’-H). 
13C NMR (101 MHz, chloroform-d) δ/ppm = 167.9 (C-2), 153.3 (C-3a), 135.3 (C-7a), 126.2 (C-
5), 124.3 (C-6), 121.5 (C-4), 121.0 (C-7), 75.2 (C-3’), 55.8 (OCH3), 40.3 (1’-CH2), 35.6 (C-2’), 
32.3 (C-1’), 31.9 (C-6’), 29.5 (C-4’), 20.2 (C-5’). 
IR (ATR): ṽ/cm-1 = 2925, 2858, 1455, 1425, 1238, 1105, 1083, 991, 943, 753, 725. 
HRMS (EI): m/z calculated for C15H19ONS2 [M]˙⁺ 293.0902; found 293.0899. 
Purity (HPLC): > 95% (λ = 210 nm), > 95% (λ = 254 nm) (method c). 
   
*The trans identification was performed retrospectively from 158.   
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2-((((1S,3R)-3-Methoxycyclohexyl)methyl)thio)benzo[d]thiazole and 2-((((1R,3S)-3-
methoxycyclohexyl)methyl)thio)benzo[d]thiazole (159) 
 
 
 
 
C15H19NOS2 
M = 293.44 g/mol 
To a solution of bromide 152b (206 mg, 0.995 mmol, 1.00 eq) and 2-mercaptobenzthiazole 
(200 mg, 1.19 mmol, 1.20 eq) in DCM (16.0 mL) at 0 °C TEA (0.277 mL, 1.99 mmol, 2.00 eq) 
was added and the reaction mixture was stirred at rt for 17 h. The reaction was stopped with 
water (10.0 mL) and the extracted with DCM (3 x 17.0 mL). The combined organic layers were 
washed with water (25.0 mL), brine (25.0 mL) and then dried over Na2SO4, filtered and the 
solvent was removed in vacuo. The title compound was purified via FCC (hexanes/EtOAc 9:1) 
and isolated as light yellow oil (122 mg, 0.416 mmol, 42%). 
 
Rf = 0.27 (hexanes/EtOAc 9:1). 
1H NMR (500 MHz, chloroform-d) δ/ppm = 7.86 (ddd, J = 8.1, 1.2, 0.6 Hz, 1H, 4-H), 7.75 (ddd, 
J = 8.0, 1.3, 0.6 Hz, 1H, 7-H), 7.41 (ddd, J = 8.4, 7.3, 1.3 Hz, 1H, 5-H), 7.29 (ddd, J = 8.3, 7.3, 
1.2 Hz, 1H, 6-H), 3.36 (s, 3H, OCH3), 3.31 (dd, J = 6.8, 5.2 Hz, 2H, 1‘-CH2), 3.14 (tt, J = 10.8, 
4.1 Hz, 1H, 3‘-H), 2.35 – 2.28 (m, 1H, 2‘-H), 2.12 – 2.04 (m, 1H, 6‘-H), 1.93 – 1.88 (m, 1H, 6‘-
H), 1.87 – 1.74 (m, 2H, 1‘, 5‘-H), 1.59 – 1.52 (m, 2H, 4‘-H), 1.40 – 1.32 (m, 1H, 5‘-H), 1.04 – 
0.96 (m, 1H, 2‘-H). 
13C NMR (101 MHz, chloroform-d) δ/ppm = 167.6 (C-2), 153.4 (C-3a), 135.3 (C-7a), 126.2 (C-
5), 124.3 (C-6), 121.6 (C-4), 121.1 (C-7), 79.1 (C-3‘), 55.9 (OCH3), 41.0 (C-4‘), 40.1 (1‘-CH2), 
38.1 (C-2‘), 36.8 (C-1‘), 31.9 (C-6‘), 23.8 (C-5‘). 
IR (ATR): ṽ/cm-1 = 2927, 2856, 1456, 1426, 1087, 993, 921, 755, 726, 704. 
HRMS (EI): m/z calculated for C15H19ONS2 [M]˙⁺ 293.0908; found 293.0901. 
Purity (HPLC): 62% (λ = 210 nm), 69% (λ = 254 nm) (method c).   
 
*The cis identification was performed retrospectively from 160. 
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2-((((1S,3S)-3-Methoxycyclohexyl)methyl)sulfonyl)benzo[d]thiazole and 2-((((1R,3R)-3-
methoxycyclohexyl)methyl)sulfonyl)benzo[d]thiazole (158) 
 
 
 
 
C15H19NO3S2 
M = 325.44 g/mol 
To a solution of 157 (154 mg, 0.525 mmol, 1.00 eq) in DCM (20.0 mL), m-CPBA (647 mg, 
2.89 mmol, 5.50 eq) was added and the reaction mixture was stirred for 24 h at rt. The reaction 
was stopped with sat. aq. Na2S2O3 (10.0 mL) and sat. aq. NaHCO3 (10.0 mL) and the aq. phase 
was extracted with DCM (3 x 30.0 mL). The combined organic layers were washed with brine 
(30.0 mL), dried over Na2SO4, filtered and the solvent was removed in vacuo. The title 
compound was purified via FCC (hexanes/EtOAc 8:2) and isolated as white oily solid (156 mg, 
0.479 mmol, 91%). 
 
Rf = 0.22 (hexanes/EtOAc 8:2). 
1H NMR (400 MHz, chloroform-d) δ/ppm = 8.21 (ddd, J = 8.1, 1.4, 0.7 Hz, 1H, 4-H), 8.02 (ddd, 
J = 7.8, 1.5, 0.7 Hz, 1H, 7-H), 7.67 – 7.55 (m, 2H, 5, 6-H), 3.51 – 3.47 (m, 1H, 3’-H), 3.44 (t, J 
= 6.3 Hz, 2H, 1’-CH2), 3.26 (s, 3H, OCH3), 2.57 – 2.46 (m, 1H, 1’-H), 2.21 – 2.12 (m, 1H, 2’-
H), 1.93 – 1.84 (m, 1H, 6’-H), 1.83 – 1.74 (m, 1H, 4’-H), 1.70 – 1.57 (m, 1H, 5’-H), 1.54 – 1.43 
(m, 1H, 5’-H), 1.42 – 1.27 (m, 3H, 2’, 4’, 6’-H).  
13C NMR (101 MHz, chloroform-d) δ/ppm = 166.9 (C-2), 152.8 (C-3a), 136.9 (C-7a), 128.1 (C-
6), 127.8 (C-5), 125.6 (C-4), 122.5 (C-7), 74.7 (C-3’), 60.6 (1’-CH2), 55.8 (OCH3), 35.5 (C-2’), 
32.3 (C-6’), 29.6 (C-4’), 27.7 (C-1’), 20.1 (C-5’). 
IR (ATR): ṽ/cm-1 = 2929, 1471, 1323, 1315, 1146, 1105, 1082, 1023, 944, 852, 759, 729, 689. 
HRMS (EI): m/z calculated for C15H18O3NS2 [M]˙⁺ 324.0723; found 324.0718. 
Purity (HPLC): 93% (λ = 210 nm), > 95% (λ = 254 nm) (method c).   
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2-((((1S,3R)-3-Methoxycyclohexyl)methyl)sulfonyl)benzo[d]thiazole and 2-((((1R,3S)-3-
methoxycyclohexyl)methyl)sulfonyl)benzo[d]thiazole (160) 
 
 
 
 
 
 
C15H19NO3S2 
M = 325.44 g/mol 
To a solution of 159 (108 mg, 0.368 mmol, 1.00 eq) in DCM (14.0 mL), m-CPBA (349 mg, 
2.02 mmol, 5.50 eq) was added and the reaction mixture was stirred for 24 h at rt. The reaction 
was stopped with sat. aq. Na2S2O3 (8.00 mL) and sat. aq. NaHCO3 (8.00 mL) and the aq. phase 
was extracted with DCM (3 x 25.0 mL). The combined organic layers were washed with brine 
(15.0 mL), dried over Na2SO4, filtered and the solvent was removed in vacuo. The title 
compound was purified via FCC (hexanes/EtOAc 8:2) and isolated as white solid (120 mg, 
0.368 mmol, quantitative). 
 
Rf = 0.20 (hexanes/EtOAc 8:2). 
mp: 55 °C. 
1H NMR (400 MHz, chloroform-d) δ/ppm = 8.21 (ddd, J = 8.1, 1.4, 0.7 Hz, 1H, 4-H), 8.02 (ddd, 
J = 7.8, 1.5, 0.7 Hz, 1H, 7-H), 7.68 – 7.54 (m, 2H, 5, 6-H), 3.50 (d, J = 6.3 Hz, 2H, 1’-CH2), 
3.31 (s, 3H, OCH3), 3.14 (tt, J = 10.7, 4.0 Hz, 1H, 3’-H), 2.32 – 2.16 (m, 2H, 1’, 2’-H), 2.06 – 
1.89 (m, 2H, 4’, 6’-H), 1.84 – 1.75 (m, 1H, 5’-H), 1.37 – 1.22 (m, 2H, 4’, 5’-H), 1.15 – 1.01 (m, 
2H, 2’, 6’-H). 
13C NMR (101 MHz, chloroform-d) δ/ppm = 166.8 (C-2), 152.8 (C-3a), 136.9 (C-7a), 128.2 (C-
6), 127.8 (C-5), 125.6 (C-4), 122.5 (C-7), 78.4 (C-3’), 60.7 (1’-CH2), 55.9 (OCH3), 38.3 (C-2’), 
32.3 (C-6’), 31.4 (C-4’), 31.4 (C-1’), 23.3 (C-5’). 
IR (ATR): ṽ/cm-1 = 2935, 2859, 1474, 1309, 1198, 1143, 1111, 1072, 1024, 978, 929, 840, 
756, 747, 731, 687. 
HRMS (EI): m/z calculated for C15H20O3NS2 [M]˙⁺ 326.0879; found 326.0877. 
Purity (HPLC): > 95% (λ = 210 nm), > 95% (λ = 254 nm) (method c).    
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tert-Butyl((S)-2-((1R,3aS,4R,7aS)-4-((E)-2-((1S/R,3S/R)-3-methoxycyclohexyl)vinyl)-7a-
methyloctahydro-1H-inden-1-yl)propoxy)dimethylsilane and tert-butyl((S)-2-
((1R,3aS,4R,7aS)-4-((Z)-2-((1R/S,3R/S)-3-methoxycyclohexyl)vinyl)-7a-
methyloctahydro-1H-inden-1-yl)propoxy)dimethylsilane (150) 
 
C28H52O2Si 
M = 448.81 g/mol 
In an oven-dried two-necked Schlenk-flask, sulfone 158 (207 mg, 0.636 mmol, 1.00 eq) was 
dissolved in dry THF (6.00 mL) and the solution was cooled to - 78 °C. LDA (2M in THF, 
0.382 mL, 0.763 mmol, 1.20 eq) was added and the reaction mixture was stirred for 30 min at 
- 78 °C. A solution of aldehyde 73b (258 mg, 0.763 mmol, 1.20 eq) in dry THF (7.00 mL) was 
added dropwise. The reaction mixture was slowly warmed to - 50 °C and stirred for 18 h. The 
reaction was stopped with sat. aq. NH4Cl (7.00 mL), the layers were separated, and the aq. 
phase was extracted with EtOAc (3 x 20.0 mL). The combined organic layers were washed 
with brine (30.0 mL), dried over Na2SO4, filtered and the solvent was removed in vacuo. The 
title compounds were purified twice via FCC (hexanes/EtOAc 98:2) to give seco-steroids 150 
as an inseparable E/Z mixture (E/Z ratio 55:45 determined via 1H, 4:5:43:48 determined via 
GC/MS) of four isomers as a light yellow oil (196 mg, 0.437 mmol, 69%).  
 
The analytical data refers to the mixture of the four isomers: 
Rf = 0.27 (hexanes/EtOAc 98:2). 
[𝜶]𝑫
𝟐𝟑: + 26.9 (c = 1.03, CHCl3). 
1H NMR (400 MHz, chloroform-d) δ/ppm = 5.57 (m, 2H, 4’-CH(E)), 5.48 (m, 2H, 4’-CH(Z)), 5.25 
(m, 2H, 1’’-CH(E)), 5.17 (m, 2H, 1’’-CH(Z)), 3.58 (m, 4H, 1-H), 3.51 – 3.44 (m, 4H, 3’’-H), 3.32 
– 3.28 (m, 12H, OCH3), 3.23 (m, 4H, 1-H), 2.87 – 2.78 (m, 2H, 4’-H(Z)), 2.67 – 2.54 (m, 2H, 
1’’-H(Z)), 2.44 – 2.39 (m, 2H, 4’-H(E)), 2.38 – 2.29 (m, 2H, 1’’-H(E)), 1.99 – 1.88 (m, 4H, 7’-H), 
1.87 – 1.71 (m, 13H, CH2), 1.69 – 1.28 (m, 51H, 2, 3a’-H, CH2), 1.27 – 1.04 (m, 20H, 1’-H, 
CH2), 0.98 – 0.93 (m, 12H, 2-CH3), 0.89 (s, 37H, SiC(CH3)3), 0.74 (m, 6H, 7a’-CH3), 0.70 (s, 
6H, 7a’-CH3), 0.06 – 0.02 (m, 24H, Si(CH3)2). 
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13C NMR (101 MHz, chloroform-d) δ/ppm = 135.3 (CH), 135.2 (CH), 134.6 (CH), 129.6 (CH), 
129.4 (CH), 129.4 (CH), 75.6 (C-3’’), 75.5 (C-3’’), 75.5 (C-3’’), 68.1 (C-1), 55.9 (OCH3), 55.8 
(OCH3), 53.8 (OCH3), 55.8 (OCH3), 53.8 (C-1‘), 53.5 (C-1‘), 52.7 (C-3a‘), 52.5 (C-3a‘), 52.5 (C-
3a‘), 42.7 (C-7a’), 42.6 (C-7a’), 40.8 (C-7‘), 40.7 (C-7‘), 40.7 (C-7‘), 39.0 (C-4’(E)), 38.9 (C-2), 
36.7 (CH2), 36.6 (CH2), 36.5 (CH2), 35.8 (CH2), 35.3 (C-1’’(E)), 35.2 (C-1’’(E)), 34.9 (C-4’(Z)), 
34.8 (C-4’(Z)), 32.9 (CH2) , 32.7 (CH2), 32.6 (CH2), 32.5 (CH2), 32.3 (CH2), 30.9 (CH2), 30.3 
(C-1’’(Z)), 30.2 (C-1’’(Z)), 29.9 (CH2), 29.7 (CH2), 29.5 (CH2), 29.4 (CH2), 29.2 (CH2), 27.0 
(CH2), 27.0 (CH2), 26.9 (CH2), 26.1 (SiC(CH3)3), 24.9 (CH2), 24.8 (CH2), 24.1 (CH2), 20.3 (CH2), 
20.2 (CH2), 20.1 (CH2), 18.7 (CH2), 18.5 (SiC(CH3)3), 16.9 (2-CH3), 16.9 (2-CH3), 16.9 (2-CH3), 
14.3 (7a’-CH3), 13.8 (7a’-CH3), 13.8 (7a’-CH3), -5.2 (Si(CH3)2), -5.2 (Si(CH3)2). 
IR (ATR) ṽ/cm-1 = 3725, 3705, 2927, 2856, 1473, 1460, 1440, 1361, 1250, 1089, 1032, 1006, 
835, 773, 670, 662. 
HRMS (EI): m/z calculated for C28H52O2Si [M]˙⁺ 448.3731; found 448.3738. 
Purity (GC): > 95% (scan mode m/z 50-650 (EI 70 eV)).  
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(S)-2-((1R,3aS,4R,7aS)-4-((E)-2-((1S/R,3S/R)-3-Methoxycyclohexyl)vinyl)-7a-
methyloctahydro-1H-inden-1-yl)propan-1-ol and (S)-2-((1R,3aS,4R,7aS)-4-((Z)-2-
((1R/S,3R/S)-3-methoxycyclohexyl)vinyl)-7a-methyloctahydro-1H-inden-1-yl)propan-1-
ol (161) 
C22H38O2 
M = 334.54 g/mol 
The (inseparable) mixture of E/Z isomers 161 was synthesised according to GP9, using E/Z 
mixture of four isomers 150 (51.0 mg, 0.110 mmol, 1.00 eq). Z-Isomer Z-161c or Z-161d could 
be separated from the mixture of E-isomers E-161a/E-161b and from the appropriate Z-isomer 
via FCC (hexanes/EtOAc 8:2). The E/Z ratio of the three isomers is 71:29 (determined via 1H 
NMR). 
 
Analytical data of inseparable mixture of E-161a / E-161b / Z-161c or Z-161d (three isomers):  
Yield: 20.0 mg, 0.0598 mmol, 53%. 
Appearance: colourless oil. 
Rf = 0.30 (hexanes/EtOAc 8:2). 
[𝜶]𝑫
𝟐𝟑: + 32.0 (c = 0.03, CHCl3). 
1H NMR (500 MHz, chloroform-d) δ/ppm = 5.59 – 5.53 (m, 2H, 4’-CH(E)), 5.51 – 5.45 (m, 0.8H, 
4’-CH(Z)), 5.29 – 5.23 (m, 2H, 1’’-CH(E)), 5.20 – 5.14 (m, 0.8H, 1’’-CH(Z)), 3.64 – 3.59 (m, 3H, 
1-H), 3.53 – 3.44 (m, 3H, 3’’-H), 3.39 – 3.34 (m, 3H, 1-H), 3.33 – 3.28 (m, 9H, OCH3), 2.85 – 
2.77 (m, 0.8H, 4’-H(Z)), 2.66 – 2.53 (m, 0.8H, 1’’-H(Z)), 2.45 – 2.39 (m, 2H, 4’-H(E)), 2.38 – 
2.28 (m, 2H, 1’’-H(E)), 1.96 – 1.89 (m, 4H, 7’-H), 1.88 – 1.72 (m, 12H, CH2), 1.70 – 1.35 (m, 
42H, 2, 3a’-H, CH2), 1.31 – 1.10 (m, 10H, 1’-H, CH2), 1.02 – 0.98 (m, 9H, 7a’-CH3), 0.78 – 0.68 
(m, 9H, 2-CH3). 
13C NMR (126 MHz, chloroform-d) δ/ppm = 135.4 (CH), 134.7 (CH), 129.5 (CH), 129.3 (CH), 
129.3 (CH), 75.6 (C-3’’), 75.5 (C-3’’), 68.1 (C-1), 55.9 (OCH3), 55.8 (OCH3), 55.8 (OCH3), 53.5 
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(C-1’), 53.2 (C-1’), 52.7 (C-3a’), 52.5 (C-3a’), 42.7 (C-7a’), 42.6 (C-7a’), 40.8 (C-7’), 40.6 (C-
7’), 38.9 (C-2), 38.7 (CH), 38.7 (C-4’(E)), 36.7 (CH2), 36.6 (CH2), 36.5 (CH2), 35.3 (C-1’’(E)), 
35.2 (C-1’’(E)), 34.8 (C-4’(Z)), 32.7 (CH2), 32.6 (CH2), 32.5 (CH2), 32.3 (CH2), 30.9 (CH2), 30.3 
(C-1’’(Z)), 29.6 (CH2), 29.5 (CH2), 29.4 (CH2), 27.0 (CH2), 27.0 (CH2), 24.7 (CH2), 24.0 (CH2), 
24.0 (CH2), 23.9 (CH2), 20.3 (CH2), 20.1 (CH2), 18.7 (CH2), 16.8 (2-CH3), 16.7 (2-CH3), 14.3 
(7a’-CH3), 13.8 (7a’-CH3), 13.8 (7a’-CH3). 
IR (ATR): ṽ/cm-1 = 3725, 3709, 3622, 3598, 2929, 2360, 1218, 771, 676, 652, 566. 
HRMS (EI): m/z calculated for C21H34O [M-OCH3]˙⁺ 302.2604; found 302.2612. 
Purity (GC): > 95% (scan mode m/z 50-650 (EI 70 eV)).  
 
Analytical data of Z-161c or Z-161d (one isomer): 
Yield: 6.00 mg, 0.0179 mmol, 16%. 
Appearance: colourless oil. 
Rf = 0.23 (hexanes/EtOAc 8:2). 
[𝜶]𝑫
𝟐𝟑: + 13.5 (c = 0.04, CHCl3). 
1H NMR (800 MHz, chloroform-d) δ/ppm = 5.48 (td, J = 10.8, 1.0 Hz, 1H, 4’-CH), 5.18 (ddd, J 
= 11.0, 9.9, 1.2 Hz, 1H, 1’’-CH), 3.63 (dd, J = 10.5, 3.2 Hz, 1H, 1-H), 3.49 – 3.46 (m, 1H, 3’’-
H), 3.36 (dd, J = 10.5, 6.9 Hz, 1H, 1-H), 3.30 (s, 3H, OCH3), 2.85 – 2.79 (m, 1H, 4’-H), 2.62 – 
2.55 (m, 1H, 1’’-H), 1.96 – 1.91 (m, 1H, 7’-H), 1.83 – 1.75 (m, 3H, 2’’, 4’’-H, 2’, 3’, 5’ or 6’-H), 
1.69 – 1.62 (m, 2H, 2’, 3’, 5’ or 6’-H), 1.60 – 1.54 (m, 3H, 5’’, 6’’-H, 2’, 3’, 5’ or 6’-H), 1.54 – 
1.41 (m, 5H, 2, 3a’, 5’’-H, 2’, 3’, 5’ or 6’-H), 1.40 – 1.29 (m, 2H, 4’’-H, 2’, 3’, 5’ or 6’-H), 1.27 – 
1.22 (m, 1H, 2’, 3’, 5’ or 6’-H), 1.21 – 1.13 (m, 3H, 1’, 7’, 2’’-H), 1.07 – 1.02 (m, 1H, 6’’-H), 1.01 
(d, J = 6.6 Hz, 3H, 2-CH3), 0.76 (s, 3H, 7a’-CH3). 
13C NMR (201 MHz, chloroform-d) δ/ppm = 135.4 (1’’-CH), 129.5 (4’-CH), 75.5 (C-3’’), 68.1 (C-
1), 55.9 (OCH3), 53.2 (C-1’), 52.5 (C-3a’), 42.6 (C-7a’), 40.6 (C-7’), 38.7 (C-2), 35.8 (C-2’’), 
34.8 (C-4’), 32.9 (C-6’’), 32.3 (C-2’, 3’, 5’ or 6’), 30.2 (C-1’’), 29.9 (C-4’’), 27.1 (C-2’, 3’, 5’ or 
6’), 24.8 (C-2’, 3’, 5’ or 6’), 20.2 (C-5’’), 18.7 (C-2’, 3’, 5’ or 6’), 16.7 (2-CH3), 14.3 (7a’-CH3). 
IR (ATR): ṽ/cm-1 = 3727, 3624, 2934, 2875, 1445, 1112, 1089, 1039, 763, 671, 656. 
HRMS (EI): m/z calculated for C22H38O2 [M]˙⁺ 334.2866; found 334.2861. 
Purity (GC): > 95% (scan mode m/z 50-650 (EI 70 eV)).  
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(1S/R,3S/R)-3-((E)-2-((1R,3aS,4R,7aS)-1-((S)-1-Hydroxypropan-2-yl)-7a-
methyloctahydro-1H-inden-4-yl)vinyl)cyclohexan-1-ol and (1R/S,3R/S)-3-((Z)-2-
((1R,3aS,4R,7aS)-1-((S)-1-Hydroxypropan-2-yl)-7a-methyloctahydro-1H-inden-4-
yl)vinyl)cyclohexan-1-ol (149, two isomers, E/Z) 
 
C21H36O2 
M = 320.52 g/mol 
The inseparable mixture of E/Z isomers 161 (two E-isomers, one Z-isomer, 14.0 mg, 
0.0418 mmol, 1.00 eq) and NaI (6.90 mg, 0.0460 mmol, 1.10 eq) were dissolved in 1:1 
DCM/MeCN (500 µL). SiCl4 (5.27 µL, 0.0460 mmol, 1.10 eq) was added and the mixture was 
heated to 60 °C for 8 h. The reaction was stopped with water (1.00 mL) and extracted with 
EtOAc (3 x 2.00 mL). The combined organic layers were dried over Na2SO4, filtered and the 
solvent was removed in vacuo. The title compound was purified via FCC (hexanes/EtOAc 7:3) 
and the inseparable mixture of E/Z diols 149 (ratio 59:41, determined via 1H NMR) was isolated 
as colourless oil (4.40 mg, 0.0137 mmol, 33%).  
 
Rf = 0.16 (hexanes/EtOAc 7:3). 
[𝜶]𝑫
𝟐𝟑: + 30.7 (c = 0.03, CHCl3). 
1H NMR (800 MHz, chloroform-d) δ/ppm = 5.60 – 5.55 (m, 1H, 4’-CH(E)), 5.50 – 5.47 (m, 0.7H, 
4’-CH(Z)), 5.29 – 5.25 (m, 1H, 3-CH(E)), 5.22 – 5.18 (m, 0.7H, 3-CH(Z)), 4.09 – 4.01 (m, 3H, 
1-H(E/Z), OH), 3.65 – 3.62 (m, 2H, 1’’-H(E/Z)), 3.38 – 3.34 (m, 2H, 1’’-H(E/Z)), 2.84 – 2.79 (m, 
0.7H, 4’-H(Z)), 2.69 – 2.63 (m, 0.7H, 3-H(Z)), 2.45 – 2.39 (m, 2H, 4’-H(E), 3-H(E)), 1.96 – 1.89 
(m, 2H, 7’-H(E/Z)), 1.82 – 1.76 (m, 3H, CH2), 1.70 – 1.58 (m, 10H, CH2), 1.57 – 1.37 (m, 11H, 
3a’-H(E/Z), 2’’-H(E/Z), CH2), 1.28 – 1.10 (m, 6H, 1’-H(E/Z), 7’-H(E/Z), CH2), 1.02 – 1.00 (m, 
5.1H, 2’’-CH3(E/Z)), 0.75 (s, 2.1H, 7a’-CH3(Z)), 0.72 (s, 3H, 7a’-CH3(E)) 
13C NMR (201 MHz, chloroform-d) δ/ppm = 134.9 (3-CH2(Z)), 134.3 (3-CH2(E)), 129.6 (4‘-
CH2(Z)), 129.6 (4‘-CH2(E)), 68.1 (C-1‘‘(E/Z)), 66.9 (C-1(E)), 66.7 (C-1(Z)), 53.5 (C-1‘(E)), 53.2 
(C-1‘(Z)), 52.7 (C-3a‘(E)), 52.5 (C-3a‘(E)), 42.7 (C-7a‘(E)), 42.6 (C-7a‘(Z)), 40.8 (C-7‘(E)), 40.6 
(C-7‘(Z)), 39.9 (CH2), 39.9 (CH2), 38.9 (CH2), 38.9 (C-4‘(E)), 38.7 (C-2‘‘(Z)), 38.7 (C-2‘‘(E)), 
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35.1 (C-3(E)), 34.8 (C-4’(Z)), 32.4 (CH2), 32.3 (CH2), 32.3 (CH2), 30.8 (CH2), 30.1 (C-3(Z)), 
29.9 (CH2), 27.0 (CH2), 26.9 (CH2), 24.7 (CH2), 24.0 (CH2), 20.1 (CH2), 19.8 (CH2), 18.7 (CH2), 
18.7 (CH2), 16.8 (2‘‘-CH3(E)), 16.7 (2‘‘-CH3(Z)), 14.2 (7a’-CH3(E)), 13.8 (7a’-CH3(Z)). 
IR (ATR): ṽ/cm-1 = 3725, 3711, 3696, 3621, 3592, 2918, 2860, 1458, 1220, 1025, 971, 769, 
673, 647. 
HRMS (EI) calculated for C18H40O4 [M]˙⁺ 320.2709; found 320.2704. 
Purity (GC): 84% (scan mode m/z 50-650 (EI 70 eV)).  
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(S)-2-((1R,3aS,4R,7aS)-4-(2-((1S,3R)-3-Methoxycyclohexyl)ethyl)-7a-methyloctahydro-
1H-inden-1-yl)propan-1-ol and (S)-2-((1R,3aS,4R,7aS)-4-(2-((1R,3S)-3-
methoxycyclohexyl)ethyl)-7a-methyloctahydro-1H-inden-1-yl)propan-1-ol (162) 
 
C22H40O2 
M = 336.56 g/mol 
The inseparable mixture of racemic E/Z isomers 150 (125 mg, 0.279 mmol, 1.00 eq) was 
dissolved in EtOAc (10.0 mL) and Pd/C (12.5 mg, 0.0117 mmol, 10 wt%) was added. The flask 
was filled with H2 and the reaction mixture was stirred at rt for 18 h. The Pd/C catalyst was 
removed via filtration through a celite pad and the resulting filtrate was concentrated under 
reduced pressure. The crude product was used without further purification.  
 
HRMS (EI): m/z calculated for C28H53O2Si [M]˙⁺ 449.3809; found 449.3801. 
 
The hydrogenated crude product (0.279 mmol) was TBDMS deprotected using GP9 and the 
title compound was purified via FCC (hexanes/EtOAc 8:2) and isolated as colourless oil 
(48.6 mg, 0.144 mmol, 52% over two steps). 
 
Rf = 0.53 (hexanes/EtOAc 8:2). 
[𝜶]𝑫
𝟐𝟑: + 37.0 (c = 0.03, CHCl3). 
1H NMR (400 MHz, chloroform-d) δ/ppm = 3.74 – 3.60 (m, 2H, 1-H), 3.51 – 3.44 (m, 2H, 3’’-
H), 3.41 – 3.33 (m, 2H), 3.30 (d, J = 1.1 Hz, 6H, OCH3), 1.92 – 1.64 (m, 14H, CH, CH2), 1.59 
– 1.31 (m, 24H, CH, CH2), 1.28 – 1.11 (m, 12H, CH, CH2), 1.07 – 0.97 (m, 12H, 2-CH3, CH, 
CH2), 0.85 (s, 6H, 7a’-CH3). 
13C NMR (101 MHz, chloroform-d) δ/ppm = 75.9 (C-3‘‘), 75.8 (C-3‘‘), 68.6 (C-2), 68.3 (CH2), 
68.1 (CH2), 66.8 (CH2), 55.8 (OCH3), 55.5 (CH), 54.6 (C-3a’), 54.6 (OCH3), 54.2 (CH), 52.9 
(CH), 44.2 (C-7a’), 42.6 (C-7a’), 42.4 (C-1’), 41.1 (CH2), 40.2 (CH2), 38.9 (CH), 38.6 (CH), 38.2 
(C-2), 37.9 (CH2), 37.2 (CH2), 36.8 (CH2), 36.4 (CH2), 35.8 (C-7’), 34.3 (CH2), 32.6 (CH2), 31.8 
(CH2), 29.8 (CH2), 27.8 (CH2), 27.4 (CH2), 27.1 (CH2), 25.7 (CH2), 24.6 (7a’-CH3), 23.9 (CH2), 
22.4 (CH2), 22.1 (CH2), 21.1 (CH2), 21.1 (CH3), 20.5 (CH2), 18.0 (CH3), 17.4 (2-CH3). 
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IR (ATR): ṽ/cm-1 = 3726, 3708, 3693, 3623, 3599, 2364, 1218, 772, 678, 651, 617. 
HRMS (EI): m/z calculated for C22H40O2 [M]˙⁺ 336.3023; found 336.3013. 
Purity (GC): n.d.  
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(1R,3S)-3-(2-((1R,3aS,4R,7aS)-1-((S)-1-Hydroxypropan-2-yl)-7a-methyloctahydro-1H-
inden-4-yl)ethyl)cyclohexan-1-ol and (1S,3R)-3-(2-((1R,3aS,4R,7aS)-1-((S)-1-
Hydroxypropan-2-yl)-7a-methyloctahydro-1H-inden-4-yl)ethyl)cyclohexan-1-ol (151) 
 
C21H38O2 
M = 322.53 g/mol 
Mixture of ethers 162 (34.0 mg, 0.100 mmol, 1.00 eq) and NaI (16.7 mg, 0.111 mmol, 1.10 eq) 
were dissolved in 1:1 DCM/MeCN (1.00 mL). SiCl4 (12.7 µL, 0.111 mmol, 1.10 eq) was added 
and the mixture was stirred at 60 °C for 8 h. The reaction was stopped with water (2.00 mL) 
and extracted with EtOAc (3 x 3.00 mL). The combined organic layers were dried over Na2SO4, 
filtered and the solvent was removed in vacuo. The title compound was purified via FCC 
(hexanes/EtOAc 7:3) and diol 151 was isolated as colourless oil (10.0 mg, 0.0310 mmol, 31%).  
 
Rf = 0.17 (hexanes/EtOAc 7:3). 
[𝜶]𝑫
𝟐𝟑: + 16.7 (c = 0.04, CHCl3). 
1H NMR (800 MHz, chloroform-d) δ/ppm = 4.06 – 4.02 (m, 2H, 1-H), 3.72 – 3.60 (m, 2H, 1’’-
H), 3.41 – 3.30 (m, 2H, 1’’-H), 1.92 – 1.83 (m, 3H, CH2), 1.81 – 1.70 (m, 6H, CH, CH2), 1.67 – 
1.57 (m, 9H, CH, CH2), 1.54 – 1.36 (m, 16H, CH, CH2), 1.25 – 1.12 (m, 24H, CH, CH2), 1.06 
(d, J = 6.7 Hz, 3H, 2’’-CH3), 1.01 (dd, J = 6.6, 1.5 Hz, 3H, 2’’-CH3), 0.86 – 0.79 (m, 6H, 7a’-
CH3). 
13C NMR (201 MHz, chloroform-d) δ/ppm = 68.6 (C-1‘‘), 67.1 (C-1), 67.1 (C-1‘‘), 66.8 (C-1), 
54.6 (C-3a‘), 54.6 (C-3a’), 44.2 (C-7a’), 42.6 (C-7a’), 42.4 (C-1’), 42.4 (C-1’), 40.3 (CH2), 39.6 
(CH2), 38.6 (CH2), 38.5 (C-2’’), 38.2 (C-2’’), 37.8 (CH2), 37.0 (C-7’), 35.8 (C-7’), 33.7 (CH2), 
33.6 (CH2), 32.7 (CH2), 32.1 (C-4’), 32.1 (CH2), 31.9 (CH2), 31.8 (C-4’), 29.5 (CH2), 27.8 (CH2), 
26.1 (C-3), 25.7 (C-3), 24.9 (CH2), 24.6 (7a’-CH3), 23.9 (7a’-CH3), 22.9 (CH2), 21.1 (CH2), 21.0 
(CH2), 20.2 (CH2), 20.2 (CH2), 20.2 (CH2), 17.4 (2’’-CH3), 16.9 (2’’-CH3). 
IR (ATR): ṽ/cm-1 = 3726, 3708, 3693, 3623, 3599, 2360, 1218, 772, 720, 671, 654. 
HRMS (EI): m/z calculated for C21H38O2 [M]˙⁺ 322.2866; found 322.2867. 
Purity (GC): n.d. 
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6.2.5. Procedures and data for seco-steroids with bridging at C-5 (chapter 3.3.2.) 
((1R,3aS,7aS)-5-(4-((tert-Butyldimethylsilyl)oxy)phenyl)-1-((S)-1-((tert-
butyldimethylsilyl)oxy)propan-2-yl)-7a-methyloctahydro-1H-inden-5-ol (164a) and 
(1R,3aS,7aS)-5-(4-((tert-Butyldimethylsilyl)oxy)phenyl)-1-((S)-1-((tert-
butyldimethylsilyl)oxy)propan-2-yl)-7a-methyloctahydro-1H-inden-5-ol (164b) 
 
C31H56O3Si2 
M = 532.96 g/mol 
Alcohols 164a and 164b were synthesised according to GP6 using ketone 28c (264 mg, 
0.814 mmol, 1.00 eq) and aryl bromide 78d (258 mg, 0.898 mmol, 1.10 eq). The title 
compounds were separated and purified via FCC (hexanes/EtOAc 9:1) and 164a was isolated 
as white oily solid (6.00 mg, 0.011 mmol, 1%) and 164b as white solid (192 mg, 0.360 mmol, 
44%). 
 
Analytical data of 164a*: 
Rf = 0.55 (hexanes/EtOAc 9:1). 
[𝛂]𝑫
𝟐𝟑: + 45.9 (c = 0.08, C HCl3). 
1H NMR (400 MHz, chloroform-d) δ/ppm = 7.38 – 7.32 (m, 2H, 2’’, 6’’-H), 6.83 – 6.77 (m, 2H, 
3’’, 5’’-H), 3.61 (dd, J = 9.6, 3.3 Hz, 1H, 1’-H), 3.29 (dd, J = 9.7, 7.4 Hz, 1H, 1’-H), 2.06 – 1.83 
(m, 4H, 3a, 7-H, 2, 3, 4 or 6-H), 1.83 – 1.73 (m, 1H, OH), 1.70 – 1.48 (m, 5H, 7, 2’-H, 2, 3, 4 or 
6-H), 1.39 – 1.11 (m, 3H, 1-H, 2, 3, 4 or 6-H), 1.03 (d, J = 6.5 Hz, 3H, 2’-CH3), 0.98 (s, 9H, 
SiC(CH3)3), 0.91 (s, 9H, SiC(CH3)3), 0.76 (s, 3H, 7a-CH3), 0.19 (s, 6H, Si(CH3)2), 0.05 (s, 3H, 
Si(CH3)2), 0.05 (s, 3H, Si(CH3)2). 
13C NMR (101 MHz, chloroform-d) δ/ppm = 154.5 (C-4‘‘), 142.5 (C-1‘‘), 125.7 (C-2‘‘, 6‘‘), 119.7 
(C-3‘‘, 5‘‘), 73.7 (C-5), 68.0 (C-1‘), 52.4 (C-1), 44.6 (C-3a), 42.0 (C-7a), 39.5 (C-2, 3, 4 or 6), 
39.3 (C-2’), 35.9 (C-7), 35.9 (C-2, 3, 4 or 6), 27.8 (C-2, 3, 4 or 6), 26.4 (C-2, 3, 4 or 6), 26.2 
(SiC(CH3)3), 25.8 (SiC(CH3)3), 18.5 (SiC(CH3)3), 18.3 (SiC(CH3)3), 17.1 (2’-CH3), 10.5 (7a-
CH3), -4.3 (Si(CH3)2), -5.2 (Si(CH3)2), -5.2 (Si(CH3)2). 
IR (ATR): ṽ/cm-1 = 2928, 1603, 1508, 1471, 1251, 1084, 912, 832, 807, 773, 674. 
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HRMS (EI): m/z calculated for C31H56O3Si2 [M]˙⁺ 532.3768; found 532.3760. 
Purity (HPLC): 91% (λ = 210 nm), > 95% (λ = 250 nm) (method e).   
 
Analytical data of 164b*: 
Rf = 0.26 (hexanes/EtOAc 9:1). 
[𝛂]𝑫
𝟐𝟑: + 46.9 (c = 0.03, CHCl3). 
1H NMR (400 MHz, chloroform-d) δ/ppm = 7.43 – 7.37 (m, 2H, 2’’, 6’’-H), 6.84 – 6.77 (m, 2H, 
3’’, 5’’-H), 3.55 (dd, J = 9.6, 3.5 Hz, 1H, 1’-H), 3.17 (dd, J = 9.7, 7.7 Hz, 1H, 1’-H), 2.32 – 2.15 
(m, 2H, 7-H, 2, 3, 4 or 6-H), 2.05 – 1.90 (m, 2H, OH, 2, 3, 4 or 6-H), 1.81 – 1.39 (m, 5H, 3a, 7, 
2’-H, 2, 3, 4 or 6-H ), 1.36 – 1.12 (m, 5H, 1-H, 2, 3, 4 or 6-H), 0.99 (s, 9H, SiC(CH3)3), 0.95 (d, 
J = 6.5 Hz, 3H, 2’-CH3), 0.87 (s, 9H, SiC(CH3)3), 0.83 (s, 3H, 7a-CH3), 0.21 (s, 6H, Si(CH3)2), 
0.00 (s, 6H, Si(CH3)2). 
13C NMR (101 MHz, chloroform-d) δ/ppm = 154.6 (C-4‘‘), 135.4 (C-1‘‘), 125.9 (C-2‘‘, 6‘‘), 119.9 
(C-3‘‘, 5‘‘), 68.1 (C-5), 52.7 (C-1‘), 46.1 (C-1), 44.6 (C-2, 3, 4 or 6), 42.3 (C-3a), 40.9 (C-7), 
39.2 (C-7a), 30.4 (C-2’), 28.0 (C-2, 3, 4 or 6), 27.0 (C-2, 3, 4 or 6), 26.1 (C-2, 3, 4 or 6), 25.9 
(SiC(CH3)3), 18.6 (SiC(CH3)3), 18.4 (SiC(CH3)3), 16.8 (SiC(CH3)3), 11.5 (2’-CH3), -4.3 (7a-CH3), 
-5.2 (Si(CH3)2), -5.2 (Si(CH3)2). 
IR (ATR): ṽ/cm-1 = 2928, 1603, 1507, 1471, 1254, 1081, 912, 832, 807, 773. 
HRMS (EI): m/z calculated for C31H56O3Si2 [M]˙⁺ 532.3768; found 532.3755. 
Purity (HPLC): > 95% (λ = 210 nm), > 95% (λ = 250 nm) (method e).   
 
*Due to very fast dehydratision the stereoconfiguration at C-5 could not be determined. 
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4-((1R,3aS,7aS)-1-((S)-1-Hydroxypropan-2-yl)-7a-methyl-2,3,3a,4,7,7a-hexahydro-1H-
inden-5-yl)phenol (166) 
 
 
 
 
 
 
C19H26O2 
M = 286.42 g/mol 
Diol 166 was synthesised according to GP9 using silyl ether 164b (50.0 mg, 93.8 µmol, 
1.00 eq). The title compound was purified via FCC (hexanes/EtOAc 7:3) and isolated as off-
white solid (18.0 mg, 62.8 µmol, 67%). 
 
Rf = 0.26 (hexanes/EtOAc 7:3). 
mp: 169 °C. 
[𝛂]𝑫
𝟐𝟑: + 67.9 (c = 0.03, MeOH). 
1H NMR (400 MHz, methanol-d4) δ/ppm = 7.26 – 7.20 (m, 2H, 2, 6-H), 6.75 – 6.69 (m, 2H, 3, 
5-H), 6.63 (s, 1H, 1-OH), 5.92 – 5.85 (m, 1H, 6’-H), 3.62 (dd, J = 10.6, 3.2 Hz, 1H, 1’’-H), 3.34 
– 3.28 (m, 2H, 1’’-H, collapses with methanol-d4), 2.48 – 2.35 (m, 2H, 4’, 7’-H), 2.20 – 2.06 (m, 
2H, 4’, 7’-H), 2.01 – 1.91 (m, 1H, 2’ or 3’-H), 1.84 – 1.71 (m, 2H, 3a’-H, 2’ or 3’-H), 1.59 (m, 
1H, 2’’-H), 1.49 – 1.26 (m, 4H, 1’, 2’, 3’-H, 1’’-OH), 1.10 (d, J = 6.5 Hz, 3H, 2’’-CH3), 0.74 (d, J 
= 0.6 Hz, 3H, 7a’-CH3). 
13C NMR (101 MHz, methanol-d4) δ/ppm = 157.3 (C-1), 136.7 (C-4), 135.1 (C-5’), 127.1 (C-2, 
6), 122.7 (C-6’), 115.9 (C-3, 5), 67.9 (C-1’’), 53.7 (C-1’), 47.4 (C-3a’), 43.3 (C-7a’), 41.9 (C-7’), 
40.2 (C-2’’), 31.5 (C-4’), 28.9 (C-2’ or 3’), 27.9 (C-2’ or 3’), 17.0 (2’’-CH3), 11.6 (7a’-CH3). 
IR (ATR): ṽ/cm-1 = 3419, 2880, 1608, 1513, 1468, 1373, 1260, 1233, 1181, 1111, 1020, 991, 
974, 835, 806, 788. 
HRMS (EI): m/z calculated for C19H26O2 [M]˙⁺ 286.1927; found 286.1927. 
Purity (HPLC): > 95% (λ = 210 nm), > 95% (λ = 254 nm) (method c).    
Experimental Part 
 
  
 
  
 203 
 
4-((1R,3aS,5R,7aS)-1-((S)-1-Hydroxypropan-2-yl)-7a-methyloctahydro-1H-inden-5-
yl)phenol (163a) and 4-((1R,3aS,5S,7aS)-1-((S)-1-Hydroxypropan-2-yl)-7a-
methyloctahydro-1H-inden-5-yl)phenol (163b) 
 
 
C19H28O2 
M = 288.43 g/mol  
Diols 163a and 163b were prepared over two steps. According to GP8, 164b (94.9 mg, 
0.178 mmol, 1.00 eq) was dehydrated and hydrogenated. The solvent was removed in vacuo 
and the crude mixture of silylethers (0.178 mmol) was then used for the preparation of diols 
163a and 163b via GP9. The title compounds were purified and separated via FCC 
(hexanes/EtOAc 7:3) and diol 163a was obtained as light yellow oily solid (21.0 mg, 
0.0728 mmol, 41%) and diol 163b was obtained as beige, crystalline solid (9.00 mg, 
0.0312 mmol, 18%). 
  
Analytical data of diol 163a: 
Rf = 0.63 (hexanes/EtOAc 70:30). 
[𝛂]𝑫
𝟐𝟑: + 4.9 (c = 0.48, CHCl3). 
1H NMR (400 MHz, methanol-d4) δ/ppm = 7.08 – 7.03 (m, 2H, 3, 5-H), 6.73 – 6.68 (m, 2H, 2, 
6-H), 4.43 (dd, J = 10.7, 3.4 Hz, 1H, 1’’-H), 4.17 (dd, J = 10.7, 7.1 Hz, 1H, 1’’-H), 2.52 – 2.41 
(m, 1H, 5’-H), 2.06 (dt, J = 12.7, 3.4 Hz, 1H, 7’-H), 1.91 (dqd, J = 13.0, 6.4, 3.1 Hz, 2H, 2’’-H, 
2’, 3’, 4’ or 6’-H), 1.66 (qd, J = 10.3, 8.6, 5.2 Hz, 3H, 2’, 3’, 4’ or 6’-H), 1.59 – 1.22 (m, 6H, 1’, 
3a’, 7’-H, 2’, 3’, 4’ or 6’-H), 1.11 (d, J = 6.7 Hz, 3H, 2’’-CH3), 0.85 (s, 3H, 7a’-CH3). 
13C NMR (101 MHz, methanol-d4) δ/ppm = 156.4 (C-1), 139.7 (C-4), 128.7 (C-3, 5), 116.0 (C-
2, 6), 74.3 (C-1’’), 53.6 (C-1’), 51.7 (C-3a’), 45.5 (C-5’), 43.3 (C-7a’), 41.3 (C-7’), 37.1 (C-2’’), 
34.8 (C-2’, 3’, 4’ or 6’), 31.7 (C-2’, 3’, 4’ or 6’), 28.5 (C-2’, 3’, 4’ or 6’), 27.5 (C-2’, 3’, 4’ or 6’), 
17.3 (2’’-CH3), 11.6 (7a’-CH3). 
IR (ATR): ṽ/cm-1 = 3726, 3705, 3623, 3598, 2938, 2860, 1783, 1514, 1221, 1171, 1032, 831, 
777, 671, 649. 
HRMS (EI): m/z calculated for C19H28O2 [M]˙⁺ 288.2084; found 288.2088. 
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Purity (HPLC): > 95% (λ = 210 nm), 95% (λ = 254 nm) (method c).  
Analytical data of diol 163b: 
Rf = 0.30 (hexanes/EtOAc 70:30). 
mp: 154 °C. 
[𝛂]𝑫
𝟐𝟑: + 28.9 (c = 0.03, MeOH). 
1H NMR (400 MHz, methanol-d4) δ/ppm = 7.07 – 7.01 (m, 2H, 3, 5-H), 6.72 – 6.66 (m, 2H, 2, 
6-H), 3.59 (dd, J = 10.6, 3.2 Hz, 1H, 1’’-H), 3.27 (dd, J = 10.6, 7.1 Hz, 1H, 1’’-H, collapses with 
methanol-d4), 2.44 (tt, J = 10.7, 4.9 Hz, 1H, 5’-H), 2.06 (dt, J = 12.6, 3.3 Hz, 1H, 7’-H), 1.91 
(dtd, J = 12.5, 9.1, 6.0 Hz, 1H, 2’, 3’, 4’ or 6’-H), 1.67 – 1.60 (m, 2H, 2’, 3’, 4’ or 6’-H), 1.60 – 
1.42 (m, 5H, 3a’, 2’’-H, 1’’-OH, 2’, 3’, 4’ or 6’-H), 1.41 – 1.19 (m, 5H, 1, 7’-H, 2’, 3’, 4’ or 6’-H), 
1.06 (d, J = 6.6 Hz, 3H, 2’’-CH3), 0.82 (s, 3H, 7a’-CH3). 
13C NMR (101 MHz, methanol-d4) δ/ppm = 156.3 (C-1), 139.9 (C-4), 128.7 (C-3, 5), 116.0 (C-
2, 6), 68.0 (C-1’’), 53.8 (C-1’), 51.8 (C-3a’), 45.6 (C-5’), 43.2 (C-7a’), 41.5 (C-7’), 40.4 (C-2’’), 
34.9 (C-2’, 3’, 4’ or 6’), 31.8 (C-2’, 3’, 4’ or 6’), 28.8 (C-2’, 3’, 4’ or 6’), 27.6 (C-2’, 3’, 4’ or 6’), 
17.4 (2’’-CH3), 11.7 (7a’-CH3). 
IR (ATR): ṽ/cm-1 = 3185, 2361, 1612, 1550, 1514, 1346, 1248, 1121, 1002, 813. 
HRMS (EI): m/z calculated for C19H28O2 [M]˙⁺ 288.2084; found 288.2086. 
Purity (HPLC): > 95% (λ = 210 nm), > 95% (λ = 254 nm) (method c).   
  
Experimental Part 
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 (4-((1R,3aS,7aS)-1-((S)-1-Hydroxypropan-2-yl)-7a-methyl-2,3,3a,4,7,7a-hexahydro-1H-
inden-5-yl)but-3-yn-1-ol (171) 
 
C17H26O2 
M = 262.39 g/mol 
Diol 171 was synthesised over two steps. In an oven-dried two-necked Schlenk flask enol 
triflate 172 (260 mg, 0.569 mmol, 1.00 eq) was dissolved in dry THF (5.00 mL) and 3-butyn-1-
ol (173, 53.3 µL, 0.683 mmol, 1.20 eq), TEA (0.198 mL, 1.42 mmol, 2.50 eq) and CuI (21.7 mg, 
0.114 mmol, 20 mol%) were added under N2 counter-flow. After purging of the solution with 
N2, PdCl2(PPh3)2 (40.0 mg, 0.0569 mmol, 10 mol%) was added and the reaction mixture was 
stirred at rt for 1.5 h. Subsequently, the reaction was quenched with sat. aq. NH4Cl (5.00 mL) 
and the aq. phase was extracted with DCM (3 x 10.0 mL). The combined organic layers were 
dried over Na2SO4, filtered and the solvent was removed in vacuo. The crude product 170 was 
purified via a short silica plug and was used without further purification.   
Diol 171 was synthesised according to GP9, using alcohol 170 (0.569 mmol) and the title 
compound was purified via FCC (hexanes/EtOAc 5:5) and isolated as white oily solid (129 mg, 
0.492 mmol, 86% over two steps). 
 
Rf = 0.33 (hexanes/EtOAc 5:5). 
[𝜶]𝑫
𝟐𝟑: + 83.7 (c = 0.04, CHCl3). 
1H NMR (400 MHz, chloroform-d) δ/ppm = 5.95 (dt, J = 5.6, 2.6 Hz, 1H, 6’-H), 3.72 (t, J = 6.2 
Hz, 1H, 1-H), 3.65 (dd, J = 10.5, 3.2 Hz, 1H, 1’’-H), 3.39 (dd, J = 10.5, 6.7 Hz, 1H, 1’’-H), 2.57 
(t, J = 6.2 Hz, 1H, 2-H), 2.26 (ddd, J = 18.2, 5.7, 2.3 Hz, 1H, 7’-H), 2.21 – 2.13 (m, 1H, 4’-H), 
2.05 (d, J = 18.6 Hz, 1H, 7’-H), 1.96 – 1.80 (m, 2H, 4’-H, 2’ or 3’-H), 1.76 – 1.53 (m, 3H, 3a’, 
2’’-H, 2’ or 3’-H), 1.41 – 1.14 (m, 3H, 1’, 2’, 3’-H), 1.04 (d, J = 6.6 Hz, 3H, 2’’-CH3), 0.65 (s, 3H, 
7a’-CH3). 
13C NMR (101 MHz, chloroform-d) δ/ppm = 133.9 (C-6’), 119.9 (C-5’), 84.3 (C-4), 83.6 (C-3), 
68.0 (C-1’’), 61.4 (C-1), 52.3 (C-1’), 45.3 (C-3a’), 42.0 (C-7’), 40.6 (C-7a’), 38.7 (C-2’’), 32.7 
(C-4’), 27.8 (C-2’ or 3’), 26.6 (C-2’ or 3’), 23.9 (C-2), 16.5 (2’’-CH3), 11.4 (7a’-CH3). 
Experimental Part 
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IR (ATR): ṽ/cm-1 = 3347, 2933, 2908, 2876, 1467, 1427, 1370, 1040, 1029, 994, 968, 907, 
853, 813, 731. 
HRMS (EI): m/z calculated for C17H26O2 [M]˙⁺ 262.1927; found 262.1924. 
Purity (HPLC): > 95% (λ = 210 nm), > 95% (λ = 254 nm) (method c).   
  
Experimental Part 
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4-((1R,3aS,7aS)-1-((S)-1-Hydroxypropan-2-yl)-7a-methyloctahydro-1H-inden-5-yl)butan-
1-ol (169) 
 
 
 
 
 
C17H32O2 
M = 268.44 g/mol 
Diol 169 was synthesised via three steps. For SONOGASHIRA cross-coupling enol triflate 172 
(260 mg, 0.569 mmol, 1.00 eq)  was dissolved in dry THF (4.00 mL) and but-3-yn-1-ol (173, 
49.4 mg, 0.683 mmol, 1.20 eq), TEA (0.198 mL, 1.42 mmol, 2.50 eq) and CuI (21.7 mg, 
0.114 mmol, 20 mol%) were added under N2 counterflow. After purging the solution with N2, 
PdCl2(PPh3)2 (40.0 mg, 0.0569 mmol, 10 mol%) was added and the reaction mixture was 
stirred for 1.5 h. The reaction was stopped with sat. aq. NH4Cl (5.00 mL) and the aq. phase 
was extracted with DCM (3 x 10 mL). The combined organic layers were dried over Na2SO4, 
filtered and the solvent was removed in vacuo to give crude alkyne 170. For the following 
hydrogenation, 170 (0.569 mmol) was dissolved in EtOAc (5.00 mL) and AcOH (30.0 µL, 
0.569 mmol, 1.00 eq). The solution was degassed and PtO2 (2.59 mg, 0.0114 mmol, 2.00 
mol%) was added under N2 counterflow. The reaction mixture was stirred at H2 atmosphere 
for 21 h and then filtered through a celite pad and concentrated under reduced pressure. The 
crude intermediate (0.569 mmol) was deprotected according to GP9 and purified via FCC 
(hexanes/EtOAc 6:4) to give diol 169 as colourless oil (32.0 mg, 0.119 mmol, 21% over three 
steps).  
 
Rf = 0.17 (hexanes/EtOAc 6:4). 
[𝜶]𝑫
𝟐𝟑: + 13.6 (c = 0.04, CHCl3). 
1H NMR (400 MHz, chloroform-d) δ/ppm = 3.70 – 3.51 (m, 3H, 1, 1’’-H), 3.36 (dd, J = 10.5, 6.9 
Hz, 1H, 1’’-H), 1.94 – 1.87 (m, 1H, 7’-H), 1.85 – 1.75 (m, 1H, 2’, 3’, 4’ or 6’-H), 1.62 – 1.44 (m, 
7H, 5’, 2’’-H, 2, 3, 4, 2’, 3’, 4’ or 6’-H), 1.40 – 1.13 (m, 9H, 1’, 3a’, 7’-H, 2, 3, 4, 2’, 3’, 4’ or 6’-
H), 1.04 (d, J = 6.6 Hz, 3H, 2’’-CH3), 0.65 (s, 3H, 7a’-CH3). 
13C NMR (101 MHz, chloroform-d) δ/ppm = 68.2 (C-2’’), 63.2 (C-1), 52.4 (C-1’), 50.2 (C-3a’), 
42.6 (C-7a’), 39.9 (C-7’), 39.0 (C-5’), 38.2 (C-2’’), 37.2 (C-2’, 3’, 4’ or 6’), 33.2 (C-2, 3 or 4), 
32.5 (C-2, 3 or 4), 29.2 (C-2’, 3’, 4’ or 6’), 27.8 (C-2’, 3’, 4’ or 6’), 26.7 (C-2’, 3’, 4’ or 6’), 23.4 
(C-2, 3 or 4), 16.9 (2’’-CH3), 11.3 (7a’-CH3). 
Experimental Part 
 
  
 
  
 208 
 
IR (ATR): ṽ/cm-1 = 3726, 3708, 3623, 3599, 2932, 2846, 1218, 1040, 770, 676, 657. 
HRMS (EI): m/z calculated for C17H31O2 [M]˙⁺ 267.2319; found 267.2322. 
Purity (GC): 80% (scan mode m/z 50-650 (EI 70 eV), compound undergoes dehydration 
during the measurement, resulting in 20% dehydrated compound). 
  
Experimental Part 
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6.2.6. Procedures and data for seco-steroids with “broken” ring C (chapter 3.4.) 
(1R,5S)-2-Oxabicyclo[3.2.1]octan-3-one and (1S,5R)-2-Oxabicyclo[3.2.1]octan-3-one 
(180a) 
 
C7H10O2 
M = 126.16 g/mol 
In an oven-dried 100 mL round bottom flask racemic 2-norboranone (3.00 g, 27.3 mmol, 
1.00 eq) was dissolved in DCM (35.0 mL) and m-CPBA (12.2 g, 54.5 mmol, 2.00 eq) was 
added. The reaction mixture was stirred at rt for 24 h. The solution was washed with aq. 2M 
NaOH (50.0 mL) and H2O (50.0 mL), the combined organic layers were dried over Na2SO4, 
filtered and the solvent was removed in vacuo. The title compound was purified via FCC 
(hexanes/EtOAc 8:2) and obtained as a colourless oil (2.77 g, 22.9 mmol, 80%).  
 
Rf = 0.15 (hexanes/EtOAc 8:2). 
1H NMR (500 MHz, chloroform-d) δ/ppm = 4.84 (tt, J = 2.9, 1.4 Hz, 1H, 1-H), 2.70 (ddd,  
J = 18.5, 5.1, 2.2 Hz, 1H, 4-H), 2.56 – 2.49 (m, 1H, 5-H), 2.46 (dt, J = 18.4, 2.0 Hz, 1H, 4-H), 
2.14 (td, J = 9.6, 2.6 Hz, 1H, 6-H), 2.00 – 1.93 (m, 1H, 7-H), 1.93 – 1.84 (m, 2H, 6-H, 8-H), 
1.75 – 1.59 (m, 2H, 7-H, 8-H). 
13C NMR (125 MHz, chloroform-d) δ/ppm = 170.9 (C-3), 81.1 (C-1), 40.8 (C-4), 35.9  
(C-7), 32.6 (C-6), 31.9 (C-5), 29.4 (C-8). 
IR (ATR): ṽ/cm-1 = 2941, 2879, 1729, 1465, 1439, 1374, 1345, 1222, 1195, 1162, 1128, 1068, 
1015, 999, 977, 923, 900, 880, 844, 725, 577, 555. 
HRMS (EI): m/z calculated for C7H11O2 [M]˙⁺ 127.0754; found 127.0754. 
Purity (GC): > 95% (scan mode m/z 50-650 (EI 70 eV)). 
  
Experimental Part 
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(1R,4R,5S)-4-Methyl-2-oxabicyclo[3.2.1]octan-3-one and (1S,4S,5R)-4-Methyl-2-
oxabicyclo[3.2.1]octan-3-one (181a) 
 
C8H12O2 
M = 140.18 g/mol 
Lactone 180a (2.00 g, 15.9 mmol, 1.00 eq) was dissolved in dry THF (15.0 mL), cooled down 
to - 78 °C and LDA (2M in THF/hexane/ethylbenzene, 15.9 mL, 31.7 mmol, 2.00 eq) was slowly 
added. After 1 h CH3I (2.96 mL, 47.6 mmol, 3.00 eq) was added and the mixture was allowed 
to warm up to - 40 °C and stirred for 2 h. The reaction was stopped with aq. sat. NH4Cl 
(10.0 mL), the two layers were separated, and the aq. layer was extracted with Et2O (3 x 
40.0 mL). The combined organic layers were washed with brine (2 x 20.0 mL), dried over 
Na2SO4, filtered and concentrated in vacuo. The crude product was purified via FCC 
(hexanes/EtOAc 5:5) and the methylated lactone 181a was obtained as a colourless oil (1.71 g, 
12.2 mmol, 77 %).  
 
Rf = 0.6 (hexanes/EtOAc 5:5). 
1H NMR (500 MHz, chloroform-d) δ/ppm = 4.81 (ddt, J = 4.3, 2.9, 1.4 Hz, 1H, 1-H), 2.52  
(m, J = 7.5, 1.5 Hz, 1H, 4-H), 2.29 – 2.22 (m, 1H, 5-H), 2.17 – 2.05 (m, 2H, 7-H, 8-H), 2.00 – 
1.83 (m, 2H, 6-H, 7-H), 1.75 – 1.67 (m, 1H, 6-H) 1.56 – 1.47 (m, 1H, 8-H) 1.32 (d, J = 7.5 Hz, 
3H, 4-CH3). 
13C NMR (125 MHz, chloroform-d) δ/ppm = 174.7 (C-3), 80.9 (C-1), 45.6 (C-4), 38.7  
(C-5), 32.4 (C-7), 32.2 (C-8), 29.9 (C-6), 19.3 (4-CH3). 
IR (ATR): ṽ/cm-1 = 2967, 2943, 2877, 1724, 1495, 1377, 1317, 1303, 1282, 1230, 1210, 1195, 
116, 1132, 1093, 1056, 1029, 991, 931, 888, 845, 816, 787, 748, 675, 645, 595. 
HRMS (EI): m/z calculated for C8H13O2 [M]˙⁺ 141.0910; found 141.0911. 
Purity (GC): > 95% (scan mode m/z 50-650 (EI 70 eV)). 
 
  
Experimental Part 
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(1R,3S)-3-((R)-1-Hydroxypropan-2-yl)cyclopentan-1-ol and (1S,3R)-3-((S)-1-
Hydroxypropan-2-yl)cyclopentan-1-ol (182a) 
 
C8H16O2 
  M = 144.21 g/mol 
A solution of lactone 181a (1.20 g, 8.56 mmol, 1.00 eq) in dry THF (5.00 mL) was added to a 
suspension of LiAlH4 (0.357 g, 9.42 mmol, 1.10 eq) in dry THF (50.0 mL) at 0 °C and stirred 
for 1 h. The reaction mixture was stopped with aq. 2M NaOH (10.0 mL) and the aq. phase was 
extracted with Et2O (3 x 50.0 mL). The combined organic layers were dried over Na2SO4, 
filtered and the solvent was removed in vacuo. Purification of the title compound via FCC 
(DCM/MeOH 95:5) yielded diol 182a as a colourless oil (1.06 g, 7.38 mmol, 86%). 
 
Rf = 0.14 (DCM/MeOH 95:5). 
1H NMR (500 MHz, chloroform-d) δ/ppm = 4.31 – 4.19 (m, 1H, 1-H), 3.58 (dd, J = 10.7, 4.9 Hz, 
1H, 1’-H), 3.39 (dd, J = 10.7, 6.7 Hz, 1H, 1’-H), 2.48 (s, 2H, 1’-OH, 1-OH), 2.14 – 2.01  
(m, 1H, 2-H), 1.70 (m, 3H, 3-H, 4-H, 5-H), 1.63 – 1.43 (m, 3H, 2’-H, 4-H, 5-H), 1.27 (m,1H, 2-
H), 0.93 (d, J = 6.7 Hz, 3H, 2’-CH3). 
13C NMR (125 MHz, chloroform-d) δ/ppm = 73.6 (C-1) 67.2 (C-1’), 41.1 (C-2’ or C-3), 41.0 (C-
2’ or C-3), 39.9 (C-2), 35.3 (C-4 or C-5), 28.0 (C-4 or C-5), 15.7 (2’-CH3). 
IR (ATR): ṽ/cm-1 = 2952, 2868, 2857, 2375, 1725, 1710, 1455, 1378, 1348, 1073, 1022, 993, 
961, 810, 736, 661, 649, 615, 592, 578, 555. 
HRMS (EI): m/z calculated for C8H15O2 [M]˙⁺ 143.1067; found: 143.1067. 
Purity (GC): > 95% (scan mode m/z 50-650 (EI 70 eV)). 
  
Experimental Part 
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(1R,3S)-3-((R)-1-((tert-Butyldimethylsilyl)oxy)propan-2-yl)cyclopentan-1-ol and (1S,3R)-
3-((S)-1-((tert-Butyldimethylsilyl)oxy)propan-2-yl)cyclopentan-1-ol (183aa) 
 
C14H30O2Si 
M = 258.48 g/mol 
Alcohol 183aa was synthesised according to GP1, using diol 182a (0.684 g, 4.74 mmol, 
1.00 eq). The title compound was purified via FCC (hexanes/EtOAc 8:2) and isolated the 
desired alchol 183aa as colourless oil (564 mg, 2.18 mmol, 46%) and the double protected diol 
183ba as a side product (Rf = 0.92, hexanes/EtOAc 8:2), 609 mg, 1.63 mmol, 35%). 
 
Rf = 0.41 (hexanes/EtOAc 8:2). 
1H NMR (500 MHz, chloroform-d) δ/ppm = 4.30 – 4.20 (m, 1H, 1-H), 3.55 (dd, J = 9.9, 4.7 Hz, 
1H, 1’-H), 3.39 (dd, J = 9.8, 6.5 Hz, 1H, 1’-H), 2.18 – 2.06 (m, 1H, 5-H), 1.72 (m, 4H, 2-H, 3-H, 
4-H), 1.55 – 1.42 (m, 3H, 2-H, 2’-H, 1-OH), 1.29 – 1.21 (m, 1H, 5-H), 0.91 (d, J = 6.7 Hz, 3H, 
3’-CH3), 0.89 (s, 9H, SiC(CH3)3), 0.03 (s, 6H, Si(CH3)2). 
13C NMR (125 MHz, chloroform-d) δ/ppm = 73.8 (C-1), 67.5 (C-1’), 41.3(C-2’ or C-3), 41.1  
(C-2’ or C-3), 40.6 (C-5), 35.5 (C-2), 27.9 (C-4), 26.1 (SiC(CH3)3), 18.5 (SiC(CH3)3), 15.6  
(3’-CH3), -5.2 (Si(CH3)2). 
IR (ATR): ṽ/cm-1 = 3506, 3461, 3439, 341, 3379, 3354, 2954, 2929, 2889, 2875, 2857, 2359, 
2347, 1471, 1387, 1360, 1252, 1086, 1005, 990, 953, 833, 809, 773, 664. 
HRMS (EI): m/z calculated for C10H19OSi [M-tBu]˙⁺ 183.1200; found 183.1200. 
Purity (GC): 94% (scan mode m/z 50-650 (EI 70 eV)). 
 
  
Experimental Part 
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(S)-3-((R)-1-((tert-Butyldimethylsilyl)oxy)propan-2-yl)cyclopentan-1-one and (R)-3-((S)-
1-((tert-Butyldimethylsilyl)oxy)propan-2-yl)cyclopentan-1-one (177a) 
 
C14H28O2Si 
M = 256.46 g/mol 
Ketone 177a was synthesised according to GP3, using alcohol 183aa (0.510 g, 1.97 mmol, 
1.00 eq). The title compound was purified via FCC (hexanes/EtOAc 9:1) and isolated as a 
colourless oil (447 mg, 1.74 mmol, 88 %).  
 
Rf = 0.40 (hexanes/EtOAc 8:2). 
1H NMR (500 MHz, chloroform-d) δ/ppm = 3.56 – 3.43 (m, 2H, 1’-H), 2.44 – 2.26 (m, 2H, 2-H, 
5-H), 2.20 – 2.01 (m, 3H, 2-H, 4-H), 1.89 (m, 1H, 5-H), 1.59 – 1.47 (m, 2H, 2’-H, 3-H), 0.97 (d, 
J = 6.7 Hz, 3H, 2’-CH3), 0.89 (s, 9H, SiC(CH3)3), 0.03 (s, 6H, Si(CH3)2). 
13C NMR (125 MHz, chloroform-d) δ/ppm = 220.1 (C-1), 67.2 (C-1’), 44.1  (C-5), 41.2 (C-2’), 
40.0 (C-3), 39.0 (C-2), 27.7 (C-4), 26.1 (SiC(CH3)3), 18.4 (SiC(CH3)3), 14.8 (3‘-CH3), -5.3  
(Si(CH3)2). 
IR (ATR): ṽ/cm-1 = 3219, 3185, 2958, 2929, 2883, 2857, 235, 1743, 1471, 1405, 1390, 1361, 
1253, 1161, 1129, 1094, 1079, 1027, 1006, 983, 939, 835, 811, 774, 670, 613. 
HRMS (EI): m/z calculated for C10H19O2Si [M-tBu]˙⁺ 199.1149; found 199.1149. 
Purity (GC): > 95% (scan mode m/z 50-650 (EI 70 eV)). 
  
Experimental Part 
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(S)-6-Bromo-1,2,3,4-tetrahydronaphthalen-2-ol and (R)-6-Bromo-1,2,3,4-
tetrahydronaphthalen-2-ol (184a) 
 
C10H11BrO 
M = 227.10 g/mol 
A solution of 6-bromo-2-tetralone (178, 253 mg, 1.09 mmol, 1.00 eq) in MeOH (10.0 mL) was 
cooled to 0 °C and NaBH4 (62.0 mg, 1.64 mmol, 1.50 eq) was slowly added. After stirring for 
20 min the mixture was allowed to warm up to rt and stirred for further 45 min. The reaction 
was stopped with ice cold water (5.00 mL) and concentrated in vacuo. The  
residue was treated with water (10.0 mL) and extracted with EtOAc (3 x 30.0 mL). The 
combined organic layers were dried over Na2SO4, filtered and the solvent was removed in 
vacuo. The title compound was purified via FCC (hexanes/EtOAc 5:5) and isolated as a 
colourless oil (252 mg, 1.11 mmol, quantitative).  
 
Rf = 0.49 (hexanes/EtOAc 5:5). 
1H NMR (500 MHz, chloroform-d) δ/ppm = 7.25 – 7.21 (m, 2H, 5-H, 7-H), 6.96 – 6.93 (m, 1H, 
8-H), 4.20 – 4.13 (m, 1H, 2-H), 3.02 (dd, J = 16.5, 5.0 Hz, 1H, 1-H), 2.94 (dt, J = 17.2, 6.0 Hz, 
1H, 4-H), 2.87 – 2.74 (m, 1H, 4-H), 2.74 – 2.65 (m, 1H, 1-H), 2.03 (m, 1H, 3-H), 1.86 – 1.75 
(m, 1H, 3-H). 
13C NMR (125 MHz, chloroform-d) δ/ppm = 138.1 (C-4a), 133.3 (C-8a), 131.5 (C-5), 131.3 (C-
8), 129.1 (C-7), 119.7 (C-6), 66.9 (C-2), 37.9 (C-1), 31.2 (C-3), 26.7 (C-4). 
IR (ATR): ṽ/cm-1 = 3018, 2924, 2857, 2355, 1894, 1737, 1590, 156, 1482, 1435, 1404, 1359, 
1328, 1281, 1233, 1179, 1119, 1044, 100, 962, 923, 903, 854, 801, 738, 693. 
HRMS (EI): m/z calculated for C10H11BrO [M]˙⁺ 225.9988; found 225.9988. 
Purity (HPLC): > 95% (λ = 210 nm), > 95% (λ = 250 nm) (method b).   
 
 
 
 
Experimental Part 
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(S)-((6-Bromo-1,2,3,4-tetrahydronaphthalen-2-yl)oxy)(tert-butyl)dimethylsilane and (R)-
((6-Bromo-1,2,3,4-tetrahydronaphthalen-2-yl)oxy)(tert-butyl)dimethylsilane (176a) 
 
 
 
 
 
C16H25BrOSi 
M = 341.36 g/mol 
Bromotetraline derivative 176a was synthesised according to GP1, using alcohol 184a (252 mg, 
1.11 mmol, 1.00 eq). The title compound was purified via FCC (hexanes/EtOAc 9:1) and 
isolated as a colourless oil (248 gm, 0.728 mmol, 66 %).  
 
Rf = 0.9 (hexanes/EtOAc 8:2).  
1H NMR (500 MHz, chloroform-d) δ/ppm = 7.23 – 7.19 (m, 2H, 5-H, 7-H), 6.91 (d, J = 8.0 Hz, 
1H, 8-H), 4.11 – 4.05 (m, 1H, 2-H), 2.95 – 2.87 (m, 2H, 1-H, 4-H), 2.74 (ddd, J = 16.4, 9.2, 5.7 
Hz, 1H, 4-H), 2.67 (dd, J = 16.4, 7.6 Hz, 1H, 1-H), 1.92 (dtdd, J = 13.0, 5.7, 3.1, 1.6 Hz, 1H, 3-
H), 1.76 (dtd, J = 12.8, 9.2, 5.6 Hz, 1H, 3-H), 0.89 (s, 9H, SiC(CH3)3), 0.09 (s, 3H, Si(CH3)2), 
0.08 (s, 3H, Si(CH3)2). 
13C NMR (125 MHz, chloroform-d) δ/ppm = 138.5 (C-4a), 134.2 (C-8a), 131.3 (C-5), 131.1 (C-
8) 128.8 (C-7), 119.4 (C-6), 67.6 (C-2), 38.6 (C-1), 31.8 (C-3), 27.2 (C-4), 26.0 (SiC(CH3)3), 
18.3 (SiC(CH3)3), -4.5 (Si(CH3)2). 
IR (ATR): ṽ/cm-1 = 295, 2929, 891, 2857, 2381, 2358, 2298, 1529, 1484, 1472, 1436, 1406, 
1360, 1252, 1181, 1092, 1018, 983, 931, 880, 835, 810, 775, 738, 672, 649, 560. 
HRMS (EI): m/z calculated for C12H16BrOSi [M]˙⁺ 283.0154; found 283.0150. 
Purity (HPLC): > 95% (λ = 210 nm), > 95% (λ = 254 nm) (method c).    
Experimental Part 
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1-(6-((tert-Butyldimethylsilyl)oxy)-5,6,7,8-tetrahydronaphthalen-2-yl)-3-(1-((tert-
butyldimethylsilyl)oxy)propan-2-yl)cyclopentan-1-ol (175a, mixture of stereoisomers) 
  
      
C30H54O3Si2 
   M = 518.93 g/mol 
Alcohol 175a was synthesised according to GP6, using racemic bromotetraline derivative 176a 
(73.4 mg, 0.215 mmol, 1.10 eq) and racemic mixture of ketone 177a (50.1 mg, 0.195 mmol, 
1.00 eq). The title compound was purified via FCC (hexanes/EtOAc 8:2) and isolated as a 
colourless oil (21.0 mg, 0.0405 mmol, 21 %). 
  
Rf = 0.59 (hexanes/EtOAc 8:2). 
1H NMR (500 MHz, chloroform-d) δ/ppm = 7.21 (q, J = 5.3, 4.6 Hz, 2H, 1’’-H, 3’’-H), 7.10 – 
7.00 (m, 1H, 4’’-H), 4.12 – 4.00 (m, 1H, 6’’-H), 3.58 (ddd, J = 9.9, 8.1, 4.7 Hz, 1H, 1’-H), 3.45 
– 3.35 (m, 1H, 1’-H), 2.95 (dd, J = 16.6, 5.6 Hz, 2H, 5’’-H, 8’’-H), 2.81 (td, J = 11.1, 10.7, 5.0 
Hz, 1H, 8’’-H), 2.73 (dd, J = 16.3, 8.5 Hz, 1H, 5’’-H), 2.33 – 2.18 (m, 1H, 2-H), 2.14 – 2.04 (m, 
1H, 2-H), 2.04 – 1.89 (m, 3H, 3-H, 5-H, 7’’-H,), 1.84 – 1.69 (m, 3H, 4-H, 5-H, 7’’-H), 1.54 (ddt, 
J = 15.2, 12.9, 5.5 Hz, 3H, 3-H, 4-H, 2’-H), 0.96 (d, J = 6.7 Hz, 3H, 2’-CH3), 0.92 – 0.88 (m, 
18H, SiC(CH3)3), 0.10 – 0.03 (m, 12H, Si(CH3)2).  
13C NMR (125 MHz, chloroform-d) δ/ppm = 145.2 (C-2’’), 135.9 (C-8a’’), 133.9 (C-4a’’), 129.3 
(C-4’’), 125.1 (C-1’’), 122.6 (C-3’’), 83.1 (C-1), 68.4 (C-6’’), 67.52(C-1’), 47.1 (C-5), 42.4 (C-3), 
41.4 (C-2’), 40.8 (C-2), 38.9 (C-5’’), 32.5 (C-7’’), 29.6 (C-4), 28.2 (C-8’’), 26.2 (SiC(CH3)3), 26.1 
(SiC(CH3)3), 18.5 (SiC(CH3)3), 18.4 (SiC(CH3)3), -4.5 (Si(CH3)2), -5.2 (Si(CH3)2), 15.6 (2’-CH3). 
IR (ATR): ṽ/cm-1 = 2954, 2928, 2857, 2360, 2341, 2298, 1498, 1471, 1440, 1360, 1252, 1189, 
1087, 1018, 1006, 933, 911, 879, 833, 811, 772, 713, 670. 
HRMS (EI): m/z calculated for C30H53O3Si2 [M]˙⁺ 517.3525; found 517.3525. 
Purity (HPLC): n.d.   
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6-(3-(1-Hydroxypropan-2-yl)cyclopentyl)-1,2,3,4-tetrahydronaphthalen-2-ol (174a, 
mixture of stereoisomers) 
 
       C18H26O2 
   M = 274.40 g/mol 
Alcohol 175a (62.9 mg, 0.121 mmol, 1.00 eq), TES (48.4 µL, 0.303 mmol, 2.50 eq) and TFA 
(0.0500 mL, 0.667 mmol, 5.50 eq) were dissolved in dry DCM (1.00 mL) and stirred at rt for 
2 h. The reaction was stopped with water (5.00 mL), conc. H2SO4 (300 µL) were added and 
the solution was stirred for 1 h. Aq. sat. NaHCO3 solution (3 mL) was added and the aq. layer 
was extracted with DCM (3 x 10.0 mL) and washed with water (2 x 10.0 mL). The organic layer 
was dried over Na2SO4, filtered and the solvent was removed in vacuo. The title compound 
was purified via FCC (hexanes/EtOAc 7:3) and isolated as colourless oil (13.1 mg, 
0.0260 mmol, 22%). 
 
Rf = 0.09 (hexanes/EtOAc 7:3). 
1H NMR (500 MHz, chloroform-d) δ/ppm = 7.00 (dd, J = 4.0, 1.7 Hz, 2H, 7-H, 8-H), 6.96 (d, J 
= 5.1 Hz, 1H, 5-H), 4.15 (dddd, J = 9.1, 8.0, 5.0, 3.1 Hz, 1H, 2-H), 3.66 (ddd, J = 10.6, 4.6, 2.1 
Hz, 1H, 1’’-H), 3.44 (ddd, J = 13.0, 10.5, 7.1 Hz, 1H, 1’’-H), 3.06 (dd, J = 16.3, 4.9 Hz, 1H, 1-
H), 2.97 – 2.90 (m, 1H, 4-H), 2.87 – 2.79 (m, 1H, 4-H), 2.73 (dd, J = 16.1, 7.9 Hz, 1H, 1-H), 
2.18 – 2.00 (m, 3H, 3-H, 2’, 3’, 4’ or 5’-H), 1.99 – 1.77 (m, 4H, 3-H, 2’’-H, 2’, 3’, 4’ or 5’-H), 1.69 
– 1.44 (m, 4H, 1’-H, 2’, 3’, 4’or 5’-H), 1.00 (dd, J = 6.7, 3.6 HzF, 3H, 2’’-CH3). 
13C NMR (125 MHz, chloroform-d) δ/ppm = 144.9 (C-6), 135.5 (C-8a), 131.8 (C-4a), 129.6 (C-
8), 127.2 (C-5), 124.8 (C-7), 67.7 (C-1’’), 67.5 (C-2), 45.6 (C-3’), 42.8 (C-2’’), 41.5 (C-1’), 
41.37(C-2‘, C-4‘ or C-5‘), 38.2 (C-1), 33.19 (C-2‘, C-4‘ or C-5‘) 31.7 (C-3), 29.47 (C-2‘, C-4‘ or 
C-5‘), 27.24 (C-4), 15.47 (2’’-CH3). 
IR (ATR): ṽ/cm-1 = 2930, 291, 2871, 2360, 2348, 2296, 174, 1698, 1610, 1502, 1456, 1365, 
1230, 1160, 1128, 1047, 1025, 950, 879, 813, 679, 649, 616. 
HRMS (EI): m/z calculated for C18H26O2 [M]˙⁺ 274,1927; found 274,1926. 
Purity (HPLC): n.d.   
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6.3. Crystallographic data 
Table 10. Crystallographic information of 35a. 
 
Compound 35a 
net formula C19H38O2Si 
Mr/g mol−1 326.58 
crystal size/mm 0.100 × 0.040 × 0.030 
T/K 173.(2) 
radiation MoKα 
diffractometer 'Bruker D8Quest' 
crystal system triclinic 
space group 'P 1' 
a/Å 7.4415(4) 
b/Å 15.6254(10) 
c/Å 19.5018(12) 
α/° 105.466(2) 
β/° 100.025(2) 
γ/° 101.490(2) 
V/Å3 2078.8(2) 
Z 4 
calc. density/g cm−3 1.043 
μ/mm−1 0.119 
absorption correction Multi-Scan 
transmission factor range 0.85–1.00 
refls. measured 7525 
Rint 0.0897 
mean σ(I)/I 0.0778 
θ range 3.158–25.342 
observed refls. 5721 
x, y (weighting scheme) 0.0925, 3.5506 
hydrogen refinement constr 
Flack parameter 0.0(2) 
refls in refinement 7525 
parameters 804 
restraints 81 
R(Fobs) 0.1036 
Rw(F2) 0.2547 
S 1.089 
shift/errormax 0.001 
max electron density/e Å−3 0.921 
min electron density/e Å−3 −0.644 
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Table 11. Crystallographic information of 163b. 
 
Compound 163b 
net formula C19H28O2 
Mr/g mol−1 288.41 
crystal size/mm 0.100 × 0.090 × 0.030 
T/K 102.(2) 
radiation MoKα 
diffractometer 'Bruker D8 Venture TXS' 
crystal system orthorhombic 
space group 'P 21 21 21' 
a/Å 6.2460(2) 
b/Å 10.2989(3) 
c/Å 26.0457(8) 
α/° 90 
β/° 90 
γ/° 90 
V/Å3 1675.44(9) 
Z 4 
calc. density/g cm−3 1.143 
μ/mm−1 0.072 
absorption correction Multi-Scan 
transmission factor range 0.97–1.00 
refls. measured 30409 
Rint 0.0308 
mean σ(I)/I 0.0191 
θ range 3.069–28.270 
observed refls. 3980 
x, y (weighting scheme) 0.0483, 0.2941 
hydrogen refinement H(C) constr, H(O) refall 
Flack parameter −0.1(3) 
refls in refinement 4144 
parameters 200 
restraints 0 
R(Fobs) 0.0351 
Rw(F2) 0.0917 
S 1.095 
shift/errormax 0.001 
max electron density/e Å−3 0.241 
min electron density/e Å−3 −0.152 
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6.4. Procedures for biological testing 
The agar diffusion assay as well as the MTT assay were performed by MARTINA STADLER. The 
cholesterol biosynthesis assay was performed by DR. CHRISTOPH MÜLLER.  
6.4.1. Agar diffusion assay 
The test compounds were dissolved in DMSO to receive a 1% (w/v) solution. In each case, 
3.00 µL were applied onto filter plates (d = 6.0 mm, dried for 24 h) from Macherey-Nagel 
(Düren, Germany), which correspond to 30.0 µg substance per filter plates. As reference 
substances, the antimycotic clotrimazole and antibiotic tetracycline (1% (w/v) solution in 
DMSO, 3.00 µL ≙ 30.0 µg onto filter plates). For the blank values, 3.00 µL DMSO was applied 
onto the filter plates. 
The fungi and bacteria were purchased from the German Collection of Microorganisms and 
Cell Cultures GmbH (DMSZ) in Braunschweig and cultivated according to the supplied 
procedures. As culture medium for Escherichia coli, Pseudomonas marginalis and Yarrowia 
lipolytica All Culture Agar (AC agar) from Sigma-Aldrich was used, whereby AC agar (35.2 g) 
and agar (20.0 g) were suspended in water (1.00 L). For Saccharomyces cerevisiae AC agar 
(35.2 g) was suspended in water (1.00 L). For Streptococcus entericus and Straphylococcus 
equorum casein peptone (10.0 g), yeast extract (5.00 g), glucose (5.00 g) and NaCl (5.00 g) 
were suspended in water (1.00 L). All culture media were autoclaved, and 15 mL of the still 
warm and fluid agar were filled in petri dishes and for at least 1 h at 8 °C cooled. The petrified 
agar plates were coated with a cotton swab, soaked with the fluid culture of the respective 
germ. Four substance filter plates, as well as filter plates with the blank value and the reference 
were setted on the agar plates. The prepared agar plates were incubated 36 h at 32 °C for 
bacteria and 28 °C for fungi, respectively. The diametres of the inhibition zones were measured 
manually.  
6.4.2. MTT assay 
The MTT assay was performed using human leukemia cell line HL-60, whereby the cell count 
per mL was adjusted to 9 x 105 cells. The cell density of the culture was determined using a 
Fuchs-Rosenthal hemocytometer. The suspension was diluted with medium to receive the 
required cell density. 
The test compounds were dissolved in DMSO to receive a 10 mM solution, which was diluted 
at least six times in a ratio of 1:2. As control DMSO was used and for the control cells pure 
medium. Triton X-100 was used as positive control with a concentration of 1.00 µg/mL. 
For the MTT solution, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide (185, 
5.00 mg) was dissolved in PBS (1.00 mL). 
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In a 96-well plate, the cell suspension (99.0 µL) was filled in each well and incubated for 24 h 
at 37 °C with 5% CO2. Subsequently, the test solutions (1.00 µL) were added to the well plate 
and incubated for additional 24 h at 37 °C with 5% CO2. MTT solution (10.0 µL) was added to 
each well, incubated for 2 h and DMSO (190 µL) was added in each well. After 1 h with 
occasional shaking, the absorption of the 96-well plate was measured photometricly at a 
wavelength of 570 nm (reference wavelength 630 nm), using an MRX microplate reader 
(DYNEX Technologies, Chantilly, USA). The analysis, as well as the calculations of the IC50 
values were perfomed using Prism 4 (GraphPad, La Jolla, USA).  
6.4.3. Cholesterol biosynthesis assay 
An assay developed in our group by GIERA et al. was used.[130] The test compounds were 
tested in final assay concentrations of 1 µM and 50 µM.  
For this assay, human leukemia cell line HL-60 is used, whereby 1 x 106 cells are transferred 
into a 24-well plate and filled up with a lipid and cholesterol free RPMI 1640 medium (PAN 
Biotech GmbH, Aidenbach, Germany), which contains 10% fetal bovine serum, to a volume of 
990 µL. The appropriate test compound solutions (10.0 µL), as well as the negative control 
ethanol (10.0 µL), were added. The plate was shaked gently for 30 sec and incubated for 24 h 
at 37 °C with 5% CO2.  
The content of the wells was transferred into 2 mL tubes and every well was rinsed with 750 µL 
PBS. After centrifugation (540 x g, 5 min) the supernatant was separated, and the residue was 
washed with PBS (1.00 mL). Under inert atmosphere 1M NaOH (1.00 mL) was added, vortexed 
and transferred into a 5 mL glass vial and heated for 1 h at 70 °C. After cooling to rt, 50 µL of 
the internal standard cholestane (10 µg/mL in TBME) and TBME (700 µL) were added. The 
samples were vortexed for 1 min and centrifugated (9200 x g, 5 min). Phases were separated 
and the procedure was repeated once. The combined organic layers were transferred into a 2 
mL tube, containing Na2SO4 and PSA (7:1, 40 mg) and vortexed for 30 sec. After centrifugation 
(9200 x g, 5 min), 1 mL of the supernatant was transferred into a 1.5 mL brown glass vial and 
dried. The residue was dissolved in TBME (950 µL), 2,2,2-trifluoro-N-methyl-N-
(trimethylsilyl)acetamide (MSTFA containing 10% TSIM, 50 µL) was added and incubated for 
30 min at rt. These samples were analysed via GC/MS.   
For GC/MS analysis, characteristic sterols were identified with the measured chromatograms 
and the inhibited enzymes with the evidence of one or several characteristic sterols. The 
evaluation of the chromatograms is performed by comparison of the AUCs (area under the 
curve) for the certain sterol. 
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1. Introduction 
Sigmatropic rearrangements are a popular tool for the formation of new σ-bonds in synthetic 
chemistry.[134-136] WOODWARD and HOFFMANN explained that the [i,j] sigmatropic rearrangement 
is thermally allowed, if 1 > i,j and i+j = 4n+2.[137] In this chapter, we focused on the [3,3] 
sigmatropic rearrangement, whose mechanistic process is depicted in Scheme 115.  
 
Scheme 115. General example of a [i,j] sigmatropic rearrangement with i = j = 3. The new and the old bond is 
marked in pink. 
1.1. Sigmatropic rearrangement of N-allylhydrazones 
Besides famous sigmatropic rearrangements like the CLAISEN-HURD rearrangement[138-139] or 
COPE rearrangement[140], N-allylhydrazones can also undergo a [3,3] sigmatropic 
rearrangement. Hereby the driving force is the formation of N2. In 1973, STEVENS et al. 
published the first successful rearrangement of N-allylhydrazones (A, Scheme 116).[141] Under 
drastic thermal induction mono-alkylated diazene B decompose with subsequent [3,3] 
sigmatropic rearrangement resulting in N2 release to the appropriate olefin (C, Scheme 116). 
 
Scheme 116. [3,3] Sigmatropic rearrangement of N-allylhydrazone A under thermal conditions. 
Nevertheless, due to very harsh reaction conditions, e.g. 300 °C reaction temperature, and low 
yields, this reaction was limited in its applicability. In 2008, MUNDAL et al. published the CuCl2-
catalysed rearrangement of N-Boc-N-allylhydrazones, whereby the Boc-protection entails 
higher stability of the starting material, resulting in ease of handling during purification process 
and storage of the compound.[142] Scheme 117 depicts the rearrangement of N-Boc-N-
allylhydrazone 187 mediated by CuCl2 and i-Pr2EtN.  
 
Scheme 117: CuCl2 catalysed rearrangement of N-Boc-N-allylhydrazone 187. 
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Besides a C-C bond formation, a C-Cl bond is formed, which means, that this reaction is a 
tandem reaction. The desired rearranged product 188 was obtained in 73% yield. With this 
method, several variations of the allylic tail could be synthesised.[142] Since the stereoselective 
elimination of the chlorine atom was very slow and the resulting alkenes were formed in low 
yields, one year later, MUNDAL et al. reported a one-pot method using NBS and DBU, which 
results in the desired diene 190 with a good yield of 68% (Scheme 118).[143]  
 
Scheme 118. Rearrangement of N-allylhydrazone 189 using NBS and DBU results in the diene 190. 
With both methods, the fundamental work for the development of the traceless bond 
construction, a method, which does not result in the chlorinated product or diene, were made.  
1.2. Traceless bond construction in STEVENS-type rearrangements and its mechanism 
In 2010, THOMSON and co-workers published the traceless bond construction (TBC), a [3,3] 
sigmatropic rearrangement of N-Boc-N-allylhydrazones using catalytic amounts of the 
Brønsted superacid triflimide (HNTf2).[144] With the usage of triflimide, the reaction temperature 
of the rearrangement could be lowered to 125 °C. During the rearrangement only gaseous side 
products are formed (N2 from the hydrazine group and CO2 and 2-methylprop-1-ene from the 
Boc deprotection), which makes the reaction traceless. In Scheme 119 the synthesised 
products are summarised.[144] With N-Boc-N-allylhydrazine precursor A, various 1,2-
disubstituted olefins and one 1,1-disubstituted olefin could be synthesised in 49 – 75%. 
 
Scheme 119. TBC published by THOMSON and co-workers, starting with condensation of N-Boc-N-allylhydrazine A 
and an aldehyde (marked in blue). The formed N-Boc-N-allylhydrazone B undergoes [3,3] sigmatropic 
rearrangement in the presence of HNTf2 to the appropriate olefin. The elimination products are marked in pink.[144] 
MUNDAL et al. also proposed a potential mechanism of the TBC, which is illustrated in Scheme 
120. While path A starts with Boc cleavage, followed by the triflimide catalysed rearrangement 
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of the N-allylhydrazone, the initial step of path B is the rearrangement with subsequent Boc 
cleavage.  
 
Scheme 120. Proposed mechanism of TBC. Path A shows Boc cleavage with subsequent [3,3] sigmatropic 
rearrangement. Path B shows [3,3] sigmatropic rearrangement followed by Boc cleavage (cf. [144]). 
1.3. Development of novel N-Boc-N-allylhydrazine precursors 
SEBASTIAN DITTRICH from our research group extended the scope of the TBC, developing novel 
N-Boc-N-allylhydrazine precursors (Scheme 121).[145] With precursor 191 bearing an i-Pr 
group in 1-position, 1,1-disubstituted olefins (E) with a terminal methylene could now be 
obtained.[146] This methylene branched end can be found in sidechains of steroidal natural 
product, for example episterol. Another precursor is allylhydrazine 192, which results in 
terminal vinylsilanes (G) via TBC.[147]  
 
Scheme 121. N-Boc-N-allylhydrazine precursors designed and synthesised by DITTRICH.[145-147] 
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The main focus of this thesis was to explore the scope and limitations of rearrangements with 
precursor N-Boc-N-allylhydrazine 193, which was designed and synthesised by DITTRICH as 
well. With the two geminal methyl groups in α-position to the hydrazine moiety, an isoprenyl 
group can be introduced to the appropriate aldehyde using TBC, resulting in olefins of type I. 
This novel precursor comes with several benefits. In previous studies of DITTRICH, undesired 
subsequent acid-catalysed isomerisation of the formed double bonds could be observed, 
which can lead to isomeric mixtures of alkenes.[146, 148] In this case, the desired trisubstituted 
olefin should be already the thermodynamically most stable isomer. Moreover, with the 
presence of the two geminal methyl groups, no E/Z isomers can be formed and additionally, 
the methyl groups may facilitate the TBC, because of the so-called gem-dimethyl effect 
(THORPE-INGOLD effect).[149-150]  
All results regarding to the novel precursor 193a in DITTRICH’S dissertation and my master 
thesis as well as the following studies were published in 2020.[2] Scheme 122 shows the 
synthesis of N-Boc-N-allylhydrazine 193. Route A was previously performed by DITTRICH in his 
dissertation, starting with commercially available silyl enol ether 195, which was activated with 
LiOTf and TBAF to form the appropriate lithium enolate. The addition of 195 to mixed 
azodicarboxylate 194 did not proceed regioselectively and resulted in an inseparable mixture 
of aldehydes 197a and 197b as an equimolar mixture. NMR spectroscopy showed only one 
set of signals and only after the final step, the Troc deprotection, the ratio could be determined. 
Consequently, the ratios for the aldehydes 197a/197b and olefins 198a/198b were only 
determined retrospectively. Olefins 198a and 198b were formed via methylenation of the 
formyl group using TEBBE reagent, and subsequent Troc deprotection gave N-Boc-N-
allylhydrazines 193a and 193b in 50:50 ratio. After this step, both isomers could be 
distinguished via 1H NMR spectroscopy, but still could not be separated on a preparative scale.  
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Scheme 122. Synthesis of N-Boc-N-allylhydrazine 193a and its regioisomer 193b. Route A (performed by DITTRICH) 
gave an isomeric ratio of 50:50 and route B an isomeric ratio of 91:9. 
During my master thesis on “Triflimide-catalysed [3,3]-sigmatropic rearrangement of novel N-
Boc-N-allylhydrazones” a new route to the desired N-Boc-N-allylhydrazine was found, whereby 
the regioisomeric mixture could be improved to 91:9 (route B).[151] Starting with an 
organocatalysed reaction between azodicarboxylate 194 and isobutyraldehyde 196, different 
catalysts were tested, whereby L-proline gave an isomeric ratio of 83:17 and (S)-5-(pyrrolidine-
2-yl)-1H-tetrazole (199), a catalyst developed by LEY and co-workers,[152] a ratio of 91:9. The 
following steps were performed as described by DITTRICH.[145] 
The structure of the desired N-Boc-N-allylhydrazine 193a was confirmed by X-ray 
crystallography (Figure 23).  
 
Figure 23. Mercury depiction of the structure of N-Boc-N-allylhydrazine 193a in the crystalline state. 
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The isomeric mixture (91:1) of N-Boc-N-allylhydrazine 193a and its regioisomer 193b, was 
used without further purification, since only isomer 193a undergoes the following condensation 
with the appropriate aldehydes, providing the corresponding N-Boc-N-allylhydrazones H 
(Scheme 121). Regioisomer 193b remains unreacted and is separated via FCC after 
condensation.  
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2. Objective 
Besides the improvement of the synthesis of precursor 193a which was developed during my 
master thesis (see chapter 1.3.), three N-Boc-N-allylhydrazones were synthesised and their 
rearrangement was studied.[151] Scheme 123 depicts the N-Boc-N-allylhydrazones which were 
synthesised in DITTRICH’S dissertation[145] and in my master thesis[151]. 
 
Scheme 123. N-Boc-N-allylhydrazones 200-203. Allyhydrazone 200 was synthesised during the dissertation of Dr. 
SEBASTIAN DITTRICH. Allylhydrazones 201, 202 and 203 were synthesised (with improved building block mixture 
193a/193b) during my master thesis. The yields refer to the content of 193a in the applied hydrazines 193a/193b 
mixture. 
The first allylhydrazone was 200 bearing a cyclohexyl methylene residue.[145] The other three 
allylhydrazones are 201 with an aliphatic chain, 202 with a benzylbromide residue and 203 
containing a phenyl propylene residue.  
The following rearrangement was performed using the standard conditions of MUNDAL et al., 
HNTf2 in diglyme at 125 °C. The results are shown in Scheme 124.  
 
Scheme 124. Results of the rearrangement of N-Boc-N-allylhydrazones 200-203 using the conditions of THOMSON 
(HNTf2, diglyme, 125 °C)[144]. Olefin 206 could not be obtained via this method.  
Allyhydrazone 200 underwent rearrangement and olefin 204 was with a yield of 38%. In my 
master thesis olefins 205 and 207 could be prepared using TBC and were isolated in 20% and 
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19%, respectively. Olefin 206, bearing an aromatic residue directly attached to the 
allylhydrazine, did not undergo the rearrangement.  
During this dissertation, the aim of this project was to synthesise further N-Boc-N-
allylhydrazones based on N-Boc-N-allylhydrazine 193a, to study the scope and the limitations 
using TBC.   
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3. Results and Discussion 
In this chapter the syntheses of various N-Boc-N-allylhydrazones based on precursor 193a are 
shown, as well as the attempts of their rearrangement.[2]  
3.1. Synthesis of further N-Boc-N-allylhydrazones and their rearrangement 
With the isomeric mixture of building blocks 193a/193b (ratio 91:1), further N-Boc-N-
allylhydrazones were synthesised via condensation between the desired regioisomer 193a and 
the appropriate aldehyde, whereby undesired isomer 193b remained unreacted. Scheme 125 
depicts all synthesised N-Boc-N-allylhydrazones. The grey marked allylhydrazones were 
synthesised in previous theses (see chapter 2.).[145, 151]   
 
Scheme 125. Synthesised N-Boc-N-allylhydrazones based on isomeric mixture of building block 193a, 
contaminated with 193b (ratio 91:9). The yields refer to starting material 193a. The grey marked allylhydrazones 
were synthesised in a previous dissertation[145] or master thesis[151].  
All in all, 17 N-allylhydrazones were successfully synthesised using the new hydrazine 
precursor 193a. The first column shows, inter alia, aliphatic residues like aliphatic chains (201, 
208, 209, 210) or cycloaliphatic residues like cyclopentyl (212) and cyclohexyl (200), whereby 
the latter was already synthesised by DITTRICH with a yield of 38%. The synthesis of 200 was 
repeated and the allylhydrazone was isolated with 34% yield. The introduction of an ester 
group to 193a resulted in ester 211 with 42% yield. Although THOMSON explained the 
introduction of the Boc group results in a higher stability of the N-Boc-N-allylhydrazones, a 
  Results and Discussion 
 
 
  
 232 
 
slow decomposition on the column was observed, which explains the moderate yields of 33 – 
48%. The second column of Scheme 125 shows (hetero)aromatic residues. Allylhydrazones 
213-216 contain benzylidene residues with distinction of the substituent in para position: 
electron withdrawing groups (nitro, bromine (weak)) as well as electron donating groups 
(methoxy, dimethylamino) should reveal if the substituents influence the rearrangement. 
Heteroaromatic residues like thiophene (217) and pyridine (218) were incorporated as well. 
Except benzylidene allylhydrazone 213, the yields were higher than those obtained for aliphatic 
residues (52 – 95%). This can be explained by the conjugation of the allylhydrazine moiety and 
the aromatic residues. The third column shows, inter alia, the 3-phenyl propylidene residue, 
which was already synthesised in the master thesis. In addition, the unsaturated form 219 
derived from cinnamaldehyde was synthesised in a good yield of 64%. The allylhydrazone 
bearing a cyclohexene residue (220) was synthesised in 51% yield.  
3.2. Optimisation reactions for the rearrangement of N-Boc-N-allylhydrazones based 
on the novel N-Boc-N-allylhydrazine precursor 193a 
Before studying the scope of the rearrangement of the further synthesised N-Boc-N-
allylhydrazones, we identified the optimum reaction conditions for the rearrangement. On the 
model compound 200, test reactions (0.050 mmol scale) were carried out, with change of the 
catalyst, solvent, time and reaction temperature using an internal standard (cholestane). With 
the usage of a measured standard curve, the outcomes of the test reactions could be 
compared to each other by GC/MS analysis. Table 12 shows all reaction conditions and the 
results.  
Table 12. Optimisation of reaction conditions for the rearrangement of 200. 
 
entryc solvent catalyst (10 mol %) T [°C] t [min] yield (204) [%]b 
1 diglyme HNTf2 23 15 1 
2 diglyme HNTf2 23 45 1 
3 diglyme HNTf2 23 75 1 
4 diglyme HNTf2 50 15 1 
5 diglyme HNTf2 50 45 2 
6 diglyme HNTf2 50 75 1 
7 diglyme HNTf2 75 15 8 
8 diglyme HNTf2 75 45 11 
9 diglyme HNTf2 75 75 11 
10 diglyme HNTf2 100 15 16 
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11 diglyme HNTf2 100 45 19 
12 diglyme HNTf2 100 75 20 
13 diglyme HNTf2 125 15 26 
14 diglyme HNTf2 125 45 28 
15 diglyme HNTf2 125 75 31 
16 diglyme HNTf2 125 15 20 
17 diglyme HNTf2 125 45 21 
18 diglyme HNTf2 125 75 23 
19 THF HNTf2 70 15 2 
20 THF HNTf2 70 45 3 
21 THF HNTf2 70 75 5 
22 diglyme TfOH 125 15 17 
23 diglyme TfOH 125 45 17 
24 diglyme TfOH 125 75 20 
25 THF TfOH 70 15 1 
26 THF TfOH 70 45 1 
27 THF TfOH 70 75 2 
28 diglyme TFA 125 15 1 
29 diglyme TFA 125 45 1 
30 diglyme TFA 125 75 1 
31 THF TFA 70 15 1 
32 THF TFA 70 45 1 
33 THF TFA 70 75 1 
      
First, the optimum reaction temperature was analysed (entries 1 – 15). Reactions were 
performed at 23, 50, 75, 100 and 125 °C, whereby after 15, 45 and 75 min an aliquot was 
taken out and analysed by GC/MS. A conversion could not be observed at 23 and 50 °C, 
respectively. When raising the temperature to 75 °C a rearrangement could now be observed, 
resulting in 11% yield. The yield could be further increased at 100 °C, but the best yield was 
obtained when using the standard conditions of Mundal et al. with 125 °C for 75 min (marked 
in yellow). Furthermore, besides diglyme as solvent, THF was used as a more common 
alternative and other acidic catalysts like TFA and TfOH were used (entries 16 – 33). These 
reactions were measured on another day with another calibration curve. Therefore, the 
reaction using triflimide in diglyme at 125 °C was again measured (entries 16 – 18). No 
conversion was observed in THF (entries 19 – 21). The reactions were only heated to 70 °C, 
since the boiling point of THF is 66 °C. Therefore, another reason for the failure of this reaction 
could be, that the temperature was too low, since a reaction in diglyme was only observed at 
a temperature of 75 °C or higher. Looking at the catalysts, no reaction could be observed when 
using TFA, neither in diglyme (entries 28 – 30) nor in THF (entries 31 – 33). The use of TfOH 
in THF also showed no rearrangement, but a reaction could be observed using TfOH in diglyme 
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(entries 22 – 24). After 75 min at 125 °C, 204 could be detected with 20% yield (marked in 
pink). The use of TfOH instead of triflimide could be a good alternative, due to the laborious 
handling of triflimide, since it decomposes immediately at air. Nevertheless, the best reaction 
conditions were again the use of triflimide in diglyme at 125 °C (marked in blue). The 
differences in the yields of entries 15 and 18 can be explained by limited reproducibility on a 
small scale. As in every chemical reaction the results are not perfectly reproducible and 
especially in this case as the extremely dry conditions required for triflimide are an error factor. 
In addition, it is crucial that the reaction mixture is immediately heated in a pre-heated oil bath, 
whereby this step influence the reproducibility. Therefore, an error of 10% yield must be 
expected for this reaction.  
The rearrangements described above were performed exclusively with BRØNSTED acids. 
Therefore, another attempt was the use of a LEWIS acid. The reaction was performed in a 
0.5 mmol scale using AlCl3 in diglyme at 125 °C. No conversion could be monitored by TLC. 
Instead, after 2 h, Boc deprotected allylhydrazone was observed by GC/MS analysis, which is 
in accordance to a publication of BOSE and LAKSHMINARAYANA, in which the N-Boc removal 
using AlCl3 was presented.[153] 
In conclusion, it could be shown, that the conditions of MUNDAL et al. are best suited for the 
rearrangement of N-Boc-N-allylhydrazones based on novel N-Boc-N-allylhydrazine precursor 
193a.   
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3.3. [3,3] Sigmatropic rearrangement of the N-Boc-N-allylhydrazones 
After determination of the optimum reaction conditions, the rearrangement of the further 
synthesised N-Boc-N-allylhydrazones, which were discussed in chapter 3.1., were performed. 
Scheme 126 shows the results of the triflimide catalysed rearrangements.   
 
Scheme 126. Triflimide catalysed [3,3] sigmatropic rearrangement of all N-Boc-N-allylhydrazones based on novel 
precursor 193a. The grey marked allylhydrazones were synthesised in a previous dissertation[145] or master 
thesis[151]. 
The allylhydrazones bearing an aliphatic residue underwent the rearrangement (first column). 
Besides 205, which was synthesised already in the master thesis, olefins 221, 222 and 223 
could be synthesised. Olefins 221 and 222 were isolated in 20% and 21% yield, respectively. 
Olefin 223 could only be detected by GC/MS but could not be isolated. A possible reason can 
be the low boiling point of the product. Ester 224 could not be obtained via this rearrangement. 
Only Boc-deprotected allylhydrazone was observed in this experiment. Besides 204, which 
was synthesised by DITTRICH, olefin 225, bearing a cyclopentyl residue was isolated in 20% 
yield. The second column of Scheme 126 shows the (hetero)aromatic residues. Unfortunately, 
none of these olefins could be obtained via this rearrangement. With the aid of the observations 
of the results in column 1, it can be derived which N-Boc-N-allylhydrazones will undergo this 
rearrangement and will not. Non-conjugated allylhydrazones like the ones bearing an aliphatic 
residue, undergo the rearrangement, while attempted rearrangements using conjugated 
allylhydrazones do not result in the appropriate olefins (column 2). This assumption could be 
confirmed with the rearrangement of allylhydrazones 203 and 219. While the saturated form 
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203 did undergo the rearrangement with 19% yield, in case of the unsaturated version 219 the 
rearrangement did not take place and only Boc-deprotected allylhydrazone was obtained. Also, 
allylhydrazone 220 bearing a cyclohexenyl residue did not undergo the rearrangement, since 
the double bond is in conjugated position to the hydrazine moiety and therefore, 233 could not 
be isolated.   
All in all, it could be shown that with the novel precursors only non-conjugated residues 
undergo the TBC. In case of 213 and 202, a crystalline solid was obtained besides the Boc-
deprotected allylhydrazones 234a and 235a, respectively. This crystalline solid was identified 
as the bishydrazones 234b and 235b (Scheme 127).     
 
Scheme 127. Rearrangement of N-Boc-N-allylhydrazone 213 and 202 resulting in Boc-deprotected allylhydrazones 
234a and 235a and bishydrazones 234b and 235b, respectively. 
Scheme 128 shows a proposed mechanism for the formation of the bishydrazones 234b and 
235b by the example of allyhydrazone 202. In the presence of triflimide, Boc-cleavage of 202 
takes place, which is unfortunately inevitable. The Boc deprotected allylhydrazone 235a was 
identified by GC/MS and NMR analysis. Hydrazine 239 is formed via elimination of isoprene 
237 of 235a. This step could only be confirmed by the GC/MS identification of hydrazine 239. 
In the second part, nucleophile hydrazine 239 attacks allylhydrazone 202 and intermediate 240 
is formed. By elimination of hydrazine precursor 193a, 235b is formed via 240. Bishydrazone 
235b was identified by GC/MS and NMR analysis. Since only 235a and 235b could be isolated 
and identified via NMR, the real mechanism is not clear.  
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Scheme 128. Proposed mechanism of the formation of bishydrazones 234b and 235b by the example of 
allyhydrazone 202. 
Furthermore, we identified, that the presence of the Boc group in the non-conjugated N-Boc-
N-allylhydrazones is crucial for the rearrangement. During the rearrangements always Boc-
deprotected allylhydrazone could be observed. But the Boc-deprotected allylhydrazones do 
not undergo the desired rearrangement. Thus, it can be shown, that the proposed mechanism 
of MUNDAL et al. follows path B, in the case of our rearrangements with precursor 193a. 
3.4. Traceless isoprenylation of aldehydes via N-CO2Et-N-allylhydrazones  
Due to very low yields as well as the limitation in the residues (only non-conjugated N-Boc-N-
allylhydrazones), another protecting group was explored as an alternative to the N-Boc group. 
Moreover, a premature acidic deprotection should be prevented with the new protecting group. 
To maintain a traceless rearrangement, only carbamates were worth considering. Ethoxy 
carbonyl was a promising protecting group. Therefore, the synthesis of the desired N-CO2Et-
N-allylhydrazine precursor 243 was performed following a synthetic protocol closely related to 
the one developed for the N-Boc analogue described above.  
3.4.1. Synthesis of N-CO2Et-N-allylhydrazine precursor 243 
The first two steps were the synthesis of azodicarboxylate 246, which was synthesised 
according to literature (Scheme 129).[154] 
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Scheme 129. Synthesis of diazene 246 bearing and ethoxycarbamate and Troc residue. 
The formation of hydrazine 245 from ethyl carbazate (244) in the presence of N-methyl 
morpholine (NMM) proceeded in quantitative yield. The following oxidation using NBS and 
pyridine gave diazene 246 in 92% yield. The next step was the introduction of an aldehyde 
function under organocatalysis (Scheme 130). The inseparable mixture of aldehydes 247 
(85:15) was obtained with a moderate yield of 43%. The ratio was determined retrospectively, 
since in this and the following step NMR spectroscopy showed only one set of signals.  
 
Scheme 130. Synthesis of aldehyde 247 via organocatalysis. *Ratio determined retrospectively from 1H NMR of 
249. 
In the synthesis of previous N-Boc-N-allyhydrazine precursor 193a a catalyst designed by 
AUREGGI et al. was used ((S)-5-(pyrrolidin-2-yl)-1H-tetrazole),[152] which gave a slightly better 
regioisomeric ratio of 91:9 of 193a and 193b. But because this catalyst is really expensive, we 
decided to use L-proline as the catalyst of choice in this step.  
Olefination of the aldehyde function was performed using TEBBE reagent. Scheme 131 depicts 
this methylenation. The inseparable mixture of olefins 248 was isolated with a poor yield of 
18%. The regioisomeric mixture of 85:15 was again determined retrospectively, since NMR 
spectra showed only one set of signals at this stage.  
 
Scheme 131. Methylenation of the aldehyde function of 247 using TEBBE reagent. *Ratio determined retrospectively 
from 1H NMR of 243. 
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The last step was Troc deprotection under standard reductive conditions (Scheme 132). The 
desired N-CO2Et-N-allylhydrazine precursor 243a was isolated as inseparable mixture with its 
regioisomer 243b. Nevertheless, the ratio could now be determined via 1H NMR spectroscopy.  
 
Scheme 132. Reductive Troc deprotection resulting in the desired N-CO2Et-N-allylhydrazine precursor 243a and 
its regioisomer 243b in an isomeric ratio of 85:15. **Ratio determined (*retrospectively) via 1H NMR. 
The mixture was used without further purification since the following condensation with an 
aldehyde only occurs with hydrazine 243a and regioisomer 243b will remain unreacted.  
3.4.2. Synthesis of two model N-CO2Et-N-allylhydrazones  
Two N-CO2Et-N-allylhydrazones were synthesised via condensation of cyclohexane-
carbaldehyde and benzaldehyde with 243a, resulting in allylhydrazones 249 and 250  
(Scheme 133). Besides cyclohexyl residue (249), a phenyl residue (250) was introduced in 
order to explore whether conjugated hydrazones would undergo the rearrangement with this 
new carbamate protecting group. 
 
Scheme 133. Synthesis of N-CO2Et-N-allylhydrazones 249 and 250. 
The yield of 249 with 44% is much lower than of the aromatic conjugated version 250 with 
91%. In the synthesis of N-Boc-N-allylhydrazones in chapter 3.1., the same observations were 
made.  
3.4.3. Attempted TBC of N-CO2Et-N-allylhydrazones 249 and 250 
The rearrangements were performed in a 0.5 mmol scale using THOMSON’S conditions 
(triflimide, diglyme, 125 °C)[144]. First, the rearrangement of allylhydrazone 249 was tried 
(Scheme 134).  
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Scheme 134. Attempted TBC of N-CO2Et-N-allylhydrazone 249. 
The reaction was monitored by TLC. The nonpolar product 251 should have a very high Rf 
value (Rf = 0.91, pentane), but no product could be detected. The reaction was stopped after 
90 min and after work up only indefinable aliphatic decomposition fragments could be isolated 
after FCC.  
The rearrangement of the conjugated aromatic version 250 showed the same outcome and 
only unidentifiable fragments were isolated (Scheme 135). 
 
Scheme 135. Attempted TBC of N-CO2Et-N-allylhydrazone 250. 
In conclusion, the Boc group is crucial for this type of rearrangement. Probably, a protecting 
group is necessary, which can be cleaved fast in the presence of acids.  
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4. Summary and Conclusion 
The traceless bond construction published by THOMSON and co-workers, is a unique [3,3] 
sigmatropic rearrangement of N-Boc-N-allylhydrazones in the presence of superacid triflimide, 
liberating only gaseous by-products. In this project, TBC was used for the isoprenylation of 
aldehydes via N-Boc-N-allyhydrazones.[2] Scheme 136 shows an overview of the studies 
towards the novel N-Boc-N-allylhydrazine precursor 193a, with the synthesis of various N-Boc-
N-allylhydrazones and their rearrangements.  
The novel N-Boc-N-allylhydrazine precursor 193a was used as a regioisomeric mixture of the 
desired allylhydrazine 193a and 193b (ratio 91:1). Based on this precursor, which was 
designed and synthesised in previous theses, 17 N-Boc-N-allylhydrazones were synthesised. 
Besides cycloaliphatic residues (208, 209, 201, 210, 212 and 200) and functional groups like 
an ester (211) or an alkene (220), (hetero)aromatic residues were attached. In addition to a 
plain benzylidene residue (213), the benzylic residues contain an electron withdrawing or 
donating substituent in para position. Furthermore, a cinnamylidine (219) and the 
corresponding non-conjugated phenylpropylidene (203) N-Boc-N-allylhydrazone were 
synthesised. The yields of the intermediate N-Boc-N-allylhydrazones are in a range of 33 – 
95%.  
Before the following [3,3] sigmatropic rearrangement was performed, various optimisation 
reactions were made to determine the optimum reaction conditions for the TBC. Variations of 
the catalyst, the solvent, the reaction temperature, and the time were made. Moreover, the 
LEWIS acid AlCl3 was used instead of LEWIS acids. Nevertheless, the best reaction conditions 
were the standard conditions of the TBC (triflimide, diglyme, 125 °C). 
The following rearrangement was only successful with non-conjugated systems, the N-Boc-N-
allyhydrazones derived from aliphatic aldehydes, but with very low yields (19 – 20%). 
Conjugated systems (marked in grey) did not undergo the desired rearrangement. This could 
be confirmed by the unsaturated and saturated version of (hydro)cinnamaldeyde-derived 
allylhydrazones. Only the saturated version (203) did undergo the rearrangement, while in the 
reaction of 219 only Boc-deprotected allylhydrazone was found. In all conjugated 
allylhydrazones, Boc-deprotected allylhydrazones could be detected by GC/MS analysis and 
no [3,3] rearrangement was observed. Hence, the mechanism of the TBC, which was proposed 
by MUNDAL et al. as well, could be confirmed as following path B (Boc deprotection after [3,3] 
sigmatropic rearrangement).  
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Scheme 136. Overview of the studies towards the novel N-Boc-N-allylhydrazine precursor 193a and its N-Boc-N-
allylhydrazones 200-203 and 208-220 with following rearrangements. 
Since the TBC with precursor 193a is limited in its application, another protecting group instead 
of Boc was explored. Carbamate protecting groups were studied to adhere the traceless 
rearrangement by liberating only gaseous byproducts. Ethoxy carbamate was used as 
protecting group and the N-CO2Et-N-allylhydrazine precursor 243 was synthesised according 
to the synthesis of N-Boc-N-allylhydrazine 193a (Scheme 137). N-CO2Et-N-allylhydrazine 
243a and its regioisomer 243b were synthesised in five steps and isolated in a ratio of 85:15. 
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Instead of ((S)-5-(pyrrolidin-2-yl)-1H-tetrazol (199)), which was used in the synthesis of 
precursor 193a, L-proline was used in the organocatalytic step.  
 
Scheme 137. CO2Et as protecting group, instead of Boc. 
With the preservation of hydrazine 243a, two model compounds were synthesised: N-CO2Et-
N-allylhydrazone bearing a cyclohexyl residue (249) and the conjugated version, bearing a 
phenyl residue (250). Unfortunately, the rearrangement of these model compounds was not 
successful, and the desired olefins could not be isolated.  
All in all, the scope and limitations of the rearrangements of the N-Boc-N-allylhydrazones 
resulting from novel precursor 193a were studied and as a result, the first isoprenylation of 
aldehydes, bearing non-conjugated residues could be developed using TBC.   
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5. Experimental Part 
5.1. Materials and methods 
General conditions 
All oxygen- and moisture-sensitive reactions were carried out in oven-dried glassware under 
nitrogen atmosphere using Schlenk-technique. Anhydrous solvents and reagents were 
transferred through syringes under nitrogen. 
Reagents and solvents 
Solvents used for anhydrous reactions were dried by standard methods of distillation over 
drying agents. DCM was dried over molecular sieve (3Å) after distillation. THF was distilled 
over sodium and benzophenone. All other solvents and reagents were obtained from 
commercial sources (abcr, Acros, Fluka, Merck, Sigma-Aldrich or TCI in the qualities puriss., 
p.a., or purum) and used without further purification. 
Chromatography 
Thin layer chromatography (TLC) for qualitative reaction and fraction controls was performed 
using pre-coated polyester sheets polygram SIL G/UV254 with SiO2 coating (0.2 mm, 
40 x 80 mm) by Macherey-Nagel. As visualisation method CAM stain (ceric ammonium 
molybdate) with subsequent heating was used. Flash column chromatography (FCC) was 
carried out using SiO2 60 (particle size 40 – 63 μm) by Merck. 
Analytical data 
Melting points were measured in single determination on a Büchi Melting Point B-540 device 
and are stated in °C. 
All NMR spectra were recorded at room temperature using JNM-Eclipse 400 (400 MHz), JNM-
Eclipse 500 (500 MHz), Avance III HD 400 MHz Bruker Biospin (400 MHz) and Avance III HD 
500 MHz Bruker Biospin (500 MHz) mit CryoProbe™ Prodigy through the NMR-division of the 
Department of Pharmacy of the LMU. Chemical shifts δ are reported as δ-values in ppm (parts 
per million) and refer to the deuterated solvent peak. Coupling constants (J) of protons are 
stated in Hz. The signal multiplicities are defined using the following abbreviations: s (singlet), 
d (doublet), dd (double doublet), dt (double triplet), t (triplet), q (quartet), p (pentet), ddd 
(doublet of doublet of doublets), tdd (triplet of doublet of doublets), dtd (doublet of triplet of 
doublets) and m (multiplet). The signal assignment was carried out using HMQC, HMBC, 
COSY and DEPT spectra. All spectra were evaluated using MestReNova by Mestrelab 
Research S.L. 
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Infrared spectra were measured on a JASCO FT/IR-4100 infrared spectrometer, using a 
Smiths Detection DuraSamp IR II Diamond ATR sensor for detection. The measured 
wavenumbers ṽ are reported in cm-1.  
High resolution mass spectra (HRMS) were recorded on a Jeol Mstation 700 or JMS GCmate 
II Jeol instrument for electron ionisation (EI). Electrospray ionisation (ESI) was measured on a 
Thermo Finnigan LTQ-FT. All measurements were performed by the mass spectroscopy 
service of the LMU. The mass is reported in m/z units with the mass of the molecular ion. 
Gas chromatography (GC) was performed on a Varian 3800 gas chromatograph coupled to a 
Saturn 2200 ion trap from Varian (Darmstadt, Germany). The auto sampler was from CTC 
Analytics (Zwingen, Switzerland) and the split/splitless injector was a Varian 1177 (Darmstadt, 
Germany). Instrument control and data analysis were carried out with Varian Workstation 6.9 
SP1 software. A VF-5-ms capillary column of 30 m length, 0.25 mm i.d. and 0.25 μm film 
thickness was used at a constant flow rate of 1.4 mL/min. Carrier gas was helium 99.999% 
from Air Liquide (Düsseldorf, Germany). The inlet temperature was kept at 300 °C and injection 
volume was 1 μL with splitless time 1.0 min. The initial column temperature was 50 °C and 
was held for 1.0 min. Then temperature was ramped up to 250 °C with 50 °C/min. Then the 
sterols were eluted at a rate of 5 °C/min until 310 °C (hold time 3 min). Total run time was 20 
min. Transfer line temperature was 300 °C and the ion trap temperature was 150 °C. The ion 
trap was operated with electron ionization (EI) at 70 eV in scan mode (m/z 50 - 650) with a 
solvent delay of 6.3 min.  
The X-ray intensity data were measured on a Bruker D8 Venture TXS system equipped with a 
multilayer mirror monochromator and a Mo Kα rotating anode X-ray tube (λ = 0.71073 Å). The 
frames were integrated with the Bruker SAINT software package. Data were corrected for 
absorption effects using the Multi-Scan method (SADABS). The structure was solved and 
refined using the Bruker SHELXTL Software Package.  
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5.2. Synthetic procedures and analytical data 
5.2.1. General procedures for synthesis 
General procedure 1 (GP1): Synthesis of N-Boc-N-allylhydrazones 
The mixture of allylhydrazines 193a/193b (1.00 eq) was dissolved in absolute EtOH to receive 
a concentration of 0.1 mmol/mL and the appropriate aldehyde (1.00 eq) was added. The 
reaction mixture was stirred at rt for 18 h. The solvent was removed in vacuo and the crude 
product was purified via FCC. Isolated yields are correlated to the amount of 193a in the 
isomeric mixture. 
General procedure 2 (GP2): Synthesis of olefins via triflimide catalysed rearrangement 
In an oven dried two-necked Schlenk flask, triflimide (10 mol%) was dissolved in dry diglyme 
(1.00 mL). A solution of the appropriate N-Boc-N-Allylhydrazone (1.00 eq) in dry diglyme 
(2.00 mL + 1.00 mL rinse) was added at rt. The reaction mixture was fitted with a N2 flashed 
reflux condenser and then immediately stirred at 125 °C in a pre-heated oil bath.  
After completion of the rearrangement detected by TLC, the reaction was cooled to rt and then 
quenched with sat. aq. NaHCO3 (5.00 mL). Pentane (10.0 mL) was added and the organic 
layer was washed with at least 100 mL water. The solvent was removed in vacuo (30 °C, max. 
700 mbar) and the crude product was purified via FCC.  
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5.2.2. Procedures and data 
tert-Butyl 1-(2-methylbut-3-en-2-yl)-2-octylidenehydrazine-1-carboxylate (208) 
 
 
 
 
 
 
C18H34N2O2 
M = 310.48 g/mol 
N-Boc-N-allylhydrazone 208 was synthesised according to GP1, using mixture of 
allylhydrazines 193a/193b (250 mg, 1.75 mmol ≙ 1.59 mmol of isomer 193a, 1.00 eq) and 
octanal (0.298 mL, 1.75 mmol, 1.00 eq). The title compound was purified via FCC 
(hexanes/EtOAc 9:1) and isolated as colourless oil (178 mg, 0.576 mmol, 36% referred to 
isomer 193a). 
 
Rf = 0.58 (hexanes/EtOAc 9:1). 
1H-NMR (400 MHz, chloroform-d) δ/ppm = 7.71 (t, J = 5.6 Hz, 1H, 1’-H), 6.11 (dd, J = 17.5, 
10.8 Hz, 1H, 3’’-H), 5.07 – 4.86 (m, 2H, 4’’-H), 2.35 (td,  J = 5.6 Hz, 2H, 2’-H), 1.59 – 1.50 (m, 
2H, 3’-H), 1.42 (s, 9H, C(CH3)3), 1.39 (s, 6H, 1’’-H), 1.34 – 1.24 (m, 8H, 4’, 5’, 6’, 7’-H), 0.87 (t, 
3H, 8’-H).  
13C NMR (126 MHz, chloroform-d) δ/ppm = 169.5 (C-1’), 154.3 (CO2tBu), 146.3 (C-3’’), 109.4 
(C-4’’), 80.9 (C(CH3)3), 61.7 (C-2’’), 33.0 (C-2’), 31.9 (C-3’, 4’, 5’, 6’ or 7’), 29.5 (C-3’, 4’, 5’, 6’ 
or 7’), 29.2 (C-3’, 4’, 5’, 6’ or 7’), 28.6 (C(CH3)3), 26.7 (C-1’’), 26.2 (C-3’, 4’, 5’, 6’ or 7’), 22.8 
(C-3’, 4’, 5’, 6’ or 7’), 14.3 (C-8’). 
IR (ATR): ṽ/cm-1 = 3084, 3004, 2972, 2958, 2927, 2857, 1698, 1641, 1455, 1412, 1391, 1366, 
1302, 1244, 1157, 1101, 1003, 991, 901, 855, 757, 724, 686. 
HRMS (ESI): m/z = calculated for C18H35N2O2 [M+H]+ 311.2693; found: 311.2694. 
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tert-Butyl 1-(2-methylbut-3-en-2-yl)-2-nonylidenehydrazine-1-carboxylate (209) 
 
 
 
 
C19H36N2O2 
M = 324.51 g/mol 
N-Boc-N-allylhydrazone 209 was synthesised according to GP1, using mixture of 
allylhydrazines 193a/193b (404 mg, 2.02 mmol ≙ 1.83 mmol of isomer 193a, 1.00 eq) and 
nonanal (0.346 mL, 2.02 mmol, 1.00 eq). The title compound was purified via FCC 
(hexanes/EtOAc 9:1) and isolated as colourless oil (284 mg, 0.877 mmol, 48% referred to 
isomer 193a). 
 
Rf = 0.58 (hexanes/EtOAc 9:1). 
1H NMR (500 MHz, chloroform-d) δ/ppm = 7.71 (t, J = 5.6 Hz, 1H, 1’-H), 6.11 (dd, J = 17.5, 
10.8 Hz, 1H, 3’’-H), 5.05 – 4.89 (m, 2H, 4’’-H), 2.34 (td, J = 5.6 Hz, 2H, 2’-H), 1.55 (m, 2H, 3’-
H), 1.42 (s, 9H, C(CH3)3), 1.39 (s, 6H, 1’’-H), 1.36 – 1.21 (m, 10H, 4’, 5’, 6’, 7’, 8’-H), 0.89 – 
0.85 (m, 3H, 9’-H). 
13C NMR (101 MHz, chloroform-d) δ/ppm = 169.4 (C-1’), 154.3 (CO2tBu), 146.3 (C-3’’), 109.4 
(C-4’’), 80.9 (C-2’), 61.7 (C-2’’), 33.0 (C-3’), 31.9 (C-4’, 5’, 6’, 7’, 8’ or 9’), 29.5 (C-4’, 5’, 6’, 7’, 
8’ or 9’), 29.4 (C-4’, 5’, 6’, 7’, 8’ or 9’), 29.3 (C-4’, 5’, 6’, 7’, 8’ or 9’), 28.5 (C(CH3)3), 26.7 (C-
1’’), 26.2 (C-4’, 5’, 6’, 7’, 8’ or 9’), 22.8 (C-4’, 5’, 6’, 7’, 8’ or 9’), 14.2 (C-9’). 
IR (ATR): ṽ/cm-1 = 3086, 2972, 2956, 2926, 2856, 1698, 1640, 1455, 1412, 1390, 1366, 1302, 
1244, 1157, 1100, 1003, 992, 900, 874, 857, 783, 756, 723, 687, 599.  
HRMS (ESI): m/z = calculated for C19H37N2O2 [M+H]+ 325.2849; found: 325.2849. 
  
  Experimental Part 
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tert-Butyl 1-(2-methylbut-3-en-2-yl)-2-(2-methylpropylidene)hydrazine-1-carboxylate 
(210) 
 
 
 
 
 
 
C14H26N2O2 
M = 254.37 g/mol 
N-Boc-N-allylhydrazone 210 was synthesised according to GP1, using mixture of 
allylhydrazines 193a/193b (519 mg, 2.59 mmol ≙ 2.36 mmol of isomer 193a, 1.00 eq) and 
isobutyraldehyde (0.237 mL, 2.59 mmol, 1.00 eq). The title compound was purified via FCC 
(hexanes/EtOAc 9:1) and isolated as colourless oil (262 mg, 1.03 mmol, 44% referred to 
isomer 193a). 
 
Rf = 0.55 (hexanes/EtOAc 9:1). 
1H NMR (400 MHz, chloroform-d) δ/ppm = 7.61 (d, J = 5.9 Hz, 1H, 1’-H), 6.11 (dd, J = 17.6, 
10.8 Hz, 1H, 3’’-H), 5.03 – 4.90 (m, 2H, 4’’-H), 2.66 – 2.56 (m, 1H, 2’-H), 1.42 (s, 9H, C(CH3)3), 
1.39 (s, 6H, 1’’-H), 1.13 (s, 3H, 3’-H), 1.12 (s, 3H, 2’-CH3). 
13C NMR (101 MHz, chloroform-d) δ/ppm = 173.2 (C-1’), 154.1 (CO2tBu), 146.3 (C-3’’), 109.4 
(C-4’’), 80.9 (C(CH3)3), 61.9 (C-2’’), 32.2 (C-2’), 28.6 (C(CH3)3), 26.6 (C-1’’), 19.6 (C-3’, 2’-CH3). 
IR (ATR): ṽ/cm-1 = 3086, 3008, 2973, 2930, 2872, 1698, 1641, 1456, 1412, 1390, 1366, 1304, 
1289, 1244, 1156, 1092, 1058, 992, 970, 902, 879, 856, 756, 686, 599, 588. 
HRMS (ESI): m/z = calculated for C14H27N2O2 [M+H]+ 255.2067; found: 255.2066. 
  
  Experimental Part 
 
 
  
 250 
 
tert-Butyl 2-(cyclopentylmethylene)-1-(2-methylbut-3-en-2-yl)hydrazine-1-carboxylate 
(212) 
 
 
 
  
 
 
C16H28N2O2 
M = 280.41 g/mol 
N-Boc-N-allylhydrazone 212 was synthesised according to GP1, using mixture of 
allylhydrazines 193a/193b (430 mg, 2.15 mmol ≙ 1.96 mmol of isomer 193a, 1.00 eq) and 
cyclopentane carboxaldehyde (0.229 mL, 2.15 mmol, 1.00 eq). The title compound was 
purified via FCC (hexanes/EtOAc 9:1) and isolated as colourless oil (245 mg, 0.874 mmol, 
45% referred to isomer 193a). 
 
Rf = 0.57 (9:1 hexanes/EtOAc). 
1H NMR (400 MHz, chloroform-d) δ/ppm = 7.62 (d, J = 6.8 Hz, 1H, C-1’’), 6.11 (dd, J = 17.5, 
10.8 Hz, 1H, 3’-H), 5.08 – 4.82 (m, 2H, 4’-H), 2.87 – 2.71 (m, 1H, 1’’’-H), 1.95 – 1.79 (m, 2H, 
2’’’, 3’’’, 4’’’ or 5’’’-H), 1.73 – 1.54 (m, 6H, 2’’’, 3’’’, 4’’’ or 5’’’-H), 1.42 (s, 9H, C(CH3)3), 1.38 (s, 
6H, 1’-H). 
13C NMR (101 MHz, chloroform-d) δ/ppm = 172.6 (C-1’’), 154.2 (CO2tBu), 146.2 (C-3’), 109.4 
(C-4’), 80.8, 61.8 (C-2’), 42.9 (C-1’’’), 30.3 (C-2’’’, 3’’’, 4’’’ or 5’’’), 28.6 (C(CH3)3), 28.5 (C-2’’’, 
3’’’, 4’’’ or 5’’’), 26.6 (C-1’), 25.7 (Cy-CH2). 
IR (ATR): ṽ/cm-1 = 3084, 2968, 2956, 2869, 1697, 1639, 1476, 1454, 1412, 1390, 1366, 1304, 
1244, 1156, 1101, 1061, 1003, 992, 900, 877, 856, 783, 757, 687.  
HRMS (ESI): m/z = calculated for C16H29N2O2 [M+H]+ 281.2224; found: 281.2225. 
  
  Experimental Part 
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tert-Butyl 2-(cyclohex-1-en-1-ylmethylene)-1-(2-methylbut-3-en-2-yl)hydrazine-1-
carboxylate (220) 
 
 
 
 
 
 
C17H28N2O4 
M = 292.42 g/mol 
N-Boc-N-allylhydrazone 220 was synthesised according to GP1, using mixture of 
allylhydrazines 193a/193b (200 mg, 0.999 mmol ≙ 0.909 mmol of isomer 193a, 1.00 eq) and 
1-cyclohexene-1-carboxaldehyde (0.114 mL, 0.990 mmol, 1.00 eq). The title compound was 
purified via FCC (hexanes/EtOAc 9:1) and isolated as colourless oil (135 mg, 0.460 mmol, 
51% referred to isomer 193a). 
 
Rf = 0.52 (9:1 hexanes/EtOAc). 
1H NMR (400 MHz, chloroform-d) δ/ppm = 7.99 (s, 1H, 1’’-H), 6.18 – 6.05 (m, 2H, 3’, 2’’’-H), 
5.05 – 4.85 (m, 2H, 4’-H), 2.37 – 2.12 (m, 4H, 3’’’, 6’’’-H), 1.70 – 1.61 (m, 4H, 4’’’, 5’’’-H), 1.43 
(s, 9H, C(CH3)3), 1.41 (s, 6H, 1’-H). 
13C NMR (101 MHz, chloroform-d) δ/ppm = 163.9 (C-1’’), 153.9 (CO2tBu), 146.6 (C-3’), 138.2 
(C-2’’’), 136.3 (C-1’’’), 109.1 (C-4’), 81.2 (C(CH3)3), 62.7 (C-2’), 28.6 (C(CH3)3), 26.9 (C-1’), 
26.3 (3’’’ or 6’’’-H), 23.4 (3’’’ or 6’’’-H), 22.5 (4’’’ or 5’’’-H), 22.1 (4’’’ or 5’’’-H). 
IR (ATR): ṽ/cm-1 =2976, 2931, 2859, 1697, 1639, 1596, 1366, 1291, 1243, 1152, 1107, 902, 
881, 754, 699. 
HRMS (ESI): m/z = calculated for C17H29N2O2 [M+H]+ 293.2224; found: 293.2223. 
 
  
  Experimental Part 
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tert-Butyl 2-benzylidene-1-(2-methylbut-3-en-2-yl)hydrazine-1-carboxylate (213) 
 
 
 
 
 
 
 C17H24N2O2 
M = 288.39 g/mol 
N-Boc-N-allylhydrazone 213 was synthesised according to GP1, using mixture of 
allylhydrazines 193a/193b (580 mg, 2.90 mmol ≙ 2.64 mmol of isomer 193a, 1.00 eq) and 
benzaldehyde (0.294 mL, 2.90 mmol, 1.00 eq). The title compound was purified via FCC 
(hexanes/EtOAc 9:1) and isolated as colourless oil (312 mg, 1.08 mmol, 41% referred to 
isomer 193a). 
 
Rf = 0.64 (hexanes/EtOAc 9:1). 
1H NMR (400 MHz, chloroform-d) δ/ppm = 8.65 (s, 1H, 1’’-H), 7.74 – 7.68 (m, 2H, 2’’’, 6’’’-H), 
7.43 – 7.34 (m, 3H, 3’’’, 4’’’, 5’’’-H), 6.17 (dd, J = 17.5, 10.8 Hz, 1H, 3’-H), 5.11 – 4.90 (m, 2H, 
4’-H), 1.52 (s, 6H, 1’-H), 1.47 (s, 9H, C(CH3)3). 
13C NMR (101 MHz, chloroform-d) δ/ppm = 157.1 (C-1’’), 153.6 (CO2tBu), 146.4 (C-3’), 135.4 
(C-1’’’), 130.2 (C-4’’’), 128.7 (C-3’’’, C-5’’’), 127.7 (C-2’’’, C-6’’’), 109.4 (C-4’), 81.8 (C(CH3)3), 
63.6 (C-2’), 28.5 (C(CH3)3), 27.2 (C-1’).  
IR (ATR): ṽ/cm-1 = 3083, 3062, 2976, 2932, 1697, 1642, 1574, 1476, 1449, 1412, 1391, 1366, 
1289, 1243, 1149, 1109, 1071, 992, 947, 898, 856, 784, 753, 692, 659, 563. 
HRMS (ESI): m/z = calculated for C17H25N2O2 [M+H]+ 289.1910; found: 289.1909. 
  
  Experimental Part 
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tert-Butyl 2-(4-(dimethylamino)benzylidene)-1-(2-methylbut-3-en-2-yl)hydrazine-1-
carboxylate (214) 
 
 
 
 
C19H29N3O2 
M = 331.46 g/mol 
N-Boc-N-allylhydrazone 214 was synthesised according to GP1, using mixture of 
allylhydrazines 193a/193b (100 mg, 0.499 mmol ≙ 0.454 mmol of isomer 193a, 1.00 eq) and 
4-dimethylaminobenzaldehyde (74.5 mg, 0.499 mmol, 1.00 eq). The title compound was 
purified via FCC (hexanes/EtOAc 9:1) and isolated as white crystalline solid (143 mg, 
0.431 mmol, 95% referred to isomer 193a). 
 
Rf = 0.35 (hexanes/EtOAc 9:1). 
mp: 74 °C. 
1H NMR (400 MHz, chloroform-d) δ/ppm = 8.30 (s, 1H, 1’’-H), 7.61 (d, J = 8.9 Hz, 2H, 2’’’, 6’’’-
H), 6.69 (d, J = 8.9 Hz, 2H, 3’’’, 5’’’-H), 6.19 (dd, J = 17.5, 10.8 Hz, 1H, 3’-H), 5.08 – 4.90 (m, 
2H, 4’-H), 3.01 (s, 6H, N(CH3)2), 1.47 (s, 6H, 1’-H), 1.44 (s, 9H, C(CH3)3). 
13C NMR (101 MHz, chloroform-d) δ/ppm = 162.4 (C-1’’), 154.2 (CO2tBu), 152.2 (C-4’’’), 146.6 
(C-3’), 129.4 (C-2’’’, C-6’’’), 122.4 (C-1’’’), 111.8 (C-3’’’, C-5’’’), 109.2 (C-4’), 80.9 (C(CH3)3), 
62.6 (C-2’), 40.4 (N(CH3)2), 28.6 (C(CH3)3), 26.9 (C-1’). 
IR (ATR): ṽ/cm-1 = 2976, 2930, 1693, 1616, 1601, 1528, 1477, 1455, 1363, 1300, 1237, 1155, 
1100, 1060, 894, 859, 816, 755, 731. 
HRMS (ESI): m/z = calculated for C19H30N3O2 [M+H]+ 332.2333; found: 332.2333. 
  
  Experimental Part 
 
 
  
 254 
 
tert-Butyl 2-(4-methoxybenzylidene)-1-(2-methylbut-3-en-2-yl)hydrazine-1-carboxylate 
(215) 
 
 
 
 
 
 
C18H26N2O3 
M = 318.42 g/mol 
N-Boc-N-allylhydrazone 215 was synthesised according to GP1, using mixture of 
allylhydrazines 193a/193b (150 mg, 0.749 mmol ≙ 0.682 mmol of isomer 193a, 1.00 eq) and 
4-anisaldehyde (102 mg, 91.1 µL, 0.749 mmol, 1.00 eq). The title compound was purified via 
FCC (hexanes/EtOAc 9:1) and isolated as colourless oil (151 mg, 0.475 mmol, 70% referred 
to isomer 193a). 
 
Rf = 0.42 (hexanes/EtOAc 9:1). 
1H NMR (400 MHz, Chloroform-d) δ/ppm = 8.48 (s, 1H, 1’’-H), 7.66 (d, J = 8.8 Hz, 2H, 2’’’, 6’’’-
H), 6.91 (d, J = 8.9 Hz, 2H, 3’’’, 5’’’-H), 6.17 (dd, J = 17.5, 10.8 Hz, 1H, 3’-H), 5.08 – 4.92 (m, 
2H, 4’-H), 3.84 (s, 3H, OCH3), 1.49 (s, 6H, 1’-H), 1.45 (s, 9H, C(CH3)3). 
13C NMR (101 MHz, Chloroform-d) δ/ppm = 161.5 (C-4’’’), 159.0 (C-1’’), 153.9 (CO2tBu), 146.5 
(C-3’), 129.3 (C-2’’’ and C-6’’’), 127.8 (C-1’’’), 114.1 (C-3’’’ and C-5’’’), 109.3 (C-4’), 81.4 
(C(CH3)3), 63.1 (C-2’), 55.5 (OCH3), 28.6 (C(CH3)3), 27.0 (C-1’). 
IR (ATR): ṽ/cm-1 = 2975, 2932, 1693, 1606, 1512, 1456, 1366, 1293, 1245, 1150, 1104, 1031, 
900, 859, 831. 
HRMS (ESI): m/z = calculated for C18H27N2O3 [M+H]+ 319.2016; found: 319.2015. 
 
  
  Experimental Part 
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tert-Butyl 1-(2-methylbut-3-en-2-yl)-2-(4-nitrobenzylidene)hydrazine-1-carboxylate (216) 
 
 
 
 
 
 
C17H23N3O4 
M = 333.39 g/mol 
N-Boc-N-allylhydrazone 216 was synthesised according to GP1, using mixture of 
allylhydrazines 193a/193b (250 mg, 1.25 mmol ≙ 1.14 mmol of isomer 193a, 1.00 eq) and 4-
nitrobenzaldehyde (0.126 mL, 1.25 mmol, 1.00 eq). The title compound was purified via FCC 
(hexanes/EtOAc 9:1) and isolated as yellow solid (233 mg, 0.698 mmol, 61% referred to isomer 
193a). 
 
Rf = 0.51 (hexanes/EtOAc 9:1). 
mp: 67 °C. 
1H NMR (400 MHz, chloroform-d) δ/ppm = 9.02 (s, 1H, 1’-H), 8.24 – 8.19 (m, 2H, 3’’, 5’’-H), 
7.82 – 7.75 (m, 2H, 2’’, 6’’-H), 6.12 (dd, J = 17.5, 10.8 Hz, 1H, 3’’’-H), 5.10 – 4.93 (m, 2H, 4’’’-
H), 1.56 (s, 6H, 1’’’-H), 1.50 (s, 9H, C(CH3)3). 
13C NMR (101 MHz, chloroform-d) δ/ppm = 152.9 (CO2tBu), 148.1 (C-4’’), 147.7 (C-1’), 145.9 
(C-3’’’), 142.7 (C-1’’), 127.6 (C-2’’, 6’’), 124.0 (C-3’’, 5’’), 110.1 (C-4’’’), 82.9 (C(CH3)3), 65.0 (C-
2’’’), 28.5 (C(CH3)3), 27.6 (C-1’’’). 
IR (ATR): ṽ/cm-1 = 1699, 1598, 1572, 1518, 1368, 1343, 1286, 1246, 1146, 1107, 907, 849, 
832, 729, 692, 647. 
HRMS (EI): m/z = calculated for C17H23N3O4 [M]˙⁺ 333.1683; found: 333.1710. 
 
 
 
 
 
 
  Experimental Part 
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tert-Butyl 1-(2-methylbut-3-en-2-yl)-2-((E)-3-phenylallylidene)hydrazine-1-carboxylate 
(219) 
 
C19H26N2O2 
M = 314.43 g/mol 
N-Boc-N-allylhydrazone 219 was synthesised according to GP1, using mixture of 
allylhydrazines 193a/193b (250 mg, 1.25 mmol ≙ 1.13 mmol of isomer 193a, 1.00 eq) and 
cinnamaldehyde (0.157 mL, 1.25 mmol, 1.00 eq). The title compound was purified via FCC 
(hexanes/EtOAc 9:1) and isolated as yellow oil (228 mg, 0.725 mmol, 64% referred to isomer 
193a). 
 
Rf = 0.56 (hexanes/EtOAc 9:1). 
1H NMR (500 MHz, chloroform-d) δ/ppm = 8.33 (dd, J = 7.2, 1.5 Hz, 1H, 1’-H), 7.49 – 7.47 (m, 
2H, 2’, 6’-H), 7.38 – 7.33 (m, 2H, 3’, 5’-H), 7.32 – 7.28 (m, 1H, 4’’-H), 6.96 – 6.93 (m, 2H, 2’, 
3’-H), 6.14 (dd, J = 17.5, 10.8 Hz, 1H, 3’’’-H), 5.07 – 4.92 (m, 2H, 4’’’-H), 1.47 (s, 6H, 1’’’-H), 
1.46 (s, 9 H, C(CH3)3). 
13C NMR (101 MHz, chloroform-d) δ/ppm = 161.7 (C-1’), 153.7 (CO2tBu), 146.2 (C-3’’’), 140.5 
(C-3’), 136.2 (C-1’’), 128.9 (C-4’’), 128.9 (C-3’, 5’), 127.2 (C-2’, 6’), 126.0 (C-2’), 109.5 (C-4’’’), 
81.6 (C(CH3)3), 62.9 (C-2’’’), 28.5 (C(CH3)3), 26.9 (C-1’’’). 
IR (ATR): ṽ/cm-1 = 1694, 1449, 1366, 1289, 1243, 1148, 1109, 1051, 973, 906, 879, 850, 749, 
689. 
HRMS (ESI): m/z = calculated for C19H27N2O2 [M+H]+ 315.2067; found: 315.2066. 
  
  Experimental Part 
 
 
  
 257 
 
tert-Butyl 2-(2-ethoxy-2-oxoethylidene)-1-(2-methylbut-3-en-2-yl)hydrazine-1-
carboxylate (211) 
 
 
 
 
C14H24N2O4 
M = 284.36 g/mol 
N-Boc-N-allylhydrazone 211 was synthesised according to GP1, using mixture of 
allylhydrazines 193a/193b (200 mg, 0.990 mmol, ≙ 0.901 mmol of isomer 193a, 1.00 eq) and 
ethyl glyoxalate solution (~ 50% in toluene, 0.198 mL, 0.990 mmol, 1.00 eq). The title 
compound was purified via FCC (hexanes/EtOAc 9:1) and isolated as yellow oil (108 mg, 
0.380 mmol, 42% referred to isomer 193a). 
 
Rf = 0.44 (hexanes/EtOAc 9:1). 
1H NMR (400 MHz, chloroform-d) δ/ppm = 8.41 (s, 1H, 1’’-H), 6.05 (dd, J = 17.5, 10.8 Hz, 1H, 
3’-H), 5.07 – 4.93 (m, 2H, 4’-H), 4.26 (q, J = 7.1 Hz, 2H, OCH2CH3), 1.52 (s, 6H, 1’-H), 1.48 (s, 
9H, C(CH3)3), 1.31 (t, J = 7.1 Hz, 3H, OCH2CH3). 
13C NMR (101 MHz, chloroform-d) δ/ppm = 164.9 (C-2’’), 151.9 (CO2tBu), 145.5 (C-3’), 135.7 
(C-1’’), 110.6 (C-4’), 83.6 (C(CH3)3), 65.9 (C-2’), 60.9 (OCH2CH3), 28.3 (C(CH3)3), 27.7 (C-1’), 
14.4 (OCH2CH3). 
IR (ATR): ṽ/cm-1 = 1742, 1708, 1585, 1477, 1456, 1369, 1339, 1288, 1242, 1206, 1181, 1148, 
1113, 1093, 1044, 911, 848, 798, 759, 744, 576. 
HRMS (EI): m/z = calculated for C9H16N2O2 [M-CO2tBu]˙⁺ 184.1206, found: 184.1205.  
  Experimental Part 
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tert-Butyl 1-(2-methylbut-3-en-2-yl)-2-(pyridin-4-ylmethylene)hydrazine-1-carboxylate 
(218) 
 
C16H23N3O4 
M = 289.38 g/mol 
N-Boc-N-allylhydrazone 218 was synthesised according to GP1, using mixture of 
allylhydrazines 193a/193b (350 mg, 1.75 mmol ≙ 1.59 mmol of isomer 193a, 1.00 eq) and 4-
pyridinecarboxaldehyde (0.165 mL, 1.75 mmol, 1.00 eq). The title compound was purified via 
FCC (hexanes/EtOAc 9:1) and isolated as light yellow oil (342 mg, 1.18 mmol, 74% referred 
to isomer 193a). 
 
Rf = 0.12 (hexanes/EtOAc 9:1). 
1H NMR (400 MHz, chloroform-d) δ/ppm = 8.90 (s, 1H, 1’-H), 8.65 – 8.55 (m, 2H, 2’’, 6’’-H), 
7.50 (dd, J = 6.1, 0.4 Hz, 2H, 3’’, 5’’-H), 6.11 (dd, J = 17.5, 10.8 Hz, 1H, 3’’’-H), 5.11 – 4.90 (m, 
2H, 4’’’-H), 1.54 (s, 6H, 1’’’-H), 1.49 (s, 9H, C(CH3)3). 
13C NMR (101 MHz, chloroform-d) δ/ppm = 152.9 (CO2tBu), 150.3 (C-2’, 6’), 147.7 (C-1’), 146.0 
(C-3’’’), 143.8 (C-4’’), 121.1 (C-3’’, 5’’), 109.9 (C-4’’’), 82.8 (C(CH3)3), 64.9 (C-2’’’), 28.5 
(C(CH3)3), 27.6 (C-1’’’). 
IR (ATR): ṽ/cm-1 = 2977, 2933, 1698, 1590, 1367, 1287, 1246, 1147, 989, 903, 859, 814, 755, 
732, 656. 
HRMS (ESI): m/z = calculated for C16H24N3O2 [M+H]+ 290.1863; found: 290.1862. 
  
  Experimental Part 
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tert-Butyl 1-(2-methylbut-3-en-2-yl)-2-(thiophen-2-ylmethylene)hydrazine-1-carboxylate 
(217) 
 
 
 
 
 
C15H22N2O2S 
M = 294.41 g/mol 
N-Boc-N-allylhydrazone 217 was synthesised according to GP1, using mixture of 
allylhydrazines 193a/193b (150 mg, 0.749 mmol ≙ 0.681 mmol of isomer 193a, 1.00 eq) and 
2-thiophenecarboxaldehyde (70.0 µL, 0.749 mmol, 1.00 eq). The title compound was purified 
via FCC (hexanes/EtOAc 9:1) and isolated as light yellow oil (104 mg, 0.352 mmol, 52% 
referred to isomer 193a). 
 
Rf = 0.60 (hexanes/EtOAc 9:1). 
1H NMR (400 MHz, chloroform-d) δ/ppm = 8.85 – 8.83 (m, 1H, 1’-H), 7.32 (dt, J = 5.0, 1.0 Hz, 
1H, 5’’-H), 7.24 (dd, J = 3.6, 1.2 Hz, 1H, 3’’-H), 7.04 (dd, J = 5.1, 3.6 Hz, 1H, 4’’-H), 6.14 (dd, 
J = 17.5, 10.8 Hz, 1H, 3’’’-H), 5.08 – 4.91 (m, 2H, 4’’’-H), 1.49 (s, 6H, 1’’’-H), 1.47 (s, 9H, 
C(CH3)3). 
13C NMR (101 MHz, chloroform-d) δ/ppm = 153.6 (CO2tBu), 150.2 (C-1’), 146.3 (C-3’’’), 140.9 
(C-2’’), 129.7 (C-3’’), 127.9 (C-5’’), 127.4 (C-4’’), 109.5 (C-4’’’), 81.9 (C(CH3)3), 63.7 (C-2’’’), 
28.5 (C(CH3)3), 27.2 (C-1’’’). 
IR (ATR): ṽ/cm-1 = 2985, 2938, 1742, 1708, 1585, 1369, 128, 1242, 1181, 1148, 1113, 1093, 
1044, 911, 848, 759, 744, 576. 
 HRMS (EI): m/z = calculated for C15H22N2O2S [M]˙⁺ 294.1396; found: 294.1392. 
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2-Methyldodec-2-ene (221) 
 
 
 
 
 C13H26 
M = 182.35 g/mol 
Olefin 221 was synthesised according to GP2, using N-Boc-N-allylhydrazone 208 (155 mg, 
0.500 mmol, 1.00 eq). The title compound was purified via FCC (pentane 100%) and isolated 
as colourless oil (18.0 mg, 0.0987 mmol, 20%). 
 
Rf = 0.94 (pentane 100%). 
1H NMR (400 MHz, chloroform-d) δ/ppm = 5.15 – 5.08 (m, 1H, 3-H), 1.96 (q, J = 7.1 Hz, 2H, 
4-H), 1.69 (d, J = 1.4 Hz, 3H, 1-H or 2-CH3), 1.60 (d, J = 1.3 Hz, 3H, 1-H or 2-CH3), 1.26 (s, 
14H, 5, 6, 7, 8, 9, 10 and 11-H), 0.88 (t, J = 2.9 Hz, 3H, 12-H). 
13C NMR (101 MHz, chloroform-d) δ/ppm = 131.3 (C-2), 125.1 (C-3), 32.1 (C-5, 6, 7, 8, 9, 10 
or 11), 30.1 (C-5, 6, 7, 8, 9, 10 or 11), 29.8 (C-5, 6, 7, 8, 9, 10 or 11), 29.8 (C-5, 6, 7, 8, 9, 10 
or 11), 29.5 (C-5, 6, 7, 8, 9, 10 or 11), 29.5 (C-5, 6, 7, 8, 9, 10 or 11), 28.2 (C-4), 25.9 (C-1 or 
2-CH3), 22.9 (C-5, 6, 7, 8, 9, 10 or 11), 17.8 (C-1 or 2-CH3), 14.3 (C-12).  
IR (ATR): ṽ/cm-1 = 2956, 2922, 2853, 1462, 1376, 1094, 985, 886, 833, 722. 
HRMS (EI): m/z = calculated for C13H26 [M]˙⁺ 182.2029, found: 182.2027. 
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2-Methyltridec-2-ene (222) 
 
 
 
 
 C14H28 
M = 196.38 g/mol 
Olefin 222 was synthesised according to GP2, using N-Boc-N-allylhydrazone 209 (162 mg, 
0.500 mmol, 1.00 eq). The title compound was purified via FCC (pentane 100%) and isolated 
as colourless oil (18.8 mg, 0.103 mmol, 21%). 
 
Rf = 0.88 (pentane/Et2O 9:1). 
1H NMR (400 MHz, chloroform-d) δ/ppm = 5.12 (tdt, J = 7.2, 2.9, 1.5 Hz, 1H, 3-H), 1.96 (q, J = 
6.8 Hz, 2H, 4-H), 1.69 (d, J = 1.4 Hz, 3H, 1-H or 2-CH3), 1.60 (d, J = 1.3 Hz, 3H, 1-H or 2-CH3), 
1.26 (s, 16H, 5, 6, 7, 8, 9, 10, 11 and 12 -H), 0.93 – 0.83 (m, 3H, 13-H). 
13C NMR (101 MHz, chloroform-d) δ/ppm = 131.3 (C-2), 125.1 (C-3), 32.1 (C-5, 6, 7, 8, 9, 10, 
11 or 12), 30.1 (C-5, 6, 7, 8, 9, 10, 11 or 12), 29.8 (C-5, 6, 7, 8, 9, 10, 11 or 12), 29.8 (C-5, 6, 
7, 8, 9, 10, 11 or 12), 29.8 (C-5, 6, 7, 8, 9, 10, 11 or 12), 29.5 (C-5, 6, 7, 8, 9, 10, 11 or 12), 
29.5 (C-5, 6, 7, 8, 9, 10, 11 or 12), 28.2 (C-4), 25.9 (C-1 or 2-CH3), 22.9 (C-5, 6, 7, 8, 9, 10, 11 
or 12), 17.8 (C-1 or 2-CH3), 14.3 (C-13). 
IR (ATR): ṽ/cm-1 = 2955, 2922, 2853, 1456, 1376, 1094, 984, 886, 832, 721, 593, 556. 
HRMS (EI): m/z = calculated for C14H28 [M]˙⁺ 196.2185, found: 196.2183. 
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(4-Methylpent-3-en-1-yl)cyclopentane (225) 
 
 
 
 
C11H20 
M = 152.28 g/mol 
Olefin 225 was synthesised according to GP2, using N-Boc-N-allylhydrazone 212 (140 mg, 
0.500 mmol, 1.00 eq). The title compound was purified via FCC (pentane 100%) and isolated 
as colourless oil (15.0 mg, 0.0985 mmol, 20%). 
 
Rf = 0.95 (pentane 100%).  
1H NMR (500 MHz, chloroform-d) δ/ppm = 5.15 – 5.10 (m, 1H, 3’-H), 2.01 – 1.95 (m, 2H, 2’-
H), 1.77 – 1.73 (m, 2H, 1’-H), 1.69 (d, J = 1.4 Hz, 3H, 5’-H or 4’-CH3), 1.60 (d, J = 1.2 Hz, 3H, 
5’-H or 4’-CH3), 1.52 – 1.46 (m, 2H, 2, 3, 4 or 5-H), 1.34 – 1.30 (m, 2H, 2, 3, 4 or 5-H, 1-H), 
1.11 – 1.05 (m, 2H, 2, 3, 4 or 5-H), 0.91 – 0.86 (m, 3H, 2, 3, 4 or 5-H). 
13C NMR (126 MHz, chloroform-d) δ/ppm = 131.1 (C-4’), 125.2 (C-3’), 39.9 (C-1’), 36.6 (C-1), 
32.8 (C-2, 3, 4 or 5), 27.4 (C-2’), 25.9 (C-5’ or 4’-CH3), 25.4 (C-2, 3, 4 or 5), 17.8 (C-5’ or 4’-
CH3). 
IR (ATR): ṽ/cm-1 = 2983, 2950, 2922, 2857, 1452, 1376, 1105, 985, 907, 830, 735, 650, 574, 
560. 
HRMS (EI): m/z = calculated for C11H20 [M]˙⁺ 152.1559, found: 152.1558. 
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1-Ethyl 2-(2,2,2-trichloroethyl) hydrazine-1,2-dicarboxylate (245) 
 
C6H9Cl3N2O4 
M = 279.49 g/mol 
To a solution of ethyl carbazate (5.20 g, 49.9 mmol, 1.00 eq) and NMM (5.55 mL, 49.9 mmol, 
1.00 eq) in THF (100 mL), 2,2,2-trichloroethylchloroformat (6.88 mL, 49.9 mmol, 1.00 eq) was 
added at 0 °C. The reaction mixture was allowed to warm up to rt and stirred for 24 h. The 
suspension was filtered and concentrated in vacuo. Purification via FCC (hexanes/EtOAc 7:3) 
gave hydrazine 245 (14.0 g, 50.1 mmol, quantitative) as a colourless oil.  
 
Rf = 0.28 (hexanes/EtOAc 7:3).  
1H NMR (400 MHz, chloroform-d) δ/ppm = 6.91 (d, J = 146.8 Hz, 2H, 1, 2-H), 4.78 (s, 2H, 1’-
H), 4.21 (q, J = 7.2 Hz, 2H, CH2CH3), 1.27 (t, J = 7.1 Hz, 3H, CH2CH3). 
13C NMR (101 MHz, chloroform-d) δ/ppm = 156.6 (CO2Et), 155.3 (CO2CH2CCl3), 94.9 (C-2’), 
75.2 (C-1’), 62.7 (CH2CH3), 14.5 (CH2CH3). 
IR (ATR): ṽ/cm-1 = 3258, 1762, 1735, 1697, 1524, 1441 1367, 1259, 1208, 1095, 1053, 1023, 
978, 886, 824, 776, 737, 707. 
HRMS (EI): m/z calculated for C6H9O4N2Cl3 [M]˙⁺ 277.9622; found 277.9617. 
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1-Ethyl 2-(2,2,2-trichloroethyl) (E)-diazene-1,2-dicarboxylate (246) 
 
 
 
 
C6H7Cl3N2O4 
M = 277.48 g/mol 
Hydrazine 245 (14.6 g, 52.2 mmol, 1.00 eq) was dissolved in toluene (120 mL), before pyridine 
(4.22 mL, 52.2 mmol, 1.00 eq) and NBS (9.30 g, 52.2 mmol, 1.00 eq) were added. The reaction 
mixture was stirred for 3 h at rt. The mixture was diluted with toluene (50.0 mL), washed with 
water (120 mL), sat. aq. Na2S2O3 solution (100 mL), aq. 1M HCl (100 mL), sat. aq. NaHCO3 
solution (100 mL), water (100 mL) and brine (110 mL). The organic layer was dried over 
Na2SO4, filtered and the solvent was removed in vacuo. Azodicarboxylate 246 (13.4 g, 
48.3 mmol, 92%) was obtained as an orange oil and was used without further purification.  
 
Rf = 0.75 (hexanes/EtOAc 7:3).  
1H NMR (400 MHz, chloroform-d) δ/ppm = 5.03 (s, 2H, 1’-H), 4.54 (q, J = 7.1 Hz, 2H, CH2CH3), 
1.47 (t, J = 7.1 Hz, 3H, CH2CH3). 
13C NMR (101 MHz, chloroform-d) δ/ppm = 159.9 (CO2CH2CCl3), 159.0 (CO2Et), 93.4 (C-2’), 
76.9 (C-1’), 65.9 (CH2CH3), 14.2 (CH2CH3). 
IR (ATR): ṽ/cm-1 = 1770, 1370, 1200, 1097, 1059, 1015, 854, 801, 718. 
HRMS (EI): m/z calculated for C6H7O4N2Cl3 [M]˙⁺ 275.9466; found 275.9458. 
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1-Ethyl 2-(2,2,2-trichloroethyl) 1-(2-methyl-1-oxopropan-2-yl)hydrazine-1,2-
dicarboxylate (247a) and 2-ethyl 1-(2,2,2-trichloroethyl) 1-(2-methyl-1-oxopropan-2-
yl)hydrazine-1,2-dicarboxylate (247b) 
 
 
 
 
 
 
C10H15Cl3N2O5 
M = 349.59 g/mol 
Azodicarboxylate 246 (6.00 g, 21.6 mmol, 1.00 eq) and L-proline (249 mg, 2.16 mmol, 
10 mol%) were disperged in dry DCM (120 mL) and the suspension was cooled to 0 °C. 
Isobutyraldehyde (2.96 mL, 32.4 mmol, 1.50 eq) was added and the reaction mixture was 
allowed to warm up to rt and stirred for 18 h. The solvent was removed in vacuo and the title 
compound was purified via FCC (hexanes/EtOAc 7:3). An inseparable mixture of aldehydes 
247 were obtained as a colourless oil (3.23 g, 9.24 mmol, 43%) in an isomeric mixture of 85:15 
(determined retrospectively via 1H NMR). 
 
Rf = 0.75 (hexanes/EtOAc 7:3).  
1H NMR (400 MHz, chloroform-d) δ/ppm = 9.51 (s, 1H, 1’-H), 7.02 – 6.57 (m, 1H, NH), 4.78 (d, 
J = 31.6 Hz, 2H, C-1’’), 4.20 (dd, J = 7.1, 2.4 Hz, 2H, CH2CH3), 1.47 – 1.20 (m, 9H, 3’-H, 
CH2CH3). 
13C NMR (101 MHz, chloroform-d) δ/ppm = 198.1 (C-1’), 155.6 (CO2Et or CO2CH2CCl3), 155.2 
(CO2Et or CO2CH2CCl3), 95.0 (C-2’’), 75.1 (C-1’’), 67.7 (C-2’), 63.6 (CH2CH3), 20.4 (C-3’), 14.4 
(CH2CH3). 
IR (ATR): ṽ/cm-1 = 3306, 1733, 1707, 1514, 1469, 1407, 1379, 1342, 1216, 1173, 1096, 1047, 
818, 757, 719. 
HRMS (ESI): m/z calculated for C10H16O5N2Cl3 [M+H]+ 349.0119; found 349.0123. 
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1-Ethyl 2-(2,2,2-trichloroethyl) 1-(2-methylbut-3-en-2-yl)hydrazine-1,2-dicarboxylate 
(248a)  and 2-ethyl 1-(2,2,2-trichloroethyl) 1-(2-methylbut-3-en-2-yl)hydrazine-1,2-
dicarboxylate (248b) 
 
 
 
 
 
 
 
C11H17Cl3N2O4 
M = 347.62 g/mol 
The isomeric mixture of aldehydes 247 (3.1 g, 8.87 mmol, 1.00 eq) and pyridine (1.29 mL, 
16.0 mmol, 1.80 eq) were added to a flame dried flask and cooled to - 80 °C.  TEBBE reagent 
(0.5M in toluene, 23.1 mL, 11.5 mmol, 1.30 eq) was added carefully by adding it along the 
flask. The reaction mixture was warmed up to 0 °C and stirred for 24 h. The reaction was 
quenched with a sat. aq. NaHCO3 solution (10.0 mL) at - 80 °C and extracted with DCM (3 x 
30.0 mL). The combined organic layers were dried over Na2SO4, filtered and the solvent was 
removed in vacuo. Purification via FCC (hexanes/EtOAc 9:1 → 4:1) gave an inseparable 
mixture of olefines 248 as a colourless oil (556 mg, 1.60 mmol, 18%) in an isomeric mixture of 
85:15 (determined retrospectively via 1H NMR). 
 
Rf = 0.39 (hexanes/EtOAc 8:2).  
1H NMR (400 MHz, chloroform-d) δ/ppm = 6.63 (s, 1H, NH), 6.10 (dd, J = 17.5, 10.7 Hz, 1H, 
3’-H), 5.10 (dd, J = 17.9, 6.7 Hz, 1H, 4’-H), 5.03 (dd, J = 10.7, 0.7 Hz, 1H, 4’-H), 4.90 – 4.68 
(m, 2H, 1’’-H), 4.19 – 4.09 (m, 2H, CH2CH3), 1.52 (s, 3H, 1’-H), 1.45 (s, 3H, 1’-H), 1.25 – 1.20 
(m, 3H, CH2CH3). 
13C NMR (101 MHz, chloroform-d) δ/ppm = 155.4 (CO2Et or CO2CH2CCl3), 155.2 (CO2Et or 
CO2CH2CCl3), 143.8 (C-3’), 111.8 (C-4’), 74.9 (C-1’’), 63.2 (C-2’), 62.4 (CH2CH3), 26.3 (C-1’), 
26.1 (C-1’), 23.9 (C-2’’), 14.5 (CH2CH3). 
IR (ATR): ṽ/cm-1 = 3291, 2985, 1749, 1695, 1517, 1403, 1375, 1338, 1251, 1216, 1181, 1096, 
1051, 915, 821, 765, 739, 719. 
HRMS (ESI): m/z calculated for C11H16O4N2Cl3 [M-H]- 345.0181; found 345.0182. 
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Ethyl 1-(2-methylbut-3-en-2-yl)hydrazine-1-carboxylate (243a) and ethyl 2-(2-methylbut-
3-en-2-yl)hydrazine-1-carboxylate (243b) 
 
 
 
 
 
 
C8H16N2O2 
M = 172.23 g/mol 
The mixture of olefins 248 (550 mg, 1.58 mmol, 1.00 eq) was dissolved in a 1:1:1 mixture of 
ethanol (1.00 mL), water (1.00 mL) and acetic acid (1.00 mL). Zinc powder (3.62 g, 55.4 mmol, 
35.0 eq) was added and the reaction mixture was stirred for 10 min at rt. After filtration of the 
reaction mixture, the filtrate was extracted with DCM (3 x 10.0 mL). The combined organic 
layers were washed was sat. aq. NaHCO3 solution (15.0 mL) and dried over Na2SO4, filtered 
and the solvent was removed in vacuo. Allyhydrazines 243a and 243b was obtained as a 
colourless oil (167 mg, 0.970 mmol, 61%) as an isomeric mixture of 85:15 (determined via 1H 
NMR) and was used without further purification. 
 
Rf = 0.47 (hexanes/EtOAc 8:2).  
1H NMR (243a) (500 MHz, chloroform-d) δ/ppm = 6.05 (dd, J = 17.5, 10.7 Hz, 1H, 3’-H), 5.01 
– 4.92 (m, 2H, 4’-H), 4.13 (q, J = 7.2 Hz, 2H, CH2CH3), 3.80 (s, 2H, NH2), 1.44 (s, 6H, 1’-H), 
1.25 (t, J = 7.1 Hz, 3H, CH2CH3). 
13C NMR (243a) (101 MHz, chloroform-d) δ/ppm = 157.9 (CO2Et), 145.3 (C-3’), 109.9 (C-4’), 
61.9 (C-2’), 61.7 (CH2CH3), 26.5 (C-1’), 14.7 (CH2CH3). 
1H NMR (243b) (500 MHz, chloroform-d) δ/ppm = 5.97 (dd, J = 17.4, 10.7 Hz, 1H, 3’-H), 5.14 
– 5.05 (m, 2H, 4’-H), 4.10 – 4.04 (m, 2H, CH2CH3), 1.39 (s, 6H, 1’-H), 1.23 – 1.20 (m, 3H, 
CH2CH3). 
13C NMR (243b) (101 MHz, chloroform-d) δ/ppm = 155.8 (CO2Et), 144.2 (C-3’), 111.8 (C-4’), 
61.5 (CH2CH3), 53.6 (C-2’), 26.5 (C-1’), 14.5 (CH2CH3). 
IR (ATR): ṽ/cm-1 = 2980, 1686, 1465, 1400, 1374, 1318, 1246, 1181, 1081, 1007, 910, 859, 
769, 686. 
HRMS (ESI): m/z calculated for C8H17O2N2 [M+H]+ 173.1285; found 173.1283. 
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Ethyl 2-(cyclohexylmethylene)-1-(2-methylbut-3-en-2-yl)hydrazine-1-carboxylate (249) 
 
 
 
 
 
C15H26N2O2 
M = 266.39 g/mol 
N-CO2Et-N-allylhydrazone 249 was synthesised according to GP1 using mixture of olefins 
243a/243b (200 mg, 1.16 mmol ≙ 0.986 mmol of isomer 243a, 1.00 eq) and cyclohexane 
carboxaldehyde (130 mg, 1.16 mmol, 1.00 eq). The title compound was purified via FCC 
(pentane/Et2O 9:1) and isolated as colourless oil (115 mg, 0.432 mmol, 44% referred to isomer 
243a).  
 
Rf = 0.32 (pentane/Et2O 9:1). 
1H NMR (400 MHz, chloroform-d) δ/ppm = 7.60 (d, J = 6.0 Hz, 1H, 1’’-H), 6.11 (dd, J = 17.5, 
10.8 Hz, 1H, 3’-H), 5.10 – 4.90 (m, 2H, 4’-H), 4.07 (q, J = 7.1 Hz, 2H, CH2CH3), 2.42 – 2.32 
(m, 1H, 1’’’-H), 1.89 – 1.62 (m, 6H, 2’’’, 3’’’, 4’’’, 5’’’ and/or 6’’’-H), 1.41 (s, 6H, 1’-H), 1.37 – 1.28 
(m, 4H, 2’’’, 3’’’, 4’’’, 5’’’ and/or 6’’’-H), 1.20 (t, J = 7.1 Hz, 3H, CH2CH3). 
13C NMR (101 MHz, chloroform-d) δ/ppm = 173.9 (C-1’’), 154.9 (CO2Et), 145.4 (C-3’), 110.1 
(C-4’), 61.9 (C-2’), 61.4 (CH2CH3), 41.4 (C-1’’’), 29.7 (C-2’’’, 3’’’, 4’’’, 5’’’ and/or 6’’’), 26.5 (C-
1’), 26.1 (C-2’’’, 3’’’, 4’’’, 5’’’ and/or 6’’’), 25.4 (C-2’’’, 3’’’, 4’’’, 5’’’ and/or 6’’’), 14.5 (CH2CH3). 
IR (ATR): ṽ/cm-1 =2979, 2927, 2853, 1699, 1448, 1369, 1281, 1240, 1177, 1097, 1004, 911, 
758, 684. 
HRMS (EI): m/z calculated for C15H26O2N2 [M]˙⁺ 266.1989; found 266.1989. 
  
  Experimental Part 
 
 
  
 269 
 
Ethyl 2-benzylidene-1-(2-methylbut-3-en-2-yl)hydrazine-1-carboxylate (250) 
 
 
 
 
 
C15H20N2O2 
M = 260.34 g/mol 
N-CO2Et-N-allylhydrazone 250 was synthesised according to GP1 using mixture of olefins 
243a/243b (200 mg, 1.16 mmol ≙ 0.986 mmol of isomer 243a, 1.00 eq) and benzaldehyde 
(123 mg, 1.16 mmol, 1.00 eq). The title compound was purified via FCC (pentane/Et2O 9:1) 
and isolated as colourless oil (234 mg, 0.899 mmol, 91% referred to isomer 243a).  
 
Rf = 0.38 (pentane/Et2O 9:1). 
1H NMR (500 MHz, chloroform-d) δ/ppm = 8.60 (s, 1H, 1’’-H), 7.74 – 7.70 (m, 2H, 2’’’, 6’’’-H), 
7.44 – 7.38 (m, 3H, 3’’’, 4’’’, 5’’’-H), 6.18 (dd, J = 17.5, 10.8 Hz, 1H, 3’-H), 5.11 – 4.96 (m, 2H, 
4’-H), 4.17 (q, J = 7.1  Hz, 2H, CH2CH3), 1.53 (s, 6H, 1’-H), 1.25 (t, J = 7.1 Hz, 3H, CH2CH3). 
13C NMR (101 MHz, chloroform-d) δ/ppm = 159.0 (C-1’’), 154.6 (CO2Et), 145.7 (C-3’), 134.9 
(C-1’’’), 130.5 (C-4’’’), 128.7 (C-3’’’, 5’’’), 127.8 (C-2’’’, 6’’’), 110.0 (C-4’), 63.6 (C-2’), 61.7 
(CH2CH3), 26.9 (C-1’), 14.5 (CH2CH3). 
IR (ATR): ṽ/cm-1 = 1698, 1597, 1455, 1368, 1282, 1202, 1166, 1098, 1073, 1015, 906, 827, 
743, 687. 
HRMS (ESI): m/z calculated for C15H21O2N2 [M+H]+ 261.1597; found 261.1596. 
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5.3. Crystallographic data 
Table 13. Crystallographic information of 193a. 
 
Compound 193a 
CCDC 1907495 
net formula C10H20N2O2 
Mr/g mol−1 200.28 
crystal size/mm 0.100 × 0.060 × 0.050 
T/K 103.(2) 
radiation MoKα 
diffractometer 'Bruker D8 Venture TXS' 
crystal system triclinic 
space group 'P -1' 
a/Å 5.9860(5) 
b/Å 9.0630(7) 
c/Å 11.4665(9) 
α/° 105.616(3) 
β/° 99.965(3) 
γ/° 97.087(3) 
V/Å3 580.52(8) 
Z 2 
calc. density/g cm−3 1.146 
μ/mm−1 0.080 
absorption correction Multi-Scan 
transmission factor range 0.95–1.00 
refls. measured 5785 
Rint 0.0312 
mean σ(I)/I 0.0416 
θ range 3.444–26.370 
observed refls. 1982 
x, y (weighting scheme) 0.0299, 0.2047 
hydrogen refinement H(C) constr, H(N) refall 
refls in refinement 2368 
parameters 140 
restraints 0 
R(Fobs) 0.0411 
Rw(F2) 0.0961 
S 1.072 
shift/errormax 0.001 
max electron density/e Å−3 0.242 
min electron density/e Å−3 −0.205 
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I. Appendix 
Designation and nomenclature 
Compounds which were synthesised by undergraduate students in the course of bachelor 
theses are marked as follows: 
a: ANNA J. STEINMETZ 
b: DOREEN REUTER (née KREMER) 
c: KATHARINA N. KRIEGLER 
d: MORITZ M. KORNMAYER 
e: PATRICIA L. SKOWRONEK 
The indicated nomenclature in all compounds follows the IUPAC rules.  
 
Abbreviations 
17β-HSD 17β-hydroxysteroid-dehydrogenase 
4-nitrobenzenesulfonyl nosyl 
9-BBN 9-borabicyclo(3.3.1)nonane 
Å  Angstrom 
abs. absolute 
ACAT acetyl-CoA-acetyltransferase (Thiolase II) 
AcOH  acetic acid 
AIBN azobisisobutyronitrile 
Alzheimer's disease AD 
aq. aqueous 
atm atmospheric pressure 
Bu butyl  
CoA coenzyme A 
CVD cardiovascular diseases 
CYP51A1 lanosterol 14a-demethylase 
DCM dichloromethane 
DHCR14 Δ14-sterol reductase  
DHCR7 Δ7-dehydrocholesterol reductase 
DIAD diisopropyl azodicarboxylate 
DIBAL-H diisobutylaluminium hydride 
DMSO  dimethyl sulfoxide 
EBP sterol-Δ8/7-Isomerase  
  Appendix 
 
 
  
 272 
 
e.g. exempli gratia 
eq  equivalent 
ESI  electron spray ionization 
Et2O diethyl ether 
EtOAc ethyl acetate 
EtOH ethanol 
eV electron volt 
FCC flash column chromatography 
FPPS farnesyl-PP synthase 
g.i. growth inhibition 
GGPPS geranylgeranyl-PP synthase  
h  hour 
HMG-CoA 3-hydroxy-3-methylglutaryl coenzyme A 
HMGCR hydroxymethylglutaryl-CoA reductase (HMG-CoA reductase) 
HMGCS hydroxymethylglutaryl-CoA synthase (HMG-CoA synthase) 
HRMS  high-resolution mass spectroscopy 
Hz  hertz 
i-PrOH isopropanol 
IDI isopentenyl diphosphate isomerase 
LDA lithium diisopropylamide 
LG leaving group 
LS lanosterol synthase 
LXR liver X receptor 
m meta 
M molar mass 
M  molar 
m  multiplet (NMR) 
m-CPBA meta-chloroperbenzoic acid 
Me methyl 
MeCN acetonitrile 
MeOH  methanol 
MHz megahertz 
min  minutes 
mmol  millimole 
mol mole 
mp  melting point 
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MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromid 
MVD diphosphomevalonate decarboxylase  
MVK mevalonate kinase 
mw microwave 
n unbranched/primary 
n.d. not determinable 
n.t. not tested 
NAFLD non-alcoholic fatty liver disease 
NaHMDS sodium bis(trimethylsilyl)amide 
NASH non-alcoholic steatohepatitis 
NMM N-methyl morpholine 
NMR  nuclear magnetic resonance 
NsCl 2-nitrobenzenesulfonyl chloride 
NSDHL sterol-4a-carboxylate-3-dehydrogenase 
o ortho 
p para 
p.a. pro analysi 
PBS phosphate buffered saline 
Pd(dppf)Cl2 (1,1′-bis(diphenylphosphino)-ferrocene]-dichloropalladium(II) 
PDC pyridinium dichromate 
PMVK phosphomevalonate kinase 
ppm  parts per million 
Pr propyl 
q  quartet (NMR) 
quant.  quantitative 
rac racemic 
RCT reverse cholesterol transport 
Rf  retardation factor 
rt  room temperature 
RXR retinoid X receptor 
s secondary 
s  singlet (NMR) 
sat. saturated 
SC5D lathosterol oxidase (∆7-sterol-C5-desaturase) 
SM squalene monooxygenase 
SMO sterol-C4-methyl oxidase 
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SQS squalene synthase 
t tertiary 
t  triplet (NMR) 
t.i. total inhibition 
TBDMSCl tert-butyldimethylsilyl chloride 
TEA triethylamine 
TES triethylsilane 
TFA  trifluoroacetic acid 
THF  tetrahydrofurane 
TLC  thin layer chromatography 
TMS trimethylsilyl 
ṽ wavenumber [cm-1] 
  
  References 
 
 
  
 275 
 
II.  References 
[1] D. Heerdegen, D. Reuter, M. M. Kornmayer, K. N. Kriegler, C. Müller, P. Mayer, F. 
Bracher, Eur. J. Org. Chem. 2020, accepted. 
[2] D. Heerdegen, J. Junker, S. Dittrich, P. Mayer, F. Bracher, Eur. J. Org. Chem. 2020, 
2020, 3680-3687. 
[3] H. Soran, S. Adam, J. B. Mohammad, J. H. Ho, J. D. Schofield, S. Kwok, T. 
Siahmansur, Y. Liu, A. A. Syed, S. S. Dhage, C. Stefanutti, R. Donn, R. A. Malik, M. 
Banach, P. N. Durrington, Arch. Med. Sci. 2018, 14, 1-21. 
[4] R. H. Nelson, Prim. Care 2013, 40, 195-211. 
[5] J. M. Berg, J. L. Tymoczko, L. Stryer, Stryer Biochemie, 6th ed., Springer Verlag, 
Heidelberg, 2007. 
[6] J. Wollam, A. Antebi, Annu. Rev. Biochem. 2011, 80, 885-916. 
[7] K. Kriegler, bachelor thesis, Ludwig-Maximilians-University (Munich, Germany), 2018. 
[8] M. A. Mitsche, J. G. McDonald, H. H. Hobbs, J. C. Cohen, Elife 2015, 4, e07999-
e07999. 
[9] H. Karlic, F. Varga, in Encyclopedia of Cancer, 3th ed. (Eds.: P. Boffetta, P. Hainaut), 
Academic Press, Oxford, 2019, 445-457. 
[10] E. J. Zerenturk, L. J. Sharpe, E. Ikonen, A. J. Brown, Prog. Lipid Res. 2013, 52, 666-
680. 
[11] H. W. Coates, A. J. Brown, J. Lipid Res. 2019, 60, 1643-1645. 
[12] S. Bernardi, A. Marcuzzi, E. Piscianz, A. Tommasini, B. Fabris, Int. J. Mol. Sci. 2018, 
19, 4058. 
[13] L.-H. Huang, A. Elvington, G. J. Randolph, Front. Pharmacol. 2015, 6, 182-182. 
[14] J. Luo, L. Jiang, H. Yang, B. L. Song, Traffic 2017, 18, 209-217. 
[15] M. S. Brown, J. L. Goldstein, PNAS 1979, 76, 3330. 
[16] J. Luo, H. Yang, B.-L. Song, Nat. Rev. Mol. Cell Bio. 2020, 21, 225-245. 
[17] L. R. Marques, T. A. Diniz, B. M. Antunes, F. E. Rossi, E. C. Caperuto, F. S. Lira, D. C. 
Gonçalves, Front. Physiol. 2018, 9, 526-526. 
[18] G. A. Francis, BBA - Mol. Cell. Biol. L. 2010, 1801, 1286-1293. 
[19] M. Ouimet, T. J. Barrett, E. A. Fisher, Circ. Res. 2019, 124, 1505-1518. 
[20] B. B. Madison, J. Lipid Res. 2016, 57, 333-335. 
[21] Z. H. Beg, D. W. Allmann, D. M. Gibson, Biochem. Biophys. Res. Commun. 1973, 54, 
1362-1369. 
[22] W. R. H. Evans, C. J. Hendriksz, BJPsych. Bull. 2017, 41, 109-114. 
[23] J. S. Weiss, Ophthalmology 2009, 116, 2260. 
[24] M. J. Nowaczyk, M. B. Irons, Am. J. Med. Genet. C. Semin. Med. Genet. 2012, 160c, 
250-262. 
[25] A. Chait, J. D. Brunzell, Endocrin. Metab. CLIN 1990, 19, 259-278. 
[26] World Heath Organisation. Global Health Observatory (GHO), Raised Cholesterol 
(https://www.who.int/gho/ncd/risk_factors/cholesterol_text/en/ accessed 12.07.2020). 
[27] N. Bhattarai, A. T. Prevost, A. J. Wright, J. Charlton, C. Rudisill, M. C. Gulliford, BMC 
Public Health 2013, 13, 1203. 
[28] G. S. Mannu, M. J. S. Zaman, A. Gupta, H. U. Rehman, P. K. Myint, Curr. Cardiol. Rev. 
2013, 9, 2-14. 
[29] J. T. Davies, S. F. Delfino, C. E. Feinberg, M. F. Johnson, V. L. Nappi, J. T. Olinger, A. 
P. Schwab, H. I. Swanson, Lipid Insights 2016, 9, 13-29. 
  References 
 
 
  
 276 
 
[30] A. C. Liwa, E. N. Barton, W. C. Cole, C. R. Nwokocha, in Pharmacognosy (Eds.: S. 
Badal, R. Delgoda), Academic Press, Boston, 2017, 315-336. 
[31] E. I. Mercer, Prog. Lipid Res. 1993, 32, 357-416. 
[32] A. Endo, Int. Congr. Ser. 2004, 1262, 3-8. 
[33] B. A. Parker, P. D. Thompson, Exerc. Sport Sci. Rev. 2012, 40, 188-194. 
[34] A. L. Catapano, I. Graham, G. De Backer, O. Wiklund, M. J. Chapman, H. Drexel, A. 
W. Hoes, C. S. Jennings, U. Landmesser, T. R. Pedersen, Z. Reiner, G. Riccardi, M. 
R. Taskinen, L. Tokgozoglu, W. M. Verschuren, C. Vlachopoulos, D. A. Wood, J. L. 
Zamorano, Atherosclerosis 2016, 253, 281-344. 
[35] L. Horlick, J. Lipid Res. 1966, 7, 116-121. 
[36] C. Wolf, F. Chevy, J. Pham, M. Kolf-Clauw, D. Citadelle, N. Mulliez, C. Roux, J. Lipid 
Res. 1996, 37, 1325-1333. 
[37] A. Körner, E. Zhou, C. Müller, Y. Mohammed, S. Herceg, F. Bracher, P. C. N. Rensen, 
Y. Wang, V. Mirakaj, M. Giera, PNAS 2019, 116, 20623-20634. 
[38] I. Greeve, I. Hermans-Borgmeyer, C. Brellinger, D. Kasper, T. Gomez-Isla, C. Behl, B. 
Levkau, R. M. Nitsch, J. Neurosci. Res. 2000, 20, 7345-7352. 
[39] T. Takano, K. Tsukiyama-Kohara, M. Hayashi, Y. Hirata, M. Satoh, Y. Tokunaga, C. 
Tateno, Y. Hayashi, T. Hishima, N. Funata, M. Sudoh, M. Kohara, J. Hepatol. 2011, 
55, 512-521. 
[40] H. R. Waterham, J. Koster, G. J. Romeijn, R. C. Hennekam, P. Vreken, H. C. 
Andersson, D. R. FitzPatrick, R. I. Kelley, R. J. Wanders, Am. J. Hum. Genet. 2001, 
69, 685-694. 
[41] J. Zolotushko, H. Flusser, B. Markus, I. Shelef, Y. Langer, M. Heverin, I. Björkhem, S. 
Sivan, O. S. Birk, Eur. J. Hum. Genet. 2011, 19, 942-946. 
[42] W. D. Nes, Chem. Rev. 2011, 111, 6423-6451. 
[43] C. Müller, S. Hemmers, N. Bartl, A. Plodek, A. Korner, V. Mirakaj, M. Giera, F. Bracher, 
Eur. J. Med. Chem. 2017, 140, 305-320. 
[44] S. H. Bae, Y. K. Paik, Biochem. J. 1997, 326 609-616. 
[45] C. Yang, J. G McDonald, A. Patel, Y. Zhang, M. Umetani, F. Xu, E. Westover, D. Covey, 
D. Mangelsdorf, J. C Cohen, H. H Hobbs, J. Biol. Chem. 2006, 281, 27816-27826. 
[46] B. Wang, P. Tontonoz, Nat. Rev. Endocrinol. 2018, 14, 452-463. 
[47] B. A. Laffitte, L. C. Chao, J. Li, R. Walczak, S. Hummasti, S. B. Joseph, A. Castrillo, D. 
C. Wilpitz, D. J. Mangelsdorf, J. L. Collins, E. Saez, P. Tontonoz, PNAS 2003, 100, 
5419-5424. 
[48] M. Ni, B. Zhang, J. Zhao, Q. Feng, J. Peng, Y. Hu, Y. Zhao, Biomed. Pharmacother. 
2019, 113, 108778. 
[49] P. J. Willy, K. Umesono, E. S. Ong, R. M. Evans, R. A. Heyman, D. J. Mangelsdorf, 
Genes Dev. 1995, 9, 1033-1045. 
[50] I. Zanotti, F. Potì, M. Pedrelli, E. Favari, E. Moleri, G. Franceschini, L. Calabresi, F. 
Bernini, J. Lipid Res. 2008, 49, 954-960. 
[51] F. F. Wiebel, K. R. Steffensen, E. Treuter, D. Feltkamp, J.-A. k. Gustafsson, J. Mol. 
Endocrinol. 1999, 13, 1105-1118. 
[52] A. Kratzer, M. Buchebner, T. Pfeifer, T. M. Becker, G. Uray, M. Miyazaki, S. Miyazaki-
Anzai, B. Ebner, P. G. Chandak, R. S. Kadam, E. Calayir, N. Rathke, H. Ahammer, B. 
Radovic, M. Trauner, G. Hoefler, U. B. Kompella, G. Fauler, M. Levi, S. Levak-Frank, 
G. M. Kostner, D. Kratky, J. Lipid Res. 2009, 50, 312-326. 
  References 
 
 
  
 277 
 
[53] T. Pfeifer, M. Buchebner, P. G. Chandak, J. Patankar, A. Kratzer, S. Obrowsky, G. N. 
Rechberger, R. S. Kadam, U. B. Kompella, G. M. Kostner, D. Kratky, S. Levak-Frank, 
Curr. Pharm. Biotechnol. 2011, 12, 285-292. 
[54] C. Hong, P. Tontonoz, Nat. Rev. Drug Discov. 2014, 13, 433-444. 
[55] Z. Ma, C. Deng, W. Hu, J. Zhou, C. Fan, S. Di, D. Liu, Y. Yang, D. Wang, Curr. Issues 
Mol. Biol. 2017, 22, 41-64. 
[56] S. B. Ahn, K. Jang, D. W. Jun, B. H. Lee, K. J. Shin, Digest. Dis. Sci. 2014, 59, 2975-
2982. 
[57] K. Griffett, L. A. Solt, B. E.-D. M. El-Gendy, T. M. Kamenecka, T. P. Burris, ACS Chem. 
Biol. 2013, 8, 559-567. 
[58] M. Benedict, X. Zhang, World J. Hepatol. 2017, 9, 715-732. 
[59] A. M. Diehl, C. Day, N. Engl. J. Med. 2017, 377, 2063-2072. 
[60] K. Griffett, R. D. Welch, C. A. Flaveny, G. R. Kolar, B. A. Neuschwander-Tetri, T. P. 
Burris, Mol. Metab. 2015, 4, 353-357. 
[61] J. Avigan, D. Steinberg, H. E. Vroman, M. J. Thompson, E. Mosettig, J. Biol. Chem. 
1960, 235, 3123-3126. 
[62] D. Steinberg, J. Avigan, E. B. Feigelson, J. Clin. Invest. 1961, 40, 884-893. 
[63] T. J. Kirby, Trans. Am. Ophthalmol. Soc. 1967, 65, 494-543. 
[64] D. Rozman, K. Monostory, Pharmacol. Therapeut. 2010, 127, 19-40. 
[65] R. J. Cenedella, Lipids 2009, 44, 477-487. 
[66] M. Giera, D. Renard, F. Plössl, F. Bracher, Steroids 2008, 73, 299-308. 
[67] H. F. DeLuca, B. P. Tadi, L. A. Plum, M. Clagett-Dame, WO2010/6135, 2010, 6-7 
(column 4). 
[68] J.-F. Lacroix, master thesis, McGill University (Montreal, Quebec), 2011. 
[69] R. R. Fraser, T. S. Mansour, J. Org. Chem. 1984, 49, 3442-3443. 
[70] T. W. G. Peter G. M. Wuts, in Greene's Protective Groups in Organic Synthesis, 4th 
ed., John Wiley & Sons, Inc., 2006, 16-366. 
[71] Z. Wang, in Comprehensive Organic Name Reactions and Reagents, John Wiley & 
Sons, 2010, 871-876. 
[72] T. Takashi, T. Ichiro, JP2002179727A, Japan, 2002. 
[73] R. H. Shapiro, in Organic Reactions, John Wiley & Sons, Inc., 2011, 405-507. 
[74] R. M. Adlington, A. G. M. Barrett, Acc. Chem. Res. 1983, 16, 55-59. 
[75] W. R. Bamford, T. S. Stevens, J. Chem. Soc. 1952, 4735-4740. 
[76] P. A. Wender, M. K. Hilinski, N. Soldermann, S. L. Mooberry, Org. Lett. 2006, 8, 1507-
1510. 
[77] P. Liu, S. Hong, S. M. Weinreb, J. Am. Chem. Soc. 2008, 130, 7562-7563. 
[78] C. D. Mayer, F. Bracher, Eur. J. Med. Chem. 2011, 46, 3227-3236. 
[79] P. O. Tawney, R. H. Snyder, R. P. Conger, K. A. Leibbrand, C. H. Stiteler, A. R. 
Williams, J. Org. Chem. 1961, 26, 15-21. 
[80] W. Mbiya, I. Chipinda, P. D. Siegel, M. Mhike, R. H. Simoyi, Chem. Res. Toxicol. 2013, 
26, 112-123. 
[81] W. Mbiya, I. Chipinda, R. H. Simoyi, P. D. Siegel, Toxicology 2016, 339, 34-39. 
[82] S. Schiesser, B. Hackner, T. Pfaffeneder, M. Müller, C. Hagemeier, M. Truss, T. Carell, 
Angew. Chem. Int. Ed. 2012, 51, 6516-6520. 
[83] B. Karimi, A. Zamani, D. Zareyee, Tetrahedron Lett. 2004, 45, 9139. 
[84] F. Caturla, C. Nájera, ChemInform 1997, 28. 
[85] Z. Li, M. K. Gupta, T. S. Snowden, Eur. J. Org. Chem. 2015, 2015, 7009-7019. 
  References 
 
 
  
 278 
 
[86] V. K. Aggarwal, A. Mereu, J. Org. Chem. 2000, 65, 7211-7212. 
[87] P. L. Skowronek, bachelor thesis, Ludwigs-Maximilians-University (Munich, Germany), 
2018. 
[88] C. H. Heathcock, J. E. Ellis, J. E. McMurry, A. Coppolino, Tetrahedron Lett. 1971, 12, 
4995-4996. 
[89] E. D. Bergmann, R. Ikan, H. Weiler-Feilchenfeld, Bull. Soc. Chim. Fr. 1957, 290-295. 
[90] P. Quinio, L. Kohout, D. S. Roman, J. Gaar, K. Karaghiosoff, P. Knochel, Synlett 2016, 
27, 1715-1719. 
[91] J. J. Li, in Name Reactions: A Collection of Detailed Reaction Mechanisms, Springer, 
Berlin, Heidelberg, 2006, 577-578. 
[92] N. Yasui, C. G. Mayne, J. A. Katzenellenbogen, Org. Lett. 2015, 17, 5540-5543. 
[93] G. B. Rosso, Synlett 2006, 2006, 0809-0810. 
[94] K. Tanino, K. Onuki, K. Asano, M. Miyashita, T. Nakamura, Y. Takahashi, I. Kuwajima, 
J. Am. Chem. Soc. 2003, 125, 1498-1500. 
[95] D. Kremer, bachelor thesis, Ludwig-Maximilians-University (Munich, Germany), 2019. 
[96] M. M. Kornmayer, bachelor thesis, Ludwig-Maximilians-University (Munich, Germany), 
2019. 
[97] J. L. Fry, F. Bracher, in Encyclopedia of Reagents for Organic Synthesis, John Wiley & 
Sons Ltd, Chichester, UK, 2001. 
[98] H. Sobotka, J. D. Chanley, J. Am. Chem. Soc. 1948, 70, 3914-3918. 
[99] R. G. Daniels, L. A. Paquette, J. Org. Chem. 1981, 46, 2901-2910. 
[100] Garima, Synlett 2010, 2010, 1426-1427. 
[101] R. Mukkamala, A. Hossain, I. Singh Aidhen, Nat. Prod. Res. 2017, 31, 1085-1090. 
[102] P. Jones, M. E. Difrancesco, A. Petroc-Chi, C. L. Carroll, J. Marszalek, B. Czako, R. 
Johnson, J. Theroff, WO2014/31936, 2014. 
[103] K. P. C. Vollhardt, N. E. Schore, Organische Chemie, WILEY-VCH, Weinheim, 2005. 
[104] R. P. Singh, D. Chakraborty, J. M. Shreeve, J. Fluorine Chem. 2001, 111, 153-160. 
[105] D. Wu, H. Mei, P. Tan, W. Lu, J. Zhu, W. Wang, J. Huang, J. Li, Tetrahedron Lett. 2015, 
56, 4383-4387. 
[106] E. Grochowski, B. D. Hilton, R. J. Kupper, C. J. Michejda, J. Am. Chem. Soc. 1982, 
104, 6876-6877. 
[107] D. L. Hughes, R. A. Reamer, J. J. Bergan, E. J. J. Grabowski, J. Am. Chem. Soc. 1988, 
110, 6487-6491. 
[108] J. Y. Boxhall, P. C. B. Page, Y. Chan, C. M. Hayman, H. Heaney, M. J. McGrath, Synlett 
2003, 2003, 0997-1001. 
[109] Y. Nagasaka, S. Shintaku, K. Matsumura, A. Masuda, T. Asakawa, M. Inai, M. Egi, Y. 
Hamashima, Y. Ishikawa, T. Kan, Org. Lett. 2017, 19, 3839-3842. 
[110] H. Zhang, P. Ruiz-Castillo, S. L. Buchwald, Org. Lett. 2018, 20, 1580-1583. 
[111] N. C. Bruno, S. L. Buchwald, Org. Lett. 2013, 15, 2876-2879. 
[112] S. Schiaffino-Ortega, L. C. López-Cara, P. Ríos-Marco, M. P. Carrasco-Jimenez, M. A. 
Gallo, A. Espinosa, C. Marco, A. Entrena, Bioorg. Med. Chem. 2013, 21, 7146-7154. 
[113] E. Uhl, master thesis, Ludwig-Maximilians-University (Munich, Germany), 2014. 
[114] Y. Miyauchi, K. Noguchi, K. Tanaka, Org. Lett. 2012, 14, 5856-5859. 
[115] S. D. Lepore, Y. He, J. Org. Chem. 2003, 68, 8261-8263. 
[116] H. Wang, G. Zhang, Y. Guo, B. Ren, Z. Wang, C. Zhou, WO2016/161960, (Ed.: L. 
BeiGene), China, 2016. 
  References 
 
 
  
 279 
 
[117] M. R. Netherton, C. Dai, K. Neuschütz, G. C. Fu, J. Am. Chem. Soc. 2001, 123, 10099-
10100. 
[118] B. Saito, G. C. Fu, J. Am. Chem. Soc. 2007, 129, 9602-9603. 
[119] L. Tanabe Seiyaku Co., WO2006/9245 A1, Japan, 2007. 
[120] M. V. Bhatt, S. S. El-Morey, Synthesis 1982, 1982, 1048-1050. 
[121] D. Seyferth, Organometallics 2009, 28, 1598-1605. 
[122] Y.-H. Lai, Synthesis 1981, 1981, 585-604. 
[123] A. Krasovskiy, P. Knochel, Angew. Chem. Int. Ed. 2004, 43, 3333-3336. 
[124] J. M. Grévy, in Encyclopedia of Inorganic and Bioinorganic Chemistry (Ed.: R. A. Scott), 
John Wiley & Sons, Ltd. , 2011. 
[125] A. J. Steinmetz, bachelor thesis, Ludwig-Maximilians-University (Munich, Germany), 
2018. 
[126] D. J. Burnell, Y.-J. Wu, Can. J. Chem. 1990, 68, 804-811. 
[127] K. Fukumoto, M. Chihiro, M. Ihara, T. Kametani, T. Honda, J. Chem. Soc., Perkin 
Trans. 1 1983, 2569-2576. 
[128] E. J. Corey, A. Venkateswarlu, J. Am. Chem. Soc. 1972, 94, 6190-6191. 
[129] D. M. Tschaen, L. Abramson, D. Cai, R. Desmond, U.-H. Dolling, L. Frey, S. Karady, 
Y.-J. Shi, T. R. Verhoeven, J. Org. Chem. 1995, 60, 4324-4330. 
[130] M. Giera, F. Plössl, F. Bracher, Steroids 2007, 72, 633-642. 
[131] T. Mosmann, J. Immunol. Methods 1983, 65, 55-63. 
[132] C. Müller, J. Junker, F. Bracher, M. Giera, Nat. Protoc. 2019, 14, 2546-2570. 
[133] S. Kawata, J. M. Trzaskos, J. L. Gaylor, J. Biol. Chem. 1985, 260, 6609-6617. 
[134] E. A. Ilardi, C. E. Stivala, A. Zakarian, Chem. Soc. Rev. 2009, 38, 3133-3148. 
[135] J. Nowicki, Molecules 2000, 5, 1033. 
[136] L. L. Anderson, M. G. Banwell, H. Bao, D. J.-Y. D. Bon, N. Chida, Y. Coquerel, D. Craig, 
L. El Kaim, X. Feng, D. Gamba-Sánchez, A. Xiang Gao, F. Garzón-Posse, G. I. Georg, 
N. Gigant, I. Gillaizeau, L.Grimaud, M. Harmata, J. E. Harvey, T. A. D. Holth, O. E. Hutt, 
M. Isobe, L. Lin, X. Liu, J. Louie, G. K. Murphy, C. Ploysuk, J. Rodriguez, C. M. Rojas, 
M. Sasaki, S. A. Snyder, K. Takeda, U. K. Tambar, A. Thakur, S. B. Thomas, F. G. 
West, T. Yamazaki, L. Zhou, Molecular Rearrangements in Organic Synthesis, (Eds.: 
C. M. Rojas), John Wiley & Sons, Inc., Hoboken, New Jersey, 2015. 
[137] R. B. Woodward, R. Hoffmann, J. Am. Chem. Soc. 1965, 87, 2511-2513. 
[138] C. D. Hurd, The Chemistry of Alkenes, Vol. 148, Interscience (Wiley), New York, 1965. 
[139] L. Claisen, Ber. Dtsch. Chem. Ges. 1912, 45, 3157-3166. 
[140] A. C. Cope, E. M. Hardy, J. Am. Chem. Soc. 1940, 62, 441-444. 
[141] R. V. Stevens, E. E. McEntire, W. E. Barnett, E. Wenkert, J. Chem. Soc., Chem. 
Commun. 1973, 662-663. 
[142] D. A. Mundal, J. J. Lee, R. J. Thomson, J. Am. Chem. Soc. 2008, 130, 1148-1149. 
[143] D. A. Mundal, K. E. Lutz, R. J. Thomson, Org. Lett. 2009, 11, 465-468. 
[144] D. A. Mundal, C. T. Avetta, R. J. Thomson, Nat. Chem. 2010, 2, 294-297. 
[145] S. Dittrich, doctoral thesis, Ludwig-Maximilians-University (Munich, Germany), 2015. 
[146] S. Dittrich, F. Bracher, Tetrahedron 2015, 71, 2530-2539. 
[147] S. Dittrich, F. Bracher, Eur. J. Org. Chem. 2015, 2015, 8024-8033. 
[148] A. J. Hubert, H. Reimlinger, Synthesis 1970, 1970, 405-430. 
[149] R. M. Beesley, C. K. Ingold, J. F. Thorpe, J. Chem. Soc. 1915, 107, 1080-1106. 
[150] M. E. Jung, G. Piizzi, Chem. Rev. 2005, 105, 1735-1766. 
  References 
 
 
  
 280 
 
[151] D. Heerdegen, master thesis, Ludwig-Maximilians-University (Munich, Germany), 
2017. 
[152] V. Aureggi, V. Franckevičius, M. O. Kitching, D. A. Longbottom, A. J. Oelke, G. 
Sedelmeier, S. V. Ley, Org. Synth. 2008, 72. 
[153] D. S. Bose, V. Lakshminarayana, Synthesis 1999, 66-68. 
[154] A. J. Oelke, D. J. France, T. Hofmann, G. Wuitschik, S. V. Ley, Angew. Chem. Int. Ed. 
2010, 49, 6139-6142. 
 
